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Abstract 
The European Centre for Disease Prevention and Control (ECDC) have estimated 
that on any given day 1 in 18 hospitalised patients have a healthcare-associated 
infection (HAI) and that a large percentage of these infections are caused by resistant 
strains of bacteria. With the global spread of antibiotic-resistance and the emergence 
of bacteria resistant to ‘last-resort antibiotics’, along with the lack of new classes of 
antibiotics being discovered, there is an urgent need for antibacterial research. 
Herein, three compound families were designed and synthesised in an effort to 
ascertain a compound with improved antibacterial activity. Each of the compounds 
synthesised were evaluated for their bacteriostatic activity against the Gram-negative 
bacteria Escherichia coli and Pseudomonas aeruginosa and the Gram positive 
bacterium Staphylococcus aureus. A selection of the compounds were also evaluated 
for their in vivo toxicity using the larvae of the greater wax moth, Galleria 
mellonella.  
Firstly, a structure-activity relationship (SAR) study of a thiourea-based, bifuctional 
organocatalyst, which was found to exhibit bacteriostatic activity (MIC90 of 4.69-
6.25 g/mL against E. coli) comparable to that of vancomycin hydrochloride, was 
used to assess the structural components responsible for its activity. A number of 
structural features important for the overall activity of this compound were 
identified. Additionally, the hit compound and a selection of the SAR study 
compounds were also found to be non-toxic to the larvae of Galleria mellonalla. 
Secondly, modifications were made to the C-3 position of the well-known 
antibacterial quinolone structure. Two functionalities were chosen to replace the 
quinolone C-3 carboxylic acid, (1) the well-known carboxylic acid bioisostere, the 
(1H)-tetrazole, and (2) a hydroxamic acid. Both the (1H)-tetrazole and hydroxamic 
acid derivatives were found to exhibit bacteriostatic activity similar to that of their 
carboxylic acid analogues.  
Finally, the synthesis of a family of dioganotin(IV) dicarboxylates, including 
acetates, picolinates and nicotinates, as well as diorgantin(IV) dichlorides and their 
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complexes with the ligands 1,10-phenanthroline (phen), 1,10-phenanthroline-5,6-
dione (dione) and dipyrido[3,2-a:2’,3’-c]phenazine (dppz) were also carried out. Of 
the compounds synthesised, the dibutyltin(IV) derivatives exhibited the broadest 
range of activity in comparison to the dimethyltin(IV) or diphenyltin(IV) derivatives. 
The addition of the picolinate or nicotinate group did not promote activity against 
any of the bacteria. Furthermore, only in the case of [Ph2SnCl2(dione)] was there 
improved activity compared to the organic ligand itself. 
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1.1 Introduction 
Almost one century ago, an outstanding, novel antibiotic was discovered in a 
London laboratory. Named after the mould from which it was derived,  penicillin 
was active against a host of microbes including Gram-positive bacteria and those 
responsible for syphilis.1 It demonstrated bacteriostatic, bactericidal, and 
bacteriolytic activity but most importantly it was non-toxic to animals.1 In 1945, its 
discoverer, Sir Alexander Fleming gave his Nobel lecture entitled ‘Penicillin’, but it 
came with a warning:1  
‘There is the danger that the ignorant man may easily underdose himself and by 
exposing his microbes to non-lethal quantities of the drug make them resistant.’ 
Two years after the introduction of penicillin the first penicillin-resistant 
Staphylococcus aureus (S. aureus) strain was reported.2 In the 1960s methicillin was 
introduced and was closely followed by the emergence of the infamous methicillin-
resistant S. aureus (MRSA).3 Today, bacterial resistance to antibiotics is a serious 
public health problem.  
The European Centre for Disease Prevention and Control (ECDC) have estimated 
that on any given day 1 in 18 hospitalised patients have a healthcare-associated 
infection (HAI).4 The four most frequently isolated microorganisms from HAIs are 
Escherichia coli (E. coli), S. aureus, Enterococcus spp. and Pseudomonas 
aeruginosa (P. aeruginosa).5 Overall, of the HAIs caused by S. aureus, 41% of these 
are caused by MRSA with 10% of Enterococci spp. infections caused by 
vancomycin-resistant Enterococci spp., 23% of E. coli HAIs caused by 
cephalosporin-resistant strains and 32% of P. aeruginosa HAIs caused by 
carbapenem-resistant strains.5 According to the ECDC, infections resulting from 
Gram-negative, multidrug-resistant (MDR) bacteria are on the rise and in Ireland 
alone the percentage of MDR E. coli has increased from 5.6% in 2006 to 13.5% in 
2012.6 In the United States (U.S.) at least 2,000,000 people become infected each 
year with bacteria that are resistant to one or more of the antibiotics used for 
treatment of the infection.7 Of the 2 million infections, approximately 23,000 people 
die as a direct result of infection by the resistant-bacteria.7 However, the increase in 
Chapter I: Introduction 
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existing antibiotic-resistant bacterial infections and emergence of new resistant 
strains are only half of the problem. 
Antibiotics are short-term use drugs, thus the return on investment is not as good as 
the return from long-term use drugs, such as antidiabetics. Therefore, pharmaceutical 
companies are not that interested in antibacterial research. Of the classes of 
antibiotics used today almost all of them belong to classes discovered before the 
1980s with the exception of the lipopeptides.8 Most of the advances that have been 
made since the 1980s have been by modifications/improvements made to existing 
antibiotic classes, for example, the fluoroquinolones are more active than nalidixic 
acid.8a  
With the global spread of antibiotic-resistance and the emergence of bacteria 
resistant to ‘last-resort antibiotics’, along with the lack of new classes of antibiotics 
being discovered, there is an urgent need for antibacterial research.7,9 
1.1.1 Drug discovery 
There are three main drug discovery methods; 1. whole-cell screening, 2. genomic-
based discovery and 3. structure-based drug discovery (SBDD).8b Whole-cell 
screening is the original method by which many of the currently used antibiotics 
were discovered.8b It is a non-target-based, high-throughput screening (HTS) method 
in which a number of compounds are screened in vitro for activity.10 The mode of 
action can be investigated after activity has been established.  
Structure-based discovery is a newer, in silico drug discovery method that includes 
virtual HTS (VHTS) and fragment-based drug discovery (FBDD).8b,11 This method 
involves the design of compounds based on the structure of the desired target.11 The 
target structures are determined using X-ray crystallography and uploaded on to a 
computer.11 Molecular modelling software is then used to design novel compounds 
that have good affinity for the target binding sites.11 Once designed, the compounds 
can be synthesised and tested in vitro with their targets.11 SBDD has a lot of 
potential, however, although it may produce compounds that have a good binding 
affinity for a given target, the compound may not exhibit antibacterial activity.12 This 
has already been observed in SBDD studies for antibacterial agents and may be due 
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to a compounds lack of ability to transverse the cell membrane thus preventing it 
from reaching its target.12  
Genomic-based discovery is a method that involves the sequencing of pathogen 
genomes and the identification of genes that are conserved amongst a given group of 
pathogens, which encode targets that lack mammalian cell homologues.8a A HTS of 
existing compound libraries is then ran to identify molecules that may bind to, and 
inhibit these targets.8a This method sounds very promising and was embraced by a 
number of pharmaceutical companies but unfortunately gave very disappointing 
results.8a,10 GlaxoSmithKline (GSK) spent a number of years (1995-2001) exploring 
the genomics-derived, target-based approach. Over 350 genes were evaluated, out of 
which 67 HTS were carried out using 260,000-530,000 compounds.10 Of the 67 
HTS, 16 hits were found and only 5 of these resulted in lead compounds. According 
to Payne et al.10, lead compounds from only one of the targets are still being 
pursued. However, none of the lead compounds from the genomics-based discovery 
approach have made it to the market.8a,10 As a result, GSK changed their strategy. 
GSK went back to known antibacterials and investigating ways to improve them for 
example, pleuromutilins, and at the same time shifted back towards an ‘old-
fashioned’ whole-cell screening approach through which they have found a novel 
class of compounds.10,13 
For our research into potential antibacterial compounds we decided to take a similar, 
whole-cell screening approach, as was used by GSK. Our research included an 
investigation into new antibacterial compounds through a structure-activity 
relationship (SAR) study of a well-known compound, an attempt to optimise an 
existing antibacterial compound and the synthesis and optimisation of both known 
and new metal-based compounds that may exhibit antibacterial activity. Herein, 
three families of compounds have been synthesised and evaluated against three 
bacterial species that are frequently isolated in HAIs and are known for developing 
resistance to antibiotics.  
Chapter I: Introduction 
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1.1.2 The bacteria 
For this study, two Gram-negative bacteria, Escherichia coli (E. coli) and 
Pseudomonas aeruginosa (P. aeruginosa), and one Gram-positive bacterium, 
Staphylococcus aureus (S. aureus), were chosen. The details for the bacterial strains 
are shown in Table 1.1, section 1.2.2. Compounds were tested for their bacteriostatic 
activity (ability to inhibit bacterial growth) using the susceptibility assay described in 
section 1.2.5. The details of the procedure are given in section 1.2.5. 
1.1.3 Bacteria cell structure 
 
 
Figure 1.1: Bacteria cell structures for (a) Gram-positive bacteria, and (b) Gram-
negative bacteria.14 
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Bacteria are prokaryotes and can be identified by their shape. The three most 
common shapes are spheres (cocci), rods (bacilli) and helices (spirilla and 
spirochetes).14 Bacterial cells are (1-5 m in diameter) made up of a cytoplasm 
centre, containing the nucleoid, surrounded by a cytoplasmic membrane (Figure 1.1). 
The cytoplasmic membrane is surrounded and supported by a cell wall.14 Bacteria 
can be assigned to two main groups based on differences in their cell walls, that is, 
Gram-positive and Gram-negative bacteria.  
As shown in Figure 1.1, the cell wall of a Gram-positive bacterium is larger than that 
of the Gram-negative bacterium and is made up of mainly peptidoglycan. The Gram-
negative cell wall is made up of an outer membrane containing lipopolysaccharide 
(LPS) and a peptidoglycan layer. Cell membranes are made up of 
glycerolphospholipid bilayers (Figure 1.2).14-15  
 
Figure 1.2: Representative structures of (a) a phospholipid (phosphatidylcholine) 
and (b) LPS.14,16 LPS consists of three domains; 1. lipid A, made up of a 
disaccharide diphosphate and fatty acid chains, 2. the core 
polysaccharide and 3. the O Antigen. 
 
The presence of unsaturated fatty acid residues prevent the tight packing of 
hydrocarbon chains resulting in lipid bilayers that are fluid in nature.15 LPS contain 
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saturated fatty acid residues, which allow for the tight packing of hydrocarbon chains 
and thus decreases the fluidity of the membrane (Figure 1.2).15 Furthermore, in 
comparison to the phospholipid that has only two fatty acid residues, LPS also has 
additional covalently linked fatty acid chains.17 The reduced fluidity of the Gram-
negative bacteria outer membrane prevents rapid penetration of lipophilic molecules 
which in turn makes Gram-negative bacteria difficult to treat in comparison to Gram-
positive bacteria.17-18  
1.1.4 Staphylococcus aureus  
Saphylococcus aureus (S. aureus) is a spherical Gram-positive bacterium (Figure 
1.3), distinguished from other staphylococcal species by its gold pigmentation.19 A 
commensal, found primarily in the anterior nares, S. aureus colonizes approximately 
20% of the human population.20 The cell wall of S. aureus is 50% peptidoglycan (by 
weight) and also contains teichoic (TAs) and lipoteichoic acids (LTAs).21 S. aureus 
has a variety of surface and secreted components that enable it to compromise 
immune responses and evade host defences. 
 
Figure 1.3: Scanning electron micrograph (SEM) of S. aureus (magnification 
20,000x), a spherical Gram-positive bacterium.22 
Infections of S. aureus occurs when a breach in the host’s physical defences, the skin 
or mucosal barriers, allows access to adjoining tissues or the bloodstream.19 The risk 
of infection is increased in patients after surgery, and by the presence of foreign 
materials, such as long-term indwelling catheters which have led to cases of 
nosocomial endocarditis.19-20 Initial attachment of S. aureus to surfaces is mediated 
by several cell-associated proteins, the microbial surface components recognising 
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adhesive matrix molecules (MSCRAMMs).20b,21 The fibrinogen-binding proteins 
(Fnbp), FnbpA and FnbpB, the collagen-binding protein (Cna) and the fibrinogen-
binding proteins clumping factor (Clf), ClfA and ClfB, are the most well-known 
MSCRAMMs.20b,21 Once attached, S. aureus has an army of toxins it can unleash on 
its host facilitating the progression of infection.  
The majority of S. aureus strains can secrete four haemolysins, -, -, - and -
haemolysin.23 These cytolytic toxins work by damaging the membranes of host 
cells.20a,23 Of the four toxins, -haemolysin has been studied the most and is known 
for its ability to lyse erythrocytes.23 It works by integrating into the target cell 
membrane where it forms cylindrical heptamers, resulting in a pore (1-2 nm) in the 
membrane. This pore allows for the rapid efflux and influx of ions and other small 
molecules leading to osmotic swelling of the cell causing the cell to rupture.23 -
Haemolysin and the Panton-Valentine (PV) leukocidin are bi-component 
leukotoxins. These toxins are made of two, non-associated secreted proteins, S and 
F, which can combine in six different forms, each of which can lyse leukocytes.23  
S. aureus can also produce eight staphylococcal enterotoxins (SEA, SEB, SEC, SED, 
SEE, SEG, SEH, SEI) and toxic shock syndrome toxin-1 (TSST-1).20a,23 The SE’s 
are known to be the causative agent of staphylococcal food poisoning (SFP), a 
condition that usually resolves itself after 24-48 hours.23 However, TSST-1 causes 
toxic shock syndrome (TSS), an acute and potentially fatal condition.20b 
Not only can S. aureus compromise its host but it also has a number of virulence 
factors that facilitate its evasion of the host’s immune response. S. aureus has an 
outer layer, known as a capsule, made up of polysaccharides. The capsule prevents 
binding of opsonins which in turn reduces the uptake of S. aureus cells by 
phagocytes.19-20 Protein A, a cell surface protein, can bind the opsonin IgG. 
However, it binds IgG in such a way that it is presented to the neutrophil in the 
incorrect orientation thus preventing the binding of the neutrophil and its ability to 
engulf the cell.20a If S. aureus is engulfed by a phagocyte it has the ability to survive 
within the phagosome.20a For example, modifications of TAs can reduce the affinity 
of cationic antimicrobial defensin peptides that are secreted into the phagosome.20  
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The expression of a variety of the S. aureus virulence factors are controlled by its 
quorum-sensing (QS) system.24 Quorum-sensing is a process by which bacterial cells 
communicate through the production and detection of signalling molecules known as 
autoinducers (AIs).25 Gram-positive bacteria have two QS systems, the accessory 
gene regulator (agr) QS system and the luxS QS system.24 The agr system has been 
shown to be essential in the virulence of S. aureus infection.24 It is believed that the 
agr system also influences the formation of biofilms by S. aureus.24  
Biofilms are sessile microbial communities of cells, enclosed in a self-produced 
exopolymer matrix (Figure 1.4).26 Bacterial biofilms can prevent or delay the entry 
of antimicrobial agents, deactivate antimicrobial agents and produce persister 
cells.26-27 Persister cells are cells that do not grow or die in the presence of 
antimicrobial agents thus enabling the survival of bacteria populations.27  
 
Figure 1.4: Biofilm stages of development; 1. Reversible adherence, 2. Irreversible 
adherence, 3. Maturation, 4. Microcolony development, 5. Dispersion of cells from 
the biofilm.28  
S. aureus has also been successful at developing resistance to antibiotics. Penicillin 
was first introduced in the 1940s, however, two years later the first penicillin-
resistant S. aureus strain was reported.2 Methicillin was introduced in 1960 and in 
the following year Methicillin-Resistant S. aureus (MRSA) strains were isolated.3 
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Methicillin-resistance of S. aureus stems from a genetic element known as the 
staphylococcal cassestte chromosome mec (SCCmec).29 In Methicillin-susceptible S. 
aureus (MSSA) strains, the cell walls contain penicillin-binding-proteins (PBPs). -
Lactam antibiotics bind to the PBPs resulting in the disruption of the synthesis of the 
peptidoglycan layer and preventing cell survival.2 SCCmec carries the mec gene 
complex which encodes PBP2a.29 PBP2a has a low affinity for -lactam 
antibiotics.30 The presence of PBP2a prevents -lactam antibiotics from binding to 
the cell wall and disrupting the synthesis of peptidoglycan thus allowing MRSA to 
survive.2  
Although we have seen a decrease in the rate of MRSA infection across Europe, S. 
aureus is still the second most frequently isolated microorganism in HAIs.5,31 
Furthermore, in 1996, a MRSA strain resistant to vancomycin was isolated in 
Japan.32 Vancomycin, often referred to as a drug of ‘last resort’, has been the drug of 
choice to treat MRSA infections.7 In addition to Japan, a number of vancomycin-
resistant S. aureus (VRSA) strains have since been reported around the world.7,32 S. 
aureus is an ever evolving pathogen with an ability to evade both host and external 
defences. A bacterium that is always one step ahead.  
1.1.5 Pseudomonas aeruginosa 
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative bacillus, commonly 
found throughout the environment in water, vegetation and soil (Figure 1.5).33 When 
given the opportunity, P. aeruginosa can cause serious infections in humans. P. 
aeruginosa infections usually occur in patients that have an underlying disease or 
injury with three of the most common sites of P. aeruginosa infection being in burn 
wounds, the cornea and the lung.33b,34 Infections can range from acute infections 
such as endocarditis and septicemia to chronic lung infections in people with cystic 
fibrosis (CF).35 Approximately 80% of CF patients may be colonised with P. 
aeruginosa.33a 
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Figure 1.5: SEM and colourised version of SEM of P. aeruginosa, a rod-shaped 
Gram-negative bacterium.22 
Being a Gram-negative bacterium, P. aeruginosa has the advantage of an additional 
outer membrane assisting in its resistance to antibiotics. With the reduced fluidity of 
the Gram-negative outer membrane, however, the bacterium needs an alternative 
method by which it takes up nutrients and disposes of waste products. This is carried 
out by pores or channels known as porins.17 P. aeruginosa lacks the ‘classical’ high 
permeability porins that are found in most Gram-negative bacteria.15 The porin 
protein, OprF, the homolog of the E. coli porin protein, OmpA, only produces 
channels when it is folded into a rare conformation.18 Furthermore, in comparison to 
OmpA of E. coli, the diffusion of molecules through the P. aeruginosa OprF channel 
is two orders of magnitude slower.36 The presence of an outer membrane and 
inefficient porins makes P. aeruginosa intrinsically very resistant to antibiotics.  
In addition to the permeability barriers, P. aeruginosa also has an arsenal of 
membrane-bound and secreted virulence factors. P. aeruginosa possess straight, 
filamentous appendages on the cell surface known as pili, specifically type IV pili.37 
They are retractable structures responsible for adhesion to the host cell surface but 
also give the bacterium a unique form of movement known as twitching motility.37-38 
Type IV pili consist of a hollow, cylindrical structure made up of pilin proteins with 
the region responsible for adhesion presented at the top of the pilus.37 Studies have 
shown that P. aeruginosa pili are responsible for approximately 90% of the 
adherence to human lung cells and that they can discriminate between healthy and 
damaged canine tracheal cells.37  
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Another important adhesin associated with P. aeruginosa is alginate. Alginate is a 
linear co-polymer exopolysaccharide that forms a capsule-like structure around the 
P. aeruginosa bacterium.18 As mentioned earlier, P. aeruginosa are a particular 
problem for CF patients. One of the reasons for this being that it undergoes a 
phenotypic change from non-mucoid to mucoid (alginate-producing) P. aeruginosa 
in the lungs of chronically infected CF patients.39 The mucoid, capsule-like structure 
can act as a barrier against phagocytes and opsonisation, it may also be capable of 
acting as an immunomodulator and may be involved in the formation of biofilms, all 
of which contribute to the pathogenesis of P. aeruginosa.39  
Once adherence has been established there are a number of secreted proteins that 
play a part in the progression of P. aeruginosa infection. The most toxic substance 
secreted by P. aeruginosa is exotoxin A.35 Exotoxin A binds to a receptor known as 
CD91 on the host cell surface. Once bound, it is internalized into the cell where it is 
broken down into N-terminal and C-terminal fragments.35 The C-terminal fragment 
makes its way to the endoplasmic reticulum and on to the cytosol where it catalyzes 
the ADP ribosylation of the eukaryotic elongation factor-2 (eEF-2).35 The ADP 
ribosylation of eEF-2 results in the inhibition of protein synthesis and ultimately cell 
death.35,40 Other virulence factors secreted by P. aeruginosa include; elastases LasA 
and LasB, type III secretion system (T3SS) effector proteins ExoS, ExoT, and ExoU, 
and phenazines such as pyocyanin.33b,40 Pyocyanin gives the green-blue colour to pus 
associated with P. aeruginosa infections.33b,41 P. aeruginosa are also well-known for 
their ability to form biofilms. Chronic P. aeruginosa infections of the lungs of CF 
patients are associated with biofilm formation.40,42  
As with S. aureus, a number of the P. aeruginosa virulence factors are controlled by 
its QS system including; alginate, exotoxin A, elastase, pyocyanin and biofilm 
formation.43   P. aeruginosa has two QS systems, the lasI system that encodes for the 
AI known as PAI-1 and the rhlR/rhlI system the AI of which is PAI-2.43  
The European Centre for Disease Prevention and Control Point Prevalence 
Surveillence (ECDC-PPS) report 2011-2012 listed P. aeruginosa as the fourth most 
frequently isolated organism in HAIs.5 P. aeruginosa infections are difficult to 
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eradicate due to its intrinsic resistance, however, as observed with S. aureus, P. 
aeruginosa strains resistant to antibiotics have also been isolated. Resistance due to 
the loss of porins has been observed in P. aeruginosa isolates, for example, the loss 
of OprD resulted in resistance to imipenem.15  
P. aeruginosa is particularly known for its multidrug resistance. Multidrug resistance 
is a mechanism of resistance that involves drug efflux by membrane transporters.44 It 
has been demonstrated that the expression of efflux systems in P. aeruginosa is 
greatest when the bacteria is under stress, for example, growth in a nutrient poor 
medium.45 In the case of P. aeruginosa, active efflux pumps contribute significantly 
to its multidrug resistance.46 These pumps are composed of three subunits, the pump 
protein, an outer membrane channel and an accessory protein (Figure 1.6).18 The 
mexA-OprM efflux system is the most well known in P. aeruginosa and is 
responsible for the efflux of fluoroquinolones, -lactams, tetracyclines and 
erythromycin.36,47 The U.S. Department of Health and Human services Centers for 
Disease Control and Prevention (CDC) have classified P. aeruginosa infections as a 
serious threat with 13% of severe HAIs being caused by multidrug resistant (Mdr) P. 
aeruginosa.7 
 
Figure 1.6: Schematic of a Gram-negative bacterial efflux pump. Drugs can 
transverse the outer membrane through the LPS/lipid bilayer or through porin 
channels. From the cytoplasm they are brought into the periplasm where they are 
expelled from the cell by the efflux pump.48  
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1.1.6 Escherichia coli 
A Gram-negative, rod shaped bacterium, Escherichia coli (E. coli), is found in the 
gastrointestinal (GI) tract of healthy humans and other animals (Figure 1.7).49 
However, some E. coli strains are pathogenic. The two most common infections 
associated with E. coli are urinary tract infections (UTIs) and diarrhoeal infections.50 
UTIs are caused by E. coli that spread from the gut to the sterile urinary tract.50 The 
clinical syndromes of UTIs are dependent on the location of infection, that is, cystitis 
is a lower UTI and pyelonephritis is an upper UTI.50 Pyelonephritis can be associated 
with septicaemia.50 There are a number of E. coli pathotypes associated with 
diarrhoeal infections, two well-known pathotypes being enteropathogenic E. coli 
(EPEC) and enterohaemorhagic E. coli (EHEC).49,51 The main difference between 
these two pathotypes is that, EHEC produces Shiga toxins (Stx) whereas EPEC do 
not produce a detectable toxin.50 EHEC is also commonly referred to as VTEC 
(verotoxin E. coli) or STEC (Shiga toxin E. coli).51a   
    
Figure 1.7: SEM of a single Gram-negative E. coli bacterium (left) and a fluorescent 
antibody-stained photomicrograph (right) of E. coli found in a faecal smear.22 
EPEC is associated with diarrhoea in young children in developing countries with 
transmission linked to close human contact, for example, in nurseries.50,51b  EHEC is 
transmitted through food, water and animal contact (in particular ruminants) and as 
the name suggests causes bloody diarrhoea.49,51b Approximately 10% of EHEC cases 
go on to develop Haemolytic Uraemic Syndrome (HUS), a clinical syndrome that 
leads to renal failure.49 Children under the age of five and the elderly are most at 
risk.49,52 Over 90% of HUS cases are believed to be caused by EHEC.49  
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The pathogenesis of E. coli can be attributed to a number of virulence factors. As 
with other Gram-negative bacteria, E. coli has an outer membrane containing LPS 
and porins.18 A combination of LPS and small size porin channels gives E. coli 
greater protection against antibiotics in comparison to Gram-positive bacteria.17-18 E. 
coli can also form capsules made up of linear polymers of repeating carbohydrate 
subunits known as K antigens.50 Encapsulated E. coli are usually more virulent than 
unencapsulated E. coli. with the quantity of K antigen being proportional to the 
degree of virulence.53 The capsule is believed to protect the bacteria from 
phagocytosis.53 
E. coli also produces a number of toxins including haemolysins and cytotoxic 
necrotising factor 1 (CNF1).50 E. coli have three haemolysins, -, -, and -
haemolysin, all of which can lyse red blood cells.51b CNF1 has been shown to cause 
the necrosis of rabbit skin and also has the ability to induce the reorganisation of the 
host actin cytoskeleton.50,54 Pathogenic EHEC also produces two types of Shiga 
toxins, SLT-I and SLT-II.50,52 Ninety-seven per cent of EHEC strains produce SLT-
II with or without SLT-I.50 These Shiga toxins are internalised by host cells in which 
they inhibit protein synthesis resulting in cell death.52 The production of Shiga toxins 
is required for the development of renal complications with SLT-II shown to be 
responsible for HUS in mice.50 
A particularly important step in initiating infection is the initial adherence to the host 
cell surface. A characteristic feature of EHEC and EPEC infection is the formation 
of ‘attaching and effacing’ (A/E) lesions (Figure 1.8).55 The formation of A/E lesions 
can be divided into three stages, initial adherence, signal transduction through 
secreted proteins, and intimate attachment.56 
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Figure 1.8: A/E lesion formed by EPEC.57 
For initial adherence E. coli use filamentous cell surface appendages known as 
fimbriae. Specifically, EPEC uses type IV pili known as bundle forming pili (BFP).56 
Little is known of the EHEC adhesins.51b Once fimbriae adhere to the host cell 
surface, EPEC and EHEC have a T3SS that can translocate effector proteins into the 
host cell.55 The Tir protein is an effector protein that is translocated to the host cell 
where it can act as a receptor for intimin, a bacterial outer membrane protein.55-56 
Intimin binds to Tir to give an irreversible intimate cell attachment that results in 
downstream signalling events leading to the reorganisation of actin filaments of the 
host cell cytoskeleton.55 This reorganisation results in the formation of actin 
pedestals directly beneath the bacterial attachment sites (Figure 1.9).55 The exact role 
of pedestals in the pathogenesis of EHEC and EPEC is not fully understood but it 
has been suggested that actin assemblies may be involved in the expansion and 
proliferation of E. coli infection.58 Pedestals may also help resist bacterial 
detachment during diarrhoea.58   
 
Figure 1.9: EPEC adhesion pedestal formed on a eukaryotic cell.59 
Chapter I: Introduction 
17 
 
Unlike most Gram-negative bacteria, E. coli does not produce the AHL 
autoinducers.28 However, it does produce AI-2, an autoinducer which is believed to 
be involved in interspecies communication, as it is produced by both Gram-negative 
and Gram-positive bacteria.25,60 AI-2 is regulated by the luxS QS system.60 
Regulation of the T3SS of EHEC and EPEC by the QS system has been observed.61 
It has been suggested that the low infection dose of EHEC (as low as two or three E. 
coli) may be due to the ability of non-pathogenic E. coli to produce AI-2 in turn 
activating the T3SS of EHEC.49,61 Furthermore, studies have shown that the flagella 
(a cell surface appendage involved in cell locomotion14) and motility of E. coli are 
regulated by its QS system, as well as E. coli biofilm formation.28,60,62 The ability to 
form biofilms, as with other bacteria, may help in the resistance of E. coli to 
antibiotics.28,63 
According to the ECDC-PPS report 2011-2012 E. coli is the most frequently isolated 
organism in HAIs.5 As seen with P. aeruginosa, the multidrug resistance of E. coli 
has been associated with the over expression of efflux pumps.45 The AcrAB-TolC 
efflux system is the predominant efflux pump in E. coli and has the ability to efflux 
fluoroquinolones, -lactams, novobiocin, and rifampicin as well as some dyes and 
organic solvents.45,48  
E. coli can also produce -lactamases and in the last few years extended--lactamase 
(ESBL)-producing E. coli have emerged as an important cause of UTIs.64 ESBL-
producing E. coli that exhibit cross-resistance to gentamicin and ciprofloxacin have 
also been reported.64  The 2013 first quarter EARS-Net report has shown that from 
2004 to 2012 the number of extended spectrum -lactamase-producing (ESBL) E. 
coli infections has been continuously increasing (1.1% in 2004 to 9.5% to the end of 
quarter one in 2013).6b Furthermore, carbapenemems are considered the drug of last 
resort for the treatment of these multiresistant E. coli, however, carbapenem-resistant 
E. coli are also on the rise.65 The CDC have classified carbapenem-resistant 
Enterobacteriaceae (CRE) infections as an immediate public health threat.7 Of the 
estimated 9000 CRE infections in the U.S. per year, 1,400 of these are carbapenem-
resistant E. coli infections.7 
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1.1.7 The immune system 
In mammals, there are two systems involved in the protection from and response to 
infection by an invading pathogen. These systems are known as the innate and 
specific adaptive immune response.66 The innate immune response is the first line of 
defence and also plays a role in the initiation of the adaptive immune response, a 
system responsible for long-lasting protective immunity.66  
Insects and mammals have been shown to share many similarities in their innate 
immune systems.67 For example, the cuticle of insects provides a physical barrier 
preventing the entry of pathogens, a feature similar to the skin of mammals.66-67 
When a pathogen enters the human body, cells known as macrophages and 
neutrophils can bind to the microbe and engulf them by a process known as 
phagocytosis.66 The resulting, microbe-containing phagosome can fuse with 
lysosomes which release substances such as lysozyme that digest the microbe.66 In 
insects, within the haemolymph (analogous to the blood of mammals), haemocytes 
or blood cells are responsible for the phagocytosis of foreign bodies.67a Lysozyme 
has also been found in insect haemocytes along with a number of antimicrobial 
peptides similar to those found in mammals, such as defensins and transferrin.67a,b  
These similarities, along with many others, between the innate immune system of 
insects and mammals have led to the use of insects as in vivo models for 
investigating the virulence of many human pathogens including Gram-negative 
bacteria, Gram-positive bacteria and fungi.68  
1.1.8 Galleria mellonella and insects as in vivo models 
The greater wax moth, Galleria mellonella (G. mellonella), is of the order 
Lepidoptera and the family Pyralidade.67a G. mellonella live in beehives in which the 
larvae feed on the honeycomb and undergo metamorphosis to become a grey moth 
(Figure 1.10).67a,69 As shown in Figure 1.11 the G. mellonella larvae are a dull white 
colour and approximately 3 cm in length.  
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Figure 1.10: Adult wax moth Galleria mellonella (printed with permission).69 
 
Figure 1.11: G. mellonella larvae. 
G. mellonella larvae have been used as an in vivo model in a number of studies to 
investigate the virulence of human pathogens. For example, Peleg et al.68e have 
demonstrated that G. mellonella can be used to investigate both the virulence and the 
relationship between the pathogensis of S. aureus and drug resistance. Studies by 
Cotter et al.68c have shown that the wax moth larvae could be used to differentiate 
between non-pathogenic and pathogenic strains of C. albicans. Furthermore, 
Brennan et al.68d have demonstrated that there is a high degree of similiarity between 
the G. mellonella and the mouse innate immune response to infection by C. albicans. 
Similar studies investigating the virulence of the Gram-negative bacterium P. 
aeruginosa have shown that there is a positive correlation between the virulence of 
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P. aeruginosa in both G. mellonella and in mice and that insects are a suitable model 
for identifying and characterising virulence genes.68b  
An important phase in drug discovery is the assessment of the toxicity of new drug 
candidates. Before a new drug candidate can reach the clinic it needs to be tested to 
ensure it is safe and effective.11 Toxicity testing is usually carried out using animal 
models such as mice, rabbits, dogs and monkeys.11 However, the use of mammalian 
models is expensive, labour intensive, time consuming and requires full ethical 
consideration. Insects such as G. mellonella are lower in cost, do not require a large 
amount of space for storage and experimental work and can give results within 24 to 
48 hours. These advantages combined with the similarity to the mammalian innate 
immune system render insects a useful preliminary model for the in vivo testing of 
new drug candidates.  
Drosphilia melanogaster (fruit fly) has been used to evaluate the therapeutic effect 
of known antifungals, alone and in combination, against Aspergillus fumigatus.68g 
The silkworm, Bombyx mori, have also been used to evaluate the effect of current 
clinical antibiotics against bacterial and fungal infections.68a The results obtained 
were consistent with those reported in mice models.68a Furthermore, silkworms have 
also been employed in investigations of the toxicity and metabolism of known 
compounds.68f These studies gave results consistent with those observed in mammals 
demonstrating that insects are a good model for studying the in vivo therapeutic 
effect of antibiotics.68f  
G. mellonella have also been used to evaluate both the therapeutic effect of current 
and novel antimicrobial agents and the in vivo tolerance of novel antimicrobial 
agents.70 Desbois et al.70a have shown that the treatment of G. mellonella infected 
with S. aureus using vancomycin, daptomycin or penicillin improved survival of 
larvae in a dose dependant manner. However, treatment of MRSA infected G. 
mellonella with penicillin did not improve the survival of the wax moth larvae. The 
doses administered to the infected G. mellonella that were most effective, were 
similar to those recommended for use in humans.70a  An investigation into the 
toxicity of copper(II) and silver(I) complexes by McCann et al.71 have demonstrated 
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that the level of toxicity exhibited by the test compounds in G. mellonella was 
similar to that observed in Swiss mice.  
Although the use of mammals as in vivo models for testing new drug candidates is 
necessary, G. mellonella can be used as a good preliminary in vivo toxicity model. 
On average, only 500 compounds out of 10,000 compounds synthesised will reach 
animal testing with only 10 reaching phase one clinical trials.11 The use of insects 
allows for the early optimisation of compounds that exhibit therapeutic potential 
which in turn reduces the number of mammals used. Insect experiments may also be 
able to supply information relating to suitable dosages and drug metabolism.68f,70a  
1.1.9 In vivo toxicity using G. mellonella 
G. mellonella are very easy to work with. In general, experiments are carried out in 
triplicate using ten healthy G. mellonella per experiment, within three weeks of 
receiving the larvae. As shown in Figure 1.12, test compounds can be administered 
into the haemocoel (body cavity) via injection into the last left pro-leg. By applying 
gentle pressure to the sides of the leg, the base of the pro-leg opens and will re-seal 
once the syringe needle has been removed, without leaving a scar (Figure 1.12). This 
needs to be carried out with care as rough handling of the larvae can affect survival 
and lead to expression of stress proteins.72 To ensure proper handling of the larvae an 
injected control can be used whereby the larvae are injected with the appropriate 
syringe needle but no substance is administered.  
 
Figure 1.12: Compound administration to G. mellonella larvae, (a) apply pressure to 
the sides of the larva to open the base of the pro-leg and (b) inject into the haemoceol 
through the last left pro-leg (reproduced from Fungal Biol. Rev. 24 (2010) with 
permission). 
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A detailed account of the toxicity assay procedure is given in section 1.2.8. The 
toxicity of a given compound is determined by calculating the percentage of G. 
mellonella larvae that survive over a period of 72 hours. The larvae are monitored 
every 24 hours and death is assessed based on a lack of movement in response to 
stimulation together with discolouration of the cuticle (Figure 1.13). Melanisation 
(discolouration of the cuticle) and development of the larvae (Figure 1.14) can also 
be monitored to determine if the larvae are responding to the test compound and if it 
is effecting larval development. 
 
Figure 1.13: A dead G. mellonella larva. 
 
Figure 1.14: G. mellonella pupal stage of development. 
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1.2 Biological studies 
1.2.1 Materials and methods 
Nutrient Broth was obtained from Scharlau Microbiology. 
Nutrient Agar was obtained from Oxoid Ltd.  
 
OD600nm values were determined using a spectrophotometer (Biophotometer, 
Eppendorf).  
Optical density was read using a microplate reader (Bio-Tek. Synergy HT 
Spectrophotometer).  
A TOMY SX-500 E autoclave (121oC and 18 lb/sp.in) was used for the sterilization 
of all growth media and materials required for aseptic techniques. 
1.2.2 Bacterial strains 
The bacterial strains used in this study are shown in Table 1.1. 
Table 1.1: Bacterial strains used in this study 
Bacterial strain Origin Reference 
Staphylococcus aureus 
Urinary tract infection, 
St. James’ Hospital, 
Dublin 
Clinical Isolate 
Escherichia coli 
Gastro-intestinal tract 
infection, St. James’ 
Hospital, 
Dublin 
Clinical isolate 
Pseudomonas aeruginosa 
10145 
American Type Culture 
Collection (ATCC) 
Marassas, VA, USA 
ATCC 
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1.2.3 Media for culturing bacteria 
Nutrient Broth 
Nutrient Broth was prepared according to the manufacturer’s instructions by 
dissolving 13 g/L in distilled water and autoclaved prior to use. 
Nutrient Agar 
Nutrient agar was prepared according to the manufacturer’s instructions by 
dissolving 28 g/L in distilled water and autoclaved. The warm agar was poured into 
sterile 9 cm petri dishes and allowed to set. The nutrient agar petri dishes were stored 
at 4 oC. 
1.2.4 Bacterial culture conditions 
For long term storage, all parent bacterial stocks were stored at -70 oC in a sterile 
mixture of 50% (v/v) glycerol and 50% nutrient broth media (v/v). For short term 
storage, bacterial strains were grown on nutrient agar plates at 37 oC for 24 hours and 
stored at 4 oC. Working stocks of the bacteria were routinely sub-cultured onto fresh 
agar plates every 4-6 weeks.  
1.2.5 Susceptibiltiy assay 
The bacterial strains used in this study are shown in Table 1.1, section 1.2.2. 
All workspaces were washed down with 70% (v/v) ethanol prior to use. Bacterial 
strains were taken from nutrient agar plates and cultures were grown in nutrient 
broth overnight in an orbital shaker at 37 °C and 200 rpm in a fully aerated conical 
flask. The cells were diluted to give an OD600 = 0.1. 
Fresh solutions (200 g/mL) of the complexes were prepared with distilled water 
and less than 1% DMSO immediately prior to testing. Complexes with low solubility 
were tested as fine suspensions.  
Nutrient broth (100 μl) was added to each well of a 96-well flat-bottomed microtitre 
plate. An additional 100 l was added to columns 1 and 2 of the plate. Serial 
dilutions (1:1) of the test complex were made from columns 12-4 giving a test 
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concentration range of 100–0.39 μg/mL. For example, 100 L of the compound 
solution was added to column 12, and mixed thoroughly using the pipette, followed 
by the transfer of 100 L of the final solution in column 12 to column 11. This 
process is repeated down to column 4 from which the final 100 L is disposed of 
(see Figure 1.15).The appropriate bacteria cell suspension to be tested against (100 
L) was added to columns 12-3. Column 3 served as the negative control. 
 
 
Figure 1.15: Bacteria susceptibility assay 
The plate was incubated for 24 hours at 37 oC. The optical density was read at max 
540 nm and growth was then quantified as a percentage of control. All assays were 
run in triplicate. The results were analysed using Excel©.  
The MIC50 (Minimum Inhibitory Concentration), MIC80 and MIC90 were taken to 
signify the concentration of compound that would inhibit the growth of the 
microorganism in question by 50%, 80% and 90%, respectively. 
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1.2.6 In vivo toxicity  
In vivo toxicity was investigated using larvae of the Greater Wax Moth, Galleria 
mellonella (Figure 1.16). 
 
Figure 1.16: G. mellonella larvae. 
1.2.7 Galleria mellonella (G. mellonella) 
G. mellonella in the sixth developmental stage were obtained from The Mealworm 
Company (Sheffield, England) and stored in wood shavings in the dark at 15 oC.   
1.2.8 G. mellonella toxicity assay 
The experiments were carried out using ten healthy G. mellonella (between 0.20-
0.30 g in weight) placed in sterile, 9 cm petri dishes containing a sheet of Whatman 
filter paper and wood shavings.  
Test compound solutions were made fresh on the day of testing prior to 
administration. Each compound was dissolved in DMSO and added to sterile, 
distilled water to give stock solutions consisting of less than 1% (v/v) DMSO. The 
compounds were tested across the concentration range of 1-100 g/mL. Using a 300 
L Thermo Myjector syringe (29G), sterile test solutions (20 L) were administered 
to the larvae by injection. Injections were made into the last, left pro-leg, of the G. 
mellonella larvae, directly into the haemocoel.  
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After injection, the larvae were incubated at 30 oC for a total of seven days.  Larvae 
were monitored for survival and melanisation, at 24 hour intervals. Death was 
assessed based on the lack of movement in response to stimulation together with 
discolouration of the cuticle. Three controls were employed for the assay: 
(1) untreated larvae maintained under the same conditions as the treated larvae, 
(2) larvae pierced with an inoculation needle into the last, left pro-leg, but no 
solution injected, and 
(3) larvae treated with 20 L of sterile water/DMSO solution, in concentrations 
analogous to those of the test compounds. 
The results are presented as the mean percentage survival of G. mellonella larvae, as 
a function of the test compounds administered dosage. All experiments were run in 
triplicate. Analysis of the results was carried out using Graph Pad Prism©. 
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1.3 Instrumentation 
Nuclear magnetic resonance spectra (1H, 13C and 19F NMR) were recorded on a 
Bruker Avance 300 MHz NMR spectrometer with resolution of 0.18 Hz at a probe 
temperature of 25 oC, except where stated otherwise. Spectra were recorded in 
DMSO-d6, CDCl3 or CD3OD with Me4Si used as the internal standard. 
Infrared (IR) spectra were recorded as KBr disks or liquid films between NaCl plates 
using a Perkin Elmer System 2000 FT-IR spectrometer in the region of 4000-370 
cm-1.  
Melting points were determined using a Stewart Scientific SMP 1 melting point 
machine.  
Microanalysis was carried out using a Flash EA 1112 Series Elemental Analyser. 
The sample is burned in oxygen and a helium carrier gas at 900 oC in a combustion 
tube. 
Mass spectrometry (MS) data were obtained with a LC/TOF-MS (Agilent Corp, 
model 6210 Time-Of-Flight LC/MS). The LC was a model 1200 Series (Agilent 
Corp) and the column was an Agilent Eclipse XBD-C18. Where required, samples 
were also obtained via direct injection. 
Optical rotations were measured with a Bellinghem and Stanley ADP410 polarimeter 
in a 0.5 dm-1 polarimeter tube. 
Reagents were purchased from Sigma-Aldrich, Alfa Aesar, Acros Organics, 
Fluorochem and TCI Europe and used without further purification. 
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2.1 Introduction 
Asymmetric synthesis, by means of organocatalysis, is another active area of 
research within the Stephens group.73 Taking advantage of the organocatalysts 
available within the group, a number of these were screened for their antibacterial 
activity in the search for a lead compound. Antibacterial screening was carried out in 
the Institute of Technology Tallaght (ITT) against S. aureus and E. coli, the results 
of which have been previously reported by Gavin.74 The majority of the 
organocatalysts exhibited bacteriostatic activity against the Gram-positive S. aureus 
with only two of the compounds exhibiting activity against the Gram-negative E. 
coli. The two compounds found to be the most active of the series of screened 
organocatalysts are shown in Figure 2.1 with their minimum inhibitory 
concentrations (MIC) given in Table 2.1.  
 
Figure 2.1: Bifunctional thiourea catalysts that exhibited greatest activity in 
antimicrobial screening.74 
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Table 2.1: MIC90a values for organocatalysts (a) and (b).74 
Organocatalyst 
S. aureusb E. colic   
MIC90 (μM) MIC90 (μM) 
Takemotos catalyst (a) 23.8 +/- 0.1 119.9 +/- 13.8 
Quinine derived catalyst (b) < 6.25 166.7 +/- 13.7 
a The minimum inhibitory concentration required to inhibit 90% of bacterial growth, 
b S. aureus NCIMB 12702, c E. coli NCIMB 9485. 
The organocatalysts shown in Figure 2.1 are bifunctional, hydrogen-bonding (H-
bonding) catalysts. Organocatalyst (a), known as Takemotos catalyst, was the first 
chiral thiourea H-bonding catalyst designed for a Michael reaction (Scheme 2.1).75  
 
Scheme 2.1: Michael reaction of diethyl malonate to trans--nitrostyrene using 
Takemotos catalyst.75b 
Investigations into the catalytic reaction mechanism have been carried out and it is 
believed to occur by deprotonation of a malonate acidic proton by the tertiary amine 
of the organocatalyst.76 H-bonding of the nitrostyrene via the catalyst thiourea 
moiety results in the formation of a ternary complex as depicted in Figure 2.2. The 
presence of the chiral scaffold restricts the approach of attack by the malonate 
nucleophile to the electrophilic nitrostyrene giving rise to the high enantioselectivity 
of the reaction.76 The thiourea-stabilised nitronate can then remove the proton from 
the protonated amino group of the catalyst resulting in formation of the product and 
regeneration of the catalyst.76  
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Figure 2.2: Bifunctional activation by thiourea catalyst.76 
The quinine derived organocatalyst (b) (Figure 2.1) was later designed by Connon77 
and Soós78 (independently) and has been used for a number of reactions such as the 
Mannich reaction.79 Investigations into the Michael addition of -diketones to -
nitrostyrene using organocatalyst (b) have also been carried out.73a It is believed that 
organocatalyst (b) works by a similar mechanism as that described above (Figure 
2.2).80 
As seen in Table 2.1, Takemotos catalyst exhibited slightly better activity against E. 
coli in comparision to organocatalyst (b). However, the anti-staphylococcal activity 
demonstrated by organocatalyst (b) was superior to that of Takemotos catalyst. For 
this reason, it was decided that the quinine derived organocatalyst (b) would act as 
our hit compound, and so, would be studied further in an attempt to understand its 
structure-activity relationship and to improve its activity and drug-like properties.  
With organocatalyst (b) as our hit compound we decided to carry out a structure-
activity relationship (SAR) study. Synthesising a series of compounds based on our 
hit compound would allow us to identify which functional groups are essential for 
activity. We could then build on this information by designing and optimising 
subsequent compounds with the intent of generating a final compound possessing 
optimum antibacterial activity. On comparing the structures of the two catalysts, (a) 
and (b), it can be seen that these compounds share a structural component, the 3,5-
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bis(trifluoromethyl))phenyl thiourea connected to a tertiary amine by a two-carbon 
chain (Figure 2.3).  
 
Figure 2.3: Organocatalyst (a) and (b) share a similar structural component. 
Thiourea-based compounds are well-known for their antithyroid activity and have 
been in use for over 70 years in the treatment of hyperthyroidism.81 Moreover, a vast 
array of biological activities including antitubercular, insectididal, rodenticidal, 
antiviral, antifungal and antibacterial activities have been associated with thiourea 
derivatives.82 A recent study on thiourea-based compounds incorporating a hippuric 
acid moiety, as shown in Figure 2.4, was carried out by Abbas et al.83 The majority 
of these compounds exhibited broad spectrum antimicrobial activity with a number 
of them demonstrating activity comparable to, and in some cases better than, 
ciprofloxacin.83  
N
H
HN
O
CO2H
N
H
S
X
X = alkyl, aromatic ring  
Figure 2.4: General structure of hippuric acid-based thiourea derivatives. 
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Based on the antibacterial activity exhibited by both Takemotos catalyst and 
organocatalyst (b) and the well-known biological activities associated with thioureas, 
it was thought that the 3,5-bis(trifluoromethyl))phenyl thiourea moiety could be the 
source of the compounds activity. Therefore, we constructed our SAR study based 
around this thiourea group. 
2.1.1 Aim 
The aim of this work was to uncover the structural components responsible for the 
antibacterial activity of the hit compound, organocatalyst (b), by means of a 
structure-activity relationship study. Identification of the functionalities and 
structural components important for its activity would allow us to design subsequent 
compounds that could then undergo further optimisation in the hopes of obtaining a 
novel compound with potent, broad spectrum antibacterial activity. 
The SAR study has been divided into two parts; (1) the identification of the 
functionalities important for the overall activity of the hit compound and (2) an 
investigation into the thiourea component and the substituents which are beneficial 
for antibacterial activity. 
The design, synthesis and biological evaluation of a series of organocatalyst (b) 
derivatives and 3,5-bis(trifluoromethyl))phenyl thiourea-based compounds was 
carried out and is described in the following sections. 
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2.2 Results and Discussion 
2.2.1 Compound Design, part one 
 
Figure 2.5: Hit compound components of possible importance; the quinine-derived 
amine moiety (blue), a methoxy group (purple) and two trifluoromethyl groups 
(green).  
Our initial investigations into the SAR study of our hit compound, organocatalyst 
(b), were based on three components of the hit compound structure (Figure 2.5). 
Firstly, we wanted to investigate the quinine-derived amine moiety of the hit 
compound (blue, Figure 2.5). Quinine (Figure 2.6) is most well-known for its 
antimalarial properties.84 The Peruvian Indians were the first to discover the 
medicinal properties of the natural source of quinine, the ‘fever tree’, known today 
as the cinchona tree.84 However, it wasn’t until the 1700’s that the first European 
was cured of malaria using quinine and it is still in use today.84  
 
Figure 2.6: Quinine. 
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Studies have shown that quinine is also bactericidal to a number of Gram-positive 
and Gram-negative bacteria.85 Wolf et al.86 have also demonstrated that quinine 
sulfate has the ability to inhibit the invasion efficacy of E. coli. Taking these studies 
into account it seemed reasonable to investigate if the quinine-derived amine 
component of the hit compound plays a role in its overall antibacterial activity. It 
was thought that compound 2 (Figure 2.7) would assist in answering this question.  
 
Figure 2.7: SAR study, part one, compound structures. 
To further investigate the functional groups that may be important for the overall 
antibacterial activity of the hit compound, we decided to synthesise compounds 3 
and 4 (Figure 2.7). Methoxy groups can be of importance with regard to their H-
bond accepting ability and thus may be involved in the binding of the hit compound 
to its target site.11 If this is the case here, then removal of this group (compound 3, 
Figure 2.7) should decrease the antibacterial activity of the hit compound.  
The two trifluoromethyl groups are present in both the hit compound and Takemotos 
catalyst suggesting that they may be important for activity. Furthermore, the addition 
of fluorine or –CF3 groups have been shown to increase the overall potency of 
various drugs.87 Therefore, to determine the importance of the –CF3 groups 
compound 4 (Figure 2.7) was synthesised and evaluated in our initial SAR study of 
our hit compound. 
An important factor to take into consideration when designing potential, drug-like 
molecules, is the ability of the compounds to be absorbed or their ability to 
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transverse cell membranes.11,88 As discussed by GSK, incorporating ‘drug-like’ 
properties into a compound is important for its progression into further 
development.10 A compound that may be very active may not be very effective in 
vivo if it does not bear properties such as good absorption.11 A useful set of rules 
have been devised by Lipinski88 as a guide for designing compounds with good oral 
absorption or permeation. The Lipinski ‘rule of 5’ states that good absorption is 
more likely when:11,88 
(1) there are < 5 H-bond donors (expressed as the sum of –OH or –NH), 
(2) the molecular weight (m.w.) is less than 500, 
(3) the calculated LogP (cLogP) is < 5, and 
(4) there are < 10 H-bond acceptors (expressed as the sum of O and N) 
In general, if two out of the five rules are violated poor absorption or permeability is 
possible. As shown in Table 2.2, we have applied the Lipinski ‘rule of 5’ to our 
compounds within our SAR study in order to gain insight into their potential ability 
to be absorbed. In the case described by GSK, although they had found a compound 
with good activity and were able to enhance its activity by further optimisation, they 
were unable to combine the compounds potency with necessary ‘drug-like’ 
properties.10 It was thought that establishing which structural features may contribute 
to good absorption early on in the study, may assist with the optimisation of 
subsequent compounds in the hopes of eventually obtaining a compound with good 
in vivo activity. 
                                               
 The partition coefficient, LogP, is a measure of the hydrophobic character of a drug.11 It is measured 
experimentally by examining the drugs relative distribution in an n-octanol/water mixture i.e. P = 
concentration of drug in n-octanol/concentration of drug in aqueous layer. A high P value indicates 
hydrophobic character whereas a low P value indicates hydrophilic character.  
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Table 2.2: Lipinski rules applied to SAR study compounds.  
Compound M.W.a # H-bond acceptors # H-bond donors cLogPb 
Organocatalyst (b) 594.19 3 2 7.33 +/- 0.63 
2 323.20 3 1 2.77 +/- 0.41 
3 564.18 2 2 7.24 +/- 0.62 
4 458.21 3 2 4.35 +/- 0.48 
a Molecular weight (amu), b calculated using ACD/Labs ChemSketch 12.0. 
As can be seen from Table 2.2, our hit compound violates two of the Lipinski rules, 
that is, it has a molecular weight greater than 500 and a cLogP greater than 5. 
Similarly the SAR study compound, compound 3, also violates both the molecular 
weight and cLogP limits. LogP is a measure of the lipophilicity of a molecule. This 
is a particularly important feature with regards to the physiochemical behaviour of a 
molecule.89 The higher the LogP value the more lipophilic a compound is likely to 
be. However, if a compound is ‘too lipophilic’ this may cause problems, for 
example, a compound may become promiscuous resulting in toxic side effects.89 
Gratifyingly, two of the SAR study compounds, 2 and 4, do obey the ‘rule of 5’ 
suggesting that they may exhibit good absorption. 
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2.2.2 Synthesis of part one SAR study compounds 
N
NH
NHS
N
F3C CF3
H N
NH
NHS
N
O
H
N
NH2
N
O
H
2
3 4  
Figure 2.8: SAR study, part one, compound structures. 
Quinine was obtained commercially and used without further purification in the 
synthesis of compound 2 (Figure 2.8). The one pot procedure used was that 
described by Oliva et al.90, wherein quinine undergoes a Mitsunobu reaction 
followed by azide reduction. As shown in Scheme 2.2, reaction of diisopropyl 
azodicarboxylate (DIAD) and triphenylphosphine generates an anion product which 
deprotonates the quinine –OH group. Diphenylphosphoryl azide (DPPA) can then be 
used to give the azide precursor to compound 2. 
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Scheme 2.2: Mitsunobu reaction. 
The use of additional triphenylphosphine (Scheme 2.3) allows the azide to undergo a 
Staudinger reduction to give the final amine product, compound 2.  
 
Scheme 2.3: The Staudinger reduction of the compound 2 azide precursor. 
Purification of compound 2 was carried out using silica gel column chromatography. 
The purification of compound 2 was difficult and required an EtOAc:MeOH:NH4OH 
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(50:50:1) mobile phase in order to facilitate elution of the primary amine. In the 1H 
NMR spectrum (Figure 2.9) of compound 2 a large shift, approximately 1 ppm, was 
observed for the C9 proton (-CH-NH2) indicating product formation. The Mitsunobu 
reaction involves nucleophilic attack via a SN2 reaction, thus inversion of 
configuration was expected. To ensure that this was the case the optical rotation of 
compound 2 was measured, the result of which matches the literature and confirms 
the formation of the (+) enantiomer.78 LC/TOF-MS returned a (M+H+) of 324.2080 
further confirming the formation of compound 2. 
 
Figure 2.9: 1H NMR spectra of compound 2 and quinine. 
The bacterial strains (Table 1.1, section 1.2.2) used within this study are different to 
those used in the original screening which identified the hit compound. Therefore, in 
order to be able to directly compare the biological activity of the SAR study 
compounds to the activity of organocatalyst (b), this compound was also synthesised. 
Organocatalyst (b) was synthesised as described by McCooey et al.77 by the 
nucleophilic addition of compound 2 to 3,5-bis(trifluoromethyl)phenyl 
isothiocyanate (Scheme 2.4). Purification was carried out using silica gel column 
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chromatography followed by a cold Et2O/n-hexane precipitation to give 
organocatalyst (b) in an acceptable yield of 50%. 
 
Scheme 2.4: Synthesis of hit compound, organocatalyst (b). 
The optical rotation of organocatalyst (b) was measured and found to match 
literature data.78 Organocatalyst (b) was further characterised using IR, 1H and 13C 
NMR spectroscopies. The characteristic (C=S) absorption band was observed at 
1278 cm-1 in the IR spectrum. Although the NMR spectra are quite complex, a large 
downfield shift (4.44 ppm to 5.85 ppm) in the resonance signal for the C9 proton (-
CH-NHC=S-), due to the electron-withdrawing effect of the 3,5-
bis(trifluoromethyl)phenyl thiourea moiety, was observed in the 1H NMR spectra.  
The presence of fluorine on a molecule can be particularly useful in the 
characterisation of a compounds structure. Fluorine has I = ½ and can thus be 
detected using 19F NMR spectroscopy. Moreover, the signals produced in 13C and 1H 
NMR spectra of a fluorinated molecule will be split due to the coupling interaction 
between the 13C and 1H atoms and neighbouring fluorine atom(s). The multiplicities 
of the individual signals resulting from H-F or C-F coupling will reflect the n + 1 
rule. In 13C NMR, the shifts for a –CF3 group are found in the range of 107-285 
ppm.91 For a one-bond C-F coupling the 1J value can be in the range of 162-280 Hz 
with the –CF3 group 1J usually in the range of 275-285 Hz.91 The two-bond C-F 
coupling for a –CF3 group (2J) is usually in the range of 25-35 Hz and a 3J coupling 
can also be observed, usually in the range of 2-3 Hz.91  
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In the 13C NMR spectra of organocatalyst (b) a quartet with 1J = 270.0 Hz was 
observed. This 1J value falls within the C-F 1J coupling constant range of 162-280 
Hz and corresponds to the characteristic –CF3 group 1J coupling constant range. A 2J 
value of 33.8 Hz was also observed representing the C atom ipso to the –CF3 groups. 
Additionally, the C=S signal has shifted downfield from 141.0 ppm in the 3,5-
bis(trifluoromethyl)phenyl isothiocyanate spectrum to 180.6 ppm indicating the 
formation of organocatalyst (b).   
As shown in Scheme 2.5, the synthesis of compound 3 was carried out by the same 
method as described for organocatalyst (b) above. Cinchonidine was obtained 
commercially and used without further purification in the Mitsunobu reaction. 
Subsequent reduction of the azide resulted in compound 5 (Scheme 2.5). 
 
Scheme 2.5: Synthesis of compound 3 via compound 5. 
Similarly to compound 2, a large upfield shift from 5.65 ppm to 4.61 ppm in the C9 
proton (-CH-NH2) of compound 5 was observed indicating the conversion of the –
OH group to the primary amine. The optical rotation of compound 5 was found to be 
(+) 100 (c 0.2, DCM) confirming inversion of configuration, resulting from the 
Mitsunobu reaction. LC/TOF-MS further confirmed the production of compound 5 
returning a (M+H+) of 294.1974. As shown in Scheme 2.5, compound 5 was used in 
a nucleophilic addition reaction with 3,5-bis(trifluoromethyl)phenyl isothiocyanate 
to give compound 3. Compound 3 was purified by silica gel column chromatography 
followed by cold precipitation from Et2O with n-hexane.   
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In the 13C NMR spectrum of compound 3 a quartet at 122.8 ppm with 1J = 271.4 Hz 
was observed for the carbon of the –CF3 groups. Additionally, a 2J  = 34.5 Hz for the 
carbon ipso to the –CF3 group  was observed along with a downfield shift in the C=S 
13C signal (141.0 ppm to 180.5 ppm), indicating formation of compound 3. As 
observed in the 1H NMR of organocatalyst (b), the addition of the thiourea moiety 
resulted in a large downfield shift from 4.61 ppm to 5.97 ppm in the C9 proton (-
CH-NHC=S-). The IR absorption band at 1278 cm-1 of the (C=S) further confirmed 
the formation of compound 3.  
Compound 4 (Scheme 2.6) was also synthesised by the method used by McCooey et 
al.77, however, phenyl isothiocyanate was used in place of the 3,5-
bis(trifluoromethyl)phenyl isothiocyanate. Again, the compound was purified by 
silica gel column chromatography followed by precipitation from cold EtOAc with 
n-hexane. The white solid was obtained in a reasonable yield of 52%.  
N
NH2
N
N
NH
NHS
N
O
O
PhNCS
12 h, rt
2 4
 
Scheme 2.6: Synthesis of compound 4. 
The loss of both –CF3 groups resulted in slightly simplified 13C NMR spectra with 
regards to the signal multiplicities, that is, only singlets were observed for the carbon 
signals of compound 4. As with organocatalyst (b) and compound 3 the C=S signal 
has undergone a large downfield shift to 180.5 ppm indicating successful addition of 
the thiourea moiety. Additionally, in the IR spectrum of compound 4 a strong 
absorption band at 1242 cm-1, characteristic of the (C=S) absorption, was observed. 
In the 1H NMR spectrum the C9 proton (-CH-NHC=S-) has shifted downfield to 
5.89 ppm further indicating the formation of compound 4. 
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2.2.3 In vitro antibacterial activity 
Organocatalyst (b) and each of the SAR study compounds described above (Figure 
2.8, section 2.2.2) were evaluated for their in vitro bacteriostatic activity against S. 
aureus, E. coli and P. aeruginosa. Bacteriostatic activity was evaluated using the 
susceptibility assay as described in section 1.2.5. The results are expressed as the 
MIC50 and MIC90, that is, the minimum inhibitory concentration that is required to 
inhibit 50% and 90% of bacterial growth. The results are summarised in Table 2.3 
and 2.4. Two well-known antibacterial agents were chosen as the positive controls, 
vancomycin hydrochloride and ciprofloxacin, which have also been included in each 
of the MIC tables below. Any compound that did not exhibit an MIC, of the given 
percentage of growth inhibition, against each of the bacteria has been excluded from 
the tables. 
In general, none of the compounds including the hit compound were active against 
P. aeruginosa. This lack of activity could be due to the intrinsic resistant 
mechanisms associated with P. aeruginosa. As mentioned previously in section 
1.1.5, the uptake of molecules by P. aeruginosa is very slow (in comparison to E. 
coli) due to its inefficient porins.36 Furthermore, P. aeruginosa is well-known for its 
ability to grow as a biofilm thus aiding its escape from the action of antibiotics.40,42 
P. aeruginosa can also form a capsule providing it with an additional physical barrier 
to prevent the entry of antibiotics.18,39 One or possibly all of these mechanisms may 
be facilitating its resistance to the action of organocatalyst (b) and the SAR study 
compounds 2-5. 
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Table 2.3: SAR study compounds antibacterial activity as MIC50 range. Values are the mean of three experiments.  
Compound E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
Vancomycin hydrochloride 1.58-2.10 2.35-3.13 >67.31 >100.00 1.58-2.10 2.35-3.13 
Ciprofloxacin >301.99 >100.00 1.18-1.77 0.39-0.59 >301.99 >100.00 
Organocatalyst (b) 2.63-3.95 1.56-2.35 >168.30 >100.00 3.95-5.26 2.35-3.13 
3 5.54-8.32 3.13-4.69 >177.25 >100.00 8.32-11.08 4.69-6.25 
4 40.92-54.56 18.75-25.00 >218.24 >100.00 54.56-81.84 25.00-37.50 
 
Table 2.4: SAR study compounds antibacterial activity as MIC90 range. Values are the mean of three experiments. 
Compound E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
Vancomycin hydrochloride 4.21-6.31 6.25-9.38 >67.31 >100.00 4.21-6.31 6.25-9.38 
Ciprofloxacin >301.99 >100.00 37.75-56.62 12.5-18.75 >301.99 >100.00 
Organocatalyst (b) 7.90-10.52 4.69-6.25 >168.30 >100.00 10.52-15.78 6.25-9.38 
3 8.32-11.08 4.69-6.25 >177.25 >100.00 16.62-22.16 9.38-12.50 
4 81.84-109.12 37.50-50.00 >218.24 >100.00 163.68-218.24 75.00-100.00 
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As can be seen in Table 2.3 our hit compound organocatalyst (b) exhibited good 
activity against E. coli, resulting in an MIC50 in the range of 1.56-2.35 g/mL and 
2.35-3.13 g/mL against S. aureus. Gratifyingly, organocatalyst (b) also inhibited E. 
coli and S. aureus growth by 90% at MIC’s comparable to that obtained for the 
reference antibacterial agent, vancomycin hydrochloride (Table 2.4). 
In the investigation into the structure-activity relationship of organocatalyst (b), 
compound 2 (Figure 2.8, section 2.2.2) was the first to be evaluated for its 
bacteriostatic activity. Here, we wanted to investigate if the quinine-derived amine 
component of the hit compound was important for activity. The results from the 
susceptibility assays of compound 2 revealed that it exhibited little or no activity 
against E. coli, P. aeruginosa and S. aureus. This is an interesting result as quinine 
has been shown by others to exhibit bactericidal activity against all three bacteria.85  
Compound 2 is structurally different to quinine in two ways, firstly, the replacement 
of the –OH group with the –NH2 group and secondly, in their C9-configurations 
(Figure 2.10). 
 
Figure 2.10: Structural differences and similarities between compound 2, quinine 
and its C9-epimer.  
Perhaps the –OH group of quinine is involved in binding to its target site through H-
bonding interactions. A H-bonding interaction involves the orbital containing a lone 
pair of electrons of one molecule (H-bond acceptor) interacting with the orbitals 
involved in the R-H bond of a second molecule, the H-bond donor. Thus there is an 
important directional influence associated with H-bonding interactions, that is, the 
optimum orientation is where the R-X bond of the H-bond donor points directly 
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towards the lone pair of the H-bond acceptor. If the –OH group of quinine is 
involved in H-bonding interactions with its target site then replacement with the –
NH2, having two H atoms, could alter the angle at which the H-bonding interaction 
occurs. This in turn may reduce the strength of the interaction and therefore result in 
a loss of the antibacterial activity. Alternatively, it has recently been reported that the 
cytostatic activity of quinine is dependent on its C9 configuration.92 Gorka et al.92 
evaluated the cytostatic activity of quinine and its C9-epimer against the malaria 
causing parasite, Plasmodium falciparum. The results show that the C-9 epimer of 
quinine (Figure 2.10) exhibited a large decrease in cytostatic activity in comparison 
to quinine, suggesting that the configuration may be important for activity. Taking 
this into consideration, it may be that compound 2 having the opposite C9-
configuration to quinine results in a loss in activity. This is not unusual as 
differences in activity have been associated with the different enantiomers of a 
compound, for example ethambutol (Figure 2.11). The (S,S)-enantiomer of 
ethambutol is used in the treatment of tuberculosis whereas the (R,R)-enantiomer is 
inactive.93 
 
Figure 2.11: (S,S)-Ethambutol. 
Another possible explanation for the lack of activity exhibited by 2 could be due to 
the presence of the three basic nitrogen groups, the quinuclidine N, the quinoline N 
and the primary amine. When compound 2 is in solution it may become triply 
charged which, in turn, may prevent it from crossing the lipid membrane of the 
bacteria. Consequently, compound 2 may not be able to inhibit bacterial growth.  
Thus far, with regards to compound 2 and the structure of the hit compound, the 
quinine-derived amine component does not appear to possess antibacterial activity 
and therefore may not be required for the activity exhibited by organocatalyst (b). 
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Moreover, the lack of activity exhibited by compound 2 suggests that the thiourea 
moiety may be important for the antibacterial activity exhibited by the hit compound. 
Next, the importance of the methoxy group with regards to the overall activity of 
organocatalyst (b) was investigated using compound 3 (Figure 2.8, section 2.2.2). As 
can be seen from Table 2.3, compound 3 exhibited activity against both E. coli and 
S. aureus. Although the MIC50 values obtained for compound 3 were slightly higher 
than those exhibited by the hit compound, the MIC90 values obtained for compound 
3 were very close to that of organocatalyst (b) (Table 2.4).  In general, the loss of the 
methoxy group resulted in a slight reduction in activity. However, it did not appear 
to have a detrimental effect on the overall activity of the compound indicating that it 
may not be crucial for activity.  
Finally, the effect of the loss of the two –CF3 groups was investigated using 
compound 4. Compound 4 was less active than the hit compound demonstrating a 
10- and 12-fold decrease in the MIC50 range against both S. aureus and E. coli, 
respectively (Table 2.3). The –CF3 groups are sterically bulky and highly electron-
withdrawing groups. Thus the loss of these groups may induce a change in the 
preferred molecular binding conformation of the hit compound, which in turn may 
reduce its binding affinity to its target site. Alternatively, the addition of fluorine is 
known to increase the lipophiliciy of molecules.87 As can be seen in Table 2.2 
(section 2.2.1) the cLogP of compound 4 is approximately 4.35, a value much lower 
than that of the hit compound (approximately 7.33). In general, the larger the LogP 
value the greater the lipophiliciy, therefore the loss of these groups may impair the 
hit compounds ability to cross the cell membranes and bind to its target site. 
Whatever the case may be, the –CF3 groups appear to be very important in the 
overall activity of organocatalyst (b). 
Of the active compounds here, greater activity was observed against E. coli in 
comparison to S. aureus. This is a little unusual as normally it is more difficult to 
inhibit Gram-negative bacteria in comparison to Gram-positive bacteria due to the 
presence of the additional bacterial outer membrane of the Gram-negative bacterial 
cell wall.18 This result suggests that these compounds may be able to cross the cell 
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membranes of both E. coli and S. aureus, however, the target within each of the 
bacteria may be different thus resulting in different levels of activity. Additionally, if 
the compound shares a similar target amongst the two bacteria, it may be that the 
transport of the compound to the target site is not carried out as efficiently in S. 
aureus as it may be in E. coli. 
The SAR study thus far has been summarised in Figure 2.12. Overall, each of the 
compounds tested were inactive against P. aeruginosa. The quinine-derived amine 
moiety alone does not exhibit bacteriostatic activity against E. coli or S. aureus 
suggesting that it may not be important in the activity of organocatalyst (b), however 
the thiourea moiety may be required for activity. Loss of the –OMe group does cause 
a slight reduction in the potency of the hit compound but does not appear to be 
essential for the overall activity. The –CF3 groups appear to be crucial for activity 
with the loss of these groups resulting in higher MIC values against E. coli and S. 
aureus in comparison to the hit compound. 
 
Figure 2.12: A summary of part one of the SAR study of organocatalyst (b). 
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2.2.4 Compound Design, part two 
Thus far, it was clear that in order to retain bacteriostatic activity the trifluoromethyl 
groups are necessary whereas the loss of the methoxy group does not appear to 
greatly affect the overall activity of the hit compound. The quinine-derived amine 
component alone is inactive suggesting that it may not be required for activity. 
However, this also suggests that the thiourea moiety may be required for activity. 
Additionally, in the original screening for a hit compound, organocatalyst (b) and 
Takemotos catalyst were found to be the compounds that exhibited greatest activity. 
As mentioned earlier, these catalysts share similarities in their structures with both 
compounds bearing a 3,5-bis(trifluoromethyl)phenyl thiourea moiety attached to a 
tertiary amine via a two-carbon chain (Figure 2.3, section 2.1.1). Taking these 
structural similarities into account and having established the structural relationships 
of the –OMe, –CF3 and quinine-derived amine component in part one of the SAR 
study, the SAR study was continued with the focus being placed on two alternative 
structural components of the hit compound as shown in Figure 2.13. 
 
Figure 2.13: Hit compound components for investigation into its structure-activity 
relationship. 
Firstly, we wanted to focus on the thiourea component (red, Figure 2.13). Thioureas 
are known for their vast array of biological properties including antibacterial 
activity.82 A variety of thiourea-based compounds that have been synthesised 
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recently have exhibited antibacterial activity, some of which have demonstrated 
activity comparable to that of known antibacterial agents.83,94   
From our initial studies we found that the presence of the –CF3 groups was important 
for activity. Therefore, in order to combine both the thiourea functionality and the –
CF3 groups it was decided that a series of 3,5-bis(trifluoromethyl)phenyl thiourea-
based derivatives would be synthesised in part two of the SAR study of 
organocatalyst (b) (Figure 2.14).  
 
Figure 2.14: General structure of SAR study compounds. 
Two simple thiourea compounds possessing the 3,5-bis(trifluoromethyl)phenyl 
thiourea group were designed, compound 6 and 7 (Figure 2.15). It was thought that 
these structurally simple molecules should help establish if the thiourea group is the 
source of activity. 
 
Figure 2.15: Structurally simple 1-(3,5-bis(trifluoromethyl)phenyl)-3-thiourea SAR 
study compounds. 
Once again, the Lipinski ‘rule of 5’ have been applied to each of the compounds in 
an effort to gain insight into their potential absorption ability (Table 2.5). As shown 
in Table 2.5 compounds 6 and 7 obey each of the Lipinksi rules unlike the hit 
compound. 
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Table 2.5: Lipinski rules applied to SAR study compounds.  
Compound M.W.a # H-bond acceptors # H-bond donors cLogPb 
Organocatalyst (b) 594.19 3 2 7.33 +/- 0.63 
6 302.03 0 2 3.87 +/- 0.49  
7 316.05 0 2 4.40 +/- 0.49 
8 359.09 1 2 4.03 +/- 0.54 
9 387.12 1 2 5.09 +/- 0.54 
10 370.09 0 2 5.93 +/- 0.50 
11 364.05 0 2 5.32 +/- 0.36 
12 437.14 1 2 5.63 +/- 0.59 
a Molecular weight (amu), b calculated using ACD/Labs ChemSketch 12.0. 
Organocatalyst (b) contains a quinuclidine ring linked via a two-carbon chain to the 
thiourea group.  In an effort to determine the importance of having a carbon chain 
linking a tertiary amine to the thiourea, compounds 8 and 9 were designed (Figure 
2.16). The presence of the tertiary amine provides compound 8 and 9 with an 
additional H-bond acceptor moiety in comparison to compounds 6 and 7. Hydrogen 
bonding interactions are one of the strongest interactions involved in drug-target 
binding thus this feature may be important for activity.11 Both of these compounds 
also obey the Lipinski rules (Table 2.5). 
 
Figure 2.16: SAR study compounds bearing a tertiary amine moiety. 
Next, taking the size of the quinuclidine ring into consideration, two compounds 
were designed in an effort to evaluate the importance of the presence of a sterically 
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bulky group. As shown in Figure 2.17 the two sterically bulky groups chosen were a 
cyclohexane ring and a phenyl ring, compound 10 and 11, respectively. Both groups 
are six-membered hydrophobic carbon cycles, however, the differences in planarity 
and aromaticity should result in different target site binding abilities. Therefore, 
different levels of activity may be demonstrated by each of the compounds. As 
shown in Table 2.5 both compounds lack H-bond acceptors, a feature that may be 
disadvantageous for activity considering the hit compound contains three. 
 
Figure 2.17: Structures of the SAR study compounds 10, 11 and 12. 
Finally, a 3,5-bis(trifluoromethyl)phenyl thiourea attached to a quinuclidine ring via 
a two-carbon chain was designed (compound 12, Figure 2.17). Investigating the 
activity of compound 12 should give insight into the structure-activity relationship of 
two components of the hit compound. Firstly, the importance of the sterically bulky 
tertiary amine containing quinuclidine ring and secondly the effect of the loss of the 
quinoline component. Compound 12 was also found to obey the Lipinski ‘rule of 5’ 
with regards to the molecular weight and number of H-bond donors and acceptors, 
however, its cLogP was found to be > 5 (Table 2.5). As it has only one violation of 
the Lipinski rules, compound 12 still presents as a compound with favourable 
absorption/permeability.   
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2.2.5 Synthesis of part two SAR study compounds 
All of the SAR study compounds described above in section 2.2.4 were synthesised 
using the method described by Andrés et al.95 with modifications. Each of the 
compounds molecular structure has been elucidated by LC/TOF-MS, 1H and 13C 
NMR and IR spectroscopies. The IR spectra of each of the compounds contained a 
strong absorption in the range of 1275-1281 cm-1 corresponding to the (C=S) of the 
thiourea moiety.  
1-(3,5-Bis(trifluoromethyl)phenyl)-3-methylthiourea (compound 6) was synthesised, 
as shown in Scheme 2.7, by the nucleophilic addition reaction of methylamine (2 
equivalents) and 3,5-bis(trifluoromethyl)phenyl isothiocyante (1 equivalent). 
Purification was carried out using silica gel column chromatography to give the 
product as a white solid in good yield, 87%.  
 
Scheme 2.7: Synthesis of SAR study compounds 6-9. 
The simplicity of the molecular structure of compound 6 gave rise to uncomplicated 
1H and 13C NMR spectra. A singlet at 3.06 ppm with an integral of three in the 1H 
NMR spectrum of compound 6 was observed for the three equivalent protons of the 
methyl group, this indicated formation of compound 6. In the 13C NMR spectrum, a 
characteristic quartet at 124.8 ppm with 1J = 270.8 Hz, was observed for the two –
CF3 groups. Additionally, a quartet at 132.8 ppm (2J = 33.0 Hz) was observed for the 
aromatic carbon directly attached to the –CF3 groups (-C-CF3) with the C=S carbon 
signal at 183.7 ppm.  
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The synthesis of compound 7 was carried out as shown in Scheme 2.7 using a 2:1 
ratio of amine:isothiocyanate. The reaction resulted in a good yield of 84%, after 
purification by silica gel column chromatography. A quartet at 3.60 ppm and triplet 
at 1.23 ppm, each with 3J = 7.3 Hz, corresponding to the protons of the ethyl group 
were observed in the 1H NMR spectrum, this indicated formation of compound 7. 
The quartets at 124.8 ppm and 132.7 ppm, in the 13C NMR spectrum, were found to 
have J values of 270.2 and 33.0 Hz, respectively. These coupling constants 
correspond to values associated with one-bond and two-bond C-F coupling constants 
and therefore correspond to the carbons of the –CF3 groups (1J = 270.2 Hz) and the 
carbons ipso to the –CF3 groups (2J = 33.0 Hz). 
Compound 8 (Scheme 2.7) was synthesised using a 1:1 ratio of 
amine:isothiocyanate. A white solid, in 75% yield, was generated after purification 
by silica gel column chromatography. LC/TOF-MS returned a (M+H+) of 360.0961 
indicating formation of the product. However, the 13C and 1H NMR spectra of 
compound 8, in CDCl3, were complex. Doubling and broadening of the 13C signals 
was observed in the 13C NMR spectrum whilst the proton signals of the 1H NMR 
spectrum were broad and poorly resolved (Figure 2.18). It was thought that perhaps 
the complex spectra were the result of some form of chemical exchange occurring in 
solution, for example, restricted bond rotation or tautomerism. 
 
Figure 2.18: 1H NMR spectrum of compound 8 in CDCl3. The residual solvent 1H 
signal was observed at 7.25 ppm. 
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In NMR, chemical exchange involves the movement of a nucleus from one 
environment to another. A commonly encountered example of chemical exchange is 
restricted bond rotation about the C-N bond of amides, for example, N,N-
dimethylformamide (DMF). As shown in Figure 2.19, DMF can be represented as 
two resonance forms. At room temperature, the partial double bond character of the 
C-N bond allows each of the methyl groups to experience different environments 
giving rise to a resonance signal for each of the methyl groups at different chemical 
shifts in the NMR spectra. However, by increasing the temperature of the NMR 
sample, the barrier to rotation (activation energy required for rotation about the 
single bond) can be overcome thus resulting in an increase in rotation about the C-N 
bond. This increase in rotation about the C-N bond allows the methyl groups to 
experience the same environment resulting in an NMR spectrum wherein both of the 
methyl groups are represented by one single resonance signal. 
 
Figure 2.19: Resonance forms of DMF. 
The organocatalytic property of the thiourea derivatives mentioned in section 2.1.1 is 
based on their ability to form H-bonds.76 A review of the literature found that 
thiourea derivatives, like Takemotos catalyst, have the ability to self-associate 
through intra- and intermolecular H-bonding interactions.96 In fact, this ability to 
self-aggregate can interfere with the catalytic ability of thiourea-based 
organocatalysts with high catalyst load and the use of protic solvents having been 
shown to result in lower enantioselectivities.96c,97 Studies by Tárkányi et al.96a,b using 
low temperature NMR spectroscopy demonstrated that at low temperature both a 
momomeric and dimeric species resulting from H-bond interactions of the thiourea 
catalysts can be observed. In both the cinchona-based thiourea organocatalyst and 
Takemotos catalyst an intramolecular H-bond interaction occurs between the tertiary 
amine and one of the thiourea NH’s giving rise to a monomeric species.96a,b 
Additionally, intermolecular H-bonding occurs between the thiourea NH’s of one 
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molecule of catalyst and the thiourea sulfur atom of a second catalyst molecule 
resulting in the formation of a dimer.96a Furthermore, it is believed that the 
monomeric and dimeric forms are in equilibrium (chemical exchange) and that these 
self-aggregrates are the cause of the broadening effect of 1H NMR signals at room 
temperature.96b  
Taking these studies into consideration, it was believed that the thiourea derivative, 
compound 8, may be undergoing self-association in CDCl3 and therefore resulting in 
a broadening effect of the signals in the NMR spectra. In order to investigate this, the 
NMR experiments were carried out using CD3OD in place of CDCl3. Methanol is a 
polar protic solvent with the ability to accept and donate H-bonds and should 
therefore interfere with the H-bonding interactions and disrupt the self-association of 
the thiourea derivatives. The disruption of H-bonding interactions should, in turn, 
result in sharper resonance signals in the NMR spectra. As observed with the 
cinchona-based organocatalysts96b, the 1H and 13C NMR spectra of compound 8 in 
CD3OD exhibited one set of sharp resonance signals indicating a loss in self-
association (Figure 2.20). 
 
Figure 2.20: 1H NMR spectrum of compound 8 in CD3OD. The residual solvent 1H 
signal was observed at 3.32 ppm and the 1H signal for H2O at 3.91 ppm.  
To further confirm the occurrence of self-association of compound 8 a number of 1H 
NMR experiments were ran at higher temperatures. If the monomeric and dimeric 
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thiourea species of the thiourea bifunctional catalysts can be observed in NMR 
spectra at low temperatures then by increasing the temperature the speed at which 
they are equilibrating should increase and give rise to sharper resonance signals in 
the NMR spectra. A series of experiments were carried out in CDCl3 at a range of 
temperatures from 25 oC to 54 oC (Figure 2.21). 
 
Proposed structure of the dimeric form of compound 8. 
 
Figure 2.21: A selection of the variable temperature (VT) 1H NMR spectra of 
compound 8 in CDCl3 and a proposed structure for the dimeric form of compound 8. 
Spectra recorded at (–) 25 oC, (–) 30 oC, (–) 40 oC and (–) 50 oC.  
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As can be seen in Figure 2.21, an increase in temperature resulted in sharper 
resonance signals. The 1H NMR signals showed no further improvement in lineshape 
above 50 oC thus the 13C NMR experiment (CDCl3) was also carried out at this 
temperature. The resulting 13C NMR spectrum exhibited only one set of sharper 
resonance signals unlike that observed at 25 oC.The results indicate that at room 
temperature compound 8 may exist as both a dimer and monomer as a result of H-
bonding interactions and that an increase in temperature can increase the rate at 
which these species are interconverting. Additionally, the use of a protic solvent 
(CD3OD) appears to interrupt the H-bonding interactions resulting in NMR spectra 
with a single set of sharp resonance signals. 
As with compound 6 and 7, in the 13C NMR spectrum of compound 8 (CD3OD) a 
quartet at 124.8 ppm with 1J = 270.8 Hz was assigned as the 13C signal of the –CF3 
groups. The 13C signal representing the carbon atoms adjacent to the –CF3 groups (-
C-CF3) was found at 132.7 ppm having a characteristic two-bond C-F coupling 
constant of 33.0 Hz. Due to the deshielding effect of the tertiary amine moiety the 
13C signals for the carbon atoms of the two-carbon chain (-CH2CH2) were found at 
58.6 and 43.0 ppm, downfield from those of the ethyl chain of compound 7. This 
was also the case for the protons of the two-carbon chain in the 1H NMR spectra 
(CD3OD), indicating formation of compound 8. The equivalent protons of the 
tertiary amine methyl groups were observed as a singlet at 2.33 ppm in the 1H NMR 
spectrum. 
The reaction of one equivalent of N,N-diethylethylenediamine and one equivalent of 
3,5-bis(trifluoromethyl)phenyl isothiocyanate at room temperature generated 
compound 9 (Scheme 2.7). As for the thiourea derivatives described thus far, 
compound 9 was purified by silica gel column chromatography, which resulted in a 
yellow oil in a 92% yield. LC/TOF-MS returned a (M+H+) of 388.1270 indicating 
formation of compound 9 and as seen with compound 8, the NMR spectra obtained 
in CDCl3 were complex with doubling of peaks and broad resonance signals being 
observed. Therefore, the NMR experiments were carried out in CDCl3 at 50 oC and 
also in CD3OD at room temperature (Figure 2.22). The resulting spectra exhibited 
only one set of sharp resonance signals indicating that in the aprotic solvent, at room 
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temperature, compound 9 may be equilibrating between a monomeric and dimeric 
form as a result of H-bonding interactions. 
 
Figure 2.22: 1H NMR spectra of compound 9 in (a) CDCl3 at 50 oC, (b) CDCl3 at 25 
oC and (c) CD3OD at 25 oC. Solvent residual 1H signals were also observed in each 
spectrum. 
In the 13C NMR spectrum the quartets at 124.7 and 132.7 ppm were found to have 
coupling constants characteristic of one-bond and two-bond C-F coupling (1J = 
270.8 and 2J = 33.0 Hz, respectively,) and were therefore assigned as the carbon 
signals of the –CF3 (124.7 ppm) and –C–CF3 (132.7 ppm) moieties. As observed for 
compound 8, the 13C signals representing the carbons of the two-carbon chain 
linking the tertiary amine to the thiourea, were found downfield from those of –
CH2CH3 group of compound 7 due to the electron-withdrawing effect of the tertiary 
amine N atom. The triplet and quartet found at 1.07 and 2.67 ppm in the 1H NMR 
spectrum (CD3OD), were assigned as the protons of the –CH2 and –CH3 of the –NEt2 
group each having 3J = 7.1 Hz.               
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The nucleophilic addition of cyclohexylamine to 3,5-bis(trifluoromethyl)phenyl 
isothiocyanate generated compound 10 (Scheme 2.8). Purification by silica gel 
column chromatography produced compound 10 as a white solid in a 95% yield. The 
presence of the cyclohexyl group gives rise to a slightly more complex 1H NMR 
spectrum in comparison to compounds 6 and 7, with multiplets representing the 
cyclohexyl protons found between 1 and 2 ppm. Two broad singlets at 8.42 and 6.13 
ppm, integrating for one proton each, were identified as the protons of the thiourea 
NH’s. In the 13C NMR spectrum, the quartets corresponding to the carbons of the –
CF3 groups and those directly attached to the –CF3 groups (-C-CF3) were observed at 
122.8 and 132.9 ppm, respectively. 
 
Scheme 2.8: Synthesis of SAR study compounds 10 and 11.  
The reaction of aniline with 3,5-bis(trifluormethyl)phenyl isothiocyanate produced 
compound 11 in good yield, 92%, after purification (Scheme 2.8). As with 
compound 10, the presence of the aromatic phenyl ring resulted in a more complex 
1H NMR spectrum in comparison to compounds 6 and 7, with the thiourea NH 
protons observed at 8.89 and 7.88 ppm as broad singlets. In the 13C NMR spectrum, 
the carbon signal of the –CF3 groups was found to have a J value of 270.0 Hz, which 
is characteristic of a one-bond C-F coupling constant. The carbon signal (a quartet) 
at 132.0 ppm was assigned as the carbon directly attached to the –CF3 groups as it 
has a coupling constant of 33.0 Hz, a value which falls within the range of the 2J C-F 
coupling constants.    
Finally, compound 12 was synthesised by the reaction of quincoridine-amine (QCD-
amine) with 3,5-bis(trifluoromethyl)phenyl isothiocyanate (Scheme 2.9). Compound 
12 was isolated as a white solid in 93% yield after purification by silica gel column 
chromatography. Similar to compounds 8 and 9, the NMR spectra of compound 12 
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in CDCl3 exhibited doubling and broadening of peaks. However, carrying out the 
NMR experiments in CDCl3 at 50 oC or in CD3OD at room temperature resulted in 
spectra containing one set of sharp resonance signals (Figure A1, Appendix A). 
These results suggest that compound 12 may also undergo self-association in aprotic 
solvents at room temperature. The presence of the quinuclidine ring results in 
complex 1H NMR spectra having a number of multiplets representing the protons of 
the quinuclidine bicycle between 1.40-3.20 ppm. In the 13C NMR spectrum the 13C 
signal for the carbon of the C=S was found at 182.8 ppm with the quartets for the 
carbons of the –CF3 groups at 124.8 ppm (1J = 270.0 Hz) and the -C-CF3 13C signal 
at 132.8 ppm, indicating formation of compound 12.  
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Scheme 2.9: Synthesis of compound 12. 
2.2.6 In vitro antibacterial activity 
Each of the part two SAR study compounds (Figure 2.23) were evaluated for their 
bacteriostatic activity using the susceptibility assay as described in section 1.2.5. As 
with the part one SAR study compounds, these compounds were tested against E. 
coli, P. aeruginosa and S. aureus. Due to the structural similarities between 
organocatalyst (b) and Takemotos catalyst (Figure 2.3, section 2.1.1), and its 
previously reported antibacterial results74, Takemotos catalyst was also evaluated 
against each of the bacteria used within this study.  
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Figure 2.23: Part two SAR study compounds evaluated for their bacteriostatic 
activity. 
The results, which have been summarised in Tables 2.6, 2.7 and 2.8, are expressed as 
the MIC50, MIC80 and MIC90. Again, vancomycin hydrochloride and ciprofloxacin 
were used as the reference drugs and their results are included in Tables 2.6, 2.7 and 
2.8. Any compound that did not exhibit an MIC, of the given percentage of growth 
inhibition, against each of the bacteria has been excluded from the tables. 
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Table 2.6: SAR study compounds antibacterial activity as MIC50 range. Values are the mean of three experiments 
Compound E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
Vancomycin hydrochloride 1.58-2.10 2.35-3.13 >67.31 >100.00 1.58-2.10 2.35-3.13 
Ciprofloxacin >301.99 >100.00 1.18-1.77 0.39-0.59 >301.99 >100.00 
Organocatalyst (b) 2.63-3.95 1.56-2.35 >168.30 >100.00 3.95-5.26 2.35-3.13 
Takemotos catalyst 60.51-90.77 25.00-37.50 >242.05 >100.00 60.51-90.77 25.00-37.50 
7 158.20-237.31 50.00-75.00 >316.41 >100.00 >316.41 >100.00 
9 96.87-129.16 37.50-50.00 >258.32 >100.00 96.87-129.16 37.5-50.00 
10 101.33-135.00 37.50-50.00 >270.20 >100.00 135.10-202.65 50.00-75.00 
11 51.50-68.67 18.75-25.00 >274.69 >100.00 >274.69 >100.00 
12 42.89-57.19 18.75-25.00 >228.76 >100.00 42.89-57.19 18.75-25.00 
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Table 2.7: SAR study compounds antibacterial activity as MIC80 range. Values are the mean of three experiments. 
Compound E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
Vancomycin hydrochloride 2.10-3.16 3.13-4.69 >67.31 >100.00 3.16-4.21 4.69-6.25 
Ciprofloxacin >301.99 >100.00 1.18-1.77 0.39-0.59 >301.99 >100.00 
Organocatalyst (b) 5.26-7.90 3.13-4.69 >168.30 >100.00 7.90-10.52 4.69-6.25 
Takemotos catalyst 90.77-121.02 37.5-50.00 >242.05 >100.00 90.77-121.02 37.50-50.00 
9 129.16-193.74 50.00-75.00 >258.32 >100.00 129.16-193.74 50.00-75.00 
11 103.01-137.35 37.50-50.00 >274.69 >100.00 >274.69 >100.00 
12 85.79-114.38 37.50-50.00 >228.76 >100.00 85.78-114.38 37.50-50.00 
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Table 2.8: SAR study compounds antibacterial activity as MIC90 range. Values are the mean of three experiments. 
Compound E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
Vancomycin hydrochloride 4.21-6.31 6.25-9.38 >67.31 >100.00 4.21-6.31 6.25-9.38 
Ciprofloxacin >301.99 >100.00 37.75-56.62 12.5-18.75 >301.99 >100.00 
Organocatalyst (b) 7.90-10.52 4.69-6.25 >168.30 >100.00 10.52-15.78 6.25-9.38 
Takemotos catalyst 121.02-181.54 50.00-75.00 >242.05 >100.00 90.77-121.02 37.50-50.00 
9 193.74-258.32 75.00-100.00 >258.32 >100.00 193.74-258.32 75.00-100.00 
11 206.02-274.69 75.00-100.00 >274.69 >100.00 >274.69 >100.00 
12 85.78-114.38 37.50-50.00 >228.76 >100.00 85.78-114.38 37.50-50.00 
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As with the SAR study compounds evaluated in part one, none of the SAR study 
compounds exhibited bacteriostatic activity against the Gram-negative bacterium P. 
aeruginosa. As suggested earlier, the lack of inhibition of growth may be due to the 
intrinsic resistance mechanisms associated with P. aeruginosa such as the ability to 
form a capsule, grow as a biofilm and its inefficient porins resulting in slow uptake 
of the molecules.18,36,39-40,42 
Of the SAR study compounds evaluated in part one (Table 2.3 and 2.4, section 
2.2.3), the compounds which exhibited activity did so against both E. coli and S. 
aureus. However, for each of the active compounds the level of activity against E. 
coli was greater than that demonstrated against S. aureus. Amongst the eight 
compounds from part two, only four of these compounds exhibited MIC50 values 
against both E. coli and S. aureus (Table 2.6). As with the active compounds in part 
one, each of the four compounds here demonstrated greater activity against E. coli in 
comparison to that exhibited against S. aureus (Table 2.6). 
The first compound, from the part two SAR study, to be evaluated was the 
structurally simple 1-(3,5-bis(trifluoromethyl)phenyl)-3-methylthiourea (compound 
6, Figure 2.23). Compound 6 exhibited little or no activity against each of the 
bacteria examined suggesting that the simple 3,5-bis(trifluoromethyl)phenyl thiourea 
moiety alone is not the source of activity.  
Next, compound 7 (Figure 2.23) was evaluated for its bacteriostatic activity. As 
shown in Table 2.6, compound 7 only demonstrated activity against E. coli resulting 
in a MIC50 of 50.00-75.00 g/mL. Although this is a slight improvement on 
compound 6, the MIC50 achieved by compound 7 is much greater than that observed 
for the hit compound (1.56-2.35 g/mL). Furthermore, compound 7 was unable to 
inhibit any more than 50% of bacterial growth again suggesting that the simple 
nature of the thiourea structure alone is not enough to exhibit antibacterial activity. 
Following on from compounds 6 and 7, the carbon chain was extended with a 
terminal tertiary amine which was bound to either two methyl (compound 8) or two 
ethyl groups (compound 9). Similar to compound 6, compound 8 demonstrated little 
or no bacteriostatic activity against all three bacteria. Compound 9 on the other hand 
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resulted in an MIC50 of 37.50-50.00 g/mL against both E. coli and S. aureus. 
Furthermore, compound 9 had the ability to inhibit up to 90% of bacterial growth, 
although a higher concentration was required to do so (Table 2.8). These results 
indicate that although the addition of the two-carbon chain bound to a simple tertiary 
amine does not improve bacteriostatic activity (compound 8), the addition of a 
slightly more hydrophobic and bulky tertiary amine is beneficial for activity. What’s 
more, in comparison to compound 7, which was inactive against S. aureus, the 
addition of the –NEt2 group resulted in a compound that can inhibit up to 80% of S. 
aureus growth at a concentration range of 50.00-75.00 g/mL (compound 9). 
According to the Lipinski ‘rule of 5’ (Table 2.5, section 2.2.4), replacement of the 
tertiary amine methyl groups with the ethyl groups results in an increase in 
lipophilicity. If the target site of the compound is inside the bacterial cell, this 
increase in lipophilicity may be helping to facilitate entry into the bacterial cells and 
therefore aid in its ability to reach the target site. 
Continuing with the investigation into the importance of the two-carbon chain 
linking a tertiary amine to the 3,5-bis(trifluoromethyl)thiourea moiety, compound 12 
was also synthesised (Figure 2.23). As shown in Table 2.6, compound 12 was more 
active than compound 7 and 9 against both E. coli and S. aureus. Furthermore, 
compound 12 can inhibit the growth of both E. coli and S. aureus by 50% at the 
same concentration with an increase in concentration resulting in an increase in 
bacteriostatic activity (Table 2.6 and 2.7).  
The cLogP of compound 12 was calculated to be approximately 5.63 (Table 2.5, 
section 2.2.4), which is a slight increase in cLogP compared to compound 9 (5.09 +/- 
0.54). Therefore, perhaps this increase in lipophilicity improves activity. 
Additionally, these results suggest that the more sterically bulky quinuclidine ring is 
favourable for activity.  
Alkyl groups and heterocycles can interact with binding regions of a target binding 
site through van der Waals interactions.11 These interactions are some of the weaker 
types of interactions involved in target site binding, consequently the distance 
between the binding region and binding group is important with regards to the 
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strength of the interaction.11 If the target binding site is large enough to allow the 
entry of a bicycle then the smaller diethylamine functionality will also, most likely, 
‘fit’ into the binding site. However, the smaller size of the diethylamine means that 
the distance between it and the binding regions of the binding site would be greater 
than the distance between the quinuclidine ring and the binding regions (Figure 
2.24). Therefore, the binding interactions between the diethylamine and the binding 
regions of the target site may be weaker resulting in a reduction in activity. A similar 
trend in activity was observed on going from compound 7 to compound 9 (Table 
2.6). 
 
Figure 2.24: Target site binding and the effect of binding group size. 
To further investigate the effect of steric bulk on the activity of the thiourea 
compounds, compounds 10 and 11 (Figure 2.23) were evaluated for their 
bacteriostatic activity. Compound 10 exhibited activity against both E. coli and S. 
aureus resulting in MIC50 ranges of 37.50-50.00 and 50.00-75.00 g/mL, 
respectively. Compound 11 on the other hand only exhibited activity against E. coli, 
however, the MIC50 obtained was less than that of compound 10 (Table 2.6). 
Additionally, an increase in compound 11 concentration resulted in an increase in 
percentage of growth inhibition whereas compound 10 did not inhibit greater than 
50% of bacterial growth (Table 2.6 and 2.7).  
With regards to structure, both groups are six-membered carbon rings with the 
difference being that compound 11 is planar and aromatic whereas compound 10 is 
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non-planar and sterically bulkier. According to the cLogP values, compound 11 is 
only slightly less lipophilic than compound 10. Therefore, perhaps the difference in 
activity against E. coli is due to the difference in their affinities to bind to the target 
site. If the two compounds share the same target then perhaps the planar aromatic 
cyclic ring is a better ‘fit’ for the target site. The presence of -bonds means that 
compound 11 has a region of high electron density and perhaps this can assist in 
better binding interactions and therefore greater activity.  
Takemotos catalyst was also evaluated for its bacteriostatic activity against the 
bacterial strains used within this study. The results show that Takemotos catalyst was 
more active than compound 10 against both E. coli and S. aureus, however, similar 
activity to Takemotos catalyst was exhibited by compound 11 against E. coli (Table 
2.6). An increase in concentration resulted in an increase in bacteriostatic activity 
with Takemotos catalyst exhibiting lower MIC90 values in comparison to compound 
11. These results indicate that a sterically bulky group attached at the 3-position of 
the thiourea moiety is beneficial for activity. Additionally, the presence of a cyclic 
group bearing a tertiary amine appears to be advantageous with Takemotos catalyst 
and compound 12 exhibiting greatest activity amongst the eight SAR study 
compounds tested (Table 2.6, 2.7 and 2.8).  
The lone pair of electrons present on the tertiary amine of Takemotos catalyst and 
compound 12 potentially allows the N atom to act as a H-bond acceptor. Hydrogen 
bond interactions are one of the stronger forms of target site binding interactions.11 
Therefore, the introduction of the H-bond acceptor may be increasing the binding 
affinity of the molecules for the target binding site leading to an increase in 
bacteriostatic activity. The difference in activity between Takemotos catalyst and 
compound 12, compound 12 being more active (Table 2.6), could be due to the 
structure of the tertiary amine and how the substituents affect access to the lone pair 
of electrons. As can be seen in Figure 2.25, in the quinuclidine ring the ‘alkyl 
groups’ are part of a rigid ring system that holds them clear of the N atom lone pair 
thus exposing the lone pair for H-bonding interactions. In contrast, the substituents 
attached to the tertiary amine N atom are not ‘held back’ and so may hinder access to 
the N atom lone pair which in turn could reduce any H-bond interaction that may be 
Chapter II: A structure-activity relationship study of thiourea-based antibacterial agents 
72 
 
occurring (Figure 2.25). The lack of, or reduction in, H-bond interactions could 
result in a lower binding affinity of Takemotos catalyst for the target binding site and 
therefore reduce the antibacterial activity. This could also be a reason why 
compound 9 is less active than compound 12. Additionally, the cLogP of Takemotos 
catalyst was found to be approximately 5.14, a value lower than that of compound 12 
and indicating that the reduced activity observed for Takemotos catalyst in 
comparison to compound 12 may also be due to a reduction in lipophilicity.   
 
Figure 2.25: Comparison of tertiary amine structures from Takemotos catalyst and 
compound 12. 
Overall, none of the part two SAR study compounds were active against P. 
aeruginsa. Of the active compounds, activity was greatest against E. coli with only 
four of the compounds also exhibiting activity against S. aureus. In comparison to 
the reference drugs MIC ranges, none of the active compounds demonstrated 
bacteriostatic activity at lower concentrations. 
The results of part two of the SAR study have been summarised in Figure 2.26. The 
structurally simple 1-(3,5-bis(trifluoromethyl)phenyl)-3-methylthiourea derivative 
exhibited little or no activity against all three bacteria. However, an increase in chain 
length alongside the addition of a tertiary amine (-NEt2, compound 9) did improve 
activity against both E. coli and S. aureus (Table 2.6). The introduction of sterically 
bulky groups appears to be beneficial for activity with compounds 10 and 11 
exhibiting antibacterial activity (Table 2.6). The quinuclidine derivative, compound 
12, exhibited greatest activity amongst the eight SAR study compounds. Although 
compound 12 exhibited greater activity than that demonstrated by Takemotos 
catalyst, compound 12 remained less active (6- to 8-fold decrease in activity) than 
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the hit compound, organocatalyst (b) (Table 2.8), therefore suggesting that the 
quinoline bicycle is important for activity. 
N
NH
NHS
N
F3C CF3
O
H
Loss of the quinoline
group greatly reduced
activity
Introduction of a
two-carbon chain linking a
–NEt2 group to the thiourea
was benef icial for activity
The simple
3,5-bis(trif luoromethyl)phenyl
thiourea derivatives alone did
not exhibit activity
The presence of a sterically
bulky group was favourable for
activity with the quinuclidine
ring derivative exhibiting
greatest activity
 
Figure 2.26: A summary of part two of the SAR study of organocatalyst (b). 
2.2.7 In vivo SAR study compound tolerance 
In an effort to further investigate the structure-activity relationship of organocatalyst 
(b) in vivo toxicity studies were carried out as described in section 1.2.8 using the 
larvae of the greater wax moth, Galleria melonella (G. melonella). Organocatalyst 
(b) and a selection of the SAR study compounds, shown in Figure 2.27, which 
exhibited antibacterial activity were chosen for evaluation of their toxicity. The 
results are presented in Table 2.9 as the survival of G. mellonella larvae (expressed 
as %) as a function of the compound dosages administered. 
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Figure 2.27: Organocatalyst (b) and the SAR study compounds evaluated for in vivo 
toxicity. 
As can be seen in Table 2.9, at a concentration of 1 g/mL a 100% survival rate was 
observed with each of the SAR study compounds tested after 72 hours. A 97% 
survival rate was observed for organocatalyst (b) at the same concentration as one G. 
mellonella larva died after 48 hours. However, increasing the administration dose to 
10, 50 and 100 g/mL did not appear to effect the G. mellonella with a 100% 
survival rate observed at each of these concentrations for every compound tested 
including organocatalyst (b) (Table 2.9). The in vivo toxicity of the hit compound 
organocatalyst (b) was also evaluated at the higher concentration of 1000 g/mL and 
was found to be non-toxic at this concentration.  
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Table 2.9: Survival of G. mellonella larvae (expressed as %) post injection at 24, 48 
and 72 h. 
Compound Dosage concentration  (g/mL) 
G. mellonella survival 
24 48 72 
     
Organocatalyst (b) 1000 100 100 100 
 100 100 100 100 
 50 100 100 100 
 10 100 100 100 
 1 100 97 97 
     
3 100 100 100 100 
 50 100 100 100 
 10 100 100 100 
 1 100 100 100 
     
4 100 100 100 100 
 50 100 100 100 
 10 100 100 100 
 1 100 100 100 
     
9 100 100 100 100 
 50 100 100 100 
 10 100 100 100 
 1 100 100 100 
     
11 100 100 100 100 
 50 100 100 100 
 10 100 100 100 
 1 100 100 100 
     
12 100 100 100 100 
 50 100 100 100 
 10 100 100 100 
 1 100 100 100 
 
The G. mellonella larvae were also monitored for their development, that is, whether 
or not the larvae become pupae. It was found that after seven days, at each test 
compound concentration, the number of the G. mellonella larvae that had pupated 
was similar to that observed for the untreated G. mellonella (≥ 60%). These results 
indicate that not only were the compounds non-toxic to the larvae of the greater wax 
moth but they also did not appear to interfere with larval development.   
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Both thiourea itself and derivatives of thiourea have been shown to possess a vast 
array of biological activities including biocidal activity towards insects and cytotoxic 
activity towards mammalian cancer cell lines.82b,94b,98 Considering the toxicity of 
thioureas and the positive correlation that has been observed between compound 
toxicity in G. mellonella and mice, the results of the in vivo toxicity evaluation of 
organocatalyst (b) and its SAR study compounds presented here are encouraging. 
2.2.8 Conclusion 
Herein, an investigation into the structure-activity relationship of organocatalyst (b) 
(Figure 2.28) was carried out in an attempt to uncover the structural components 
responsible for its antibacterial activity. The study was divided into two parts. 
 
Figure 2.28: Hit compound, organocatalyst (b) 
Initial studies involved the design and synthesis of derivatives of organocatalyst (b) 
lacking functional groups which may be important for activity. A total of five 
derivatives, including organocatalyst (b), were synthesised. Each of the derivatives, 
were purified by silica gel column chromatography followed by additional 
purification by precipitation. The organocatalyst (b) derivatives were isolated as 
white solids in reasonable yields in the range of 50-56%. 
Part two of the study involved a more in depth investigation into the structure-
activity relationship of organocatalyst (b) with the focus placed on the thiourea 
moiety. A series of compounds bearing the 3,5-bis(trifluoromethyl)phenyl thiourea 
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moiety were designed and synthesised. The nucleophilic addition of the chosen 
amine to 3,5-bis(trifluoromethyl)phenyl isothiocyanate generated the SAR study 
compounds in good to excellent yields, 75-95%, after purification by silica gel 
column chromatography. 
All compound structures were elucidated by LC/TOF-MS, 1H and 13C NMR and IR 
spectroscopies. In some cases (compounds 8, 9 and 12) complex NMR spectra 
(CDCl3) consisting of peak doubling and broadened resonance signals were 
obtained. It was believed that these effects were due to the formation of self-
aggregates, a process known to occur with thiourea compounds, as a result of intra- 
and intermolecular H-bonding interactions.96a,b NMR experiments carried out in a 
protic solvent and at higher temperatures proved that this may indeed be the case for 
compounds 8, 9 and 12. 
Each of the compounds synthesised were evaluated for their bacteriostatic activity 
against two Gram-negative bacteria, E. coli and P. aeruginosa, and the Gram-
positive bacterium S. aureus. No compound exhibited activity against P. aeruginosa, 
a result that may be due to the intrinsic resistance mechanisms associated with this 
particular bacterium. In general, the SAR study compounds exhibited greatest 
activity against E. coli with a number of compounds also demonstrating activity 
against S. aureus. 
A summary of the structure-activity relationships associated with organocatalyst (b) 
has been given in Figure 2.29. In part one of the SAR study, it was found that the –
OMe group, although beneficial for activity, was not crucial for activity. However, 
the loss of –CF3 groups severely reduced activity, with a 10- and 12-fold decrease in 
the MIC50 range observed for compound 4 (Figure 2.23, section 2.2.6), in 
comparison to the hit compound. 
Part two revealed that the simple 3,5-bis(trifluoromethyl)phenyl thiourea derivative 
bearing a methyl group was inactive suggesting that the thiourea may not be the 
source of activity. The addition of a two-carbon chain with a terminal tertiary amine 
(-NEt2) to the aryl thiourea was advantageous for activity. Steric bulk appears to be 
favourable for activity with the phenyl and cyclohexyl thiourea derivatives 
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exhibiting bacteriostatic activity in MIC50 ranges of 37.50-50.00 and 18.75-25.00 
g/mL, respectively. However, a combination of both a tertiary amine and a 
sterically bulky group (compound 12 and Takemotos catalyst) proved to be most 
effective amongst the part two SAR study compounds. Both compound 12 and 
Takemotos catalyst exhibited activity against E. coli and S. aureus with an increase 
in concentration resulting in an increase in the percentage of growth inhibition.  
 
Figure 2.29: A summary of the SAR study of organocatalyst (b). 
Organocatalyst (b) inhibited up to 90% of bacterial growth at the concentration 
ranges of 4.69-6.25 g/mL (E. coli) and 6.25-9.38 g/mL (S. aureus). These results 
are comparable to the results obtained here for the well-known antibacterial agent, 
vancomycin hydrochloride (MIC90 in the range of 6.25-9.38 against both E. coli and 
S. aureus). Of the SAR study compounds synthesised within this study, compounds 
3 and 12 (Figure 2.30) exhibited greatest activity and although the MICs achieved by 
compound 3 were comparable to those of the hit compound neither compound 3 nor 
compound 12 exhibited activities greater than that achieved by organocatalyst (b). 
Chapter II: A structure-activity relationship study of thiourea-based antibacterial agents 
79 
 
N
NH
NHS
N
F3C CF3
H
3
F3C
CF3
N
H
N
H
S
NH
12  
Figure 2.30: SAR study compounds that exhibited greatest activity. 
In order for a compound to progress into the clinical setting, it must not only be 
effective but also safe to use. Organocatalyst (b) and a selection of the active SAR 
study compounds were chosen for in vivo toxicity studies using the larvae of the 
greater wax moth, G. mellonella. Each compound was found to be non-toxic to the 
G. mellonella at a range of concentrations (1-100 g/mL). The hit compound was 
also found to be non-toxic at the higher concentration of 1000 g/mL. Additionally, 
none of the compounds appeared to effect larval development as similar numbers of 
pupae were found for both treated and untreated larvae after one week. 
To conclude, organocatalyst (b) was found to exhibit bacteriostatic activity against 
both Gram-negative and Gram-positive bacteria at concentrations comparable to that 
of the currently prescribed antibacterial agent, vancomycin hydrochloride. 
Additionally, the hit compound was both non-toxic to and did not appear to affect 
the development of G. mellonella larvae, at concentrations up to 1000 g/mL. 
Although none of the compounds synthesised within this study exhibited greater 
activity than that of the hit compound, we have gained a valuable insight into which 
structural components may be beneficial for activity. Further studies into the 
structure-activity relationship of organocatalyst (b) could potentially lead to the 
generation of a broad spectrum, potent antibacterial agent.        
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2.2.9 Future work 
The hit compound, organocatalyst (b), exhibited bacteriostatic activity against both 
E. coli and S. aureus at concentrations comparable to that of vancomycin 
hydrochloride. As mentioned in section 1.1, antibiotic resistance is a global problem 
and in particular infections resulting from MDR Gram-negative bacteria are on the 
rise. Therefore, it would be of interest to evaluate the bacteriostatic activity of 
organocatalyst (b) against resistant bacterial strains such as vancomycin-resistant E. 
coli. Furthermore, an evaluation of the bactericidal activity of organocatalyst (b) 
could also be carried out.  
The study presented here disclosed some valuable information into the structure-
activity relationships associated with the hit compound. However, none of the 
compounds described above achieved activity equivalent to or better than the hit 
compound thus further SAR studies are required.  
As shown in section 2.2.6, the combination of the 3,5-bis(trifluoromethyl)phenyl 
thiourea with a sterically bulky group bearing a tertiary amine was beneficial for 
activity. Additionally, the loss of the quinoline moiety resulted in a significant 
decrease in activity. A review of the literature found that the antimalarial derivatives 
of quinine, chloroquine and hydroxychloroquine (Figure 2.31), have been shown to 
exhibit antibacterial, antifungal and antiviral activity.99 In fact, chloroquine is used in 
the treatment of Q fever, a disease resulting from infection by the uncommon, Gram-
negative bacterium, Coxiella burnetii. Considering the results of the SAR study thus 
far and the biological activity exhibited by the quinoline bearing antimalarial agents, 
chloroquine and hydroxychloroquine, an investigation into the bacteriostatic activity 
of 3,5-bis(trifluoromethyl)phenyl thiourea compounds bearing the quinoline moiety 
could be worthwhile. 
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Figure 2.31: Antimalarial derivatives of quinine (a) chloroquine and (b) 
hydroxychloroquine. 
The bacteriostatic mode of action of the hit compound, organocatalyst (b), is 
currently unknown. Identification of the bacterial target could be useful in the design 
of more potent SAR study compounds. In order to investigate if the hit compound is 
having an effect on the bacterial cell membrane an assessment of amino acid leakage 
from bacterial cells upon exposure to organocatalyst (b) could be carried out. 
Furthermore, an evaluation of the proteomic response exhibited by the bacteria as a 
result of organocatalyst (b) exposure could give insight into a possible mode of 
action. 
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2.3 Experimental 
General procedure for the synthesis of 9-amino-(9-deoxy)-epi-quinine (2) and 9-
amino-(9-deoxy)-epi-cinchonidine (5)100 
Quinine or cinchonidine (6.14 mmol) and triphenylphosphine (2.11 g, 8.04 mmol) 
were dissolved in dry THF (30 mL) and the solution was cooled to 0 oC. Diisopropyl 
azidodicarboxylate (1.52 mL, 7.72 mmol) was added to the solution. A solution of 
diphenylphosphorylazide (1.63 mL, 7.56 mmol) in dry THF (13 ml) was then added 
dropwise at 0 oC. After addition, the mixture was allowed to warm to room 
temperature and was stirred for 12 hours. The solution was then heated at 50 oC for 2 
hours. Triphenylphosphine (2.29 g, 8.73 mmol) was added and heating continued for 
a further 2 hours. The reaction mixture was allowed to cool to room temperature, 
water (0.70 mL) was added and the reaction mixture stirred for 3 hours. The solvent 
was removed under reduced pressure and the resulting residue was dissolved in 
DCM (30 mL) and 10% HCl (30 mL). The aqueous phase was washed with DCM (3 
x 30 mL). The aqueous phase was then alkalinized with an excess of ammonium 
hydroxide solution and the product extracted with DCM (3 x 30 mL). The DCM 
solutions were dried over Na2SO4, filtered, and the solvent was removed under 
reduced pressure. The product was purified by column chromatography on silica gel 
and eluted with EtOAc:MeOH:NH4OH (50:50:1). 
9-Amino-(9-deoxy)-epi-quinine (2) 
N
NH2
N
O
H
 
Yellow oil (yield 0.75 g, 38%); Rf: 0.37 (EtOAc:MeOH:NH4OH, 50:50:1); []D22: 
+90 (c 0.2, DCM); 1H NMR (300 MHz, CDCl3) 8.57 (d, J = 4.1 Hz, 1H, ArH) 7.88 
(d, J = 8.6 Hz, 1H, ArH), 7.44-7.58 (m, 1H, ArH), 7.30 (d, J = 4.1 Hz, 1H, ArH), 
7.21 (dd, J = 8.6, 3.6 Hz, 1H, ArH), 5.58-5.69 (m, 1H, CH=CH2), 4.78-4.87 (m, 2H, 
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CH=CH2), 4.44 (d, J = 10.1 Hz, 1H, CH-NH2), 3.78 (s, 3H, OCH3), 3.00-3.14 (m, 
2H, H*), 2.89-2.98 (m, 1H, H*), 2.57-2.67 (m, 2H, H*), 2.32-2.46 (m, 3H, H* and 
NH2), 2.05-2.15 (m, 1H, H*), 1.35-1.45 (m, 3H, H*), 1.22-1.30 (m, 1H, H*), 0.57-
0.64 (m, 1H, H*), these data match reported literature values100; 13C NMR (75 MHz, 
CDCl3)  157.5 (ArC), 147.7 (ArC), 146.9 (ArC), 144.6 (ArC), 141.7 (CH=CH2), 
131.6 (ArC), 128.7 (ArC), 121.2 (ArC), 119.9 (ArC), 114.2 (CH=CH2), 101.9 (ArC), 
61.7 (C*), 56.2 (C*), 55.4 (OCH3), 52.8 (CH-NH2), 40.8 (C*), 39.7 (C*), 28.1 (C*), 
27.5 (C*), 25.9 (C*); IR (DCM film on NaCl plate) 3367 (NH2), 2940 (CH) cm-1; 
LC/TOF-MS calcd for C20H26N3O 324.2070, found 324.2080 (M+H+). 
* Quinuclidine ring. 
9-Amino-(9-deoxy)-epi-cinchonidine (5) 
N
NH2
N
H
 
Yellow oil (yield 1.19 g, 66%); Rf: 0.56 (EtOAc:MeOH:NH4OH, 50:50:1); []D22: 
+100 (c 0.2, DCM); 1H NMR (300 MHz, CDCl3) 8.81 (d, J = 4.4 Hz, 1H, ArH), 
8.26 (br s, 1H, ArH), 8.05 (d, J = 8.3 Hz, 1H, ArH), 7.61 (app t, 1H, ArH), 7.49 (app 
t, 1H, ArH), 7.44 (d, J = 4.4 Hz, 1H, ArH), 5.64-5.76 (m, 1H, CH=CH2), 4.84-4.93 
(m, 2H, CH=CH2), 4.61 (d, J = 9.5 Hz, 1H, CH-NH2), 3.05-3.21 (m, 2H, H*), 2.93-
3.02 (m, 1H, H*), 2.67-2.76 (m, 2H, H*), 2.13-2.20 (m, 1H, H*), 2.08 (br s, 2H, 
NH2), 1.42-1.52 (m, 3H, H*), 1.28-1.35 (m, 1H, H*), 0.60-0.68 (m, 1H, H*), these 
data match reported literature values100; 13C NMR (75 MHz, CDCl3)  150.3 (ArC), 
148.7 (ArC), 148.5 (ArC), 141.8 (CH=CH2), 130.4 (ArC), 129.0 (ArC), 127.8 (ArC), 
126.4 (ArC), 123.3 (ArC), 119.6 (ArC), 114.3 (CH=CH2), 61.9 (C*), 56.2 (C*), 51.6 
(CH-NH2), 40.9 (C*), 39.8 (C*), 28.0 (C*), 27.5 (C*), 26.0 (C*); IR (DCM film on 
NaCl plate) 3368 (NH2), 2940 (CH) cm-1; LC/TOF-MS calcd for C19H24N3 
294.1965, found 294.1974 (M+H+). 
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* Quinuclidine ring. 
1-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)-
3-phenylthiourea (3) 
 
9-Amino-(9-deoxy)-epi-quinine (0.15 g, 0.46 mmol) was dissolved in dry DCM (5 
mL) under nitrogen and cooled to 0 oC. After 10 minutes at this temperature, phenyl 
isothiocyanate (86 L, 0.72 mmol) was added. The resulting solution was allowed to 
warm to room temperature and was stirred for 12 hours. The solvent was removed 
under reduced pressure and the resulting residue was purified by column 
chromatography on silica gel. The product was eluted with EtOAc:Et3N:MeOH 
(90:5:5), followed by purification by precipitation from cold EtOAc with n-hexane. 
White solid (yield 0.11 g, 52%); Rf: 0.24 (EtOAc:Et3N:MeOH, 90:5:5); []D: -220 (c 
0.2, DCM); 1H NMR (300 MHz, CDCl3)  8.88-9.10 (br s, 1H, ArH), 8.50 (d, J = 
4.5 Hz, 1H, ArH), 8.1 (br s, 1H, NH), 7.96 (d, J = 9.2 Hz, 1H, ArH), 7.72-7.80 (m, 
1H, ArH), 7.32-7.37 (m, 3H, ArH), 7.16-7.23 (m, 3H, ArH), 5.89 (d, J = 8.3 Hz, 1H, 
CHNHC=S), 5.57-5.69 (m, 1H, CH=CH2), 4.88-4.95 (m, 2H, CH=CH2), 3.92 (s, 3H, 
OCH3), 3.24-3.40 (m, 1H, H*), 3.05-3.15 (m, 2H, H*), 2.59-2.69 (m, 2H, H*), 2.18-
2.30 (m, 1H, H*), 1.57-1.70 (m, 3H, H*), 1.24-1.35 (m, 1H, H*), 0.89-0.96 (m, 1H, 
H*); 13C NMR (75 MHz, CDCl3)  180.5 (C=S), 157.8 (ArC), 147.5 (ArC), 144.7 
(ArC), 140.9 (CH=CH2), 137.5 (ArC), 131.6 (ArC), 129.5 (ArC), 128.2 (ArC), 126.6 
(ArC), 125.2 (ArC), 121.9 (ArC), 114.8 (CH=CH2), 102.4 (ArC), 60.8 (C*), 55.7 
(OCH3), 55.3 (C*), 41.4 (C*), 39.3 (C*), 27.7 (C*), 27.3 (C*), 25.8 (C*), these data 
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match reported literature values101; IR (KBr) 3418 (NH), 2937 (CH), 1242 (C=S) 
cm-1; LC/TOF-MS calcd for C27H31N4OS 459.2213, found 459.2207 (M+H+). 
* Quinuclidine ring. 
1-(3,5-bis(trifluoromethyl)phenyl)-3-((S)-(6-methoxyquinolin-4-yl)- 
((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)thiourea (organocatalyst (b))102 
 
9-Amino-(9-deoxy)-epi-quinine (0.18 g, 0.56 mmol) was dissolved in dry DCM and 
cooled to 0 oC. After 10 minutes at this temperature, 3,5-bis(trifluorophenyl)methyl 
isothiocyanate (168 L, 0.92 mmol) was added. The resulting solution was allowed 
to warm to room temperature and was stirred for 12 hours. The solvent was removed 
under reduced pressure and the resulting residue was purified by column 
chromatography on silica gel. The product was eluted with EtOAc:MeOH:Et3N 
(90:5:5), followed by purification by precipitation from cold Et2O with n-hexane. 
White solid (yield 0.17 g, 50%); Rf: 0.37 (EtOAc:MeOH:Et3N, 90:5:5); []D: -100 (c 
0.2, DCM); 1H NMR (300 MHz, CDCl3)  8.54 (app br s, 1H, ArH), 7.96 (d, J = 9.0 
Hz, 1H, ArH), 7.81 (s, 2H, ArH), 7.66 (s, 2H, ArH), 7.36 (dd, J = 9.0, 2.8 Hz, 1H, 
ArH), 7.13 (app br s, 1H, ArH), 5.85 (app br s, 1H, CHNHC=S), 5.63-5.74 (m, 1H, 
CH=CH2), 4.96-5.02 (m, 2H, CH=CH2), 3.95 (s, 3H, OCH3), 3.28-3.48 (m, 2H, H*), 
3.10-3.18 (m, 1H, H*), 2.67-2.86 (m, 2H, H*), 2.26-2.39 (m, 1H, H*), 1.58-1.77 (m, 
3H, H*), 1.35-1.44 (m, 1H, H*), 0.86-0.94 (m, 1H, H*); 13C NMR (75 MHz, CDCl3) 
 180.6 (C=S), 158.1 (ArC), 147.3 (ArC), 144.5 (ArC), 140.3 (CH=CH2), 132.5 (q, 
2J = 33.8 Hz, C-CF3), 131.4 (ArC), 128.1 (ArC), 123.6 (ArC), 122.9 (q, 1J = 270.0 
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Hz, CF3), 122.2 (ArC), 118.6 (ArC), 115.3 (CH=CH2), 102.1 (ArC), 60.7 (C*), 55.9 
(OCH3), 54.7 (C*), 41.6 (C*), 38.9 (C*), 27.3 (C*), 27.1 (C*), 25.7 (C*), these data 
match reported literature values73a; IR (KBr) 3241(NH), 2946 (CH), 1278 (C=S) cm-
1; LC/TOF-MS calcd for C29H29F6N4SO 595.1961, found 595.1936 (M+H+). 
* Quinuclidine ring. 
1-(3,5-Bis(trifluoromethyl)phenyl)-3-((S)-quinolin-4-yl((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)thiourea (4) 
 
9-Amino-(9-deoxy)-epi-cinchonidine (0.20 g, 0.68 mmol) was dissolved in dry 
DCM and cooled to 0 oC. After 10 minutes at this temperature 3,5-
bis(trifluorophenyl)methyl isothiocyanate (204 L, 1.12 mmol) was added. The 
resulting solution was allowed to warm to room temperature and was stirred for 12 
hours. The solvent was removed under reduced pressure and the resulting residue 
was purified by column chromatography on silica gel. The product was eluted with 
EtOAc:Et3N:MeOH (90:5:5), followed by purification by precipitation from cold 
Et2O with n-hexane.. 
Light yellow solid (yield 0.22 g, 56%); m.p. 148-154 oC; Rf: 0.42 (EtOAc:MeOH 
95:5); []D: -80 (c 0.2, DCM); 1H NMR (300 MHz, CDCl3)  8.38-8.54 (m, 2H, 
ArH), 7.97 (d, J = 8.9 Hz, 1H, ArH), 7.83 (s, 2H, ArH), 7.54-7.64 (m, 3H, ArH), 
7.02-7.12 (m, 1H, ArH), 5.97 (br s, 1H, CHNHC=S), 5.55-5.66 (m, 1H, CH=CH2), 
4.87-4.94 (m, 2H, CH=CH2), 3.26-3.40 (m, 1H, H*), 3.08-3.22 (m, 1H, H*), 2.96-
3.04 (m, 1H, H*), 2.58-2.74 (m, 2H, H*), 2.18-2.30 (m, 1H, H*), 1.50-1.74 (m, 3H, 
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H*), 1.23-1.31 (m, 1H, H*), 0.82-0.96 (m, 1H, H*); 13C NMR (75 MHz, CDCl3)  
180.5 (C=S), 149.6 (ArC), 148.0 (ArC), 146.7 (ArC), 140.6 (CH=CH2), 140.0 (ArC), 
132.3 (q, 2J = 34.5 Hz, C-CF3), 129.6 (ArC), 129.4 (ArC), 127.0 (ArC), 126.8 (ArC), 
123.7 (ArC), 123.4 (ArC), 122.8 (q, 1J = 271.4 Hz, CF3), 118.4 (ArC), 114.7 
(CH=CH2), 60.9 (C*), 54.7 (C*), 41.2 (C*), 38.9 (C*), 27.3 (C*), 27.0 (C*), 25.5 
(C*); IR (KBr) 3237 (NH), 2947 (CH), 1278 (C=S) cm-1, these data match reported 
literature values103; LC/TOF-MS calcd for C28H27F6N4S 565.1855, found 565.1843 
(M+H+). 
* Quinuclidine ring. 
1-(3,5-Bis(trifluoromethyl)phenyl)-3-methylthiourea (6)104 
 
Methylamine (33% in EtOH, 188 l, 2.0 mmol) was added to dry DCM (2 mL) 
under nitrogen and cooled on an ice-bath for 10 minutes. 3,5-
Bis(trifluormethyl)phenyl isothiocyanate (183 L, 1.0 mmol) was slowly added to 
the solution. The reaction mixture was allowed to warm to room temperature and 
was stirred overnight. The solvent was removed under reduced pressure and the 
product was purified by column chromatography on silica gel and eluted with 
CHCl3:MeOH (90:10). 
White solid (0.26 g, 87%); m.p. 118-122 oC; Rf: 0.33 (CHCl3:MeOH 90:10); 1H 
NMR (300 MHz, CD3OD)  8.16 (s, 2H, H2), 7.62 (s, 1H, H4), 3.06 (s, 3H, CH3); 
13C NMR (75 MHz, CD3OD)  183.7 (C=S), 143.3 (C1), 132.8 (q, 2J = 33.0 Hz, C3), 
124.8 (q, 1J = 270.8 Hz, CF3), 123.6 (C2), 117.8 (C4), 31.8 (CH3); IR (KBr) 3226 
(NH), 1278 (C=S) cm-1; LC/TOF-MS calcd for C10H9F6N2S 303.0385, found 
303.0386 (M+H+). 
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1-(3,5-Bis(trifluoromethyl)phenyl)-3-ethylthiourea (7)  
 
Anhydrous triethylamine (279 L, 2.0 mmol) and ethylamine hydrochloride (82 mg, 
1.0 mmol) were dissolved in dry DCM (2 mL) under nitrogen. The reaction mixture 
was cooled on an ice-bath for 10 minutes followed by the slow addition of 3,5-
bis(trifluoromethyl)phenyl isothiocyanate (183 L, 1 mmol). After addition, the 
reaction mixture was allowed to warm to room temperature and was stirred 
overnight. The solvent was removed under reduced pressure and the product purified 
by column chromatography on silica gel and eluted with CHCl3:MeOH (90:10).    
White solid (0.27 g, 84%); m.p. 147-150 oC; Rf: 0.49 (CHCl3:MeOH 90:10); 1H 
NMR (300 MHz, CD3OD)  8.16 (s, 2H, H2), 7.62 (s, 1H, H4), 3.60 (q, J = 7.3 Hz, 
2H, CH2), 1.23 (t, J = 7.3 Hz, 3H, CH3); 13C NMR (75 MHz, CD3OD)  182.5 (C=S) 
143.2 (C1), 132.7 (q, 2J = 33.0 Hz, C3), 124.8 (q, 1J = 270.2 Hz, CF3), 123.8 (C2), 
117.8 (C4), 40.3 (CH2), 14.3 (CH3); IR (KBr) 3240 (NH), 1278 (C=S) cm-1; 
LC/TOF-MS calcd for C11H11F6N2S 317.0542, found 317.0545 (M+H+). 
General procedure for the synthesis of 1-(3,5-bis(trifluoromethyl)phenyl)-3-
thiourea derivatives 8-12 
The appropriate amine (1.0 mmol) was dissolved in dry DCM (2 mL) under 
nitrogen. The solution was cooled on an ice-bath for 10 minutes. 3,5-
Bis(trifluoromethyl)phenyl isothiocyante (183 L, 1.0 mmol) was added slowly to 
the solution. The reaction mixture was allowed to warm to room temperature and 
was stirred overnight. The solvent was removed under reduced pressure and the 
product purified by column chromatography on silica gel. 
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1-(3,5-Bis(trifluoromethyl)phenyl)-3-(2-(dimethylamino)ethyl)thiourea (8) 
 
The product was eluted with CHCl3:MeOH (90:10). White solid (0.27 g, 75%); m.p. 
151-153 oC (154 oC)105; Rf: 0.26 (CHCl3:MeOH 90:10); 1H NMR (300 MHz, 
CD3OD) 8.21 (s, 2H, H2), 7.62 (s, 1H, H4), 3.68-3.80 (app br s, 2H, 
CH2CH2N(CH3)2), 2.62 (t, J = 6.4 Hz, 2H, CH2CH2N(CH3)2), 2.33 (s, 6H, CH3); 13C 
NMR (75 MHz, CD3OD)  182.9 (C=S), 143.3 (C1), 132.7 (q, 2J = 33.0 Hz, C3), 
124.8 (q, 1J = 270.8 Hz, CF3), 123.7 (C2), 117.8 (C4), 58.6 (CH2CH2N(CH3)2), 45.5 
(CH3), 43.0 (CH2CH2N(CH3)2); IR (KBr) 3292 (NH), 1281 (C=S) cm-1; LC/TOF-
MS calcd for C13H16F6N3S 360.0964, found 360.0961 (M+H+); Anal. (%) calcd for 
C13H16F6N3S C, 43.45; H, 4.21; N, 11.69; found C, 43.44; H, 3.99; N, 11.60. 
NMR data for compound 8 was also obtained in CDCl3 at 25 oC and at 50 oC. 
1H NMR (300 MHz, CDCl3, 25 oC)  13.28 (br s, 1H, NHa), 7.96 (br s, 2H, H2), 
7.77 (br s, 1H, NHb), 7.58 (s, 1H, H4), 3.68 (app br s, 1H, CH2), 3.40 (app br s, 1H, 
CH2), 2.61 (app br s, 2H, CH2), 2.38 (app br s, 6H, CH3); 13C NMR (75 MHz, 
CDCl3)  183.0, 180.0, 142.1, 139.7, 131.8, 123.1, 122.7, 117.7, 61.3, 56.8, 45.0, 
43.4, 42.3.  
1H NMR (300 MHz, CDCl3, 50 oC)  7.93 (s, 2H, H2), 7.58 (s, 1H, H4), 3.52 (app br 
s, 2H, CH2CH2N(CH3)2), 2.59 (app br s, 2H, CH2CH2N(CH3)2), 2.32 (s, 6H, CH3); 
13C NMR (75 MHz, CDCl3, 50 oC)  181.9 (C=S), 141.1 (C1), 132.3 (q, 2J = 30.8 
Hz, C3), 123.1 (q, 1J = 271.1 Hz, CF3), 122.7 (C2), 117.9 (C4), 59.7 
(CH2CH2N(CH3)2), 44.9 (CH3), 43.0 (CH2CH2N(CH3)2). 
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1-(3,5-Bis(trifluoromethyl)phenyl)-3-(2-(diethylamino)ethyl)thiourea (9) 
 
The product was eluted with CHCl3:MeOH (90:10). Yellow oil (0.36 g, 92%); Rf: 
0.34 (CHCl3:MeOH, 90:10); 1H NMR (300 MHz, CD3OD)  8.19 (s, 2H, H2), 7.59 
(s, 1H, H4), 3.71 (app br s, 2H, CH2CH2N(CH3)2), 2.72-2.82 (m, 2H, 
CH2CH2N(CH3)2), 2.67 (q, J = 7.1 Hz, 4H, CH2-CH3), 1.07 (t, J = 7.1 Hz, 6H, CH3); 
13C NMR (75 MHz, CD3OD)  183.0 (C=S), 143.1 (C1), 132.7 (q, 2J = 33.0 Hz, C3), 
124.7 (q, 1J = 270.8 Hz, CF3), 123.6 (C2), 117.9 (C4), 51.8 (CH2CH2N(CH3)2), 48.2 
(CH2-CH3), 42.4 (CH2CH2N(CH3)2), 11.5 (CH3); IR (DCM film on NaCl plate) 3224 
(NH), 2977 (CH), 1280 (C=S) cm-1; LC/TOF-MS calcd for C15H20F6N3S 388.1277, 
found 388.1270 (M+H+). 
NMR data for compound 9 was also obtained in CDCl3 at 25 oC and at 50 oC. 
1H NMR (300 MHz, CDCl3, 25 oC)  8.05 (br s, 1H, NH), 7.91 (s, 2H, H2), 7.52 (s, 
1H, H4), 3.73 (app br s, 1H, CH2), 3.38 (app br s, 1H, CH2), 2.64 (m, 6H, CH2), 0.98 
(t, J = 7.3 Hz, 6H, CH3); 13C NMR (75 MHz, CDCl3)  182.8, 180.4, 141.7, 139.9, 
131.5, 123.3, 123.0, 117.6, 55.6, 50.6, 47.0, 44.1, 41.3, 10.4. 
1H NMR (300 MHz, CDCl3, 50 oC)  7.95 (s, 2H, H2), 7.53 (s, 1H, H4), 3.52 (app br 
s, 2H, CH2CH2N(CH3)2), 2.72 (app br s, 2H, CH2CH2N(CH3)2), 2.65 (q, J = 7.2 Hz, 
4H, CH2-CH3), 1.00 (t, J = 7.2 Hz, 6H, CH3); 13C NMR (75 MHz, CDCl3, 50 oC)  
182.3 (C=S), 141.1 (C1), 131.8 (q, 2J = 33.0 Hz, C3), 123.3 (C2), 123.0 (q, 1J = 
271.1 Hz, CF3), 117.6 (C4), 54.5 (CH2CH2N(CH3)2), 47.2 (CH2-CH3), 43.2 
(CH2CH2N(CH3)2), 10.6 (CH3). 
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1-(3,5-Bis(trifluoromethyl)phenyl)-3-cyclohexylthiourea (10)   
 
The product was eluted with CHCl3 (100%). White solid (0.35 g, 95%); m.p. 152-
156 oC; Rf: 0.31 (CHCl3 100%);  1H NMR (300 MHz, CDCl3)  8.42 (br s, 1H, 
NHa), 7.75 (s, 2H, H2), 7.68 (s, 1H, H4), 6.13 (br s, 1H, NHb), 4.19 (app br s, 1H, 
ipso CH*), 2.00-2.05 (m, 2H, CH*), 1.57-1.71 (m, 3H, CH*), 1.31-1.44 (m, 2H, 
CH*), 1.08-1.28 (m, 3H, CH*), these data match reported literature values106; 13C 
NMR (75 MHz, CDCl3)  179.1 (C=S), 139.0 (C1), 132.9 (q, 2J = 32.3 Hz, C3), 
123.8 (C2), 122.8 (q, 1J = 271.5 Hz, CF3), 119.2 (m, C4), 54.0 (ipso C*), 32.3 (C*), 
25.2 (C*), 24.5 (C*); IR (KBr) 3296 (NH), 1280 (C=S) cm-1; LC/TOF-MS calcd for 
C15H17F6N2S 371.1011, found 371.1014 (M+H+). 
* Cyclohexane ring. 
1-(3,5-Bis(trifluoromethyl)phenyl)-3-phenylthiourea (11) 
 
The product was eluted with CHCl3 (100%). White solid (0.33 g, 92%); m.p. 128-
130 oC; Rf: 0.44 (CHCl3 100%); 1H NMR (300 MHz, CDCl3)  8.89 (br s, 1H, 
NHb), 7.94 (s, 2H, H2), 7.88 (br s, 1H, NHa), 7.66 (s, 1H, H4), 7.44-7.49 (m, 2H, 
phenyl H), 7.30-7.38 (m, 3H, phenyl H); 13C NMR (75 MHz, CDCl3)  179.6 (C=S), 
139.5 (C1), 135.6 (phenyl C), 132.0 (q, 2J = 33.0 Hz, C3), 130.4 (phenyl CH), 128.2, 
(phenyl CH), 125.4 (phenyl CH), 124.7 (C2), 122.9 (q, 1J = 270.0 Hz, CF3), 119.3 
(m, C4), these data match reported literature values107; IR (KBr) 1275 (C=S) cm-1; 
LC/TOF-MS calcd for C15H11F6N2S 365.0542, found 365.0545 (M+H+). 
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1-(3,5-Bis(trifluoromethyl)phenyl)-3-(((1S,2S,4S,5R)-5-vinylquinuclidin-2-
yl)methyl)thiourea (12)  
 
The product was eluted with CHCl3:MeOH (90:10). White solid (0.41 g, 93%); m.p. 
53-57 oC (lit 54-59 oC)108; Rf: 0.47 (CHCl3:MeOH, 90:10); []D: +120 (c 0.2, DCM); 
1H NMR (300 MHz, CD3OD)  8.18 (s, 2H, H2), 7.60 (s, 1H, H4), 5.93 (ddd, J = 
17.7, 10.7, 7.1 Hz, 1H, CH=CH2), 5.04-5.11 (m, 2H, CH=CH2), 3.76 (app br s, 1H, 
CH2NHC=S), 3.55-3.63 (m, 1H, CH2NHC=S), 3.08-3.19 (m, 1H, H*), 2.85-2.95 (m, 
4H, H*), 2.31-2.39 (m, 1H, H*), 1.64-1.74 (m, 4H, H*), 1.37-1.45 (m, 1H, H*); 13C 
NMR (75 MHz, CD3OD)  182.8 (C=S), 143.3 (C1), 141.2 (CH=CH2), 132.8 (q, 2J 
= 31.5 Hz, C3), 124.8 (q, 1J = 270.0 Hz, CF3), 123.7 (C2), 117.8 (C4), 115.5 
(CH=CH2), 56.3 (CH*), 49.8 (CH2*), 47.8 (CH2*), 47.1 (CH2NHC=S), 40.9 (CH*), 
29.0 (CH*), 27.3 (CH2*), 26.3 (CH2*); IR (KBr) 3267 (NH), 2944 (CH), 1279 (C=S) 
cm-1; LC/TOF-MS calcd for C19H22F6N3S 438.1433, found 438.1435 (M+H+). 
NMR data for compound 12 was also obtained in CDCl3 at 25 oC and at 50 oC. 
1H NMR (300 MHz, CDCl3, 25 oC)  7.92 (s, 2H, H2), 7.47 (s, 1H, H4), 5.67-5.78 
(m, 1H, CH=CH2), 4.94-5.00 (m, 2H, CH=CH2), 3.44-3.64 (m, 1H, CH2NH2), 2.70-
3.20 (m, 5H, CH2NH2 and H*), 2.20-2.36 (m, 1H, H*), 1.73 (app br s, 1H, H*), 1.60 
(app br s, 3H, H*), 1.18-1.34 (m, 1H, H*); 13C NMR (75 MHz, CDCl3)  182.1, 
180.2, 142.1, 140.4, 138.3, 131.4, 122.8, 122.3, 117.1, 115.2, 58.5, 55.2, 47.9, 45.9, 
38.6, 27.1, 25.2, 24.4. 
1H NMR (300 MHz, CDCl3, 50 oC)  7.91 (s, 2H, H2), 7.57 (s, 1H, H4), 5.76-5.90 
(ddd, J = 17.2, 10.6, 6.7 Hz, 1H, CH=CH2), 5.01-5.11 (m, 2H, CH=CH2), 3.46-3.64 
(m, 1H, CH2NHC=S), 2.97-3.07 (m, 2H, CH2NHC=S and H*), 2.73-2.92 (m, 4H, 
H*), 2.30-2.38 (m, 1H, H*), 1.81 (app br s, 1H, H*), 1.59-1.71 (m, 3H, H*), 1.32-
Chapter II: A structure-activity relationship study of thiourea-based antibacterial agents 
93 
 
1.39 (m, 1H, H*); 13C NMR (75 MHz, CDCl3, 50 oC)  182.3 (C=S), 141.0 (C1), 
139.0 (CH=CH2), 131.6 (q, 2J = 33.0 Hz, C3), 123.1 (q, 1J = 270.8 Hz, CF3), 122.6, 
(C2), 117.7 (C4), 115.5 (CH=CH2), 58.5 (CH*), 48.3 (CH2*), 46.6 (CH2*), 46.3 
(CH2NHC=S), 39.2 (CH*), 27.6 (CH*), 25.9 (CH2*), 25.1 (CH2*). 
* Quinuclidine ring. 
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3.1 An Introduction to Quinolones 
During the synthesis of the antimalarial agent, chloroquine, chemists at Sterling-
Winthorp laboratories isolated compound 1 as a by-product (Figure 3.1). Due to the 
antibacterial properties exhibited by compound 1 a series of derivatives were 
synthesised in an attempt to find a novel antibacterial agent.109 In 1963, one of these 
derivatives, nalidixic acid, was introduced into the clinical settings for the treatment 
of UTIs (Table 3.1).109-110 Since the discovery of nalidixic acid numerous quinolone 
derivatives have been developed, many of which have made it to the clinical setting.  
 
Figure 3.1: By-product isolated during chloroquine production, compound 1.110 
Quinolones are classified into generations based on their spectrum of activity against 
bacteria (Table 3.1). The first-generation quinolones include the naphythyridone 
derivative, nalidixic acid, and the dioxolane bearing compounds, cinoxacin and 
oxolinic acid. These compounds were active against Enterobacteria with cinoxacin 
and oxolinic acid exhibiting increased activity in comparison to nalidixic acid.109 The 
introduction of a piperazine ring at C-7, as in pipemidic acid, gave rise to activity 
against P. aeruginosa.109 In the 1980’s, the combination of the C-7 piperazine and a 
fluorine atom at the C-6 position resulted in the fluoroquinolone, norfloxacin (Table 
3.1). In comparison to the first-generation quinolones, norfloxacin demonstrated 
improved anti-Gram-negative bacteria and some activity against Gram-positive 
bacteria.109 Replacement of the N-1 ethyl group with a cyclopropyl group produced 
one of the most well-known fluoroquinolones, ciprofloxacin (Table 3.1). 
Ciprofloxacin exhibited enhanced activity against both Gram-negative and Gram-
positive bacteria and was the first quinolone to be used in the treatment of infections 
other than UTIs.109     
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Table 3.1: Quinolone classification109,111 
Generation Quinolone Structure Activity Clinical application 
1st 
Nalidixic acid 
 
Anti-Gram-negative 
bacteria (Enterobacteria 
only) UTI 
Cinoxacin 
 
Oxolinic acid 
 
Pipemidic acid 
 
Introduction of anti-P. 
aeruginosa activity 
2nd 
Flumequine 
 
Anti-Gram-negative 
activity (less active than 
piperazinyl derivatives) 
UTI 
Norfloxacin 
 
Enhanced anti-Gram-
negative activity including  
P. aeruginosa and 
limited anti-Gram-positive 
activity 
UTI, sexually transmitted 
diseases, skin and soft 
tissue infections 
Ciprofloxacin 
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Table 3.1 continued 
3rd 
Levofloxacin 
 
Broad-spectrum activity 
with enhanced anti-Gram-
positive activity and anti-
pneomonoccal activity 
Respiratory tract infections 
Sparfloxacin 
 
4th 
Trovafloxacina 
 
Enhanced potency and 
expanded spectrum 
including anerobic 
bacteria 
As for 1st, 2nd, and 3rd 
generations 
Gemifloxacin 
 
In Development: 
Nemonoxacin (TG-
873870)112 
 
Enhanced anti-Gram-
positive activity including 
MDR S. pneumoniae and 
quinolone-resistant 
MRSA 
Skin infections and 
community-acquired 
pneumonia  
JNJ-Q2 (Avarofloxacin)113 
 
a Withdrawn due to adverse side effects. 
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In the third-generation quinolones the introduction of a C-8 moiety has led to 
improved activity against Gram-positive bacteria.109,111b The fourth-generation 
quinolones exhibit increased potency and a broader spectrum of activity, including 
anaerobic bacteria.109,111b Currently under development are two quinolone 
compounds JNJ-Q2 and nemonoxacin (Table 3.1). These compounds exhibit activity 
against MDR S. pneuminiae as well as quinolone-resistant MRSA.111b,112-113 
The quinolones are attractive antibacterial agents not only because of their broad 
spectrum activity but also because of their molecular target. Quinolone antibacterials 
work by interfering with bacterial DNA replication.109,114 DNA consists of two 
polynucleotide strands paired together through H-bonds which results in the 
formation of a double helix structure (Figure 3.2).14 During DNA replication, the two 
strands are unwound and pulled apart, forming a replication bubble, allowing each 
strand to act as a template for the synthesis of two new strands (Figure 3.2).14 DNA 
replication proceeds in both directions thus the replication bubble expands laterally, 
which can induce supercoiling ahead of the replication fork.14 
 
Figure 3.2: DNA replication. 
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In bacteria, an enzyme known as DNA gyrase (a type II topoisomerase) is 
responsible for relieving the strain caused by supercoiling during DNA 
replication.109,115 As shown in Figure 3.3, DNA gyrase is a tetramer consisting of 
two GyrA units and two GyrB units. When double stranded DNA (the G-segment) 
binds to the DNA gyrase a conformational change occurs resulting in the 
dimerization of the GyrA units, (2) Figure 3.3. The binding of ATP (indicated by *) 
initiates the dimerization of the ATPase which leads to the capture of a second 
segment of double stranded DNA, the T-segment (3). A conformational cascade 
occurs, leading to the cleavage of the G-segment and passage of the T-segment 
through the DNA gate (4). The G-segment is then resealed and the T-segment 
released (5), relieving the supercoiling. The GyrA units dimerise and ATP is 
hydrolysed regenerating the initial enzyme state.  
 
Figure 3.3: Topoisomerase II mechanism.114-115 
Quinolones can bind to the gyrase-DNA complexes resulting in a quinolone-
stabilised cleavage complex.109,111b,114 The stabilisation of the enzyme-DNA complex 
blocks replication fork movement and therefore inhibits DNA synthesis.111b,114 
However, this process is reversible meaning that other events must be involved in the 
bactericidal activity of quinolones.111b,114 Cell death is believed to occur as a result of 
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the release of DNA breaks.111b,114 The exact molecular mechanisms involved in the 
release of DNA breaks are not fully understood.111b,114 
Bacteria also have a second type II topoisomerase, known as topoisomerase IV. Like 
DNA gyrase, toposiomeras IV is a tetramer and is involved in the separation of 
linked DNA molecules.109 Topoisomerase IV is said to be the main target in Gram-
positive bacteria whereas DNA gyrase is believed to be the main target in Gram-
negative bacteria.109 A most favourable feature of the quinolone antibacterial agents 
is their selectivity for bacterial topoisomerase over mammalian topoisomerase. A 
number of quinolones, including ciprofloxacin, have demonstrated that much greater 
inhibitory concentrations are required to inhibit mammalian topoisomerase II 
reactions in comparison to those required to inhibit the bacterial enzyme reactions.116 
3.1.1 Aim 
The quinolones are broad spectrum antibacterial agents that have found use in a 
variety of infections including UTIs, sexually transmitted diseases, bone, skin and 
soft-tissue infections.117 Fluoroquinolones are also used in the treatment of 
tuberculosis and some quinolone derivatives have been shown to exhibit anticancer 
and anti-HIV activity.117 Modifications to the basic quinolone structure such as the 
introduction of the C-7 piperazine, a fluorine atom at C-6 and the N-1 cyclopropyl 
group have resulted in the generation of compounds with increased potency and an 
expanded spectrum of activity.109 However, as can be seen from Table 3.1 (section 
3.1) the C-3 carboxylic acid moiety, believed to be particularly important for the 
activity of the quinolones, has remained throughout the quinolone generations.  
In this study we wanted to synthesise a basic quinolone molecule with an alternative 
C-3 moiety, a bioisostere. A bioisostere is a group that can be used in place of 
another group while maintaining the desired biological activity.11 Bioisosteres are 
often used to investigate the structure-activity relationship of a drug or to replace 
substituents that are important for target interaction but responsible for toxic side 
effects.11 Replacement of a functional group with a bioisostere has also been shown 
to improve activity. For example, replacement of the amide moiety of the dopamine 
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antagonist, sultopride, with a pyrrole ring resulted in increased activity and 
selectivity (Figure 3.4). 
NHO
N
Et
EtO2S
OMe
EtO2S
OMe
NH
NEt
(a) (b)  
Figure 3.4: Replacement of the amide functionality of sultopride (a) by a non-
classical isostere pyrrole to give DU 122290 (b), resulted in increased activity and 
selectivity.11 
Tetrazoles are popular bioisosteres for carboxylic acids (Figure 3.5). Similar to a 
carboxylic acid, tetrazoles contain an acidic proton and are planar in structure.11 In 
comparison to the carboxylate anion, tetrazoles are also 10 times more lipophilic.11 
Furthermore, many modern day drugs contain the tetrazole moiety, for example, 
Cefazolin (Figure 3.6), a broad spectrum first generation cephalosporin antibiotic.118 
Therefore, in an effort to improve activity the 1H-tetrazole was chosen as the 
bioisostere for the quinolone C-3 carboxylic acid. 
 
Figure 3.5: Similarities in structure and acidity of the carboxylic acid, the (1H)-
tetrazole and the hydroxamic acid. 
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Figure 3.6: The tetrazole-containing antibiotic, Cefazolin. 
In addition to the C-3 tetrazole, a second functional group was chosen to replace the 
carboxylic acid moiety, a hydroxamic acid. Hydroxamic acids, as well as being 
acidic, also possess a similar structure to that of a carboxylic acid (Figure 3.5). 
Furthermore, a wide spectrum of biological properties have been associated with 
hydroxamic acids including, anticancer, antifungal and antibacterial activity.119    
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3.2 Results and Discussion 
The structure of each of the compounds synthesised in this section was elucidated 
using LC/TOF-MS, IR, 1H and 13C NMR spectoscopies. Starting materials were 
obtained commercially and used without further purification. 
The retrosynthetic analysis for the C-3 (1H)-tetrazole and its carboxylic acid 
analogue can be seen in Scheme 3.1.  
 
Scheme 3.1: Retrosynthetic analysis for the C-3 (1H)-tetrazole quinolone and its 
carboxylic acid analogue. 
Generation of the C-3 (1H)-tetrazole can be carried out via a 1,3-dipolar 
cycloaddition of an azide with the quinolone C-3 nitrile precursor, whilst hydrolysis 
of a C-3 carboxylate quinolone will give the carboxylic acid analogue. The C-3 
nitrile and carboxylate derivatives can be produced by the nucleophilic subsititution 
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reaction of piperazine and the fluorinated quinolone molecule. N-1 alkylation of the 
quinolone molecule, resulting from the electrophilic aromatic substitution of a 
phenylamino acrylate (or malonate in the case of the carboxylic acid derivative), can 
be carried out via the nucleophilic substitiution with ethyl iodide. The conjugate 
addition of aniline to a cyanoacetate, or a malonate in the case of the carboxylic acid 
derivative, generates the phenylamino acrylate (or malonate). 
3.2.1 Synthesis of the phenylamino acrylates 
The phenylamino acrylates 3.1 and 3.2 were synthesised using the procedure 
described by Stern et al.120 with modification (Scheme 3.2). Ethyl 
(ethoxymethylene)cyanoacetate and aniline (3-fluoroaniline in the case of 3.2) were 
allowed to reflux in EtOH for 45 minutes. On cooling, the product precipitated out of 
solution and the resulting solid was collected by filtration and washed with cold 
EtOH. 
 
Scheme 3.2: Synthesis of phenylamino acrylates 3.1 and 3.2. 
In the NMR spectra of 3.1 and 3.2 two sets of resonance signals were observed 
indicating the presence of two isomers, the (E)- and (Z)-isomers. Two broad doublets 
at approximately 11 ppm and 9 ppm for the NHs of each isomer were observed in the 
1H NMR spectra of each compound, 3.1 and 3.2, indicating successful addition of 
the aniline group. The loss of a set of ethoxy proton signals along with a shift in the 
vinyl proton signal in the 1H NMR spectra from 8.00 ppm to 8.37 and 7.87 ppm in 
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3.1 and 8.36 and 7.90 ppm in 3.2 further confirmed formation of the phenylamino 
acrylates.  
As mentioned in section 2.2.2, fluorine has I = ½ thus it can be detected using NMR 
spectroscopy. As shown in Figure 3.7, a fluorine substituent on an aromatic ring will 
give rise to characteristic C-F coupling constants for each of the carbon atoms in the 
ipso, ortho, meta and para positions. In a fluorinated aromatic ring the one-bond C-F 
coupling (ipso) is always large, approximately 245 Hz. Similarly to the C-F coupling 
in an aromatic ring characteristic three-bond, four-bond and five-bond H-F couplings 
can also be observed (Figure 3.7). 
 
Figure 3.7: Characteristic C-F and H-F coupling constants.91 
For 3.2, characteristic one-bond C-F coupling constants of 245.9 and 246.5 Hz for 
the carbon directly attached to the fluorine atom were observed, one for each isomer. 
For each isomer a 2J value of 21.8 Hz was also observed for the carbons ortho to the 
fluorine substituent and a 4J value of 3.0 Hz for the carbon in the para position. The 
3J values for the carbon atoms at the meta position in 3.2 were also in the 
characteristic three-bond C-F coupling constant range of 8-10 Hz. The presence of 
two isomers, along with H-H and H-F coupling in the 1H NMR spectrum of 3.2, 
gave rise to mulitplets for the protons of the fluorinated phenyl ring. Therefore, no 
H-F coupling constants could be calculated.      
A strong absorption band at 2211 and 2217 cm-1 for the (C≡N) was observed in the 
IR spectrum of 3.1 and 3.2, respectively. Both compounds were obtained as white 
solids, in good yield, and were used without further purification in the synthesis of 
3.5 and 3.6 (section 3.2.4). 
Chapter III: A study of quinolone antibacterial agents 
106 
 
3.2.2 Synthesis of the phenylamino malonates 
As shown in Scheme 3.3, the synthesis of the phenylamino malonates 3.3 and 3.4 
was carried out using the same method as that described for 3.1 and 3.2 above. 
Compounds 3.3 and 3.4 were obtained in good yields of 80% and 82%, respectively, 
and used without further purification.  
NH2
CO2EtEtO2C
OEt
CO2EtEtO2C
HN
X
X
EtOH
3.3: X= H
3.4: X = F
X= H or F
 
Scheme 3.3: Synthesis of phenylamino malonates 3.3 and 3.4. 
In the 1H NMR spectra of both 3.3 and 3.4 a broad doublet at approximately 11 ppm 
was observed for the NH proton indicating formation of the products. The NH 
protons of each compound were found to couple to the vinyl CH proton, having a 3J 
value of approximately 13 Hz, further confirming the formation of the phenylamino 
malonates. In the 13C NMR spectra of 3.3 and 3.4 two carbon signals for each of the 
ester carbonyl carbons were observed. The 13C signals for the carbons of the phenyl 
ring of 3.3 at 117.2, 124.9, 129.8 and 139.3 ppm were also observed.  
For 3.4, the presence of the fluorine substituent resulted in characteristic C-F 
coupling constants for each of the phenyl ring carbon atoms with the largest of these 
being 245.3 Hz for the one-bond coupling of the fluorine atom to the ipso carbon. A 
doublet at 103.9 and 110.0 ppm with 2J values in the range of 21-26 Hz were 
assigned as the ortho carbon atoms with the meta carbon atoms observed at 140.6 
and 130.8 ppm having a characteristic 3J value of approximately 10 Hz. The 13C 
resonance signal for the carbon para to the fluorine substituent was observed at 
112.4 ppm with the smallest C-F coupling constant of 2.3 Hz. As was observed for 
3.2, the presence of H-H and H-F coupling resulted in multiplets being observed for 
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the protons of the fluorinated phenyl ring in the 1H NMR spectrum, thus no H-F 
coupling constants could be calculated. 
3.2.3 Synthesis of the quinolones 
N
H
O
2
3
45
6
7
8 1
8a
4a
 
Figure 3.8: Quinolone structure with numbering system for 1H and 13C NMR 
shown. 
3.2.4 The 3-carbonitrile quinolone derivatives  
As shown in Scheme 3.4, the quinolone 3.5 was synthesised via the intramolecular 
electrophilic aromatic substitution reaction of 3.1. The reaction was carried out using 
a procedure described by Stern et al.120 Compound 3.1 was added slowly to hot 
diphenyl ether (240 oC). The solution was brought to reflux for four hours after 
which the reaction mixture was allowed to cool and petroleum ether was added. The 
resulting solid precipitate was collected by filtration and washed with petroleum 
ether to give the crude quinolone in 71% yield.      
 
Scheme 3.4: Electrophilic aromatic substitution of 3.1. 
In the IR spectrum the (C≡N) absorption was observed at 2224 cm-1 and the ketone 
(C=O) absorption at 1628 cm-1. In the 1H NMR spectrum only one set of resonance 
signals were observed with the loss of the ethyl ester proton signals indicating 
formation of the quinolone product. As with the 1H NMR spectrum, the 13C NMR 
spectrum was much simpler in comparison to the quinolone precursor with only one 
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13C signal observed for the ketone C=O at 174.4 ppm.  A large downfield shift 
(117.3 to 125.0 ppm) of the 13C signal, for the phenyl ring ortho carbon of 3.1, was 
observed confirming the C-C bond formation of C-4a to C-4 (Figure 3.8 and Scheme 
3.4). 
The synthesis of the fluorine derivative, 3.6, was carried using the same procedure as 
was described for 3.5 above. In the IR spectrum of 3.6 a strong absorption band at 
2228 cm-1 was observed for (C≡N). As with 3.5, loss of the –OCH2CH3 proton 
signals, in the 1H NMR spectrum, indicated formation of a quinolone. However, 
unlike 3.5, two sets of resonance signals were observed in both the 1H and 13C NMR 
spectra of 3.6.  
It was thought that each set of resonance signals may represent a different 
regioisomer (Scheme 3.5). From the 1H NMR spectrum, a ratio of 1.00:0.30 was 
found for 3.6a:3.6b, respectively. As depicted in Scheme 3.5, the production of the 
two regioisomers could result from nucleophilic attack at the carbonyl carbon from 
one of two possible carbon atoms of the phenyl ring. The atomic radius of a fluorine 
atom is greater than that of the hydrogen atom.121 Therefore, the presence of the 
fluorine atom at C-5 may be sterically less favourable, resulting in the generation of 
only a small proportion of the 5-fluoro quinolone, 3.6b.   
CN
NH
R1 EtO
O
R2
N
H
O
F N
H
OF
CN CN
N
H
OF
CN
H
N
H
O
CN
H
F
3.6a
R1 = F, R2 = H
or
R1 = H, R2 = F
3.6b  
Scheme 3.5: Proposed reaction mechanism for the synthesis of regioisomers 3.6a 
and 3.6b. 
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In the 1H NMR spectrum, two 1H signals were observed at 8.75 and 8.68 ppm in the 
form of singlets, each having an integral of one. These were believed to be the 1H 
signals of H-2 of each of the products. Focusing on the product of greatest 
abundance, a signal with an integral of one was observed at 8.18 ppm in the 1H 
NMR spectrum. Considering its chemical shift, it is most likely the 1H signal of 
either H-5 or H-8. However, as it was a doublet of doublets, and if this set of 
resonance signals were of the 7-fluoro derivative 3.6a, then this 1H signal belonged 
to H-5. For this doublet of doublets at 8.18 ppm, the coupling constants were 8.8 and 
6.3 Hz. These J values are within the range of both the H-H ortho coupling as well 
as three- and four-bond H-F coupling. Using a C-H correlation NMR experiment, it 
was found that this 1H signal corresponded to a 13C signal with a C-F coupling 
constant of 11.3 Hz. A J value characteristic of a 3J C-F coupling and therefore 
confirms that the 1H signal at 8.18 ppm represents H-5. The observed J values of 8.8 
and 6.3 Hz correspond to the ortho H-H coupling between H-5 and H-6 and the four-
bond H-F coupling, respectively. 
Examination of the 1H NMR spectrum of the compound of least abundance reveals a 
doublet of doublets at 7.17 ppm. It was thought that this set of resonance signals 
belonged to the 5-fluoro derivative (3.6b), and as they are the most shielded 1H 
signal, they most likely belonged to either H-6 or H-8. The two J values calculated 
for the doublet of doublets were found to be 11.8 and 8.1 Hz. For a typical ortho H-
H coupling, the 3J value falls within the range of 6.0 to 9.0 Hz, a range consistent 
with the J value of 8.1 Hz but not with the second J value obtained for the 1H signal 
at 7.17 ppm. Although the coupling constant of 11.8 Hz is outside that of a typical 
aromatic 3J value it is very similar to that observed for the three-bond C-F coupling 
of 1-fluoronaphthalene (10.7 Hz).91 The C-H correlation NMR experiment showed 
that the 1H signal at 7.17 ppm corresponded to a 13C signal with a C-F coupling 
constant of 22.5 Hz (Table 3.2). This J value is consistent with the characteristic 2J 
C-F coupling, thus confirming that the 1H signal is that of H-6. 
The presence of the fluorine substituent proved very useful in the characterisation of 
these quinolone products. As shown in Table 3.2, C-F coupling constants 
characteristic of fluorine coupling to ipso, ortho, meta and para carbon atoms were 
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observed for each set of resonance signals. Further analysis of the mixture of 
products using COSY and HSQC equivalent NMR experiments together with the 
observed C-F coupling constants confirmed the connectivity of the carbon atoms as 
shown in Figure 3.9. 
Table 3.2: The C-F coupling constants observed for 3.6a and 3.6b. 
Quinolone 1J (Hz) 2J (Hz) 3J (Hz) 4J (Hz) 
Fluorobenzene91 245 20-26 8-10 4 
3.6a 248.9 23.3, 24.8 12.9, 11.3  1.5 
3.6b 259.9 22.5, 9.8 9.9, 4.5 4.5 
 
 
Figure 3.9: Structures of (a) 3.6a (b) 3.6b. 
3.2.5 The 3-carboxylate quinolone derivatives 
Quinolone 3.7 was synthesised as described by Lager et al.122 (Scheme 3.6). The 
procedure was carried out in the same way as was described for quinolones 3.5 and 
3.6 above, however, only a one hour reflux was required. A four hour reflux in 
diphenyl ether resulted in a complex mixture being returned. The resulting white 
solid quinolone was obtained in 72% yield and was used in the next step without 
further purification (section 3.2.8). 
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3.7: X = H
3.8: X = F
X = H or F  
Scheme 3.6: Synthesis of 3.7 and 3.8. 
In the 1H NMR spectrum of 3.7, the loss of both the ethoxy group proton signals and 
the 1H signal of one phenyl CH proton indicated formation of the bicycle. A large 
downfield shift in the 13C signal for an ortho carbon atom of the phenyl ring in 3.3, 
from 124.9 to 127.2 ppm, signified formation of the C4a-C4 bond. The presence of 
only one carbonyl 13C signal, the ketone carbon, at 173.4 ppm further confirmed 
formation of 3.7. In the IR spectrum obtained for 3.7 a strong absorption band at 
1698 cm-1 for the (C=O) of the ketone was observed. 
As shown in Scheme 3.6, the synthesis of 3.8 was carried out using the same 
procedure as was described for 3.7. Again, loss of the 1H signals for the protons of 
the ethyl ester, together with a loss of a phenyl proton signal in the 1H NMR 
spectrum, indicated formation of the product. However, two sets of resonance signals 
were observed in the 1H NMR spectrum. It was presumed that the two sets of signals 
were the result of a mixture of the 5-fluoro and 7-fluoro derivatives (Figure 3.10), as 
was observed for 3.6 above. From the 1H NMR spectrum, the mixture of the isomers 
was found to be in a ratio of 1.00:0.08, 3.8a:3.8b.  
Focusing on the product of greater abundance, in the 1H NMR spectrum, a doublet of 
doublets was observed at 8.22 ppm. The coupling constants associated with this 1H 
signal were found to be 9.1 and 6.1 Hz. These values are consistent with ortho H-H 
and four-bond H-F coupling constants. Considering the chemical shift and observed 
J values, it was thought that this 1H signal was that of the C-5 proton of the 7-fluoro 
quinolone derivative. A C-H correlation NMR experiment found that the 1H signal 
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corresponded to a 13C signal with a characteristic C-F 3J value (10.5 Hz, Table 3.3), 
thus confirming that the 1H signal at 8.22 ppm was that of H-5.  
 
Figure 3.10: Proposed structures of the 7-fluoro- and 5-fluoro quinolone derivatives. 
As shown in Table 3.3, the calculated C-F coupling constants of 3.8a were found to 
be characteristic of a fluorine atom coupling to the ipso, ortho, meta and para carbon 
atoms of an aromatic ring. Together with the COSY and HSQC equivalent NMR 
experiments, these results were found to be consistent with the 7-flouro quinolone 
derivative, 3.8a, as shown in Figure 3.10. 
Table 3.3: The C-F coupling constants observed for 3.8a. No 4J value was observed 
for 3.8b.  
Quinolone 1J (Hz) 2J (Hz) 3J (Hz) 4J (Hz) 
Fluorobenzene91 245 20-26 8-10 4 
3.8a 248.3 24.8, 22.5 10.5, 12.8 - 
 
Due to the generation of only a small quantity of what was thought to be the 5-fluoro 
derivative, 3.8b Figure 3.10, the H-H and C-F coupling constants of 3.8b could not 
be calculated. However, the structure of this second isomer will be discussed in more 
detail in section 3.2.8. 
3.2.6 Alkylation of the quinolones 
3.2.7 N-1 alkylation of the 3-carbonitrile quinolones 
The alkylation of quinolone 3.5 was initially carried out using the method described 
by Frank and Mesaros123 with modification. A mixture of quinolone 3.5 (Scheme 
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3.7) and K2CO3 in triethylphosphate, were brought to reflux for one hour. The 
reaction mixture was cooled to room temperature followed by the addition of 
deionised water. The resulting precipitate was collected by filtration and purified by 
precipitation from DCM with n-hexane to give N-alkyl quinolone 3.9 (Scheme 3.7). 
Although the reaction was successful, only yields of 45% were obtained and 
repetition of the purification step was often required resulting in further loss of 
material. Thus an alternative method was explored. 
A review of the literature revealed a procedure whereby the quinolone can be 
alkylated using ethyl iodide with K2CO3 as base.124 Compound 3.5 was dissolved in 
DMF and stirred at room temperature for two hours with ethyl iodide and K2CO3 
followed by heating at 80 oC for three hours (Scheme 3.7). Upon cooling, the 
reaction mixture was reduced in concentration by removal of the solvent in vacuo 
followed by the addition of water. The resulting precipitate was collected by 
filtration and purified by precipitation from DCM with n-hexane. It was found that 
the two hour stirring step was not necessary and that 3.9 could be obtained in similar 
yields when the reaction was carried out at 80 oC for three hours with no prior 
stirring at room temperature (Scheme 3.7). Using this procedure, 3.9 was obtained in 
a yield of 72% after purification. 
 
1-H-quinolone R3 R5 R7 1-Ethyl-quinolone 
3.5 C≡N H H 3.9 
3.6a C≡N H F 3.10a 
3.6b C≡N F H 3.10b 
 
Scheme 3.7: Quinolone alkylation, (i) K2CO3, EtI, DMF at 80 oC for 3 h. 
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In the 1H NMR spectrum of 3.9 the appearance of a new triplet at 4.40 ppm and 
quartet at 1.49 ppm representing the protons of the N-ethyl group indicated N-1 
alkylation. The 3J value for both the triplet and quartet was calculated to be 7.1 Hz, a 
value characteristic of vicinal H-H coupling in a saturated system. The 
corresponding 13C signals were observed at 48.3 (CH2) and 14.2 ppm (CH3) in the 
13C NMR spectrum together with a shift in the C-2 and C-8a 13C signals, further 
confirming formation of 3.9. 
The N-1 alkylation of 3.6 to give 3.10 was carried out as shown in Scheme 3.7. As 
mentioned earlier, the cyclisation of 3.2 resulted in the generation of two 
regiosiomers (3.6a and 3.6b, section 3.2.4). Considering the small quantity of the 5-
fluoro isomer (3.6b) that was obtained the crude mixture of isomers was used in the 
alkylation reaction thus producing two N-ethyl quinolone products, 3.10a and 3.10b 
in a yield of 72% and 15%, respectively (Scheme 3.7). The alkylated 5-fluoro and 7-
fluoro quinolone derivatives were then separated by silica gel column 
chromatography. 
The presence of two new 13C signals at approximately 49.0 ppm and 14.0 ppm in the 
13C NMR spectrum of both 3.10a and 3.10b together with a shift in the C-2 13C 
signals indicated the addition of the ethyl group. In the 1H NMR spectra of 3.10a and 
3.10b two new signals, a triplet and quartet, were also observed. For each quinolone 
a 3J coupling constant of 7.1 Hz was observed for both the triplet and quartet 
confirming that these 1H signals represented the protons of the CH2 and CH3 
components of the new ethyl group.  
In addition to 1H and 13C NMR experiments, NOEdiff (Nuclear Overhauser Effect 
difference) experiments were used to assess the H-H spatial proximity within the 
quinolone structures in an effort to further confirm alkylation at the N-1 position as 
opposed to O-alkylation (Figure 3.11). 
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Figure 3.11: Possible O-alkyl and N-alkyl products. 
NOEdiff experiments allow us to determine which two protons (or groups of 
protons) in a molecule are in close proximity to one another by using through-space 
coupling. The NOE is the change in intensity of one resonance due to the relaxation 
of another neighbouring saturated signal.125 In a NOEdiff experiment a 1H signal can 
be selectively irradiated, resulting in a build-up of NOE at a neighbouring 1H 
resonance which can then be detected by the NMR spectrometer.125 Thus, it can be 
used to determine which protons (or group of protons) are spatially close to one 
another by selectively irradiating a 1H resonance and observing which other 1H 
resonances are detected.125 
The resulting spectra from the NOEdiff experiments of 3.10a are given in Figure 
3.12. The first hydrogen chosen to be irradiated was H-2. As can be seen in Figure 
3.12, spectrum (a), irradiation of H-2 resulted in an increase in intensity of the 1H 
resonance signals of the CH2 and CH3 groups presenting a positive NOE of 8% and 
2%, respectively. Irradiation of the 1H resonance signal of the CH2 group was also 
carried out (spectrum (b) Figure 3.12). Both signals for H-2 and H-8 showed 
increased intensities resulting in a positive NOE of 15% and 13%, respectively. 
These results confirm alkylation at N-1 of 3.10a. 
NOEdiff experiments were also carried out for 3.10b, the results of which were 
similar to that observed with 3.10a thus confirming N-alkylation (Appendix B, 
Figure B1). 
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Figure 3.12: NOEdiff spectra obtained for 3.10a. 
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3.2.8 Alkylation of the 3-carboxylate quinolones 
 
1-H-quinolone R3 R5 R7 Alkyl quinolone Alkylation 
3.7 CO2Et H H 3.11a N 
3.7 CO2Et H H 3.11b O 
3.8a CO2Et H F 3.12a O 
3.8a CO2Et H F 3.12b N 
3.8b CO2Et F H 3.12c N 
 
Scheme 3.8: Quinolone Alkylation, (i) K2CO3, EtI, DMF at 80 oC for 3 h. 
Quinolone 3.7 was alkylated to give 3.11 using the same method as was described 
for 3.9 and 3.10 above (Scheme 3.8). Analysis of the crude product by 1H NMR 
spectroscopy revealed two sets of resonance signals for what appeared to be two 
different alkylated quinolones. Using silica gel column chromatography the two 
quinolone products, 3.11a and 3.11b, were separated. 
In the 1H NMR spectrum of each product a new set of 1H signals characteristic of an 
ethyl group were observed indicating successful alkylation. To confirm alkylation at 
N-1, NOEdiff experiments were carried out on both products. The resulting spectra 
of the NOEdiff experiments of 3.11a are given in Figure 3.13 and 3.14. 
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Figure 3.13: NOEdiff spectra obtained for 3.11a. 
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Figure 3.14: NOEdiff spectra obtained for 3.11a. 
The first hydrogen chosen for irradiation was H-2. As can be seen in Figure 3.13, 
spectrum (a), irradiation of H-2 resulted in an increase in the 1H signal intensity of 
one of the CH2 groups (4.41 ppm). The 1H signal for the same CH2 group was 
irradiated in a subsequent NOEdiff experiment the result of which was an increase in 
the intensity of the 1H signals for H-2 and a second aromatic CH, H-8. Both signals 
for H-2 and H-8 presented a positive NOE of 15% and 13%, respectively (spectrum 
(b), Figure 3.13). As shown in Figure 3.13, these results indicate that the ethyl group 
is attached at N-1 in 3.11a. Finally, upon irradiation of the second CH2 group 
protons at 4.22 ppm, an increase in the 1H signal intensity was observed for the 
attached CH3 group only (spectrum (a), Figure 3.14). No other 1H signal increased in 
intensity, suggesting that this CH2 group belongs to the C-3 ester ethyl moiety. 
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The spectra obtained from the NOEdiff experiments of 3.11b are given in Figure 
3.15. The similarity in chemical shift of the CH2 signals made it difficult to irradiate 
only one of the signals. However, looking at the resulting spectrum it can be seen 
that the 1H signal for the attached CH3 group plus the 1H signal of an aromatic CH 
increased in intensity (Figure 3.15). Although the 1H signal of H-2 also appears to 
have increased in intensity, this increase is less than 1% and may be a result of the 
slight irradiation of the ester CH2 1H signal. These results suggest that the ethyl 
group is not attached at N-1. 
 
 
Figure 3.15: NOE spectra of 3.11b. Both signals for CH3 and an aromatic CH 
showed increased intensities presenting a positive NOE of 6% and 2%, respectively. 
To ensure that this was the case, a second NOEdiff experiment was carried out 
wherein H-2 was irradiated. As seen in Figure 3.16, irradiation of H-2 did not 
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increase the intensity of any other 1H signal thus H-2 is not in close proximity to the 
new ethyl group. 
 
Figure 3.16: Irradiation of H-2 in 3.11b (CDCl3) did not increase the intensity of 
any other 1H signal. 
Further analysis of 3.11b by 13C NMR spectroscopy revealed two 13C signals at 
165.3 and 164.2 ppm. By comparison, in the 13C NMR spectrum of 3.11a, the 13C 
signal for the ester carbonyl carbon was observed at 164.6 ppm whilst the C-4 
carbonyl carbon signal was observed further downfield at 172.7 ppm. These results, 
together with the results from the NOEdiff experiments, suggest that alkylation also 
occurred at the C-4 oxygen atom thus generating 3.11b (Figure 3.17). 
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Figure 3.17: Structures of N-ethyl and O-ethyl quinolones, 3.11a and 3.11b. 
During alkylation, the deprotonation of the quinolone NH gives rise to a negative 
charge on the nitrogen atom (Scheme 3.9). As shown in Scheme 3.9, quinolone 3.7 is 
a highly conjugated system thus electrons can delocalise around the ring from the 
nitrogen atom to the C-4 carbonyl oxygen atom resulting in alkylation at the C-4 
oxygen. 
 
Scheme 3.9: Proposed mechanism for the synthesis of 3.11b. 
The synthesis of 3.12 was carried out using the same procedure described above in 
Scheme 3.8. As with 3.10, the starting material was a mixture of two isomers and it 
was assumed that two N-ethyl quinolones would be produced. As expected, analysis 
by TLC revealed two spots, however, an additional third spot was also observed. 
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Silica gel column chromatography was carried out and each of the products were 
isolated. 
The first product to elute was 3.12a. Analysis by 1H NMR spectroscopy revealed 
two sets of signals characteristic of an ethyl group, that is, one doublet and triplet for 
the CH2 and CH3 of the ester ethyl group and a second doublet and triplet for the 
protons of the new ethyl group. The C-F coupling constants were calculated from the 
13C NMR spectrum and are given in Table 3.4. As can be seen from Table 3.4 the C-
F coupling constants corresponded to the characteristic ranges for 1J, 2J, 3J, and 4J C-
F coupling. These values, together with the observed 13C and HSQC equivalent 
NMR spectra, suggested that the fluorine atom was at the C-7 position in 3.12a. 
Additionally, the ester C=O quaternary 13C signal was observed at 164.1 ppm, 
together with a second quaternary 13C signal at 165.1 ppm, indicating that 3.12a may 
be an O-ethyl derivative, similar to 3.11b above. 
Table 3.4: C-F coupling constants for 3.12a, 3.12b and 3.12c. 
Quinolone 1J (Hz) 2J (Hz) 3J (Hz) 4J (Hz) 
Fluorobenzene91 245 20-26 8-10 4 
3.12a 250.5 24.7, 20.0 10.8, 12.0 1.13 
3.12b 246.8 22.5, 27.0 11.3, 12.0 2.25 
3.12c 264.8 21.8, 6.9 11.0, 3.0 4.7 
 
To confirm O-alkylation, differential NOE experiments were carried out on 3.12a 
the results of which are shown in Figure 3.18. As can be seen in the NOEdiff 
spectrum, irradiation of H-2 did not result in a significant increase in intensity of any 
other 1H signal. A similar outcome was observed in the NOEdiff spectrum of 3.11b 
above (Figure 3.16), thus, 3.12a is also an O-alkyl derivative (Figure 3.18). 
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Figure 3.18: NOEdiff spectrum for irradiation of H-2 in 3.12a. 
The second product to be eluted was 3.12b, in a yield of 73%. In its 13C NMR 
spectrum, the appearance of two new peaks at approximately 14.0 and 48.0 ppm 
indicated addition of the ethyl group.  The 13C signal for the ester carbonyl carbon 
was observed at 164.4 ppm, with an additional quaternary 13C signal at 172.1 ppm, 
characteristic of C-4. The J values for the coupling of the fluorine substituent to the 
ipso, ortho, meta and para carbon atoms were obtained from the 13C NMR spectrum 
and are shown in Table 3.4. In addition to the C-F J values in Table 3.4, the 13C, 
HSQC equivalent and COSY NMR experiments, suggested that the fluorine 
substituent is at C-7 of the quinolone.  
The presence of an additional triplet at 4.38 ppm and quartet at 1.35 ppm in the 1H 
NMR spectrum 3.12b also indicated formation of the alkyl product. Assessment of 
Chapter III: A study of quinolone antibacterial agents 
125 
 
the spatial proximity of H-H using differential NOE experiments confirmed 
alkylation at N-1 (Appendix B, Figure B2). A melting point range of 126-130 oC was 
also obtained for 3.12b and found to correspond with the literature m.p. of 128-129 
oC.126 Together, these results suggest that 3.12b is ethyl 1-ethyl-7-fluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate (Scheme 3.8). 
As mentioned in section 3.2.5, cyclisation of 3.4 resulted in the generation of two 
products, 3.8a and 3.8b. However, the structure of only one of these products, the 
abundant 7-fluoro quinolone 3.8a, could be fully characterised. Having isolated both 
an N-ethyl and O-ethyl 7-fluoro quinolone derivative it was believed that the third 
and final alkylation reaction product, 3.12c (Scheme 3.8), was most likely the 
alkylated derivative of the second quinolone product obtained in the cyclisation of 
3.4.  
After separation by silica gel column chromatography, 3.12c was obtained with a 
yield of 3%. In the 1H NMR spectrum, the presence of two triplets and two quartets 
in the range of 4.20-4.40 ppm and 1.35-1.55 ppm, respectively, indicated that two 
ethyl groups were attached to the quinolone compound. One set of signals belonging 
to the C-3 ethyl ester protons and the second belonging to the protons of the new 
ethyl group. To determine if the new ethyl group was attached to either the nitrogen 
atom at position one or the C-4 oxygen atom, an assessment of the H-H spatial 
proximity was carried out using differential NOE experiments. 
The hydrogen chosen for irradiation was H-2 (spectrum (a), Figure 3.19). As a 
result, one CH2 signal showed increased signal intensity presenting a positive NOE 
of 8%, thus suggesting that alkylation had occurred at N-1. The 1H signal for the 
same CH2 group was irradiated and resulted in an increase in intensity of three 1H 
signals, CH3, H-2 and an aromatic CH (spectrum (b), Figure 3.19). These results 
confirm alkylation at N-1. 
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Figure 3.19: 1H and NOEdiff spectra of 3.12c. 
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In the 13C NMR spectrum the 13C signal for the ester carbonyl carbon was observed 
at 165.8 ppm with a second quaternary 13C signal at 173.3 ppm for C-4, further 
confirming that O-alkylation had not occurred. The C-F coupling constants were 
obtained from the 13C NMR spectrum and are given in Table 3.4. It can be seen that 
the calculated C-F J values correspond to the characteristic coupling constants for 
one-, two-, three- and four-bond C-F coupling. These values, in conjunction with C-
H correlation and COSY NMR experiments, suggest that the fluorine substituent is 
at C-5 on the quinolone molecule 3.12c (Figure 3.19). A C-F coupling constant of 
2.3 Hz was also observed for C-4, further indicating that the fluorine substituent is at 
the C-5 position. 
3.2.9 Hydrolysis of the quinolone carboxylates 
Hydrolysis of 3.11a was carried out using a procedure described by Sayyed et al.127 
The method involves ester hydrolysis under basic conditions as shown in Scheme 
3.10. 
OEt
O
OH
OEt
O OH
OH
O
EtO
N
O
N
O
N
O
3.133.11a
 
Scheme 3.10: Base-catalysed ester hydrolysis. 
Compound 3.11a was dissolved in a methonal:water solution of KOH and brought to 
reflux for three hours, after which, the methanol was removed under reduced 
pressure. Water was added to the remaining solution and acidified with HCl to give 
3.13 (Scheme 3.10) as a white solid with a yield of 95%. 
In the 1H NMR spectrum of 3.13, the loss of the 1H signals for the ethyl protons, 
together with the appearance of a broad singlet at 15.27 ppm for the –OH proton,  
indicated formation of the carboxylic acid. A downfield shift in the carbonyl 13C 
signal from 172.7 ppm to 177.6 ppm, due to the loss of the –CH2CH3, further 
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confirmed formation of the carboxylic acid. These NMR data were found to be in 
agreement with the reported literature values127, thus confirming the structure of 3.13 
(Scheme 3.10).  
The procedure described for the hydrolysis of 3.11a above was also used for the 
hydrolysis of the 7-fluoro derivative 3.12b. As with 3.11a, the loss of the ethyl group 
1H signals together with a downfield shift in the carbonyl 13C signal (172.1 ppm to 
176.9 ppm) indicated formation of the carboxylic acid. However, a new sharp singlet 
at 3.99 ppm was also observed in the 1H NMR spectrum. In addition to this new 
peak, the 13C NMR spectrum appeared to be less complex, in comparison to the ester 
precursor, as no peak splitting was observed. The lack of C-F coupling in the 13C 
NMR spectrum suggested that the fluorine substituent had been removed from C-7. 
A 19F NMR experiment was carried out and confirmed that this was indeed the case. 
 
Scheme 3.11: Loss of the C-7 fluorine substituent resulted in the formation of 3.15. 
Taking these results into account, it was believed that perhaps a nucleophilic 
methoxide ion, generated during the hydrolysis reaction, had attacked the 
electrophilic C-7 thus replacing the fluorine substituent and resulting in the 
formation of a 7-methoxy quinolone (Scheme 3.11). These NMR data presented here 
are consistent with the structure of 3.15 and were found to be in agreement with 
reported literature data128, thus confirming the structure of 3.15. 
Having lost the fluorine substituent during hydrolysis by the method described by 
Sayyed et al.127 an alternative method was employed for the hydrolysis of 3.12b 
(Scheme 3.12). 
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Scheme 3.12: Ester hydrolysis, (i) dioxane:H2O, LiOH, at 50 oC for 30 mins.129 
Quinolone 3.12b was dissolved in a 1:1 dioxane:H2O mixture followed by addition 
of  LiOH. The reaction was allowed to stir at 50 oC for 30 minutes after which the 
solvent was removed under reduced pressure followed by the addition of water. The 
solution was acidified and the resulting white precipitate collected by filtration. 
A 19F NMR experiment was carried out, the result of which confirmed the presence 
of the fluorine substituent. In the 1H NMR spectrum the loss of the triplet and quartet 
signals of the ester ethyl group indicated generation of the carboxylic acid. In the 13C 
NMR spectrum, the C-5, C-6, C-7 and C-8 13C signals exhibited characteristic C-F 
coupling constants, further confirming the presence of the fluorine substituent. A 
downfield shift in the 13C signal for the carbonyl carbon, from 172.1 ppm to 176.8 
ppm, also indicated formation of the carboxylic acid. The m.p. range of 126-130 oC 
obtained for 3.14 was found to be in agreement with the literature m.p. range of 128-
129 oC126, thus confirming the formation of the carboxylic acid derivative 3.14. 
3.2.10 Synthesis of the C-7 piperazine quinolones 
The C-7 piperazine quinolones were synthesised via a nucleophilic substitution 
reaction (Scheme 3.13). Quinolone 3.10a (or 3.14) and piperazine were dissolved in 
pyridine and allowed to reflux for 16 hours, after which the solvent was removed 
under reduced pressure.130 The resulting residue was purified from cold EtOH to 
give the solid product, 3.16, in a yield of 57% (86% for 3.17). 
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Scheme 3.13: Synthesis of 7-piperazine quinolone derivatives. 
In the 1H NMR spectrum of 3.16, the appearance of two additional peaks at 3.32 and 
2.85 ppm, each having an integral of four, signified formation of the C-7 piperazine 
quinolone. The two corresponding 13C signals were found at 47.7 and 45.2 ppm in 
the 13C NMR spectrum. Consistent with replacement of the fluorine substituent by a 
less electronegative nitrogen atom, a large upfield shift of the C-7 13C signal from 
164.9 to 154.4 ppm was also observed. Additionally, the 13C NMR spectrum was 
less complex in comparison to the C-7 precursor, having only singlets. No C-F 
coupling was observed in the 13C NMR spectrum, indicating replacement of the 
fluorine substituent with the new piperazine group. A 19F NMR experiment, having 
no 19F signal, further confirmed the loss of the fluorine substituent. 
Similar to 3.16 (Scheme 3.13), the appearance of two new peaks in the 1H NMR 
spectrum of 3.17, at 3.40 and 2.85 ppm for the piperazine CH2’s, were observed. In 
the 13C NMR spectrum, the corresponding 13C signals were observed at 47.7 and 
45.3 ppm. In addition to the piperazine 13C signals, no C-F coupling was observed, 
with all 13C signals appearing as singlets. A large upfield shift of approximately 10 
ppm, of the C-7 13C signal indicated replacement of the fluorine substituent with the 
piperazine group. Furthermore, no signal was observed in the 19F NMR spectrum, 
thus confirming loss of the C-7 fluorine atom. 
The synthesis of the N-methylpiperazine quinolones, 3.18 and 3.19, was carried out 
using the same method as described for 3.16 and 3.17 above (Scheme 3.13). Similar 
to the piperazine derivatives, the appearance of two new signals, at approximately 
Chapter III: A study of quinolone antibacterial agents 
131 
 
3.40 and 2.60 ppm, suggested formation of the C-7 piperazine derivatives, 3.18 and 
3.19 (Scheme 3.13). An additional singlet, at approximately 1.50 ppm, with an 
integral of three for the three equivalent protons of the piperazine N-Me was also 
observed in each of the quinolone’s 1H NMR spectra. In the 13C NMR spectra of 
both 3.18 and 3.19, all of the 13C signals appeared as singlets and no C-F coupling 
was observed indicating loss of the fluorine substituent. This was confirmed by 19F 
NMR experiments of each quinolone. The replacement of the C-7 fluorine 
substituent by the N-methylpiperazine group was further confirmed by an upfield 
shift of approximately 10 ppm for the C-7 13C signal. 
3.2.11 Synthesis of tributyltin azide (TBTA) 
The synthesis of TBTA was carried out using the procedure described by Gernon 
(Scheme 3.14).131 A solution of sodium azide in distilled water and tributyltin 
chloride in diethyl ether were shaken together for 10 minutes. The organic and 
aqueous phases were separated followed by a second diethyl ether extraction of the 
aqueous layer. TBTA was obtained as a yellow oil (74%) after removal of the diethyl 
ether solvent.  
 
Scheme 3.14: Synthesis of TBTA. 
In the 1H NMR spectrum of TBTA, a triplet at 0.93 ppm was observed for the 
protons of the three CH3 groups, with the 1H signals of the CH2 groups presenting as 
three multiplets in the region of 1.20-1.70 ppm. A 13C signal for the carbons of the 
three equivalent CH3 groups was observed at 13.6 ppm, with the 13C signals for the 
carbons of the CH2 groups being observed at 27.8, 26.9 and 15.4 ppm. A strong 
absorption at 2073 cm-1, characteristic of the azide stretching frequency, was 
observed in the IR spectrum, thus confirming formation of TBTA. 
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3.2.12 Synthesis of quinolone (1H)-tetrazoles 
The (1H)-tetrazoles were synthesised via a 1,3-dipolar cycloaddition reaction as 
shown in Scheme 3.15. In this study, the azide was employed as the 1,3-dipole 
whilst the dipolarophile was the quinolone C-3 nitrile. The [2+3] cycloaddition is 
known to occur, traditionally, by a concerted mechanism (Scheme 3.15).132 
However, it has also been suggested to occur via a two-step, anionic process wherein 
the nucleophilic azide attacks the nitrile first followed by ring closure.132b,133 
 
Scheme 3.15: Concerted mechanism of the 1,3-dipolar cycloaddition of a nitrile and 
azide.132a 
Tetrazoles can be synthesised via the neat reaction of a nitrile with TBTA.134 Thus, 
initial synthesis of the C-3 tetrazole quinolone 3.20 (Figure 3.21) was carried out by 
the neat reaction of 3.9 with TBTA under nitrogen gas. The reaction was monitored 
using IR spectroscopy, with the disappearance of the (C≡N) at ca. 2220 cm-1 and 
(N3) at ca. 2070 cm-1 indicating completion. Reactions were carried out at 60, 140 
and 175 oC for one hour. However, as can be seen in the IR spectra below, the 
absorption bands of (C≡N) and (N3) were still observed (Figure 3.20). The 
reaction was repeated with overnight heating at 175 oC and again both the nitrile and 
N3 absorption bands remained. Thus, the reaction was repeated at 200 oC overnight 
(15 hours). The resulting IR spectrum (Appendix B, Figure B3) indicated that the 
reaction had gone to completion. The tributyltin moiety was cleaved, using HCl, 
producing 3.20 in 75% yield. 
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Figure 3.20: IR spectra of the reaction of TBTA with 3.9 at (a) 60 oC, (b) 140 oC 
and (c) 175 oC degrees after one hour. All samples were prepared as KBr discs. 
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In the 1H NMR spectrum, a shift in the 1H signals was observed, with the largest 
shift, from 8.86 ppm to 9.11 ppm, being observed for H-2, indicating formation of 
the tetrazole. A large downfield shift in the 13C signal for C-3 (93.5 ppm to 104.5 
ppm) was also observed in the 13C NMR spectrum. Additionally, the 13C signal of 
the nitrile carbon exhibited a dramatic downfield shift of approximately 30 ppm. 
This result is consistent with the addition of three electronegative nitrogen atoms, 
thus confirming formation of the C-3 tetrazole. Both 1,5- and 2,5-tetrazoles can be 
formed, with the CN4 13C signals usually found at ca. 155.0 and 162.0 ppm, 
respectively.132a,135 For 3.20, the chemical shift of the CN4 13C signal was 150.1 ppm 
and is, therefore, consistent with the (1H)-tetrazole product (Figure 3.21). 
 
Figure 3.21: 1-Ethyl-3-(1H-tetrazol-5-yl)quinolin-4(1H)-one. 
Although the synthesis of 3.20 employing TBTA as the azide source was successful, 
cleavage of the tributyltin group proved difficult and often had to be repeated. 
Therefore, an alternative synthetic method was investigated. 
Tetrazoles have also been synthesised by the reaction of sodium azide with a nitrile 
in the presence of a Lewis acid.136 Coordination of the Lewis acid can cause a 
decrease in the energy difference between the HOMO and LUMO of the reactants, 
therefore, resulting in a faster reaction.136a The synthesis of 3.20 was attempted using 
sodium azide and AlCl3 with DMF as the reaction solvent (Scheme 3.16).136b 
However, after 24 hours only starting material was returned. Thus, an alternative 
method was sought. 
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Scheme 3.16: Synthesis of 3.20. (i) NaN3, AlCl3, DMF, 24 h.  
Another method of tetrazole synthesis employs ammonium azides as the 1,3-dipole. 
It has been suggested that the reaction occurs via the two-step anionic pathway, 
however, it has also been demonstrated that tetraalkylammonium salts are not 
competent dipoles whereas, ammonium azides bearing a proton, are.132b,133 
Computational studies by Himo et al.132b have demonstrated that the proton may be 
involved in activating the nitrile, as shown in Figure 3.22. 
 
Figure 3.22: Proposed stepwise reaction by activation of the nitrile by a proton.132b 
A. The tetrazole reaction proceeds via intermediate P when a proton is available. B. 
When NH4+ is the proton source, it is believed that intermediate P can form via two 
possible pathways (1) a neutral NH3 mediates the transfer of a proton from the azide 
to the nitrile or by (2) which involves a NH4+ and azide ion (N3-). The ammonium-
mediated reaction was found to have a barrier lower than that in the concerted 
mechanism of the anionic [2+3] cycloaddition. 
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An attempt to synthesise 3.20 was also carried out using a modified procedure of that 
described in reference 137 (Scheme 3.17). As shown in Scheme 3.17, the reaction 
was carried out using various ratios of reactants with the best result obtained from 
the reaction of 3.9 with 11 equivalents of sodium azide and ammonium chloride 
(method C). After 27.5 hours, the solvent was removed and the remaining residue 
dissolved in water. Acidification of the solution resulted in precipitation of the 
product. Production of 3.20 by this method was confirmed by 1H and 13C NMR 
spectroscopies. 
 
Method 3.9 NaN3 NH4Cl LiCl 3.20 % yield 
A 1 2.2 2.2 0.7 12 
B 1 5.5 5.5 1.74 63 
C 1 11 11 3.48 83 
 
Scheme 3.17: Synthesis of 3.20 using ammonium azide.137 Table presents the 
equivalents of the reactants used and the resulting % yields. 
Further confirmation of the structure of 3.20 was obtained by X-ray crystallography. 
The yellow, needle-shaped crystals of 3.20 were obtained from a DMF/water 
solution. The crystal structure is shown in Figure 3.23, with crystal data and 
structure refinement for 3.20 given in Tables B4-B6 (Appendix B). 
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Figure 3.23: Crystal structure of 3.20. 
Molecules of 3.20 were linked into pairs by H-bonds between the C-4 C=O and 
tetrazole N-1 H atom and these pairs were -stacked. The individual stacks were 
linked via H-bonds to water (Figure 3.24). Similar types of -stacking interactions 
have been observed with nalidixic acid.138 It has been suggested that these 
interactions play a role in the binding of the quinolone molecule to its target. Shen et 
al.138 have proposed that once one quinolone molecule has bound to the DNA target, 
through H-bonds with the carbonyl oxygen atoms, a second molecule can then bind, 
not only through H-bonds but also through interactions with its neighbouring 
quinolone. Therefore, the drug is granted a strong binding affinity to the target by 
acquiring extra binding domains.   
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Figure 3.24: Crystal packing diagram of 3.20. 
Having successfully synthesised 3.20 the synthesis of 3.21 was attempted using the 
same procedure as was described for 3.20 above (Scheme 3.18). The reaction was 
again monitored by IR spectroscopy, with the disappearance of the (C≡N) at ca. 
2220 cm-1 and (N3) at ca. 2070 cm-1 used as an indicator for reaction completion. 
After 27.5 hours, a weak absorption band for (C≡N) was observed in the IR 
spectrum. A sample was taken from the reaction mixture and the acid work-up 
carried out. In the 1H NMR spectrum of the product resulting from the mini work-up, 
two sets of resonance signals were observed. One set of the 1H resonance signals 
appeared to be starting material, 3.16. A singlet, belonging to the second set of 1H 
resonance signals, was shifted downfield from the 1H singlet for H-2 of 3.16 to ca. 
9.00 ppm. A similar result was observed with the H-2 1H signal of 3.9 and 3.20, thus 
suggesting formation of a possible tetrazole product. However, after a full work-up 
of the reaction of 3.16 in the synthesis of 3.21, the resulting product produced a 
complex 1H NMR spectrum. The product mixture was analysed by TLC but the 
crude product remained baseline with a variety of mobile phases and hence could not 
be purified and fully characterised. 
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Scheme 3.18: Synthesis of the (1H)-tetrazole quinolone, 3.21. (i) NaN3, NH4Cl, LiCl 
in DMF at 110 oC for 27.5 h. 
In an effort to synthesise a 7-piperazine quinolone bearing a tetrazole at C-3 the N-
methylpiperazine quinolone 3.18 (Scheme 3.19) was synthesised as described earlier 
in section 3.2.10. It was hoped that the presence of the methyl group in place of the 
hydrogen atom on the C-7 piperazine (3.22, Scheme 3.19) would facilitate better 
separation by column chromatography. Therefore, the reaction was repeated as for 
3.21 above but with 3.18 instead (Scheme 3.19). 
 
Scheme 3.19: Synthesis of the (1H)-tetrazole quinolone, 3.22. (i) NaN3, NH4Cl, LiCl 
in DMF at 110 oC for 27.5 h. 
Again, the reaction was monitored by IR spectroscopy. However, after 27.5 hours 
two medium absorptions for the (C≡N) and (N3) were observed, therefore, the 
reaction was allowed to continue for a further 24 hours. Again, the IR spectrum 
contained both the (C≡N) and (N3) absorptions. The reaction was allowed to 
continue and was monitored every 24 hours. Only after 14 days did the reaction 
appear to have gone to completion, thus the acid work-up was carried out. Upon 
acidification, however, no precipitate formed. The water was removed under reduced 
pressure and the resulting crude product analysed by 1H NMR spectroscopy. In the 
1H NMR spectrum, a complex mixture was observed. From the TLC it appeared that 
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the starting nitrile, 3.18, may be present, however, the crude mixture could not be 
separated. 
The formation of tetrazoles is greatly influenced by the substituent on the nitrile. 
Electronegative substituents assist the formation of the partial positive charge on the 
nitrile carbon atom, which in turn, facilitates the approach of the azide ion.132b,133,139 
Therefore, it was thought that, as the quinolone molecule has a highly conjugated 
system, perhaps the presence of the electronegative C-7 fluorine substituent, in place 
of the piperazine groups, would be more favourable for reaction. Replacement of the 
C-7 fluorine substituent with a piperazine group could then be carried out in a 
subsequent reaction by the method described earlier in section 3.2.10.  
In a final attempt to synthesise a 7-piperazine quinolone derivative bearing a C-3 
tetrazole group the reaction was carried out using the C-7 fluoro quinolone,  3.10a, 
in place of the C-7 piperazine derivative, 3.18 (Scheme 3.20). The reaction was 
monitored using IR spectroscopy and, as was observed with 3.21 and 3.22, long 
reaction times were required before completion of the reaction appeared to have 
occurred. The acid work-up was carried out as for 3.20, 3.21 and 3.22, but again a 
complex mixture was observed in the 1H NMR spectrum. A 19F NMR experiment 
was also carried out. Similar to that observed with the hydrolysis of 3.12b with KOH 
under reflux conditions (section 3.2.9), no 19F signal was observed, suggesting that 
the fluorine substituent had been removed during the reaction. 
 
Scheme 3.20: Synthesis of the (1H)-tetrazole quinolone, 3.23. (i) NaN3, NH4Cl, LiCl 
in DMF at 110 oC for 27.5 h. 
Quinolone 3.20 was synthesised in good yield, however, when the same method was 
applied to 3.16, 3.18 and 3.10a a complex mixture resulted. As mentioned above, the 
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type of substituent attached to the nitrile is important in the synthesis of tetrazoles, 
with electronegative substituents assisting in the activation of the nitrile.132b,133,139 
Considering that the piperazine and fluorine substituents are seven bonds away from 
the nitrile and, in particular, that the fluorine substituent is a good electron-
withdrawing group, it seems unlikely that these substituents are having a negative 
effect on the activation of the nitrile. Perhaps the problem lies with C-7 itself. The 
presence of the fluorine substituent at C-7 results in the carbon atom becoming 
electrophilic. Indeed, it is this property which allows for the formation of the C-7 
piperazine quinolone derivatives (section 3.2.10). Therefore, perhaps the 
electrophilic nature of C-7 in the 7-fluoro quinolone interferes with the formation of 
the tetrazole due to competing SNAr with N3- acting as the nucleophile. The loss of 
the fluorine substituent, during the reaction of 3.10a in an attempt to synthesise 3.23 
(Scheme 3.20), supports this theory. 
3.2.13 Esterification of levofloxacin 
The C-3 ethyl ester of levofloxacin, 3.24, was synthesised using acid catalysed 
esterification (Scheme 3.21). The ethyl ester product was obtained as a white solid in 
a yield of 87%. 
 
Scheme 3.21: Esterification of levofloxacin. H2SO4 was employed as the acid for 
this reaction. 
In the 13C NMR spectrum, two new peaks were observed at 60.8 and 14.5 ppm for 
the new CH2 and CH3 groups, respectively. Consistent with the replacement of the 
carboxylic acid –OH by an –OEt group, an upfield shift from 176.9 ppm to 172.8 
ppm in the 13C signal of the C-3 carbonyl carbon was observed. In the 1H NMR 
spectrum a new triplet, at 1.39 ppm, having an integral of three, was observed for the 
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three equivalent protons of the ethyl CH3 group. The expected quartet 1H signal for 
the protons of the ethyl CH2 group was found at the same chemical shift (m at 4.27-
4.40 ppm) as the 1H signals for the morpholine ring CH and CH2 (C-12 and C-11) 
protons. This was confirmed by COSY and C-H correlation NMR experiments. 
Formation of the ethyl ester of levofloxacin was further confirmed by LC/TOF-MS, 
which returned a (M+H+) of 390.1843 for C20H25FN3O4. 
3.2.14 Synthesis of the quinolone C-3 hydroxamic acid 
In an effort to synthesise a quinolone derivative with enhanced activity, the well-
known quinolone, levofloxacin, was chosen as the quinolone derivative for 
modification with the hydroxamic acid.  The synthesis of a C-3 hydroxamic acid 
derivative of levofloxacin, 3.25, was first attempted using the coupling reagents 
HOBt and TBTU, in the presence of Et3N, with DMF as the reaction solvent 
(Scheme 3.22). 
 
Scheme 3.22: Synthesis of levofloxacin C-3 hydroxamic acid 3.25. Reaction carried 
out under nitrogen, (i) HOBt, TBTU, Et3N, DMF, 10 min (ii) NH2OH.HCl, Et3N, 
DMF, 24 h, rt. 
Coupling reagents are most commonly used in the synthesis of peptides.140 TBTU is 
a (1H)-benzotriazole-based coupling reagent that is believed to exist as both the 
uronium and aminium salt in solution (Figure 3.25).140-141 These uronium/aminium 
salts work by activating the carboxylic acid moiety which in turn facilitates the 
nucleophilic attack of an amine, resulting in formation of an amide bond.141 
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Figure 3.25: TBTU (a) uronium salt and (b) aminium salt.140-141 
As shown in Scheme 3.23, the deprotonated carboxylic acid nucleophile attacks the 
electrophilic centre of TBTU. The resulting intermediate reacts with HOBt, 
generating the activated ester. Attack at the carbonyl carbon of the activated ester, by 
the amine, results in the formation of the amide bond. When carrying out the 
reaction, the carboxylic acid is usually stirred with base and the activating agent 
(TBTU) for approximately 10 minutes, to ensure formation of the activated ester, 
prior to the addition of the amine.     
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Scheme 3.23: HOBt/TBTU coupling mechanism.141 
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After 24 hours the solvent was removed under reduced pressure and the resulting 
residue analysed by 1H NMR spectroscopy. In the 1H NMR spectrum, only the 
starting material appeared to be present with no shifts in the 1H signals being 
observed. Thus, an alternative coupling method was attempted. 
COMU, shown in Figure 3.26, is a relatively new coupling reagent.142 The presence 
of the oxyma leaving group in place of a benzotriazole along with the replacement of 
a dimethylamino group by a morpholino moiety enhances stability, solubility and 
reactivity of the reagent.142-143 As mentioned earlier, the benzotriazole-type coupling 
reagents, such as TBTU, are believed to co-exist as the uronium and aminium salts. 
However, COMU exists solely as the more reactive uronium structure.142,144 
Additionally, the by-products formed by COMU are water soluble, allowing their 
removal by simple extraction.143,145 
 
Figure 3.26: COMU coupling reagent with the oxyma moiety shown in red. 
The synthesis of 3.25 was attempted using COMU coupling as described in Scheme 
3.24. After 24 hours, the solvent was removed under reduced pressure and the 
resulting residue was analysed by 1H NMR spectroscopy. As with the previous 
HOBt/TBTU coupling reaction, in the 1H NMR spectrum, no shifts were observed 
for the levofloxacin 1H signals, suggesting that only starting material was returned. 
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Scheme 3.24: Synthesis of 3.25 under COMU coupling conditions.143 The reaction 
was carried out under nitrogen, (i) DIEA, 0 oC, 10 min, (ii) NH2OH.HCl, DIEA, 10 
min, (iii) COMU, 0 oC, 1 h followed by 24 h, rt. 
After the unsuccessful attempts to synthesise 3.25, using two different coupling 
reagents, a trial coupling reaction was carried out in an effort to determine if a simple 
amine could be coupled to the C-3 carboxylic acid of levofloxacin. As shown in 
Scheme 3.25, a reaction of levofloxacin with n-butylamine using standard coupling 
conditions of HOBt/TBTU in the presence of Et3N was carried out. 
 
Scheme 3.25: Synthesis of 3.26. (i) HOBt, TBTU, nBuNH2, DMF, 24 h, rt. 
In the 1H NMR spectrum, the appearance of a triplet at 0.92 ppm for the protons of 
the n-butylamine –CH3 group was observed, together with mulitplets at ca. 1.58 and 
1.40 ppm for the protons of the n-butyl –CH2 groups, indicating formation of 3.26. A 
triplet at 9.95 ppm was also observed for the NH proton confirming generation of the 
amide bond. A small shift in the 1H signal of H-5 was also observed. An upfield shift 
of the 13C signal of the C-3 carbonyl carbon, from 177.0 ppm to 175.5 ppm, was 
observed in the 13C NMR spectrum, further confirming formation of the amide 
derivative. 
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These results prove that a simple amine can be coupled to the carboxylic acid of 
levofloxacin. However, 3.26 was obtained in a low yield of 42% suggesting that this 
reaction, although successful, is not very efficient in the synthesis of a simple 
levofloxacin carboxamide. Therefore, an alternative synthetic approach was sought. 
Reddy et al.146 have demonstrated the synthesis of a variety of aliphatic and aromatic 
hydroxamic acid derivatives, in yields of 80-95%, using ethylchloroformate and 
NH2OH.HCl (Scheme 3.26). The reaction of the carboxylic acid with 
ethylchloroformate in the presence of base should produce the ester derivative 
bearing a better leaving group in comparison to the carboxylic acid –OH (Scheme 
3.26). This, in turn, should facilitate attack by the hydroxylamine, resulting in 
formation of the hydroxamic acid derivative.   
 
 
Scheme 3.26: Synthesis of 3.25. 
Hydroxylamine hydrochloride was dissolved in MeOH and added to a stirred 
solution of KOH in MeOH at 0 oC. After stirring for 15 minutes the solution was 
filtered. Levofloxacin was dissolved in DCM followed by the addition of EtCO2Cl 
and NMM (as base) at 0 oC. The solution was stirred for 10 minutes followed by 
filtration. The resulting filtrate was added to the freshly prepared hydroxylamine 
followed by stirring at room temperature for 30 minutes after which the solvent was 
removed under reduced pressure. The resulting 1H NMR spectrum of the crude 
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product appeared to be a mixture of reactants, with no shifts observed in the 1H 
signals of levofloxacin. 
In a final attempt to synthesise the C-3 hydroxamic acid derivative of levofloxacin, a 
reaction of the C-3 ethyl ester of levofloxacin with hydroxylamine hydrochloride 
was carried out (Scheme 3.27).147 Levofloxacin ethyl ester, 3.24, was synthesised as 
described earlier in section 3.2.13. A methanol solution of 3.24 was added slowly to 
a solution of hydroxylamine and allowed to stir at room temperature for 24 hours. 
After 24 hours, the reaction mixture was acidified (pH 6) using concentrated HCl. 
The solvent was concentrated under reduced pressure and the resulting precipitate 
collected by filtration. 
 
Scheme 3.27: Synthesis of 3.25. 
In the 1H NMR spectrum of the resulting white solid, the disappearance of the 1H 
signals for the ethyl group protons indicated formation of the hydroxamic acid. A 
downfield shift of the 13C signals for C-2 (145.1 ppm to 146.4 ppm) and the C-3 
carbonyl carbon (172.8 ppm to 176.4 ppm) was observed in the 13C NMR spectrum. 
The strong absorption bands of the carboxylic acid and ketone (C=O) at 1719 cm-1 
and 1617 cm-1, respectively, had shifted to 1722 cm-1 and 1623 cm-1, further 
indicating formation of 3.25 (Scheme 3.27). LC/TOF-MS also confirmed formation 
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of the C-3 hydroxamic acid derivative of levofloxacin returning a (M+H+) of 
390.1843. 
3.2.15 In vitro antibacterial activity 
Each of the compounds, the quinolones and their precursors (Appendix B, Table B1-
B3), described in section 3.2, were evaluated for their antibacterial activity against E. 
coli, P. aeruginosa and S. aureus using the susceptibility assay described in section 
1.2.5.  
In general, the quinolone precursors, the phenylamino malonates and acrylates, were 
inactive against all three bacteria. The 1-H-quinolones also exhibited little or no 
activity against all three bacteria. Alkylation at the N-1 position of the quinolones 
did not improve activity, in comparison to the 1-H-quinolones, with the N-ethyl 
quinolone derivatives also exhibiting little or no activity against each of the three 
bacteria tested. 
Neither the C-3 carboxylic acid derivative 3.13 nor the C-3 tetrazole derivative 3.20 
exhibited an MIC50 against any of the bacteria, with the greatest bacteriostatic 
activity (although minimum) achieved only at the highest concentration of 100 
g/mL (Table 3.5). However, on comparing 3.13 to 3.20, similar activity was 
observed for both compounds against E. coli, P. aeruginosa and S. aureus (Table 
3.5). This result suggests that although the replacement of the carboxylic acid with 
the tetrazole bioisostere did not improve activity, it also does not appear to have 
decreased the activity of the quinolone. This result contradicts the earlier studies by 
Gilis et al.148, wherein the presence of a tetrazole at C-3 of nalidixic acid diminished 
the antibacterial activity exhibited by nalidixic acid. 
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Table 3.5: Percentage growths of 3.13 versus 3.20 as a function of concentration of 
each compound. 
Quinolone Concentration (g/mL) 
E. coli P. aeruginosa S. aureus 
% Growth % Growth % Growth 
3.13 
25 88 100 100 
50 82 92 96 
100 77 74 81 
3.20 
25 91 95 98 
50 90 94 96 
100 88 79 91 
 
As shown in Graph 3.1, 3.2 and 3.3, the addition of the piperazine moiety at C-7 
greatly improved the bacteriostatic activity of the quinolones, not only against P. 
aeruginosa, but also against E. coli and S. aureus. In particular, 3.17 exhibited 
greatest activity against P. aeruginosa (Graph 3.2), producing an MIC50 in the range 
of 12.50-18.75 g/mL. A similar trend in activity was also observed with the 
addition of the piperazine to 3.10 to give 3.16. The addition of the N-
methylpiperazine at C-7 of 3.14 also improved the antibacterial activity against both 
P. aerugionsa and S. aureus but resulted in a decrease in activity against E. coli 
(Graph 3.1, 3.2, and 3.3). For the nitrile derivative, 3.18, the presence of the C-7 N-
methylpiperazine moiety resulted in similar activity to that of 3.16. Although the 
addition of the piperazine (and N-methylpiperazine) was advantageous for activity 
against all three bacteria, the nitrile derivatives, 3.16 and 3.18, were less active in 
comparison to the carboxylic acid derivatives, 3.17 and 3.19. 
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Graph 3.1: Activity profile for the C-7 quinolone derivatives versus E. coli. 
 
Graph 3.2: Activity profile for the C-7 quinolone derivatives versus P. aerugionsa. 
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    Graph 3.3: Activity profile for the C-7 quinolone derivatives versus S. aureus. 
The bacteriostatic activity of levofloxacin versus the C-3 hydroxamic acid derivative 
of 3.25, are summarised in Table 3.6. The results are expressed as the MIC50, the 
minimum inhibitory concentration that is required to inhibit 50% of bacterial growth. 
As can be seen in Table 3.6, 3.25 exhibited similar activity against both the Gram-
negative bacteria, E. coli and P. aeurginosa, as well as the Gram-positive bacterium, 
S. aureus. In comparison to levofloxacin, 3.25 demonstrated similar activity against 
E. coli, S. aureus and P. aeruginosa (Table 3.6). Furthermore, the bacteriostatic 
activity of 3.25 increased with increasing concentration, resulting in an MIC90 in the 
range of 1.17-1.56 g/mL against P. aeruginosa, which is an MIC90 value similar to 
that exhibited by levofloxacin. 
Table 3.6: Antibacterial activity as MIC50 range, values are mean of three 
experiments. 
Compound 
E. coli P. aeruginosa S. aureus 
M g/ml M g/ml M g/ml 
Levofloxacin 0.54-1.08 0.2-0.39 1.62-2.16 0.59-0.78 3.24-4.33 1.17-1.56 
3.25 1.56-2.08 0.59-0.78 1.04-1.56 0.39-0.59 1.56-2.08 0.59-0.78 
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3.2.16 Conclusion 
In this study, the synthesis of a (1H)-tetrazole and hydroxamic acid quinolone 
derivatives was undertaken. For comparison, the carboxylic acid analogues were also 
synthesised. The structure of each synthesised compound was elucidated by means 
of LC/TOF-MS, 1H and 13C NMR and IR spectroscopies. 
The synthesis of the quinolone compounds involved formation of the phenylamino 
acrylates or malonates, which were then cyclised, followed by alkylation at N-1. It 
was found that cyclisation of the phenylamino acrylates and malonates bearing a 
fluorine substituent resulted in the generation of two regioisomers, the 5-fluoro and 
7-fluoro quinolones. Additionally, with the carboxylate derivatives, both N-ethyl and 
O-ethyl derivatives were generated during alkylation, the structures of which were 
confirmed by NOEdiff NMR experiments. The carboxylate derivatives were 
hydrolysed and the 7-fluoro quinolones were then used in the synthesis of the 7-
piperazine derivatives. 1-Ethyl-3-(1H-tetrazol-5-yl)quinolin-4(1H)-one (3.20) was 
successfully synthesised with a yield of 83%. However, the synthesis of a 7-
piperazine derivative bearing a tetrazole moiety proved difficult and could not be 
generated using the same method. 
The X-ray crystal structure was obtained for 3.20, and revealed that the quinolone 
molecules were linked into pairs by H-bonds between the C-4 C=O and tetrazole N-1 
H atom and that these pairs were -stacked.  
The synthesis of the C-3 hydroxamic acid derivative was carried out by the reaction 
of levofloxacin with hydroxylamine hydrochloride. Initial attempts employing 
different coupling reagents or ethylchloroformate were unsuccessful. However, the 
levofloxacin C-3 hydroxamic acid derivative was successfully synthesised in the 
simple reaction of hydroxylamine with the ethyl ester of levofloxacin. 
Each of the quinolone compounds and their precursors were evaluated for their 
bacteriostatic activity against two Gram-negative bacteria (E. coli and P. aeruginosa) 
and a Gram-positive bacterium, S. aureus. The phenylamino acrylates and malonates 
were found to be inactive against each of the bacteria tested. In general, the 
quinolones exhibited similar activity, although poor, against each of the bacteria. In 
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comparison to the carboxylate analogue, the C-3 tetrazole derivative exhibited 
similar activity against all three bacteria. Addition of a piperazine or N-
methylpiperazine at C-7, resulted in improved activity against all three bacteria, 
exhibiting MIC50 values in the range of 25-100 g/mL.  
The hydroxamic acid derivative of levofloxacin, 3.25, however, was the quinolone 
that exhibited greatest activity against each of the bacteria. Compound 3.25 
demonstrated an increase in activity with increasing concentration against each of 
the bacteria with greatest activity observed against P. aeruginosa (MIC90 1.17-1.56 
g/mL). Although the presence of the hydroxamic acid did not improve on the 
bacteriostatic activity of levofloxacin, the results obtained were similar (Table 3.6, 
section 3.2.15). 
3.2.17 Future work 
Tetrazoles have been shown to from complexes with a variety of metal ions.149 
Additionally, the coordination of metal ions to quinolone compounds have resulted 
in enhanced activities.150 As mentioned earlier the bacteriostatic activity exhibited by 
both the C-3 tetrazole and its carboxylic acid analogue, although poor, was very 
similar. Taking this into account, an investigation into the complexation of metal 
ions with the quinolone tetrazole derivative may generate a quinolone with enhanced 
activity. 
An initial study into the complexation of the (1H)-tetrazole, 3.20, with copper(II) 
chloride in MeOH was carried out. The IR spectrum of the resulting green precipitate 
suggested that coordination had occurred. Thus, further investigations into metal 
complexes of a (1H)-tetrazole quinolone derivative could be carried out. 
Additionally, considering hydroxamic acids are well known for their role as 
siderophores119b, an investigation into the metal complexation of the hydroxamic 
acid quinolone could also be carried out. The bacteriostatic activity results obtained 
for 3.25 were very similar to those exhibited by the parent compound, levofloxacin. 
The complexation of metal ions to 3.25 may enhance its antibacterial activity. 
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3.3 Experimental 
General procedure for the synthesis of 3.1 and 3.2 
Ethyl (ethoxymethylene)cyanoacetate (50 mmol) and the appropriate aniline (50 
mmol) were dissolved in EtOH (25 mL) and heated to reflux for 45 minutes. The 
reaction mixture was allowed to cool to room temperature. On cooling, the product 
precipitated out of solution and the resulting solid was collected by filtration and 
washed with ice-cold EtOH. In each case, the crude product was used for the next 
step without further purification. 
Ethyl 2-cyano-3-(phenylamino)acrylate (3.1) 
 
White solid (10.42 g, 96%), 1.00:0.63 mixture of isomers; m.p. 90-94 oC (lit 108 
oC)151; 1H NMR (300 MHz, CDCl3) 10.73 (d, J = 13.4 Hz, 1H, NH), 8.59 (d, J = 
14.8, 1H, NH), 8.37 (d, J = 14.8 Hz, C=CH), 7.87 (d, J = 13.4 Hz, 1H, C=CH), 7.33-
7.39 (m, 4H, E & Z isomers, phenyl CH), 7.14-7.20 (m, 4H, E & Z isomers, phenyl 
CH), 7.07 (d, J = 7.3 Hz, 2H, E & Z isomers, phenyl CH), 4.22-4.30 (m, 4H, E & Z 
isomers, CH2), .29-1.35 (m, 6H, E & Z isomers, CH3), these data match reported 
literature values152; 13C NMR (75 MHz, CDCl3) 167.5 (C=O), 164.6 (C=O), 151.9 
(C=CH), 151.8 (C=CH), 138.6 (phenyl C), 138.3 (phenyl C), 130.0 (phenyl CH), 
129.9 (phenyl CH), 125.7 (phenyl CH), 125.5 (phenyl CH), 117.9 (CN), 117.3 
(phenyl CH), 117.2 (phenyl CH), 115.7 (CN), 77.2 (C-CN), 75.4 (C-CN), 61.2 
(CH2), 14.4 (CH3), 14.3 (CH3); IR (KBr) 3441 (NH), 2211 (CN) cm-1; LC/TOF-MS 
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calcd for C12H13N2O2 217.0972, found 217.0975 (M+H+); Anal. (%) calcd for 
C12H12N2O2 C, 66.64; H, 5.60; N, 12.96; found C, 66.49; H, 5.68; N, 12.92.  
Ethyl 2-cyano-3-((2-fluoro)phenylamino)acrylate (3.2) 
 
White solid (9.17 g, 78%), 1.08:1.00 mixture of isomers; m.p. 87-90 oC; 1H NMR 
(300 MHz, CDCl3)  10.76 (d, J = 13.2 Hz, 1H, NH), 8.91 (d, J = 14.5 Hz, 1H, NH), 
8.36 (d, J = 14.5 Hz, 1H, C=CH), 7.90 (d, J = 13.2 Hz, 1H, C=CH), 7.28-7.39 (m, 
2H, E & Z isomers, phenyl CH), 6.81-7.01 (m, 6H, E & Z isomers, phenyl CH), 4.30 
(app q, J = 7.1 Hz, 4H, E & Z isomers, CH2), 1.32-1.38 (m, J = 7.1 Hz, 6H, E & Z 
isomers, CH3); 13C NMR (75 MHz, CDCl3)  167.2 (C=O), 164.3 (C=O), 163.5 (d, 
1J = 246.5 Hz, CF) 163.4 (d, 1J = 245.9 Hz, CF), 151.7 (C=CH), 151.7 (C=CH), 
140.5 (d, 3J = 10.1 Hz, phenyl C), 139.8 (d, 3J = 10.0 Hz, phenyl C), 131.4 (d, 3J = 
9.4 Hz, phenyl CH), 131.1 (d, 3J = 9.4 Hz, phenyl CH), 117.4 (CN), 115.5 (CN), 
112.8 (d, 4J = 3.0 Hz, phenyl CH), 112.7 (d, 4J = 3.0 Hz, phenyl CH), 112.3 (d, 2J = 
21.8 Hz, phenyl CH), 112.0 (d, 2J = 21.8 Hz, phenyl CH), 104.7 (app t, J = 26.3 Hz, 
2 x phenyl CH), 77.4 (C-CN), 76.3 (C-CN), 61.3 (CH2), 61.2 (CH2), 14.2 (CH3), 
14.1 (CH3); 19F NMR (282 MHz, CDCl3)  -109.7, -109.8 (E & Z isomers, phenyl-
F); IR (KBr) 3440 (NH), 2982, 2217 (CN) cm-1; LC/TOF-MS calcd for 
C12H12FN2O2 235.0877, found 235.0887 (M+H+).  
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General procedure for the synthesis of 3.3 and 3.4 
Diethyl (ethoxymethylene)malonate (25 mmol) and the appropriate aniline (25 
mmol) were dissolved in EtOH (12.5 mL) and heated to reflux for 1 hour. The 
reaction mixture was allowed to cool to room temperature. The solvent was removed 
under reduced pressure and the resulting oil was cooled on ice to give the solid 
product. The product was collected by filtration and washed with ice-cold EtOH.  In 
each case, the crude product was used for the next step without further purification. 
Diethyl 2-((phenylamino)methylene)malonate (3.3) 
O
O
O
O
NH
 
White solid (5.25 g, 80%); m.p. 34-38 oC; 1H NMR (300 MHz, CDCl3)  11.01 (d, J 
= 13.7 Hz, 1H, NH), 8.54 (d, J = 13.7 Hz, 1H, C=CH), 7.35-7.40 (m, 2H, phenyl 
CH), 7.12-7.17 (m, 3H, phenyl CH), 4.31 (q, J = 7.1 Hz, 2H, CH2), 4.25 (q, J = 7.1 
Hz, 2H, CH2), 1.38 (t, J = 7.1 Hz, 3H, CH3), 1.33 (t, J = 7.1 Hz, 3H, CH3); 13C NMR 
(75 MHz, CDCl3)  169.1 (C=O), 165.7 (C=O), 151.9 (C=CH), 139.3 (phenyl C), 
129.8 (phenyl CH), 124.9 (phenyl CH), 117.2 (phenyl CH), 93.5 (C(CO2Et)2), 60.4 
(CH2), 60.1 (CH2), 14.4 (CH3), 14.3 (CH3), these data match reported literature 
values153; IR (KBr) 3445 (NH), 2988 (CH), 1692 (C=O) cm-1; LC/TOF-MS calcd for 
C14H18NO4 264.1230, found 264.1234 (M+H+). 
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Diethyl 2-(((3-fluorophenyl)amino)methylene)malonate (3.4) 
 
White solid (5.79 g, 82%); m.p. 33-37 oC; 1H NMR (300 MHz, CDCl3)  11.02 (d, J 
= 13.5 Hz, 1H, NH), 8.48 (d, J = 13.5 Hz, 1H, C=CH), 7.31-7.38 (m, 1H, phenyl 
CH), 6.83-6.94 (m, 3H, phenyl CH), 4.33-4.23 (m, J = 7.1 Hz, 4H, CH2), 1.40 (t, J = 
7.1 Hz, 3H, CH3), 1.35 (t, J = 7.1 Hz, 3H, CH3), these data match reported literature 
values154; 13C NMR (75 MHz, CDCl3)  168.4 (C=O), 165.0 (C=O), 163.2 (d, 1J = 
245.3 Hz, CF), 150.8 (C=CH), 140.6 (d, 3J = 10.5 Hz, phenyl C), 130.8 (d, 3J = 9.8 
Hz, phenyl CH), 112.4 (d, 4J = 2.3 Hz, phenyl CH), 110.0 (d, 2J = 21.0 Hz, phenyl 
CH), 103.9 (d, 2J = 25.5 Hz, phenyl CH), 94.2 (C(CO2Et)2), 60.1 (CH2), 59.8 (CH2), 
14.0 (CH3), 13.8 (CH3); 19F NMR (282 MHz, CDCl3)  -110.5 (phenyl-F); IR (KBr) 
2985 (NH), 1689 (C=O) cm-1; LC/TOF-MS calcd for C14H17FNO4 282.1136, found 
282.1145 (M+H+). 
General procedure for the synthesis of 3.5 and 3.6 
Diphenyl ether (26 mL) was heated to 240 oC. The appropriate malonate (13.8 
mmol) was added slowly to the hot diphenyl ether and the resulting solution was 
allowed to reflux for 4 hours. The reaction mixture was allowed to cool and 
petroleum ether 60-80 (130 mL) was added. The resulting precipitate was collected 
by filtration and washed with excess petroleum ether 60-80. In each case, the product 
was used in the next step without further purification. 
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4-Oxo-1,4-dihydroquinoline-3-carbonitrile (3.5) 
 
Yellow solid (1.66 g, 71%); m.p. dec; 1H NMR (300 MHz, DMSO-d6) 12.83 (br s, 
1H, NH), 8.73 (d, J = 3.9 Hz, 1H, H2), 8.13 (dd, J = 8.1, 1.2 Hz, 1H, H5), 7.77 (app 
t, J = 8.3, 7.1, 1.2 Hz, 1H, H7), 7.63 (d, J = 8.3 Hz, 1H, H8), 7.46 (app t, J = 8.1, 7.1, 
1.0 Hz, 1H, H6); 13C NMR (75 MHz, DMSO-d6)  174.4 (C=O), 146.6 (C2), 139.0 
(C8a), 133.2 (C7), 125.5 (C6), 125.0 (C4a), 124.9 (C5), 119.2 (C8), 116.8 (CN), 
93.5 (C3), these data match reported literature values155; IR (KBr) 3481 (NH), 2916, 
2224 (CN), 1628 (C=O) cm-1; LC/TOF-MS calcd for C10H6N2ONa 193.0372, found 
193.0378 (M+Na+). 
7-Fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile (3.6a) and 5-fluoro-4-oxo-
1,4-dihydroquinoline-3-carbonitrile (3.6b) 
 
Yellow solid (1.61 g, 62%); 1.00:0.30 mixture of isomers; m.p. >300 oC; 1H NMR 
(300 MHz, DMSO-d6)  8.75 (s, 1H, H2), 8.68 (s, 1H, H2*), 8.18 (dd, J = 8.8, 6.3 
Hz, 1H, H5), 7.69-7.76 (m, 1H, H7*), 7.30-7.43 (m, 3H, H6, H8, and H8*), 7.17 (dd, 
J = 11.8, 8.1 Hz, 1H, H6*), these data match reported literature values156,157; 13C 
NMR (75 MHz, DMSO-d6)  173.6 (C=O), 172.8 (d, 3J = 2.3 Hz, C=O*), 164.3 (d, 
1J = 248.9, CF), 160.0 (d, 1J = 259.9 Hz, CF*), 147.5 (C2), 146.5 (C2*), 141.3 (d, 3J 
= 4.5 Hz, C8a*), 140.8 (d, 3J = 12.9 Hz, C8a), 133.9 (d, 3J = 9.9 Hz, C7*), 128.4 (d, 
3J = 11.3 Hz, C5), 122.1 (d, 4J = 1.5 Hz, C4a), 116.5 (CN), 116.4 (CN*), 115.2 (d, 4J 
= 4.5 Hz, C8*), 114.9 (d, 2J = 9.8 Hz, C4a*), 114.1 (d, 2J = 23.3 Hz, C6), 111.6 (d, 
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2J = 22.5 Hz, C6*), 104.8 (d, 2J = 24.8 Hz, C8), 95.3 (C-CN*), 93.9 (C-CN); 19F 
NMR (282 MHz, DMSO-d6)  -105.0 (C7-F), 112.2 (C7-F); IR (KBr) 2228 (CN), 
1631 (C=O) cm-1; LC/TOF-MS calcd for C10H5FN2OK 227.0017, found 227.0025 
(M+H+). 
* 5-Fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile (3.6b) 
General procedure for the synthesis of 3.7 and 3.8 
Diphenyl ether (4 mL) was heated to 240 oC. The appropriate acrylate (3.5 mmol) 
was added slowly to the hot diphenyl ether and the resulting solution was allowed to 
reflux for 1 hour. The reaction mixture was allowed to cool and petroleum ether 60-
80 (20 mL) was added. The resulting precipitate was collected by filtration and 
washed with excess petroleum ether 60-80. In each case, the product was used in the 
next step without further purification. 
Ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate (3.7) 
 
White solid (0.55 g, 72%); m.p. 252-256 oC; 1H NMR (300 MHz, DMSO-d6)  
12.31 (br s, 1H, NH), 8.54 (s, 1H, H2), 8.16 (d, J = 8.1 Hz, 1H, H5), 7.70 (app t, 1H, 
H7), 7.61 (d, J = 7.8 Hz, 1H, H8), 7.41 (app t, 1H, H6), 4.22 (q, J = 7.1 Hz, 2H, 
CH2), 1.28 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (75 MHz, DMSO-d6)  173.4 (C=O) 
164.8 (C=O), 144.8 (C2), 138.9 (C8a), 132.4 (C7), 127.2 (C4a), 125.6 (C5), 124.6 
(C6), 118.8 (C8), 109.8 (C3), 59.5 (CH2), 14.3 (CH3), these data match reported 
literature values155; IR (KBr) 3438 (NH), 2978 (CH), 1698 (C=O) cm-1; LC/TOF-MS 
calcd for C12H11NO3Na 240.0631, found 240.0635 (M+Na+). 
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Ethyl 7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (3.8a) and ethyl 5-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (3.8b) 
 
White solid (0.45 g, 55%); 1.00:0.08 mixture of isomers; m.p. dec. 
The product showed improved solubility in DMSO-d6 at 60 oC and hence the data 
were recorded at 60 oC. 
1H NMR (300 MHz, DMSO-d6, 60 oC)  8.52 (s, 1H, H2), 8.40 (s, 1H, *H2), 8.22 
(dd, J = 9.1, 6.1 Hz, 1H, H5), 7.61-7.68 (m, 1H, *CH), 7.37 (dd, J = 9.3, 2.7 Hz, 1H, 
H8), 7.40-7.42 (m, 1H, *CH), 7.21-7.27 (m, 1H, H6), 7.03-7.10 (m, 1H, *CH), 4.24 
(q, J = 7.1 Hz, 2H, CH2), 1.30 (t, J = 7.1 Hz, 3H, CH3), these data match reported 
literature values126, 154; 13C NMR (75 MHz, DMSO-d6, 60 oC)  172.7 (C=O), 164.6 
(C=O), 164.1 (d, 1J = 248.3, CF), 145.2 (C2), 140.6 (d, 3J = 12.8 Hz, C8a), 129.0 (d, 
3J = 10.5 Hz, C5), 124.3 (C4a), 113.1 (d, 2J = 22.5 Hz, C6), 110.6 (C3), 104.2 (d, 2J 
= 24.8, C8), 59.6 (CH2), 14.2 (CH3), the peaks representing the second *isomer 
could not be observed in the 13C NMR spectrum; 19F NMR (282 MHz, DMSO-d6, 60 
oC)  -107.6, -112.9 (C7-F); IR (KBr) 3435 (NH), 3114, 2981 (CH), 1695 (C=O) 
cm-1; LC/TOF-MS calcd for C12H11FNO3 236.0717, found 236.0725 (M + H+). 
* 5-Fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (3.8b) 
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The synthesis of 1-ethyl-4-oxo-1,4-dihydroquinoline-3-carbonitrile (3.9)   
 
Method A: 
Quinolone 3.5 (0.50 g, 2.94 mmol) and K2CO3 (0.41 g, 2.96 mmol) were heated to 
reflux in triethyl phosphate (2.65 mL) for 1 hour. The reaction mixture was allowed 
to cool to room temperature and was added to deionised water (14.7 mL). The 
resulting precipitate was collected by filtration and purified by precipitation from hot 
DCM with n-hexane. 
Method B: 
The quinolone 3.5 (0.50 g, 2.94 mmol) was dissolved in anhydrous DMF (14.5 mL) 
under nitrogen. Iodoethane (355 L, 4.41 mmol) and K2CO3 (1.22 g, 8.82 mmol) 
were added to the solution and the reaction mixture was heated to 80 oC for 3 hours. 
The solvent was removed under reduced pressure. Distilled water was added to the 
remaining residue and the solid product was collected by filtration. The product was 
purified by precipitation from hot DCM with n-hexane. 
Brown solid (method A: 0.26 g, 45%, method B: 0.42 g, 72%); m.p. 227-230 oC 
(226 o C)123; 1H NMR (300 MHz, DMSO-d6)  8.86 (s, 1H, H2), 8.22 (d, J = 7.6 Hz, 
1H, H5), 7.82-7.89 (m, 2H, H7 & H8), 7.51-7.58 (m, 1H, H6), 4.40 (q, J = 7.1 Hz, 
2H, CH2), 1.39 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (75 MHz, DMSO-d6)  173.8 
(C=O), 150.4 (C2), 138.6 (C8a), 133.6 (C7), 126.1 (C4a), 125.8 (C5), 125.6 (C6), 
117.6 (C8), 116.5 (CN), 93.5 (C3), 48.3 (CH2), 14.2 (CH3); IR (KBr) 2219 (CN), 
1615 (C=O) cm-1; LC/TOF-MS calcd for C12H11N2O 199.0866, found 199.0868 
(M+H+). 
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General procedure for the synthesis of 3.10-3.12 
The appropriate quinolone (2.94 mmol) was dissolved in anhydrous DMF (14.5 mL) 
under nitrogen. Iodoethane (355 L, 4.41 mmol) and K2CO3 (1.22 g, 8.82 mmol) 
were added to the solution and the reaction mixture was heated to 80 oC for 3 hours. 
The solvent was removed under reduced pressure and the remaining residue was 
dissolved in CHCl3 and filtered. The filtrate was reduced under vacuum and the 
product was purified by column chromatography on silica gel. The product was 
eluted with EtOAc:EtOH (90:10). 
1-Ethyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile (3.10a) 
 
White solid (0.46 g, 72%); m.p. 230-234 oC; Rf: 0.75 (EtOAc:EtOH 90:10); 1H NMR 
(300 MHz, DMSO-d6)  8.88 (s, 1H, H2) 8.26 (dd, J = 8.7, 6.7 Hz, 1H, H5), 7.81 (d, 
J = 11.4 Hz, 1H, H8), 7.38-7.44 (m, 1H, H6), 4.34 (q, J = 7.1 Hz, 2H, CH2), 1.37 (t, 
J = 7.1 Hz, 3H, CH3), 1H NMR assignments are supported by NOEdiff experiments; 
13C NMR (75 MHz, DMSO-d6)  173.0 (C=O), 164.9 (d, 1J = 248.8 Hz, CF), 151.2 
(C2), 140.5 (d, 3J = 12.5 Hz, C8a), 129.2 (d, 3J = 10.9 Hz, C5), 123.0 (d, 4J = 1.7 Hz, 
C4a), 116.1 (CN), 114.1 (d, 2J = 23.3 Hz, C6), 104.2 (d, 2J = 27.0 Hz, C8), 94.1 (C-
CN), 48.5 (CH2), 14.1 (CH3); 19F NMR (282 MHz, DMSO-d6)  -103.7 (C7-F); IR 
(KBr) 2226 (CN), 1642 (C=O) cm-1; LC/TOF-MS calcd for C12H10FN2O 217.0772, 
found 217.0772 (M + H+). 
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1-Ethyl-5-fluoro-4-oxo-1,4-dihydroquinoline-3-carbonitrile (3.10b) 
N
O
2
3
4
4a
8a
5
6
8
N
7
F
 
White solid (0.10 g, 15%); m.p. 210-212 oC; Rf: 0.50 (EtOAc:EtOH 90:10);  1H 
NMR (300 MHz, DMSO-d6)  8.83 (s, 1H, H2), 7.79-7.86 (m, 1H, H7), 7.67 (d, J = 
8.6 Hz, 1H, H8), 7.27 (dd, J = 11.6, 8.2 Hz, 1H, H6), 4.34 (q, J = 7.1 Hz, 2H, CH2), 
1.37 (t, J = 7.1 Hz, 3H, CH3), 1H NMR assignments are supported by NOEdiff 
experiments; 13C NMR (75 MHz, DMSO-d6)  172.4 (d, 3J = 1.8 Hz, C=O) 160.7 (d, 
1J = 260.8 Hz, CF), 150.4 (C2), 140.7 (d, 4J = 3.2 Hz, C8a), 134.3 (d, 3J = 11.0 Hz, 
C7), 116.1 (CN), 115.9 (d, 2J = 8.0 Hz, C4a), 113.6 (d, 3J = 4.5 Hz, C8), 112.2 (d, 2J 
= 20.7 Hz, C6), 95.5 (C3), 49.1 (CH2), 14.0 (CH3); 19F NMR (282 MHz, DMSO-d6) 
 -111.2 (C5-F); IR (KBr) 2223 (CN), 1633 (C=O) cm-1; LC/TOF-MS calcd for 
C12H10FN2O 217.0772, found 217.0782 (M + H+). 
Ethyl 1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (3.11a) 
 
White solid (0.55 g, 76%); m.p. 61-64 oC; Rf: 0.49 (EtOAc:EtOH 90:10); 1H NMR 
(300 MHz, DMSO-d6)  8.70 (s, 1H, H2), 8.24 (d, J = 8.0 Hz, 1H, H5), 7.73-7.81 
(m, 2H, H7 and H8), 7.43-7.49 (m, 1H, H6), 4.41 (q, J = 7.0 Hz, 2H, CH2), 4.22 (q, J 
= 7.1 Hz, 2H, CH2), 1.36 (t, J = 7.0 Hz, 3H, CH3), 1.28 (t, J = 7.1 Hz, 3H, CH3), 1H 
NMR assignments are supported by NOEdiff experiments; 13C NMR (75 MHz, 
DMSO-d6)  172.7 (C=O), 164.6 (C=O), 148.9 (C2), 138.5 (C8a), 132.6 (C7), 128.3 
(C4a), 126.4 (C5), 124.7 (C6), 117.1 (C8), 109.9 (C3), 59.6 (CH2), 47.8 (CH2), 14.3 
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(2 x CH3), these data match reported literature values155; IR (KBr) 2971 (CH), 1719 
(C=O) cm-1; LC/TOF-MS calcd for C14H16NO3 246.1125, found 246.1136 (M + H+). 
Ethyl 4-ethoxy-1,4-dihydroquinoline-3-carboxylate (3.11b) 
 
Clear oil (0.40 g, 5%); Rf: 0.85 (EtOAc:EtOH 90:10); 1H NMR (300 MHz, CDCl3)  
9.18 (s, 1H, H2), 8.26 (app d, J = 8.3 Hz, 1H, H5), 8.07 (d, J = 8.5 Hz, 1H, H8), 
7.74-7.79 (m, J = 8.5, 6.9, 1.5 Hz, 1H, H7), 7.54-7.59 (m, J = 8.3, 6.9, 1.3 Hz, 1H, 
H6), 4.45 (q, J = 7.1 Hz, 2H, CH2), 4.32 (q, J = 6.8 Hz, 2H, CH2), 1.52 (t, J = 6.8 
Hz, 3H, CH3), 1.44 (t, J = 7.1 Hz, 3H, CH3), 1H NMR assignments are supported by 
NOEdiff experiments; 13C NMR (75 MHz, CDCl3)  165.3 (C=O), 164.2 (C-O), 
152.1 (C2), 151.0 (C8a), 131.6 (C7), 129.3 (C8), 126.8 (C6), 123.9 (C4a), 123.4 
(C5), 114.2 (C3), 72.3 (CH2), 61.5(CH2), 15.8 (CH3), 14.3 (CH3); IR (neat film on 
NaCl plate) 2982 (CH), 1722 (C=O) cm-1; LC/TOF-MS calcd for C14H16NO3 
246.1125, found 246.1127 (M + H+). 
Ethyl 4-ethoxy-7-fluoroquinoline-3-carboxylate (3.12a) 
 
White solid (0.08 g, 10%); m.p. 31-33 oC; Rf: 0.88 (EtOAc:EtOH 90:10); 1H NMR 
(300 MHz, CDCl3)  9.16 (s, 1H, H2), 8.28 (dd, J = 9.2, 6.1 Hz, 1H, H5), 7.68 (dd, J 
= 9.9, 2.4 Hz, 1H, H8), 7.29-7.36 (m, 1H, H6), 4.45 (q, J = 7.1 Hz, 2H, CH2), 4.32 
(q, J = 7.0 Hz, 2H, CH2), 1.51 (t, J = 7.0 Hz, 3H, CH3), 1.43 (t, J = 7.1 Hz, 3H, 
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CH3), 1H NMR data is supported by NOEdiff experiments; 13C NMR (75 MHz, 
CDCl3)  165.1 (C=O), 164.5 (d, 1J = 250.5 Hz, CF), 164.1 (C-O), 153.5 (C2), 152.3 
(d, 3J = 12.0 Hz, C8a), 126.0 (d, 3J = 10.8 Hz, C5), 120.8 (d, 4J = 1.13 Hz, C4a), 
117.1 (d, 2J = 24.7 Hz, C6), 113.6 (d, J = 2.5 Hz, C3), 113.2 (d, 2J = 20.0 Hz, C8), 
72.4 (CH2), 61.5 (CH2), 15.7 (CH3), 14.3 (CH3); 19F NMR (282 MHz, CDCl3)  -
106.5 (C7-F); IR (KBr) 2982 (CH), 1727 (C=O) cm-1; LC/TOF-MS calcd for 
C14H15FNO3 264.103, found 264.1038 (M + H+). 
Ethyl 1-ethyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (3.12b) 
 
White solid (0.56 g, 73%); m.p. 126-130 oC (lit 128-129 oC)126; Rf: 0.55 
(EtOAc:EtOH 90:10); 1H NMR (300 MHz, DMSO-d6) 8.69 (s, 1H, H2), 8.29 (dd, 
J = 8.9, 6.7 Hz, 1H, H5), 7.72 (d, J = 11.3, 2.2 Hz, 1H, H8), 7.34 (app t, J = 2.2 Hz, 
1H, H6), 4.38 (q, J = 7.1 Hz, 2H, CH2), 4.23 (q, J = 7.1 Hz, 2H, CH2), 1.35 (t, J = 
7.1 Hz, 3H, CH3), 1.28 (t, J = 7.1 Hz, 3H, CH3), 1H NMR assignments are supported 
by NOEdiff experiments; 13C NMR (75 MHz, DMSO-d6)  172.1 (C=O), 164.6 (d, 
1J = 246.8 Hz, CF), 164.4 (C=O), 149.5 (C2), 140.3 (d, 3J = 12.0 Hz, C8a), 129.6 (d, 
3J = 11.3 Hz, C5), 125.2 (d, 4J = 2.25 Hz, C4a), 113.2 (d, 2J = 22.5 Hz, C6), 110.5 
(C3), 103.5 (d, 2J = 27.0 Hz, C8), 59.8 (CH2), 48.0 (CH2), 14.3 (CH3), 14.2 (CH3); 
19F NMR (282 MHz, DMSO-d6)  -105.6 (C7-F); IR (KBr) 2982 (CH), 1679 (C=O) 
cm-1; LC/TOF-MS calcd for C14H15FNO3 264.1030, found 264.1043 (M + H+). 
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Ethyl 1-ethyl-5-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (3.12c) 
 
White solid (0.03 g, 3%); m.p. 108-112 oC (lit 115-118 oC)126; Rf: 0.38 
(EtOAc:EtOH 90:10); 1H NMR (300 MHz, CDCl3)  8.39 (s, 1H, H2), 7.54-7.62 (m, 
J = 13.7, 8.4 Hz, 1H, H7), 7.20 (d, J = 8.4 Hz, 1H, H8), 7.03 (dd, J = 11.2, 8.4 Hz, 
1H, H6), 4.37 (q, J = 7.1 Hz, 2H, CH2), 4.21 (q, J = 7.2 Hz, 2H, CH2), 1.52 (t, J = 
7.2 Hz, 3H, CH3), 1.39 (t, J = 7.1 Hz, 3H, CH3), 1H NMR assignments are supported 
by NOEdiff experiments; 13C NMR (75 MHz, CDCl3)  173.3 (d, 3J = 2.3 Hz, C=O), 
165.8 (C=O), 163.0 (d, 1J = 264.8 Hz, CF), 148.2 (C2), 140.8 (d, 3J = 3.0 Hz, C8a), 
132.9 (d, 3J = 11.0 Hz, C7), 119.1 (d, 2J = 6.9 Hz, C4a), 112.8 (C3), 112.1 (d, 2J = 
21.8 Hz, C6), 111.2 (d, 4J = 4.7 Hz, C8), 61.0 (CH2), 49.5 (CH2), 14.4 (CH3), 14.2 
(CH3); 19F NMR (282 MHz, CDCl3)  -109.4 (C5-F); IR (KBr) 2972 (CH), 1720 
(C=O) cm-1; LC/TOF-MS calcd for C14H15FNO3 264.1030, found 264.1032 (M + 
H+). 
The synthesis 1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3.13) 
 
Compound 3.11a (0.25 g, 1.01 mmol) was added to 3.0 mL of a 1:1 
water:methanolic KOH (20%) solution and brought to reflux for 3 hours. The MeOH 
was removed under reduced pressure. Distilled water (5 mL) was added to the 
remaining residue and the solution was acidified to pH 6 with conc. HCl. The 
resulting precipitate was collected by filtration and washed with distilled water.  
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White solid (0.21 g, 95%); m.p. 246-248 oC; 1H NMR (300 MHz, DMSO-d6)  
15.27 (s, 1H, OH), 9.08 (s, 1H, H2), 8.40 (d, J = 8.1 Hz, 1H, H5), 8.07 (d, J = 8.6 
Hz, 1H, H8), 7.96-8.01 (m, 2H, H7), 7.65-7.71 (app t, 1H, H6), 4.62 (q, J = 7.1 Hz, 
2H, CH2), 1.43 (t, J = 7.1 Hz, 3H, CH3); 13C NMR (75 MHz, DMSO-d6)  177.6 
(C=O), 166.0 (C=O), 149.1 (C2), 139.0 (C8a), 134.3 (C7), 126.2 (C6), 125.9 (C5), 
125.5 (C4a), 118.0 (C8), 107.6 (C3), 48.9 (CH2), 14.5 (CH3), these data match 
reported literature values155; IR (KBr) 1712 (C=O) cm-1; LC/TOF-MS calcd for 
C12H12NO3 218.0812, found 218.0811 (M + H+). 
The synthesis of 1-ethyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(3.14) 
 
Compound 3.12b (0.26 g, 1.00 mmol) was dissolved in a 1:1 water:dioxane (8.60 
mL) solution. Lithium hydroxide (0.08 g, 3.34 mmol) was added to the solution and 
the reaction mixture was stirred at 50 oC for 30 minutes. The solvent was removed 
under reduced pressure and distilled water (5 mL) was added to the resulting residue. 
The solution was acidified to pH 6 with 6M HCl. The resulting precipitate was 
collected by filtration and washed with distilled water. 
White solid (0.20 g, 83%); m.p. >300 oC (lit 302-304 oC)158. 
The product showed improved solubility in DMSO-d6 at 60 oC and hence the data 
were recorded at 60 oC. 
1H NMR (300 MHz, DMSO-d6, 60 oC)  14.92 (br s, 1H, OH), 9.01 (s, 1H, H2), 
8.46 (dd, J = 9.0, 6.5 Hz, 1H, H5), 7.91 (dd, J = 11.2, 2.2 Hz, 1H, H8), 7.52 (app t, J 
= 2.2 Hz, 1H, H6), 4.56 (q, J = 7.1 Hz, 2H, CH2), 1.43 (t, J = 7.1 Hz, 3H, CH3); 13C 
NMR (75 MHz, DMSO-d6, 60 oC)  176.8 (C=O), 165.3 (C=O), 165.1 (d, 1J = 250.5 
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Hz, CF), 149.4 (C2), 140.7 (d, 3J = 12.2 Hz, C8a), 129.0 (d, 3J = 11.0 Hz, C5), 122.4 
(d, 4J = 1.4 Hz, C4a), 114.6 (d, 2J = 23.6 Hz, C6), 108.0 (C3), 104.0 (d, 2J = 27.1 Hz, 
C8), 48.8 (CH2), 14.0 (CH3); 19F NMR (282 MHz, DMSO-d6, 60 oC)  -102.6 (C7-
F); IR (KBr) 1722 (C=O) cm-1; LC/TOF-MS calcd for C12H11FNO3 236.0717, found 
236.0728 (M + H+). 
The synthesis of 1-ethyl-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid (3.15) 
 
Compound 3.12b (0.26 g, 1.01 mmol) was added to 3.0 mL of a 1:1 
water:methanolic KOH (20% w/v) solution and brought to reflux for 3 hours. The 
MeOH was removed under reduced pressure. Distilled water (5 mL) was added to 
the remaining residue and the solution was acidified to pH 6 with conc. HCl. The 
resulting precipitate was collected by filtration and washed with distilled water.  
White solid (0.22 g, 88%); m.p. 258-262 oC; 1H NMR (300 MHz, DMSO-d6)  8.98 
(s, 1H, H2), 8.29 (d, J = 8.9 Hz, 1H, H5), 7.25-7.30 (m, 2H, H6 and H8), 4.59 (q, J = 
7.1 Hz, 2H, CH2), 3.99 (s, 3H, OCH3), 1.42 (t, J = 7.1 Hz, 3H, CH3), these data 
match reported literature values128; 13C NMR (75 MHz, DMSO-d6)  176.9 (C=O), 
166.1 (C=O), 163.9 (C7), 149.0 (C2), 141.1 (C8a), 127.8 (C5), 119.3 (C4a), 115.7 
(C6), 107.3 (C3), 99.9 (C8), 56.2 (OCH3), 48.8 (CH2), 14.3 (CH3); IR (KBr) 2975 
(CH), 1713 (C=O) cm-1; LC/TOF-MS calcd for C13H13NO4Na 270.0737, found 
270.0744 (M + H+). 
General procedure for the synthesis of 7-piperazine and 7-N-methylpiperazine 
quinolones 3.16-3.19 
Anhydrous piperazine or N-methylpiperazine (4.55 mmol) and the appropriate 
quinolone (0.50 mmol) were brought to reflux at 125 oC in anhydrous pyridine (1 
Chapter III: A study of quinolone antibacterial agents 
169 
 
mL) under nitrogen. After 16 hours the solvent was removed under reduced pressure 
and the resulting solid was recrystallised from cold EtOH. The product was collected 
by filtration.    
1-Ethyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carbonitrile (3.16) 
 
White solid (0.08 g, 57%); m.p. 226-230 oC; 1H NMR (300 MHz, DMSO-d6)  8.67 
(s, 1H, H2), 7.99 (d, J = 9.6 Hz, 1H, H5), 7.16 (dd, J = 9.6, 2.2 Hz, 1H, H6), 6.82 (d, 
J = 2.2 Hz, 1H, H8), 4.32 (q, J = 7.7 Hz, 2H, CH2), 3.32 (app br s, 4H, H9), 2.83-
2.87 (m, 4H, H10), 1.36 (t, J = 7.7 Hz, 3H, CH3); 13C NMR (75 MHz, DMSO-d6)  
172.7 (C=O), 154.4 (C7), 150.0 (C2), 140.4 (C8a), 127.0 (C5), 117.3 (C4a), 116.8 
(CN), 113.5 (C6), 98.3 (C8), 92.9 (C3), 47.8 (CH2), 47.7 (C9), 45.2 (C10), 14.0 
(CH3); IR (KBr) 2215 (CN), 1620 (C=O) cm-1; LC/TOF-MS calcd for C16H19N4O 
283.1553, found 283.1561 (M + H+). 
1-Ethyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (3.17) 
N
O O
OH
2
3
4
4a
8a
5
6
7
8
N
HN
9
10
 
White solid (0.13 g, 86%); m.p. 236-240 oC (lit 272-275 oC)159; 1H NMR (300 MHz, 
DMSO-d6)  8.86 (s, 1H, H2), 8.12 (d, J = 9.3 Hz, 1H, H5), 7.31 (d, J = 9.3 Hz, 1H, 
H6), 6.92 (s, 1H, H8), 4.52 (q, J = 7.0 Hz, 2H, CH2), 3.38-3.42 (m, 4H, H9), 2.85 
(app br s, 4H, H10), 1.39 (t, J = 7.0 Hz, 3H, CH3); 13C NMR (75 MHz, DMSO-d6)  
176.3 (C=O), 166.6 (C=O), 154.8 (C7), 148.4 (C2), 141.1 (C8a), 127.0 (C5), 116.1 
Chapter III: A study of quinolone antibacterial agents 
170 
 
(C4a), 114.5 (C6), 106.7 (C3), 97.9 (C8), 48.5 (CH2), 47.7 (C9), 45.3 (C10), 14.2 
(CH3); IR (KBr) 1620 (C=O) cm-1; LC/TOF-MS calcd for C16H20N3O3 302.1499, 
found 302.1510 (M + H+). 
1-Ethyl-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carbonitrile 
(3.18) 
 
White solid (0.07 g, 47%); m.p. 222-225 oC; 1H NMR (300 MHz, CDCl3)  8.23 (d, 
J = 9.1 Hz, 1H, H5), 7.91 (s, 1H, H2), 7.01 (d, J = 9.1 Hz, 1H, H6), 6.57 (s, 1H, H8), 
4.16 (q, J = 6.8 Hz, 2H, CH2), 3.39 (app br s, 4H, H9), 2.57 (app br s, 4H, H10), 2.35 
(s, 3H, N-CH3), 1.52 (t, J = 6.8 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3)  173.7 
(C=O), 154.5 (C7), 147.6 (C2), 140.6 (C8a), 128.5 (C5), 118.6 (C4a), 116.1 (CN), 
114.1 (C6), 98.0 (C8), 95.5 (C3), 54.6 (C10), 48.9 (CH2), 47.4 (C9), 46.1 (N-CH3), 
14.3 (CH3); IR (KBr) 2218 (CN), 1623 (C=O) cm-1; LC/TOF-MS calcd for 
C17H21N4O 297.1710, found 297.1721 (M + H+). 
1-Ethyl-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid (3.19) 
 
White solid (0.14 g, 87%); m.p. 207-210 oC (lit 220.5-222.5 oC)159; 1H NMR (300 
MHz, CDCl3)  15.38 (br s, 1H, OH), 8.56 (s, 1H, H2), 8.24 (d, J = 9.2 Hz, 1H, H5), 
7.09 (dd, J = 9.2, 2.0 Hz, 1H, H6), 6.63 (d, J = 2.0 Hz, 1H, H8), 4.25 (q, J = 7.2 Hz, 
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2H, CH2), 3.44 (t, J = 5.1 Hz, 4H, H9), 2.58 (t, J = 5.1 Hz, 4H, H10), 2.35 (s, 3H, N-
CH3), 1.54 (t, J = 7.2 Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3)  177.4 (C=O), 
167.7 (C=O), 154.8 (C7), 147.3 (C2), 141.3 (C8a), 128.3 (C5), 117.9 (C4a), 114.7 
(C6), 108.3 (C3), 97.6 (C8), 54.6 (C10), 49.3 (CH2), 47.4 (C9), 46.1 (N-CH3), 14.4 
(CH3); IR (KBr) 1702 (C=O) cm-1; LC/TOF-MS calcd for C17H22N3O3 316.1656, 
found 316.1670 (M + H+). 
The synthesis of 1-ethyl-3-(1H-tetrazol-5-yl)quinolin-4(1H)-one (3.20) 
 
Method A: 
Quinolone 3.9 (0.13 g, 0.65 mmol) and tributyltin azide (0.21 g, 0.65 mmol) were 
heated at 200 oC under nitrogen for 15 hours. The reaction mixture was allowed to 
cool to room temperature. MeOH (7.9 mL) and conc. HCl (80 L) were added to the 
reaction mixture and it was brought to reflux for 2 hours. The solvent was removed 
under reduced pressure and n-hexane (20 mL) was added. The product was collected 
by filtration and washed with n-hexane (100 mL).  
Method B: 
Quinolone 3.9 (0.50 g, 2.50 mmol) was dissolved in anhydrous DMF (25 mL) under 
nitrogen. Sodium azide (1.79 g, 27.53 mmol), ammonium chloride (1.47 g, 27.50 
mmol), and lithium chloride (0.38 g, 8.96 mmol) were added to the solution and the 
reaction mixture was heated to reflux at 110 oC for 27.5 hours. The reaction mixture 
was filtered and the filtrate was reduced in volume under vacuum. Distilled water 
was added to the resulting residue and the solution acidified with conc. HCl. The 
resulting precipitate was collected by filtration and washed with distilled water.  
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Light yellow solid (method A: 0.12 g, 75%, method B: 0.50 g, 83%); m.p. 284-288 
oC; 1H NMR (300 MHz, DMSO-d6)  9.11 (s, 1H, H2), 8.40 (dd, J = 7.9, 1.5 Hz, 1H, 
H5), 7.94 (d, J = 8.4 Hz, 1H, H8), 7.87 (app t, J = 8.4, 6.8, 1.5 Hz, 1H, H7), 7.57 
(app t, J = 7.9, 6.8, 1.0 Hz, 1H, H6), 4.55 (q, J = 7.1 Hz, 2H, CH2), 1.43 (t, J = 7.1 
Hz, 3H, CH3); 13C NMR (75 MHz, DMSO-d6)  172.8 (C=O), 150.1 (CN4), 144.9 
(C2), 138.6 (C8a), 133.0 (C7), 126.5 (C4a), 126.0 (C5), 125.0 (C6), 117.4 (C8), 
104.5 (C3), 48.1 (CH2), 14.41 (CH3); IR (KBr) 1628 (C=O) cm-1; LC/TOF-MS calcd 
for C12H12N5O 242.1036, found 242.1047 (M+H+). 
The synthesis of levofloxacin ethyl ester (3.24) 
 
Levofloxacin (0.36 g, 1 mmol) was heated to reflux overnight in EtOH (30 mL) with 
conc. H2SO4 (3 mL). The reaction mixture was allowed to cool and the solvent 
volume reduced by half under vacuum. Distilled water (15 mL) was added and the 
solution neutralised with aqueous saturated K2CO3 and then washed with DCM (2 x 
50 mL). The combined DCM extracts were washed with 2.5 M potassium hydroxide 
(2 x 25 mL). The organic phase was dried over Na2SO4, filtered, and the solvent 
removed under reduced pressure.  
White solid (0.34 g, 87%); m.p. 223-225 oC; 1H NMR (300 MHz, CDCl3)  8.25 (s, 
1H, H2), 7.61 (d, J = 13.4 Hz, 1H, H5), 4.27-4.40 (m, 5H, H11, H12 and CH2CH3), 
3.26-3.39 (m, 4H, H9), 2.51-2.54 (m, 4H, H10), 2.34 (s, 3H, N-CH3), 1.53 (d, J = 6.7 
Hz, 3H, CH3), 1.39 (t, J = 7.4 Hz, 3H, CH2CH3); 13C NMR (75 MHz, CDCl3)  
172.8 (C=O), 165.6 (C=O), 155.7 (d, 1J = 245.5 Hz, CF), 145.1 (C2), 139.6 (d, 3J = 
6.7 Hz, C8), 131.7 (d, 2J = 14.4 Hz, C7), 123.7 (C8a), 123.4 (d, 3J = 8.4 Hz, C4a), 
109.7 (C3), 105.5 (d, 2J = 23.9 Hz, C5), 68.1 (C11), 60.8 (CH2CH3), 55.7 (C10), 
54.7 (C12), 50.6 (d, 4J = 3.8 Hz, C9), 46.5 (N-CH3), 18.3 (CH3), 14.5 (CH2CH3); IR 
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(KBr) 1719 (C=O), 1617 (C=O) cm-1; LC/TOF-MS calcd for C20H25FN3O4 
390.1824, found 390.1843 (M + H+). 
The synthesis of levofloxacin C-3 hydroxamic acid (3.25) 
 
Sodium hydroxide (0.05 g, 1.12 mmol) and hydroxylamine hydrochloride (0.04 g, 
0.56 mmol) were dissolved in distilled water (3 mL) and stirred at 25 oC for 30 
minutes. Compound 3.24 (0.20 g, 0.51 mmol) was dissolved in MeOH (2 mL) and 
slowly added to the hydroxylamine solution over 10 minutes. The reaction mixture 
was allowed to stir at 25 oC for 24 hours. After 24 hours, conc. HCl was slowly 
added to the reaction mixture until pH 6 was reached. The solution was reduced 
under vacuum until a precipitate began to form and this was collected by filtration. 
The resulting solid was washed with a minimum of cold MeOH and allowed to dry. 
White solid (0.02 g, 11%); 1H NMR (300 MHz, DMSO-d6)  15.16 (br s, 1H, OH), 
9.00 (s, 1H, H2), 7.60 (d, J = 12.2 Hz, 1H, H5), 4.89-5.02 (m, 1H, H12), 4.57-4.67 
(m, 1H, H11), 4.35-4.46 (m, 1H, H11), 3.55 (app br s, 4H, H9), 3.18 (app br s, 4H, 
H10), 2.73 (s, 3H, N-CH3), 1.45 (d, J = 6.7 Hz, CH3); 13C NMR (75 MHz, DMSO-
d6)  176.4 (C=O), 166.0 (C=O), 155.3 (d, 1J = 245.3 Hz, CF), 146.4 (C2), 140.5 (d, 
3J = 6.8 Hz, C8), 130.7 (d, 2J = 14.3 Hz, C7), 124.7 (C8a), 120.4 (d, 3J = 9.2 Hz, 
C4a), 106.8 (C3), 103.2 (d, 2J = 23.7 Hz, C5), 68.2 (C11), 54.8 (C12), 53.3 (C10), 
47.4 (C9), 42.8 (N-CH3), 18.0 (CH3); IR (KBr) 1712 (C=O), 1623 (C=O) cm-1; 
LC/TOF-MS calcd for C18H22FN4O4 377.1620, found 377.1633 (M + H+). 
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The synthesis of levofloxacin C-3 n-butylamine (3.26) 
 
Levofloxacin (0.10 g, 0.28 mmol) was added to a solution of TBTU (0.10 g, 0.31 
mmol) and HOBt (0.04 g, 0.031 mmol) in anhydrous DMF (3.0 mL), under nitrogen, 
and stirred at room temperature for 10 minutes. Triethylamine (0.06 mL, 0.43 mmol) 
was added to the solution and allowed to stir for a further 10 minutes. In a separate 
flask, n-butylamine (0.03 mL, mmol) and triethylamine (0.06 mL, 0.43 mmol) were 
stirred at room temperature in anhydrous DMF (2 mL) for 10 minutes. The n-
butylamine solution was added to the levofloxacin solution and allowed to stir at 
room temperature for 24 hours, after which the solvent was removed under reduced 
pressure. The resulting residue was dissolved in DCM and washed with 1M HCl 
followed by sat. aq. NaHCO3.The organic layer was dried over Na2SO4, and filtered, 
followed by removal of the solvent under reduced pressure.    
Yellow oil (0.05 g, 42%); 1H NMR (300 MHz, CDCl3)  9.95 (t, J = 6.6 Hz, 1H, 
NH), 8.62 (s, 1H, H2), 7.68 (d, J = 12.2 Hz, 1H, H5), 4.28-4.43 (m, 1H, H12), 4.24 
(app d, 2H, H11), 3.20-3.48 (m, 6H, H9 and N-CH2), 2.50-2.54 (m, 4H, H10), 2.34 
(s, 3H, N-CH3), 1.53-1.64 (m, 5H, CH3 and n-butyl CH2) 1.35-1.48 (m, 2H, n-butyl 
CH2), 0.92 (t, J = 7.2 Hz, n-butyl CH3); 13C NMR (75 MHz, CDCl3)  175.5 (C=O), 
165.0 (C=O), 155.8 (d, 1J = 245.6 Hz, CF), 143.9 (C2), 139.6 (d, 3J = 6.8 Hz, C8), 
131.7 (d, 2J = 14.4 Hz, C7), 124.4 (C8a), 122.6 (d, 3J = 8.7 Hz, C4a), 111.4 (C3), 
105.2 (d, 2J = 23.9 Hz, C5), 68.3 (C11), 55.7 (C10), 54.9 (C12), 50.4 (d, 4J = 4.5 Hz, 
C9), 46.3 (N-CH3), 39.1 (N-CH2), 31.78 (n-butyl CH2), 20.4 (n-butyl CH2), 18.4 
(CH3), 13.9 (n-butyl CH3); IR (KBr) 3445 (NH), 1633 (C=O) cm-1; LC/TOF-MS 
calcd for C22H30FN4O3 417.2296, found 417.2305 (M + H+). 
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The synthesis of tributyltin azide (TBTA)131 
 
A solution of sodium azide (3.99 g, 61.4 mmol) in distilled water (31.9 mL) and 
tributyltin chloride (10 g, 30.7 mmol) in diethyl ether (80.9 mL) were shaken 
together for 10 minutes. The organic phase was separated and the aqueous phase 
washed with diethyl ether (50 mL). The organic washings were combined, dried over 
magnesium sulphate, and the solvent removed under reduced pressure. 
Clear yellow oil (5.53 g, 74%); 1H NMR (300 MHz, CDCl3)  1.42-1.67 (m, 6H, 
CH2), 1.32-1.40 (m, 6H, CH2), 1.24-1.32 (m, 6H, CH2), 0.93 (t, 9H, J = 7.3 Hz, 
CH3); 13C NMR (75 MHz, CDCl3)  27.8 (CH2), 26.9 (CH2), 15.4 (CH2), 13.6 
(CH3)IR (neat film on NaCl plate) 2073 (N3) cm-1. 
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4.1 An Introduction to Tin 
4.1.1 Tin metal 
Tin metal has been mined and used by man since ca. 3000 B.C.160 The chemical 
symbol for tin, Sn, originates from its latin name: stannum.160 The Earth’s crust 
contains an approximate distribution of 2 ppm of tin; considerably less than zinc (94 
ppm), copper (63 ppm) or lead (12 ppm).161 Cassiterite (tin oxide, SnO2) is the 
principal tin-containing ore, and is excavated by hard rock and alluvial mining.161,162 
China and Indonesia have been the major producers of tin over the last few 
years.160,163 Between the 1950s and 2011, China produced 2.7 million tonnes and 
Indonesia 2.6 million tonnes of tin metal.160 Tin metal is obtained through a smelting 
and refining process by reducing SnO2 in the presence of carbon monoxide 
(Equation 4.1) in a blast, electric or reverberatory furnace.161 The recycling of tin 
metal by re-refining is on the rise; over 65,000 tonnes were produced by re-refining 
in 2010.160  
Equation 4.1: SnO2 + 2CO   Sn + 2CO2 
Tin metal has found use in a number of applications (Figure 4.1). Its major use is in 
soldering. The Pb/Sn alloy was 40:60, Pb:Sn, but due to the toxicity of lead, today’s 
solders are almost purely tin (95% tin in 2012).160 Tinplate constitutes almost 20% of 
tin usage.164 The process coats a thin layer of tin (0.4 – 25 m) over sheet steel, 
providing a corrosion-resistant cover that is ideal for packaging and product 
containers, for example, drink cans.164 
Solder 
52%
Tinplate 
17%
Chemical 
15%
Other 
16%
 
Figure 4.1: Tin applications.165 
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The biggest use of tin chemicals is in PVC (polyvinyl chloride) stabilisers.160 During 
the fabrication of PVC, HCl is eliminated and this continuous elimination of HCl 
results in the formation of a brittle polyolefin by-product (Scheme 4.1).  
 
Scheme 4.1: The elimination of HCl from PVC.166  
Organotins stabilise the PVC in two ways (Scheme 4.2):  
(a) the organotin compounds react with the eliminated HCl to give organotin 
chlorides, which in turn do not catalyse any further elimination of HCl, and 
(b) the organotin stabilisers introduce other groups, which are not easily 
eliminated, in place of the chlorides, thus preventing the formation of a 
polyolefin structure. 
There are two main types of tin-based PVC stabilisers: sulfur containing stabilisers 
(containing sulfides and mercaptides) and sulfur-free stabilisers (containing 
carboxylates).161 Tin has also found use in a variety of other areas including alloys, 
catalysis, gas sensors, flame retardants, biocides, antimicrobials, dental formulations, 
construction and the manufacture of high-quality glass by the Pilkington 
process.160,161,162 
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Scheme 4.2: (a) The reaction of a sulphur-based organotin stabiliser with HCl and 
(b) the substitution of an organotin stabiliser with PVC.166 
4.1.2 Tin: the element and its chemistry 
Tin is a group 14 (IV) p-block metal with the electronic configuration: [Kr] 4d10 5s2  
5p2. Of all of the elements, tin has the largest number of isotopes; 10 stable isotopes 
(Table 4.1), giving it a characteristic isotopic pattern as shown in Figure 4.2. The 
117Sn and 119Sn isotopes have spin ½ and can therefore be used in NMR 
spectroscopy. 
Table 4.1: The isotopes of tin. 
Isotope Mass Spin Abundance (%) 
112 111.90494 0 0.95 
114 113.90296 0 0.65 
115 114.90353 1/2 0.34 
116 115.90211 0 14.24 
117 116.90306 1/2 7.57 
118 117.90339 0 24.01 
119 118.90213 1/2 8.58 
120 119.90213 0 32.97 
122 121.90341 0 4.17 
124 123.90524 0 5.98 
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Figure 4.2: Tin isotope pattern.167 
There are two allotropes of tin; -tin (white tin) has a body centred tetragonal form 
and -tin (grey tin) which has a diamond cubic structure.168 Above 10 oC tin exists 
as -tin, but below 10 oC, its volume increases by ca. 27% and it changes into -tin, 
this is known as tin pest or tin plaque (Figure 4.3).161,168 
 
Figure 4.3: The allotropes of tin.168  
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Tin mainly forms compounds that have either the Sn(II) or Sn(IV) oxidation state, 
and examples of the types of structures that can form are shown in Figure 4.4. In the 
Sn(II) state compounds, it is mainly the 5p orbitals that are involved in bonding and 
as a result, the 5s2 electrons exist as a lone pair on the Sn atom.164 This lone pair is 
often stereochemically active e.g. [:SnCl3]- has a pyrimidal structure (Figure 4.5).169 
This non-bonding pair of electrons allows the Sn(II) compounds to act as donors 
with Lewis acids.164 The simplest structure formed by Sn(II) compounds are of the 
type :SnX2 (stannylenes, Figure 4.4 (a)).164 These compounds are most stable when 
X is a bulky group or an electron-withdrawing group, otherwise these compounds 
are readily oxidised to the Sn(IV) oxidation state to give compounds such as the 
stannanes (d) with a tetrahedral type structure (Figure 4.4).161  
 
Sn(II) compound structures 
Sn
X
X X
X
Sn
X
X
X
X
X Sn
X
X
X
X X
X
(d) (e) (f )  
Sn(IV) compound structures 
Figure 4.4: Tin compound structures.161 
 
Figure 4.5: [:SnCl3]-  
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In addition to having the ability to act as donors, Sn(II) compounds can act as 
acceptors; likewise for Sn(IV) compounds.164,169 The Sn(IV) compounds use the 5s2 
5p2 valence electrons for bonding.164 The vacant 5d orbitals of the Sn(II) and Sn(IV) 
compounds permit the bonding of ligands, giving structures of the type b, c, e, and f 
(Figure 4.4.) These structures are often distorted and, depending on the type of 
ligand or X group, the coordination number of the Sn(II) and Sn(IV) compounds can 
be increased through intramolecular or intermolecular coordination to the Sn 
atom.161 For example, SnF2 (Figure 4.6), exists as a cyclic tetramer in the solid state 
but in the vapour phase it exists as a monomer.161  
 
Figure 4.6: Structures of SnF2 in (a) monomer, vapour phase and (b) cyclic tetramer, 
solid state. 
4.1.3 The synthesis of organotin compounds 
In 1849, Frankland synthesised the first organotin compound, Et2SnI2.161 Löwig later 
demonstrated that ethyl iodide could react with a tin/sodium alloy to give the 
polymer diethyltin which in turn could react with air to give Et2SnO, and with 
halogens to give Et2SnX2 (X = halogen).170 Since then, numerous organotin 
compounds have been synthesised. An overview of the synthesis of the principal 
classes of organotin compounds is shown in Scheme 4.3.  
The most commonly used reaction is of SnCl4 with a Grignard reagent to produce 
R4Sn, (R can be an alkyl, allyl, aryl alkenyl or alkynyl).161,170 Unless the R group is 
bulky it is difficult to stop this reaction at an organotin halide stage.161 The R4Sn can 
then be used in a Kocheshkov redistribution reaction to yield the organotin halide 
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RnSnCl4-n (n = 1, 2 or 3).171 Substitution of the chlorine with a nucleophile, X-, 
occurs readily to give RnSnX4-n.170 If the nucleophile is a metal hydride, RnSnH4-n is 
produced, which can undergo hydrostannation with an alkene or alkyne to give the 
corresponding stannane or vinyl stannane.132a The organotin hydrides can react with 
metallic bases such as BuLi, LDA, NaH and Grignard reagents to give the 
stannylmetallic compounds, R3SnM (M = Li, Na, MgX).161 These compounds can 
react with electrophiles such as organic halides.164 In the presence of base or a 
palladium catalyst, the organotin hydrides can give the distannanes, R2SnSnR2, and 
the oligostananes, (R2Sn)n.170 The organotin hydroxides are produced by hydrolysis 
of RnSnX4-n which can undergo spontaneous dehydration to give the organotin 
oxides.161 The stannylenes (:SnX2) can be produced via alkylation or arylation of 
SnCl2, but as stated earlier, these are only stable when X is very bulky or electron-
withdrawing.161 Reaction of SnCl2 with cyclopentadienyl lithium can be used to 
prepare stannocene (CpSn:) and reduction of SnCl2 can produce the distannynes 
(RSnSnR).161 
 
Scheme 4.3: Overview of some of the methods of preparation of organotin(IV) 
compounds. (Note: the reactions that occur with R3SnCl can also occur with R2SnCl2 
and RSnCl3.)161,170  
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4.1.4 Biological activity of organotin compounds 
The toxicity of organotin compounds was reported back in 1886.172 However, studies 
into the toxicities of organotins only started to be carried out in the 1950s.172,173 In 
1955, Stoner et al.173 carried out a number of studies of mono-, di-, tri- and 
tetraorganotins and their effects on rats, rabbits, guinea-pigs and fowls. Their results 
showed that, of all of the compounds tested, the triethyltin-containing compounds 
were the most toxic, with animals exhibiting muscular weakness followed by 
muscular tremors, convulsions, and, eventually death. In the rabbit studies, a dose of 
10 mg/kg resulted in death within three hours of intravenous administration. Since 
then, numerous organotin toxicity studies have been carried out and as a result a 
general trend has emerged. The toxicity of organotins is governed mainly by the type 
and number of organic groups attached to the tin atom.172 Organotins containing 
alkyl groups are generally more toxic than aryltin compounds.161,172 Triorganotin 
compounds are considered to be the most toxic followed by the di-substituted and 
mono-substituted organotins, with the ethyl derivative of each exhibiting greatest 
toxicity.172,174,175 The toxicity of tetraorganotins is believed to be due to their 
decomposition to the more toxic triorganotin derivative.175 As the length of the 
carbon chain increases, a decrease in activity is seen with R3SnX compounds; tri-n-
octyl derivatives are essentially non-toxic to mammals.161,176 The nature of the 
triorganotin substitutent is also important in determining the species to which the 
organotin compound is most toxic against (Table 4.2.).161,172,171 The role of the X 
group, in R3SnX, has been reported as playing a minor role in the toxicity, unless the 
X group itself exhibits biological activity and/or increases the solubility of the 
compound.161,172 A decrease in activity has been associated with the ability of the X 
group to chelate to the tin atom.172  
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Table 4.2: The organic substituents of the triorganotins and the species to which 
they are toxic.161,172,171  
Triorganotin R group Species 
Methyl Insects and mammals 
Ethyl Mammals 
n-Propyl Gram negative bacteria 
n-Butyl Gram positive bacteria, fungi, fish and molluscs 
Phenyl Fungi, fish and molluscs 
Cy Mites 
 
Due to their various biocidal activities, the organotin compounds have found use in a 
number of biological applications.161,174,175,177  For example, a number of tributyl- 
and triphenyltin compounds have been used in antifouling paints including Bu3SnO, 
Bu3SnF, Bu3SnCl, Ph3SnX (X = F, Cl, OAc, OH).176  One of the first to be used was 
Bu3SnO.176 Not only can it inhibit growth of fouling species such as algae at 
concentrations as low as 0.005 ppm, but it is also effective against fungi and Gram-
positive bacteria.176 The use of organotins in antifouling paints had many 
advantages: 
(1)  they are very active against a range of fouling species (Table 4.3); 
(2)  they did not cause corrosion of aluminium hulls; 
(3)  they are colourless, allowing a wide range of coloured paints to be made; 
and 
(4)  most importantly, they could be easily degraded by UV light and 
microogranisms into less toxic organotins and ultimately harmless tin 
residues (Scheme 4.4).176,178 
However, in the 1980s it was suspected that tributyltin compounds were having 
adverse effects on marine species other than fouling species.176 It has since been 
shown that organotins can act as endocrine disruptors resulting in imposex (imposed 
sexual organ) of marine species such as gastropods.178 Studies into the half-lives of 
organotins found that organotins could be stable in sediments for up to 9 years and, 
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more worrying, is the bioaccumulation of organotins in marine species.176 For 
example. the bioaccumulation levels of tributyltin in dogwhelks was found to be 
1000 times greater than that found in surrounding water.178  As a result, a number of 
countries started to ban the use of organotin antifouling paints and, in 1999, a global 
ban was introduced by the International Maritime Organisation (IMO).176 As of 
January 1, 2008, the use of organotin antifouling paints on vessels is prohibited.176  
Table 4.3: The growth inhibition concentrations (ppm) of tributyltin antifouling 
agents against a range of fouling species.176 
Organotin Barnacles Enteramorpha Chlamydomas Lobsters 
Bu3SnO 0.01 0.02 0.005 0.02 
Bu3SnF 0.1 0.01 0.001 0.005 
 
 
Scheme 4.4: General scheme for the environmental degradation of tributyl and 
triphenyltin compounds.176 
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Despite the unfortunate outcome of the use of organotin antifouling paints, there has 
been a great deal of research into the use of organotins in other areas in which its 
biocidal activity can be exploited.175,177,179  
The anti-tumour properties of tin complexes were first observed in 1929.177 
However, it wasn’t until the 1980’s that organotin anticancer compounds were 
synthesised and these were based on cisplatin or its analogues.180 Gielen et al.180 
synthesised the di-n-butyl analogue of carboplatin and screened it against mammary 
and colon cancer cell lines. The organotin analogue exhibited almost 10 times 
greater activity compared to that of cisplatin against these cell lines.180 Numerous di- 
and triorganotin derivatives have been synthesised and tested against various cancer 
cell lines.181 Over 2000 organotin compounds have been screened by the NCI 
(National Cancer Institute), rendering tin as the metal with the greatest number of 
compounds to be screened.182 Some compounds have exhibited lower toxicity and 
better activity than cisplatin.183  
It has been suggested that there are a couple of factors that may play a role in the 
antiproliferative activity of organotin compounds: 
(1) the availability of coordination sites at the Sn atom, and  
(2) the existence of stable Sn-ligand bonds and their slow hydrolytic 
decompostition.184  
Crowe et al.185 also demonstrated that R2SnCl2.L (L = N containing bidentate ligand) 
complexes with Sn-N bond lengths < 2.39 Å are inactive whereas complexes with 
Sn-N bond lengths > 2.39 Å are active and suggested that predissociation of the 
ligand is important in activity. The mode of action of organotin anticancer agents is 
not fully understood, however, DNA interaction and apoptosis have been 
observed.186,187  The ID50 (the dose required to inhibit 50% of the cell line) values of 
a selection of organotin compounds and the various cell lines they are active against 
in comparison to cisplatin are given in Table 4.4.  
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Table 4.4: ID50 values of some organotin compounds against a variety of human cell 
lines. Flu = flufenamic acid and HL-7 = Gly-Leu. 
Cell Cancer Cisplatin Organotin compound Organotin 
A549 Lung 3.3a [Bu2(flu)SnOSn(flu)Bu2]b 0.24181f 
A498 Renal 2.253 Ph3Sn(HL-7) 0.03181e 
IGROV Ovarian 0.169 Ph3Sn(HL-7) 0.006181e 
M19 Melanoma 0.558 Ph3Sn(HL-7) 0.016181e 
MCF7 Mammary 0.699 [(Bu2Sn(O2CCF3)2)2O]2 0.057181h 
WiDr Colon 0.697 Ph3Sn(HL-7) 0.008181e 
HeLa Cervix 1.443 2-PhC2N3CO2SnPh3 0.005181c 
a ID50 value obtained from Matysiak et al.188 b The complex also exhibited better 
activity than carboplatin (108.0 g/mL) against A549. 
An important area in organotin research is in antimicrobial activity.161,175 Organotins 
are well known for their fungicidal properties.161,171 Triphenyltin acetate (Brestan®) 
and triphenyltin hydroxide (Du-ter®) were in use (discontinued in 1993 and 2002 
respectively) as fungicides for leaf spot on sugar beet and celery, rice blast, coffee 
leaf rust and potato blight.171,189 Numerous organotin compounds have been 
synthesised for antimicrobial purposes with a variety of ligands including 
carboxylates,190 amino acids and peptides,191 Schiff bases175,192, hydrazones,193 
triazoles,194 sulfur containing ligands,195 and biologically active ligands.196 The 
literature shows that many of the organotins have a tendency to be more active 
against Gram-positive bacteria compared to Gram-negative bacteria.191d,193a,194a,197 
The general known trends of toxicity are usually followed: for example, tri- are 
better than diorganotins,190b,190c and alkyl are more active than aryl organotins.191c It 
has also been noted that the organotin complexes are more active than their ligands 
alone.190d,191b It has been suggested that this may be due to chelation theory.198 Due 
to the partial sharing of positive charge by the metal with the ligand donor groups 
and the possible -electron delocalisation created over the chelate ring, a reduction 
in the polarity of the metal ion occurs upon chelation.198,199 This in turn increases the 
lipophilicity of the metal-chelate assisting its passage through cell membranes.198,199  
But the opposite affect has also been observed i.e. chelation results in a decrease in 
activity.193b,195  This may be due to the metal-chelate being unable to bind to an 
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active site.172 An interesting  study by Eng et al.200 of the inhibition of Ceratocystis 
ulmi by triaryltin chlorides indicated that it is the R3Sn+ cation that is responsible for 
toxicity.  Again, the mode of action of the organotin compounds is not fully 
understood.161,175 One possibility is the inhibition of oxidative phosphorylation 
which in turn prevents ATP (adenosine triphosphate) synthesis.190a,190b ATP is the 
energy source for cellular work.14 
Organotin compounds are also well known for their use as insecticides and 
larvicides.161,192,201 According to the US EPA (United States Environmental 
Protection Ageny), Torque® (bis(trineophyltin)oxide) is still in use as an 
acaricide.189 Many di- and triorganotins have been shown to be active against 
mosquitos (Aedes aegypti and Anopheles stephensi) with the toxicity dependant on 
both the organotin compound and the species of mosquito.179,201a Organotins are 
biodegradable and so far there are no known reports of An. Stephaesi and Ae. Aegypti 
resistance to triorganotins, making them very attractive compounds.201b Research 
into organotins as anti-inflammatory, anti-hypertensive and antiviral agents has also 
been carried out.174,181e,202 
4.2 1,10-Phenanthroline and its derivatives 
 
Figure 4.7: (a) 1,10-Phenanthroline (phen), (b) 1,10-phenanthroline-5,6-dione 
(dione) and (c) dipyrido[3,2-a:2’,3’-c]phenazine (dppz). 
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4.2.1 1,10-Phenanthroline (phen) 
First synthesised by Blau in 1898, 1,10-phenanthroline (phen), is a rigid, 
hydrophobic, electron-poor, heteroaromatic molecule consisting of two pyridine 
rings fused together by a central benzene ring (Figure 4.7).203,204 A number of 
methods have been investigated for the synthesis of phen and its derivatives, one of 
the earliest methods being the Skraup reaction (Scheme 4.5).203,204,205  
 
Scheme 4.5: The Skraup Reaction. 
In the phen molecule, the shortest bonds (1.36 Å) are the C-N bonds, while the 
longest are the C-C bonds (1.49 Å) linking the pyridyl groups together.206 Phen is a 
weak -donor but a good -acceptor and can form complexes with a variety of metal 
ions.203,207 Coordination occurs through the two N atoms in a cis fashion, resulting in 
the formation of a five-membered chelate ring that is coplanar with the rest of the 
phen molecule.207 It has long been known that phen and substituted derivatives of 
phen can disturb a variety of biological systems in both the metal-free state and as 
ligands coordinated to transition metals.208 The bioactivity of metal-free phen is 
believed to be due to its ability to sequester metal ions within the medium or 
biological system and that the resulting complexes are the active species or that the 
‘seized’ metal ions are ions that are necessary for normal cell function and so are no 
longer able to carry out their role.209,210  
Phen derivatives and their metal complexes have been used as intercalating or 
groove binding agents for DNA and RNA and some metal complexes of phen can 
efficiently cleave the DNA backbone, for example, [Cu(phen)2]2+.203 Investigations 
into Cu, Ag, and Mn complexes of phen as anticancer and antimicrobial agents have 
been carried out.71,211,212 Moreover, the addition of phen to a metal complex has been 
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shown to enhance the anticancer and antimicrobial activity with some complexes 
demonstrating values comparable to or better than that of standard drugs.213,214,212   
4.2.2 1,10-Phenanthroline-5,6-dione (dione) 
1,10-Phenanthroline-5,6-dione (dione) has been known for many years and can be 
synthesised by the oxidation of phen (Scheme 4.6).215  
 
Scheme 4.6: The synthesis of 1,10-phenanthroline-5,6-dione. 
Dione is a non-planar, bidentate ligand, with an o-quinoid functionality (Figure 
4.7).206 It has a similar structure to that of phen, the C-N bonds in dione are the 
shortest bonds (1.34 Å, excluding the C=O bonds, 1.21 Å in length) and the longest 
bonds are the OC-CO bonds (1.53 Å).206  As with phen, dione has the ability to 
coordinate to metal ions through its diiminic functionality, but it can also bind to 
metal ions through the quinonoid functionality or through both.206,216 Coordination 
through the N atoms results in a complex that can be used as a ‘quinone equivalent’ 
in reactions with compounds containing metals in low oxidation states, and 
coordination through O results in a complex that can act as a ‘phenanthroline 
equivalent’ in reactions with Lewis bases.216  
Dione exhibits both anticancer and antimicrobial activity and improved activity in 
comparison to phen.71,217 Dione and Co(II) complexes of dione have been shown to 
bind to DNA and cleave plasmid DNA.218 Due to this biological activity, many metal 
complexes of dione have been investigated for their anticancer and antimicrobial 
activity.219,220,221,222 The addition of dione to a metal ion has been shown to enhance 
biological activity.219,71   
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4.2.3 Dipyrido[3,2-a:2’,3’-c]phenazine (dppz) 
From dione, dipyrido[3,2-a:2’,3’-c]phenazine (dppz) can be synthesised (Scheme 
4.7).215  
NNNN
O O NN
H2N NH2
 
Scheme 4.7: The Synthesis of dipyrido[3,2-a:2’,3’-c]phenazine (dppz). 
Dppz is a planar, bidentate ligand with an extended aromatic system which facilitates 
its binding to DNA by intercalation (Figure 4.7).217 This attractive property has 
resulted in the synthesis of various metal complexes of dppz.223 One of the most well 
known complexes is the molecular ‘light switch’ Ru(2,2’-bipyridine)2(dppz)2+.224 
This complex displays metal-to-ligand-charge-transfer photoluminescence in 
hydrophobic solvents but in aqueous solution the photoluminescence is quenched by 
protonation of the phenazine N.224 However, in the presence of DNA, intense 
photoluminescence is observed and the photoluminescence intensity and emission 
maximum will differ depending on the DNA substrate allowing the complex to 
behave as a DNA probe.224  
Not only can dppz metal complexes bind to DNA but they have also demonstrated 
DNA cleavage.218,225 It has been found that dppz itself can cleave DNA and is also 
cytotoxic.217 Dppz and its metal complexes have been investigated for anticancer, 
antibacterial, antifungal, antiprotozoal and antiviral activity.217,225,226,227 The Co(III) 
complex synthesised by Reddy et al.225 displayed better antifungal and antibacterial 
activity than that of the well-known standards, fluconazole and streptomycin. 
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4.2.4 Aim 
The aim of this study was to synthesise a series of diorganotin(IV) compounds 
([R2SnX2L]) and evaluate their antibacterial activity against Gram-negative and 
Gram-positive bacteria. Three R groups were chosen for synthesis; Me, a structurally 
small and simple organic group, n-Bu a medium length alkyl chain, and a larger, 
aromatic phenyl group. These three R groups were chosen in the hopes that their 
differences in both structure and electronic features would give rise to differences in 
their biological activity. As mentioned earlier with the triorganotin compounds, the 
nature of the R group is important in determining the species to which it is most 
toxic against, for example, the tributyl tin compounds are known to be active against 
Gram-positive bacteria.161,171 
Since a variety of tin carboxylates have been investigated in a number of biological 
systems and have exhibited some promising antimicrobial results, three carboxylate 
groups were chosen as the X group of the [R2SnX2(L)] compounds in this study.190a,b, 
190f Firstly, the CH3CO2- group was chosen due to its small and simple structure. 
Secondly, taking into account the fact that the X group in R3SnX compounds has 
been reported as playing a minor role in the toxicity unless the X group itself 
exhibits biological activity, two biologically active carboxylates were chosen.161,172 
These are nicotinic acid and its isomer, picolinic acid.  
Nicotinic acid, better known as niacin or vitamin B3, is an essential vitamin in 
humans and is produced from L-tryptophan.14,228 As well as being a precursor to the 
coenzyme NAD (nicotinamide adenine dinucleotide), nicotinic acid is known for its 
antidyslipidemic effects and its ability to inhibit vascular inflammation and 
atherosclerosis progression.228-229 Picolinic acid is also a naturally occurring 
metabolite of L-tryptophan.230 It is known for its ability to facilitate the absorption of 
dietary zinc in rats and has been shown to act as a costimulator of macrophage 
tumoricidal activity in vitro.231 
Finally, 1,10-phenanthroline (phen) and two of its derivatives, 1,10-phenanthroline-
5,6-dione (dione) and dipyrido[3,2-a:2’,3’-c]phenazine (dppz), were chosen as the 
ligands, L, of the [R2SnX2L] compounds. The phen, dione and dppz ligands are 
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attractive ligands to work with not only because of their differences in electronic and 
steric features, and their varying degrees of biological activity, but also the ease at 
which the dione and dppz can be synthesised from phen.208,210,217,232 
It was envisioned that a diorganotin(IV) compound combined with a carboxylate 
moiety and either a phen, dione or dppz ligand could potentially produce a metal-
based antibacterial compound with exceptional activity. 
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4.3 Results and Discussion 
4.3.1 Synthesis of the ligands  
 
Figure 4.8: (a) 1,10-Phenanthroline (phen), (b) 1,10-phenanthroline-5,6-dione 
(dione) and (c) dipyrido[3,2-a:2’,3’-c]phenazine (dppz). Numbering system for 1H 
and 13C NMR also shown. 
1,10-Phenanthroline (phen) was obtained commercially and used without any further 
purification. 1,10-Phenanthroline-5,6-dione (dione) was synthesised from phen as 
previously described by Paw and Eisenberg232a resulting in a fine, yellow solid, upon 
purification. The dione was then reacted further with o-phenylenediamine in EtOH to 
produce dppz in good yield, 75%.232b A proposed mechanism for the synthesis of 
dppz is given in Scheme 4.8. Nucleophilic attack of the primary amine of o-
phenylenediamine at the electrophilic carbonyl carbon of the dione, followed by the 
loss of water, results in formation of the new imine bond to give the dppz ligand. 
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Scheme 4.8: Proposed mechanism for the synthesis of dppz. (For clarity, the full 
structure of the dione ligand has been excluded throughout the reaction scheme.) 
The simplicity of the 1H NMR spectra of each of the phen ligands is due to the plane 
of symmetry in the molecules (Figure 4.9). In the 1H NMR spectrum of dione it can 
be seen that the H-5 of phen, found at 7.99 ppm, has disappeared. A new carbonyl 
carbon signal appears in the 13C NMR spectrum of dione (at 177.7 ppm), the 
formation of which is confirmed further by the presence of the characteristic (C=O) 
absorption band at 1686 cm-1 in the IR spectrum. Formation of the dppz ligand is 
confirmed by the disappearance of the dione 13C NMR C=O signal, along with the 
appearance of two new signals (8.36 and 8.04 ppm, the protons of the new aromatic 
ring in the dppz molecule) in the 1H NMR spectrum. The protons of each of the 
ligands, phen, dione and dppz, expected to be affected most by complexation to tin 
were the H-2 protons. These signals appear as a doublet of doublets at 9.10, 8.98 and 
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9.49 ppm in the 1H NMR spectra of the free ligands phen, dione and dppz, 
respectively.  
 
Figure 4.9: 1H NMR spectra of (a) phen, (b) dione and (c) dppz in DMSO-d6. 
4.3.2 Synthesis of the diorganotin(IV) monoacetate compounds 
The organotin(IV) monoacetate compounds (R2Sn(O2CMe)Cl, R = Me, n-Bu, or Ph) 
were synthesised from the corresponding diorganotin(IV) dichlorides. The 
diorganotin(IV) dichlorides were obtained commercially and used without any 
further purification. For the dimethyl- and dibutylchlorotin(IV) acetate compounds, 
Et3N was added slowly to a solution of the appropriate dichloride and acetic acid in 
toluene followed by a three hour reflux (Scheme 4.9). The resulting Et3N.HCl salt 
by-product was removed by filtration through celite to give [Me2Sn(O2CMe)Cl] and 
[n-Bu2Sn(O2CMe)Cl] with yields of 73% and 88%, respectively. 
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Scheme 4.9: Synthesis of diorganotin(IV) monoacetate compounds 
[R2Sn(O2CMe)Cl] (i) AcOH, Et3N, , 3h, toluene for R = Me and n-Bu, and AcOH, 
K2CO3, , overnight, benzene for R = Ph. 
The same method was used in an attempt to synthesise the diphenyltin derivative but 
was unsuccessful. From the 1H NMR spectrum it appeared that a mixture of starting 
materials was being returned. This may be due to the limited solubility in toluene of 
diphenyltin(IV) dichloride. Diphenyltin(IV) dichloride has greater solubility in 
benzene thus, the reaction was repeated as in Scheme 4.9 using benzene as the 
reaction solvent. Again, it appeared that a mixture of starting materials was being 
returned, so the reaction was repeated but allowed to reflux over longer periods of 
time, that is, 5, 9, 12 and 24 hours. However, no difference in the 1H NMR spectra 
was observed with increasing reaction time. After changing both the solvent and 
increasing the reaction times proved unsuccessful, a change in base was attempted. 
The reaction was allowed to reflux in benzene overnight, with K2CO3 instead of 
triethylamine, which successfully gave the white solid product, [Ph2Sn(O2CMe)Cl]. 
The molecular structure of each of the three compounds was elucidated by elemental 
analysis, 1H and 13C NMR and IR spectroscopies. Elemental analysis confirmed the 
presence of a single Cl in each molecule. The 1H NMR of the [Me2Sn(O2CMe)Cl] 
and [n-Bu2Sn(O2CMe)Cl] showed a distinct singlet for the acetate signals at 1.93 and 
1.95 ppm, respectively, corresponding to the three protons of the acetate group in 
each case. 
A variety of di- and trimethyltin(IV) compounds have been studied in an effort to 
investigate if there is a correlation between the magnitude of the Sn-carbon (1J) or  
Sn-hydrogen (2J) coupling constants and the Me-Sn-Me angle ().233 It was found 
that in both the solid and solution state, the molecular structure of methyltin(IV) 
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compounds could be estimated from 1J and 2J as they are dependent on the Me-Sn-
Me angle (Equation 4.2 and 4.3).233 The following conclusions have been drawn:233 
 for di- and tetramethyltin(IV) compounds with a coordination number of four 
1J ≤ 430 Hz, pentacoordinated tri- and dimethyltin(IV) compounds have 1J 
in the range 470-610 Hz and for hexacoordinated dimethyltin(IV) compounds 
1J ≥ 630, 
 2J is less than 59 Hz for trimethyltin(IV) compounds with a coordination 
number of four and tetracoordinated dimethyltin(IV) compounds bearing 
electronegative substituents can have a higher 2J, for example, Me2SnCl2 
has 2J = 69 Hz, 
 pentacoordinated dimethyltin(IV) compounds have 2J in the range of 64-79 
Hz (corresponding to  = 115o and 130o) and 
 hexacoordinated dimethyltin(IV) compounds have Me-Sn-Me between 
109.1 and 180o. 
It was noted that caution should be taken when using the equations if 2J is < 80 Hz 
(or 1J < 650 Hz) and the dimethyltin(IV) compound is likely to be hexacoordinated, 
as cis-dimethyltin(IV) compounds can have  values that are much smaller than that 
predicted by Equation 4.3.233a   
Equation 4.2: 1J = 11.4 - 875 
Equation 4.3:  = 0.01612J2 – 1.322J + 133.4 
For [Me2Sn(O2CMe)Cl], 2J(119/117Sn) = 92.7/82.2 Hz were found. Using Equation 
4.3. Me-Sn-Me was calculated to be 149.4o suggesting a hexacoordinate structure 
in solution. 
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For [Ph2Sn(O2CMe)Cl], the 1H NMR spectrum was poorly resolved due to lack of 
solubility which resulted in indistinct integrations. However, the 13C NMR spectrum 
confirms the presence of the carbonyl carbon at 178.5 ppm which is shifted 
downfield in comparison to the acetic acid carbonyl carbon (175.9 ppm). A HSQC 
equivalent experiment verified that the 1H NMR singlet at 2.15 ppm corresponds to 
the three equivalent protons of the acetate. 1J and 2J (119/117Sn) could not be found for 
either [n-Bu2Sn(O2CMe)Cl] or [Ph2Sn(O2CMe)Cl] due to their complex NMR 
spectra.   
A range of different coordination modes exist for the carboxylate ion, RCO2- (Figure 
4.10). Deacon and Phillips234 have studied the coordination modes of a variety of 
acetato and trifluoroacetato metal complexes and have proposed that the 
coordination mode of the carboxylate ion can be defined by measuring ; the 
difference between the asymmetric and symmetric carboxylate stretching frequencies 
(asCOO- - symCOO-). The  values proposed by Deacon and Phillips are tentative 
values, as some exceptions have been observed.234 The general conclusions obtained 
by Deacon and Phillips for the diagnosis of the nature of the coordination mode of 
the carboxylate group have been widely used (over 2000 citings235) and are as 
follows:179,190g,234 
(i) for unidentate coordination,  is larger than that observed for ionic acetates 
( > 200 cm-1 for acetates and  > 260 cm-1 for trifluoroacetates), 
(ii) if  values are less than 200 cm-1, then the carboxylate group coordinates in 
a bidentate manner,  
(iii) for acetates only, a  value considerably less than that observed for ionic 
acetates (<105 cm-1) is indicative of chelating or of both chelating and 
bridging and 
(iv) for all of the complexes studied, those that have a  value in the range of 
150-200 cm-1  have chelating and/or bridging acetate groups. 
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Figure 4.10: Possible coordination modes of a carboxylate ion, RCO2-; (a) 
unidentate, (b) chelating, (c) bidentate bridging, (d) monatomic bridging and (e) 
chelation and bridging.234 
In the IR spectra of each of the monoacetate derivatives a strong absorption band in 
the range 1550-1640 cm-1 corresponding to (C=O) of the carboxyl group can be 
seen. The asCOO- and symCOO- stretching frequencies for each of the monoacetate 
compounds are given in Table 4.5. For [Me2Sn(O2CMe)Cl], [n-Bu2Sn(O2CMe)Cl] 
and [Ph2Sn(O2CMe)Cl],  = 144, 143 and 122 cm-1 respectively. All three 
compounds have a  less than 200 cm-1 suggesting a bidentate coordination mode 
for the carboxylate group.  
Table 4.5: IR stretching frequencies (cm-1). 
Compound νasCOO-  νsymCOO-  
Na(O2CMe)234 1578 1414 164 
[Me2Sn(O2CMe)Cl] 1564 1420 144 
[n-Bu2Sn(O2CMe)Cl] 1637, 1571 1376, 1428 261, 143 
[Ph2Sn(O2CMe)Cl] 1551 1429 122 
 
The crystal structure for [Me2Sn(O2CMe)Cl] has been reported, and consists of 
Me2SnCl units linked together by bridging acetates with the two methyl group 
Chapter IV: A study of organotin(IV) antibacterial agents 
202 
 
carbons and the chlorine atom forming a trigonal arrangement about the Sn atom.236 
The compound is described as having a distorted trigonal bipyramidal structure with 
distortions being attributed to a second, weak Sn-O intramolecular interaction which 
increases the overall Sn coordination number to six (Figure 4.11).236 The above 
results are in agreement with the reported crystal structure. 
 
Figure 4.11: Molecular structure of [Me2Sn(O2CMe)Cl] (see Allen et al.236).   
Interestingly, the dibutyltin(IV) derivative appears to have a second set of asCOO- 
and symCOO- stretching frequencies (1637 and 1376 cm-1), where  = 261 cm-1. 
This value is greater than  of sodium acetate which would imply that the 
carboxylate may also be coordinating in a second, unidentate manner. In general, a 
asCOO- absorption in the range ca. 1560-1540 cm-1 is found for bridging 
organotin(IV) carboxylate compounds whereas for the unidentate structures a  
asCOO- absorption in the range ca. 1660-1640 has been observed.237 In the IR 
spectrum of [n-Bu2Sn(O2CMe)Cl], the asCOO-  absorption at 1637 cm-1 is weaker in 
comparison to the 1571 cm-1 absorption band. The two sets of asCOO- and 
symCOO- stretching frequencies observed for [n-Bu2Sn(O2CMe)Cl] could be due to 
both a dimeric and a monomeric form being present in the solid state (Figure 4.12). 
Elemental analysis for [n-Bu2Sn(O2CMe)Cl] suggests the presence of one acetate 
molecule, one Cl atom and two n-butyl groups per tin atom, a composition that 
supports both the dimeric and monomeric forms in the solid state. On review of the 
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literature, there appears to be no reported crystal structure for [n-Bu2Sn(O2CMe)Cl] 
thus the exact mode of coordination is unclear.  
 
Figure 4.12: Proposed structures for [n-Bu2Sn(O2CMe)Cl], (a) dimer and (b) 
monomer. 
However, Honnick and Zuckerman237 have carried out studies on [n-
Bu2Sn(O2CMe)Cl] in an effort to determine its structure. They found that in the solid 
state IR spectrum a asCOO- absorption in the range 1560-1551 cm-1 was observed 
and in the solution state IR spectrum an additional asCOO- absorption at a frequency 
ca. 100-125 cm-1 higher than the solid state asCOO- absorption was observed.237 The 
appearance of an additional band suggests that there is a change in structure on going 
from the solid to the solution state. The authors suggested a dimeric structure for [n-
Bu2Sn(O2CMe)Cl] in which a four-membered SnO2 or SnOX ring exists giving a 
free carboxyl group (Figure 4.13). Organotin compounds consisting of these 
structures are known and exhibit asCOO- absorption bands at ca. 1700 cm-1.237  
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Figure 4.13: Possible dimeric equilibrium structures proposed by Honnick and 
Zuckerman for di-n-butyltin chloride acetate (R = n-Bu and X = Cl).237 
4.3.3 Synthesis of the diorganotin(IV) diacetate compounds; diorganotin(IV) 
dipicolinate 
Sn
ON
N
O
O
O R
R
b
c
d
a
e
 
  Figure 4.14: Diorganotin(IV) dipicolinate where R = Me, n-Bu or Ph. Labelling 
system for 1H and 13C NMR also shown. 
 
The synthesis of the [Me2Sn(picolinate)2] was first carried out by a method similar to 
that of the diorganochlorotin(IV) acetate compounds above (section 4.3.2); two 
equivalents of picolinic acid were stirred with two equivalents of Et3N in toluene 
followed by the addition of Me2SnCl2 and a three hour reflux. The reaction mixture 
was allowed to cool and the resulting precipitate was collected by filtration. From the 
1H NMR spectrum, the reaction appeared to be successful, however, both the filter 
and filtrate contained the product along with the Et3N.HCl by-product. In an effort to 
purify the product, the crude mixture was dissolved in DCM and washed with 
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distilled water. However, some Et3N.HCl was still present in the 1H NMR spectrum. 
The crude mixture was dissolved in DCM and n-hexane was added slowly in an 
attempt to purify the product by precipitation. Unfortunately, this only removed 
some of the Et3N.HCl. Thus, on review of the literature, a different approach to the 
synthesis was taken which would exclude the production of Et3N.HCl as a by-
product.  
 
Scheme 4.10: Synthesis of [R2Sn(picolinate)2]; (i) picolinic acid, , 2h, toluene 
(method B). 
[Me2Sn(picolinate)2] was synthesised by the procedure described by Szorcsik et 
al.238 with some modification (Scheme 4.10). After a two hour reflux, the reaction 
mixture was allowed to cool and the product was collected by filtration and washed 
with cold MeOH. This procedure was used for the synthesis of the [n-
Bu2Sn(picolinate)2] and [Ph2Sn(picolinate)2] compounds also. The compounds 
[Me2Sn(picolinate)2], [n-Bu2Sn(picolinate)2] and [Ph2Sn(picolinate)2] were obtained 
in good yields of 83, 80 and 77%, respectively. 
In the 1H NMR spectra of the diorganotin(IV) dipicolinate compounds a 1:1 
acid:organic group ratio can be seen. Only small shifts in the proton signals of the 
picolinate groups were observed, with the largest shift observed for H-d, indicating 
coordination to the tin atom (Figure 4.14). However, in the 13C NMR spectra a large 
upfield shift in C-a can be seen, indicating coordination of the pyridine ring N atom 
to the Sn centre. Although 2J(119/117Sn,1H) coupling constants of 76.5 and 73.5 Hz 
were obtained for [Me2Sn(picolinate)2] Equation 4.3 cannot be used to determine  
for this compound. Studies by Lockhart et al.239 have found that Me2Sn(chelate)2 
compounds (chelate = tropolonate, kojate or picolinate) do not obey these equations. 
It is unclear why these compounds, containing five-membered chelate rings, do not 
obey the equations.239  
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Due to the complex butyl region of the [n-Bu2Sn(picolinate)2] 1H NMR spectrum, no 
2J(119/117Sn,1H) coupling constants could be obtained, but the 2J and 3J(119Sn, 13C)  
coupling constants (33.8 Hz and 124.5 Hz) were found. These values are in 
accordance with other dibutyltin(IV) compounds with 3J  larger than 2J but without 
the 1J(119Sn, 13C) value the coordination number about the tin atom cannot be 
predicted.240 Unfortunately, no 119/117Sn coupling constants for the diphenyltin(IV) 
dipicolinate compound could be calculated from the 1H or 13C NMR spectra. 
For the free picolinic acid, the OH of the carboxylate moiety occurs at ca. 2500 cm-
1 and disappears in the IR spectra of the dipicolinate compounds, indicating 
deprotonation of the COOH and coordination with the Sn(IV) molecule. In both the 
[Me2Sn(picolinate)2]  and [n-Bu2Sn(picolinate)2] IR spectra, the presence of two 
asCOO- and symCOO- stretching frequencies suggest coordination by two different 
modes (Table 4.6). The  values of 326 and 323 cm-1 are greater than that of the 
picolinate sodium salt which according to Deacon and Phillips, indicate a unidentate 
mode of coordination.234 The second set of asCOO- and symCOO- stretching 
frequencies give  values in the range ca. 150-200 cm-1, suggesting a bridging 
bidentate coordination mode. 
Table 4.6: IR stretching frequencies (cm-1) for the diorganotin(IV) diacetate 
compounds. 
Compound νaCOO-  νsCOO-  
Na-picolinate238 1607 1411 196 
[Me2Sn(picolinate)2] 1675, 1561 1349, 1386 326, 175 
[n-Bu2Sn(picolinate)2] 1670, 1564 1347, 1384 323, 180 
[Ph2Sn(picolinate)2] 1678 1332 346 
Na-nicotinate241 1615 1375 240 
[Me2Sn(nicotinate)2] 1605 1399 206 
[n-Bu2Sn(nicotinate)2] 1609 1409 201 
[Ph2Sn(nicotinate)2] 1608 1411 197 
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The crystal structures of [Me2Sn(picolinate)2], [n-Bu2Sn(picolinate)2], and 
[Ph2Sn(picolinate)2] have been previously reported.239,242 In each of the compounds, 
the two picolinic acid molecules coordinate to the Sn centre through the pyridine 
ring N atom and one O atom of the carboxylate moiety resulting in a five-membered 
chelate ring.239,242 In [Me2Sn(picolinate)2] and [n-Bu2Sn(picolinate)2] each Sn atom 
is also bridged by a second O atom of one of the picolinic acids giving rise to a 
polymeric structure wherein the compounds are seven-coordinate with a distorted, 
pentagonal bipyramidal geometry (Figure 4.15).239 [Ph2Sn(picolinate)2] is slightly 
different in structure, as it is monomeric in nature with a distorted octahedral 
geometry.242 The lack of molecular aggregation in [Ph2Sn(picolinate)2] is believed to 
be due to the steric bulk of the phenyl groups.242  The results presented above are in 
accordance with the reported crystal structures of the diorganotin(IV) dipicolinate 
compounds. 
 
Figure 4.15: X-ray crystal structures of diorganotin(IV) dipicolinate compounds, (a) 
[Me2Sn(picolinate)2] and (b) [n-Bu2Sn(picolinate)2].239,242 
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4.3.4 Synthesis of the diorganotin(IV) diacetate compounds; diorganotin(IV) 
dinicotinate 
 
 Figure 4.16: Diorganotin(IV) dinicotinate where R = Me, n-Bu or Ph. Labelling 
system for 1H and 13C NMR also shown. 
 
The [Me2Sn(nicotinate)2], [n-Bu2Sn(nicotinate)2] and [Ph2Sn(nicotinate)2] 
derivatives were synthesised by the same method as described for the dipicolinate 
compounds earlier (Scheme 4.10). CHN analysis indicated formation of a 2:1 
acid:metal complex and as with the dipicolinate compounds, only small shifts in the 
1H NMR signals were observed for the protons of the nicotinate groups. 
2J(119/117Sn,1H) coupling constants for [Me2Sn(nicotinate)2] were not observed, 
however, 3J(119Sn, 13C) = 51.8 ppm for C-e (Figure 4.16) was found, indicating 
coordination of the carboxylate group to the Sn atom. In the 13C NMR spectra, a 
large downfield shift has occurred with the carbonyl carbon signal for each of the 
dinicotinate derivatives. This is quite different to that observed for the dipicolinate 
compounds, in fact, unlike the dipicolinate compounds, the carbon signal for the C-H 
atoms adjacent to the pyridine ring N in the dinicotinate compounds do not seem to 
have been effected by binding to the Sn(IV) molecule. This would imply that the 
nicotinic acid N atom is not involved in coordination and that the carboxylate moiety 
is binding to the Sn(IV) molecule by a different mode of coordination to that 
observed for the dipicolinate compounds.  
On comparing the nicotinic acid IR spectrum to the IR spectra of the dinicotinate 
compounds, the OH band (ca. 2400 cm-1) has disappeared, indicating deprotonation 
of, and binding through, the carboxylate group. Furthermore, the shift in the C=O 
band in the IR spectra of the three diorganotin dinicotinate compounds from 1713 
cm-1 in nicotinic acid to 1605, 1609 and 1608 cm-1 was also proof of the formation of 
the [Me2Sn(nicotinate)2], [n-Bu2Sn(nicotinate)2] and [Ph2Sn(nicotinate)2] products. 
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Unlike the dimethyl- and di-n-butyltin(IV) dipicolinate compounds however, only 
one set of the asCOO- and symCOO- stretching frequencies are present giving  
values of 206 and 201 cm-1 for [Me2Sn(nicotinate)2] and [n-Bu2Sn(nicotinate)2], 
respectively (Table 4.6). These  values fall within the range of 150-200 cm-1 
suggesting a bidentate bridging coordination mode. The diphenyltin(IV) dinicotinate 
compound, like [Ph2Sn(picolinate)2], exhibited only one asCOO- and symCOO- 
stretching frequency with a  = 197 cm-1, suggesting a bridging coordination mode 
for the carboxylate moiety. These results suggest that, unlike the dimethyl- and 
dibutyltin(IV) dipicolinates, the dinicotinate compounds do not appear to coordinate 
through the pyridine N atom. However, coordination does appear to be occurring 
through the carboxylate group most likely in a bridging behaviour. 
On review of the literature there are no reported crystal structures for any of the three 
diorganotin(IV) dinicotinate compounds. However, Mössbauer and 119Sn NMR 
studies have been carried out on [Me2Sn(nicotinate)2], [n-Bu2Sn(nicotinate)2] and 
[Ph2Sn(nicotinate)2] and the results point towards a distorted trans octahedral 
geometry, whereby the nicotinate groups are coordinated through the two O atoms of 
the carboxylate group either by a bridging or chelating mode (Figure 4.17). 
 
Figure 4.17: Proposed structures of diorgano(IV) dinicotinate compounds (R = Me, 
n-Bu or Ph).241,243 
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4.3.5 Complexation Reactions 
4.3.5.1 Synthesis of [R2SnCl2L] complexes (R = Me, n-Bu or Ph and L = phen, 
dione or dppz) 
Complexation reactions with the 1,10-phenanthroline ligands were first carried out 
with the diorganotin(IV) dichlorides, [R2SnCl2] (R = Me, n-Bu and Ph). The 
reactions involved mixing equimolar quantities of the dichlorides with the chosen 
ligand in EtOH at reflux temperature for three hours. After cooling the solution, the 
solid products precipitated out and were collected by filtration. Yields of 92, 98 and 
93% were obtained for [Me2SnCl2(phen)], [n-Bu2SnCl2(phen)] and 
[Ph2SnCl2(phen)], respectively. Elemental analysis indicated that a 1:1 complex was 
formed between each of the the organotin(IV) compounds and the phen ligands.  
In the IR spectra of [Me2SnCl2(phen)], [n-Bu2SnCl2(phen)] and [Ph2SnCl2(phen)] the 
C=N absorption of the phen ligand has shifted in frequency, from 1644 cm-1 to ca. 
1622 cm-1, indicating coordination of the phen to the organotin(IV) dichlorides. A 
large downfield shift in each of the proton signals of the phen ligand can also be seen 
in the 1H NMR spectra of each of the organotin(IV) phen complexes, further 
confirming coordination. 1H NMR data for the diorganotin(IV) dichloride complexes 
is given in Table 4.7. 
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Table 4.7: Selected 1H NMR data for 1,10-phenanthroline ligands and their 
[R2SnCl2] compounds (R  Me, n-Bu or Ph) obtained in DMSO-d6.  
Compound H-2a H-3a H-4a H-5a H-6a 
phen 9.10 7.77 8.49 7.99 - 
dione 8.98 7.68 8.39 - - 
dppz 9.49 7.92 9.20 8.36 8.04 
[Me2SnCl2(phen)] 9.32 8.00 8.74 8.16 - 
[Me2SnCl2(dione)] 9.00 7.69 8.41 - - 
[Me2SnCl2(dppz)] 9.42 7.91 9.20 8.29 8.01 
[n-Bu2SnCl2(phen)] 9.44 8.16 8.90 8.27 - 
[n-Bu2SnCl2(dione)] - - - - - 
[n-Bu2SnCl2(dppz)]b 9.93 8.14 9.83 8.41 8.03 
[Ph2SnCl2(phen)]* 9.50 8.05 8.74 8.12 - 
[Ph2SnCl2(phen)]# 9.06 8.17 8.54 8.43 - 
[Ph2SnCl2(dione)] 9.00 7.68 8.40 - - 
[Ph2SnCl2(dppz)] 9.44 7.95 9.26 8.28 8.00 
dppzb 9.64 7.80 9.26 8.35 7.92 
a Numbering system shown in Figure 4.8,b obtained in CDCl3, * trans-isomer, # cis-
isomer. 
An unexpected 1H NMR spectrum was obtained for [Ph2SnCl2(phen)], containing 
what appeared to be two sets of signals. A closer inspection of the 1H NMR spectra 
using a COSY experiment indicated that there were two different [Ph2SnCl2(phen)] 
complexes present (Appendix C, Figure C1), one being more abundant than the 
other. These two complexes may be the cis- and trans-isomers of [Ph2SnCl2(phen)]. 
In order to investigate this possibility the 1H NMR experiment was repeated but at a 
higher temperature (70 oC) (Appendix C, Figure C2). The resulting 1H NMR 
spectrum had only one set of signals present, supporting the above suggestion. 
The X-ray crystal structures for [Me2SnCl2(phen)], [n-Bu2SnCl2(phen)] and 
[Ph2SnCl2(phen)] have been reported (Figure 4.18). In each derivative, the organo 
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groups sit in the axial positions with the phen ligand and two chlorine atoms 
occupying the equatorial positions, resulting in an octahedral geometry about the 
Sn(IV) centre.244 For [Ph2SnCl2(phen)], having the phenyl groups trans to one 
another must be the most stable arrangement which is understandable considering 
the bulky nature of the phenyl groups. However, in the 1H NMR spectrum there 
appears to be two complexes present. Tin complexes are known to alter their 
structure on changing from one phase to another, thus, it may be that in solution the 
complex can exist as two isomers, the most abundant being the more favourable 
trans-isomer.161  
 
Figure 4.18: X-ray crystal structures of (a) [Me2SnCl2(phen)], (b) [n-
Bu2SnCl2(phen)] and (c) [Ph2SnCl2(phen)].244  
For the dione and dppz organotin(IV) complexes, shifts in the 1H NMR signals of the 
ligands were also observed, although these are much smaller in nature in comparison 
to the organotin(IV) phen complexes (Table 4.7). This is unusual as both ligands are 
1,10-phenanthroline derivatives and so chelation is expected to occur through the 
two nitrogen atoms which should result in shifts in the 1H NMR signals similar in 
size to those of the phen complexes. These small shifts suggest that there is little 
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interaction between the ligand and the Sn(IV) centre. If the size of the ligand was an 
issue then it would be expected that the dppz ligand would cause problems and not 
the dione ligand. However, the size of the ligand cannot really be an issue, as the 
binding site is remote from the rest of the molecule and is consistent amongst the 
series.   
A second explanation for the lack of interaction, with regards to the dione ligand, 
may be because of its dual binding ability. As mentioned earlier, dione has two 
potential binding sites through the diiminic and o-quinonoid functionalities. If 
binding is occurring through the o-quinonoid functionality then little effect on the 
proton NMR signals of dione would be expected. If it is binding through both 
functionalities then it may be forming a polymer. This may also be the reason why 
the NMR data for the [n-Bu2SnCl2(dione)] derivative was very complex.  
In the IR spectrum of the free dione ligand, the stretching frequency of the C=O 
band occurs at 1686 cm-1 (Table 4.8). On examining the IR spectra of the 
organotin(IV) dione complexes a shift of ca. 10-30 cm-1 in the (C=O) absorption to 
a higher frequency (in the range 1690-1720 cm-1) can be seen, indicating interaction 
of the ligand with the organotin(IV) dichloride. If binding was occurring through the 
o-quinonoid functionality of dione, much larger shifts (ca. 200-300 cm-1) would be 
expected.216 Considering that the C=O moieties are far from the coordination site of 
the ligand these small shifts suggest the formation of N,N’-coordinated complexes 
with the tin atom.206,216,245  
Table 4.8: IR absorption bands for the free dione ligand and the [R2SnCl2(dione)] 
complexes (R = Me, n-Bu and Ph). 
Compound (C=O) (C=N)/(C=C) (C-N-C) 
dione 1686 1574, 1566 738 
[Me2SnCl2(dione)] 1700 1573 732 
[n-Bu2SnCl2(dione)] 1718 1584 720 
[Ph2SnCl2(dione)] 1694 1574 727 
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The crystal structure of [Ph2SnCl2(dione)]·2MeCO has been reported, and is similar 
to the structure reported for [Ph2SnCl2(phen)] with the phenyl groups in a trans 
arrangement and the dione ligand coordinated through its diiminic 
functionality.244c,246 The Sn-N bond lengths, 2.394 and 2.405 Å, are only slightly 
longer than those of [Ph2SnCl2(phen)] (2.341 and 2.378 Å).244c,246 With regards to 
the dione complexes synthesised here, perhaps the dione ligand does bind through 
the N atoms as suggested by the IR data but only associates weakly in solution 
giving rise to only small shifts in the 1H NMR signals. Similarly, with the dppz 
complexes, the IR spectra of each of the complexes indicate binding through the N 
atoms of the ligand (Table 4.9). Absorption bands for (C=N) and (C=C) in the 
1640-1400 cm-1 range were observed for the free dppz ligand. These bands have 
shifted to a lower frequency in the IR spectra of the complexes, thus, indicating 
coordination of the N atoms to the metal centre. However, in the 1H NMR spectra of 
the dppz complexes, the small shifts in the proton signals of the dppz ligand suggest 
weak binding has occurred in solution. The elemental analysis for the dione and dppz 
complexes suggest formation of 1:1 complexes with the organotin(IV) dichlorides. 
Table 4.9: IR absorption bands for the free dppz ligand and the [R2SnCl2(dppz)] 
complexes (R = Me, n-Bu and Ph). 
Compound (C=N)/(C=C) (C-N-C) Other absorption bands 
dppz 1634, 1586 740 1490, 1415, 1362, 1338, 1074 
[Me2SnCl2(dppz)] 1632, 1572 734 1493, 1420, 1359, 1075 
[n-Bu2SnCl2(dppz)] 1631, 1574 736 1493, 1419, 1361, 1076 
[Ph2SnCl2(dppz)] 1627, 1574 735 1494, 1420, 1428, 1361, 1078 
4.3.5.2 Synthesis of [R2Sn(O2CMe)Cl(L)] complexes (R = Me, n-Bu or Ph and L 
= phen, dione or dppz) 
An attempt to synthesise [R2Sn(O2CMe)Cl(phen)] was first carried out using the 
most soluble of the three organochlorotin(IV) acetates, [n-Bu2Sn(O2CMe)Cl], under 
the same reaction conditions as described earlier for the synthesis of [R2SnCl2(phen)] 
(section 4.3.5.1). Unexpectedly, the reaction was unsuccessful, returning only a 
mixture of starting materials. Hence the reaction was repeated with longer reaction 
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times. The reaction was allowed to reflux for a total of 24 hours and monitored by 1H 
NMR spectroscopy, but no shift in the proton signals of the phen ligand was 
observed. It was thought that perhaps a different solvent was required, therefore, 
MeCN was chosen in an effort to increase the Lewis acidity of the Sn(IV) centre and 
thus help drive the reaction forward. 
The first reaction was carried out at room temperature with stirring overnight, but 
was unsuccessful. Heating of the reaction mixture (40-50 oC) was attempted with 
monitoring over 24 hours but was also unsuccessful. Finally, a 24 hour reflux in 
MeCN was attempted but this also failed to give the [n-Bu2Sn(O2CMe)Cl(phen)] 
complex. With the steric bulk of the n-butyl groups in mind, the reaction was 
attempted with [Me2Sn(O2CMe)Cl] instead. The reaction was carried out in EtOH at 
reflux temperature for three hours but no product was observed in the 1H NMR 
spectrum. The reaction was also attempted in MeCN but again the reaction failed to 
produce the [Me2Sn(O2CMe)Cl(phen)] complex.  
After the unsuccessful attempts to synthesise [Me2Sn(O2CMe)Cl(phen)] and [n-
Bu2Sn(O2CMe)Cl(phen)] it was unlikely that the dione and dppz complexes would 
form. An attempt was made to synthesise both the dione and dppz complexes of the 
dimethyltin and dibutyltin monoacetate derivatives. As expected, these experiments 
were unsuccessful. Due to the failed attempts of these reactions no attempts were 
made to synthesise the [Ph2Sn(O2CMe)Cl(L)] derivatives (L = phen, dione or dppz). 
As mentioned earlier, the [Me2Sn(O2CMe)Cl] is polymeric in nature and can achieve 
a six-coordinate geometry through bridging of the carboxylate group. If the 
organotin(IV) monoacetate compounds have achieved the six-coordinate geometry in 
solution then in order for the phen ligands to bind to the Sn(IV) centre the bridging 
must initially be disrupted. Binding of a phen-based ligand would result in the 
formation of a seven-coordinate tin species as proposed in Figure 4.19. However, the 
phen ligands are relatively large, planar (or near planar) and rigid in nature and so 
may be unable to ‘fit’ into the geometry constraint required by the proposed seven 
coordination.   
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Figure 4.19: Proposed seven-coordinate organotin(IV) structure (R = Me, n-Bu, or 
Ph and NN = phen, dione or dppz). 
4.3.5.3 Synthesis of [R2Sn(picolinate)2L] complexes (R = Me, n-Bu or Ph and L 
= phen, dione or dppz) 
In an effort to synthesise [Me2Sn(picolinate)2(phen)] a 1:1 mixture of phen and 
[Me2Sn(picolinate)2] were heated to reflux in EtOH for one, three, five and eight 
hours. In all cases, the resulting precipitate that formed on cooling was 
[Me2Sn(picolinate)2] only, with the filtrate containing phen and a small proportion of 
[Me2Sn(picolinate)2]. With the lack of complexation in EtOH the reaction was 
attempted in MeCN. Again, on cooling [Me2Sn(picolinate)2] precipitated out of 
solution and the filtrate contained mostly phen. However, there was a shift in the 1H 
NMR signals of the phen ligand suggesting the possible formation of a complex. In 
an effort to remove the excess phen the crude solid was washed with cold ethanol 
returning [Me2Sn(picolinate)2] as the solid product. A second wash of the crude solid 
obtained from the filtrate was then carried out with hot toluene, the resulting filter 
was [Me2Sn(picolinate)2] and the filtrate contained phen. No 
[Me2Sn(picolinate)2(phen)] was found.  
The complexation reactions were also attempted with [n-Bu2Sn(picolinate)2] and 
[Ph2Sn(picolinate)2] in EtOH and MeCN but the same result was obtained. An 
attempt to synthesise the dione and dppz complexes of [Me2Sn(picolinate)2] was also 
carried out in EtOH but with no success. 
It is not entirely surprising that these complexation reactions did not work. As 
mentioned earlier, the structures of the three organotin(IV) dipicolinates used in this 
study are known. Each of the compounds contain two bulky picolinate groups, each 
of which forms a five-membered chelate ring resulting from the coordination of the 
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pyridine ring N atom and a carboxylate O atom. Although coordination numbers of 
eight and even ten have been reported for tin complexes, the phen ligands are planar 
(or near planar), rigid molecules which will probably not ‘fit’ into the existing seven- 
and six-coordinate geometries of the organotin(IV) dipicolinates.161,247 If a phen 
ligand is to bind to the tin atom then either the Sn-N or the Sn-O bond of the five-
membered chelate rings must first be broken in order to make way for the phen 
ligand, as shown in Figure 4.18. It is believed that these complexes did not form 
because of these steric restrictions. 
Sn
NO
O N
R'
O
R'
O
R
R
 
Figure 4.18: Expected structure of 1:1 complex of organotin(IV) dipicolinate and 
1,10-phenathroline derivatives, where R = Me, n-Bu or Ph; NN = 1,10-
phenathroline derivative; R’CO2 = picolinate group. 
4.3.5.4 Synthesis of [R2Sn(nicotinate)2L] complexes (R = Me, n-Bu or Ph and L 
= phen, dione or dppz) 
The [R2Sn(nicotinate)2(phen)] and dppz complexes were synthesised using the same 
procedure as that of the [R2SnCl2(phen)] complexes (section 4.3.5.1). In the 1H 
NMR spectra of both [Me2Sn(nicotinate)2(phen)] and [n-Bu2Sn(nicotinate)2(phen)] a 
large downfield shift was observed for the proton signals of the phen ligand (Table 
4.10). As expected, H-2 has the largest shift indicating coordination through the two 
N atoms of the phen ligand. 
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Table 4.10: Selected 1H NMR data for 1,10-phenanthroline ligands and their 
[R2Sn(nicotinate)2] complexes obtained in DMSO-d6 (R  Me, Bu or Ph). 
Compound H-2a H-3a H-4a H-5a H-6a 
phen 9.10 7.77 8.49 7.99 - 
[Me2Sn(nicotinate)2(phen)] 9.46 8.00 8.73b 8.15 - 
[n-Bu2Sn(nicotinate)2(phen)] 9.48 8.04 8.77 8.17 - 
[Ph2Sn(nicotinate)2(phen)] 9.09 7.78 8.49 7.96c - 
dppz 9.49 7.92 9.20 8.36 8.04 
[Me2Sn(nicotinate)2(dppz)] 9.55 7.98 9.27 8.39 8.07 
[n-Bu2Sn(nicotinate)2(dppz)] 9.40 7.98 9.31 8.23 7.98 
a Numbering system shown in Figure 4.8, b shares peak with nicotinate proton, c 
shares peak with phenyl proton. 
Only the [Me2Sn(nicotinate)2] and [n-Bu2Sn(nicotinate)2] compounds could be 
complexed with the dppz ligand. In comparison to the [R2Sn(nicotinate)2(phen)] 
analogues, much smaller shifts in the 1H NMR signals of the dppz ligand were 
observed. A similar trend was observed earlier for the [R2SnCl2L] complexes 
(section 4.3.5.1). It may be that in solution the dppz ligand only associates weakly 
with the tin atom resulting in smaller shifts in the 1H NMR spectra. 
Amongst the [R2Sn(nicotinate)2(phen)] complexes synthesised here, the smallest 
shifts in the 1H NMR signals of the phen ligand were observed for  
[Ph2Sn(nicotinate)2(phen)]. The [Ph2Sn(nicotinate)2] compound consists of two 
phenyl groups and two nicotinate groups bound to the tin atom. These bulky groups 
may be making it sterically difficult for the relatively large and planar phen ligand to 
interact strongly with the Sn centre resulting in only small shifts in the 1H NMR 
signals. The complexation reaction of [Ph2Sn(nicotinate)2] and dppz was 
unsuccessful. The dppz ligand is a larger molecule with an extended aromatic 
structure in comparison to phen making it even more difficult to ‘fit in’ and bind to 
the tin centre.  
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Elemental analysis for each of the complexes synthesised indicated formation of a 
1:1 phen:metal or dppz:metal complex. In the IR spectra of the phen and dppz free 
ligands the absorption bands for (C=N) and (C=C) are found in the 1640-1400 cm-
1 range (Table 4.11), so too are the as(COO-) and sym(COO-) stretching frequencies 
of the [R2Sn(nicotinate)2] compounds, resulting in complicated IR spectra. However, 
in the IR spectra of the [R2Sn(nicotinate)2] phen and dppz complexes the absorption 
bands in the 1640-1400 cm-1 range have broadened and shifted frequency, 
confirming coordintation of the ligands to the tin centres (Table 4.11). 
Table 4.11: A selection of the IR absorption bands in the 1700-1400 cm-1 range.  
Compound IR absorption bands (cm-1) 
phen 1643, 1617, 1586, 1561, 1504, 1495, 1422 
[Me2Sn(nicotinate)2(phen)] 
 
1645, 1625, 1590, 1428, 1332, 
[n-Bu2Sn(nicotinate)2(phen)] 
 
1648, 1625, 1599,1588, 1552, 1426 
[Ph2Sn(nicotinate)2(phen)] 
 
1709, 1655, 1596, 1419 
dppz 1634, 1586, 1490, 1415 
[Me2Sn(nicotinate)2(dppz)] 
 
1605, 1592, 1554, 1486, 1415 
[n-Bu2Sn(nicotinate)2(dppz)] 
 
1606, 1593, 1553, 1407 
 
The synthesis of the [R2Sn(nicotinate)2(dione)] complexes was attempted using the 
same procedure as described for the phen and dppz derivatives, but were 
unsuccessful. Extended reaction times (24 hours) and a change in solvent (MeCN) 
were also attempted but the reaction still failed to produce a 
[R2Sn(nicotinate)2(dione)] complex. If the size of the dione ligand was the issue then 
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a similar outcome to that of the dppz complexes would be expected where the 
[Me2Sn(nicotinate)2(dione)] and [n-Bu2Sn(nicotinate)2(dione)] would form but 
perhaps the [Ph2Sn(nicotinate)2(dione)] complex would not. However, none of the 
[R2Sn(nicotinate)2(dione)] complexes could be synthesised. As suggested earlier 
with the [R2SnCl2(dione)] complexes, maybe the dual binding ability of the dione 
ligand is causing problems. However, being the stronger site of Lewis basicity, 
coordination is expected to occur through the diiminic functionality of dione as is 
seen with the phen and dppz ligands.206 In comparison to phen, the dione ligand is 
slightly non-planar.206 Perhaps this slight deviation in planarity prohibits the dione 
ligand from accessing the tin centre of the R2Sn(nicotinate)2 compounds thus 
preventing formation of the [R2Sn(nicotinate)2(dione)] complexes. 
All attempts to obtain 119Sn NMR spectra of the complexes obtained during this 
study always resulted in broad signals being observed, no matter what solvent was 
chosen or the number of scans used. This is despite the fact that clean 1H and 13C 
spectra were readily obtained for the same samples.  
4.3.6 Biological studies 
4.3.6.1 Antibacterial activity 
The antibacterial activity of the organotin(IV) complexes synthesised in this study, 
along with their starting materials, was investigated using the susceptibility assay 
described in section 1.2.5. Three bacteria were chosen for the study, two Gram-
negative bacteria, Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. 
aeruginosa), and one Gram-positive bacterium Staphylococcus aureus (S. aureus). 
The MIC50 and MIC80 values were taken to signify the concentration of compound 
that would inhibit the growth of the microorganism by 50% and 80%, respectively. 
The results are summarised in Tables 4.12 and 4.13. Any compound which did not 
exhibit an MIC80 and/or MIC50 for any of the three chosen bacteria has been 
excluded from the tables. Vancomycin hydrochloride and ciprofloxacin were chosen 
as the positive controls.  
Of all of the organotin(IV) starting materials tested, the n-Bu2SnCl2 was the most 
active, exhibiting activity against all three bacteria. In general, the organotin(IV) 
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oxides were less active than the dichlorides. However, n-Bu2SnO could not be tested 
due to its lack of solubility in the water/DMSO mixture. Acetic acid, picolinic acid 
and nicotinic acid were inactive against each of the bacteria tested. Amongst the 
phen ligands investigated, the only ligand to exhibit activity against all three bacteria 
was the dione. This ligand has been previously shown to be very active against 
several microbes, including the yeast, Candida albicans.71,217 Furthermore, McCann 
and co-workers have shown that when a silver(I) ion is complexed with dione, an 
increase in activity is observed.220 
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Table 4.12: Antibacterial activity as MIC50 range, values are the mean of three experiments. 
Compound 
E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
Vancomycin hydrocloride 1.58-2.10 2.35-3.13 >67.31 >100.00 1.58-2.10 2.35-3.13 
Ciprofloxacin 2.36-3.53 0.78-1.17 0.20-0.39 0.59-1.18 28.31-37.75 9.38-12.5 
phen > 554.91 >100.00 416.18-554.91 75.00-100.00 277.45-416.18 50.00-75.00 
dione 14.88-22.34 3.13-4.69 14.88-22.34 3.13-4.69 29.76-44.63 6.25-9.38 
[Me2SnCl2] 341.08-454.78 75.00-100.00 341.08-454.78 75.00-100.00 > 454.78 >100.00 
[n-Bu2SnCl2] 15.44-20.56 4.69.-6.25 164.48-246.73 50.00-75.00 20.56-30.84 6.25-9.38 
[Ph2SnCl2] 54.52-72.69 18.75-25.00 > 290.77 >100.00 > 290.77 >100.00 
[Me2SnO] 451.96-602.61 75.00-100.00 451.96-602.61 75.00-100.00 > 602.61 >100.00 
[n-Bu2Sn(O2CMe)Cl] 28.58-38.11 9.38-12.50 > 304.85 >100.00 38.11-57.16 12.50-18.75 
[Ph2SnCl(O2CMe)] 25.48-33.97 9.38-12.50 > 271.77 >100.00 16.99-25.48 6.25-9.38 
[Me2SnCl2(phen)] > 250.03 >100.00 125.01-187.52 50.00-75.00 > 250.03 >100.00 
[n-Bu2SnCl2(phen)] 25.82-38.74 12.50-18.75 103.30-154.94 50.00-75.00 25.82-38.74 12.50-18.75 
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Table 4.12 continued. 
Compound 
E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
[Me2SnCl2(dione)] 43.61-58.15 18.75-25.00 21.81-29.07 9.38-12.50 29.08-43.61 12.50-18.75 
[n-Bu2SnCl2(dione)] 18.24-24.32 9.38-12.50 145.91-194.54 75.00-100.00 48.64-72.95 25.00-37.50 
[Ph2SnCl2(dione)] 22.57-33.85 12.50-18.75 22.57-33.85 12.50-18.75 5.64-8.47 3.13-4.69 
[n-Bu2SnCl2(dppz)] 16.00-21.33 9.38-12.50 170.63+ 100.00+ 21.33-31.99 12.50-18.75 
[Ph2SnCl2(dppz)] > 159.74  79.87-119.81  59.90-79.87 
[n-Bu2Sn(picolinate)2] 39.22-52.29  > 209.17  26.15-39.22 
[Ph2Sn(picolinate)2] > 193.04  > 193.04  96.52-144.78 
[n-Bu2Sn(nicotinate)2] 39.22-52.29  > 209.17  26.15-39.22 
[Ph2Sn(nicotinate)2] 72.39-96.52  > 193.04  > 193.04 
[n-Bu2Sn(nicotinate)2(phen)] 56.98-75.97  > 151.94  75.97-113.95 
[n-Bu2Sn(nicotinate)2(dppz)] 32.89-49.33  > 131.55  98.66-131.55 
 224 
 
Table 4.13: Antibacterial activity as MIC80 range, values are the mean of three experiments. 
Compound 
E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
Vancomycin hydrochloride 2.10-3.16 3.13-4.69 >67.31 >100.00 3.16-4.21 4.69-6.25 
Ciprofloxacin >301.99 >100.00 1.18-1.77 0.39-0.59 >301.99 >100.00 
dione 29.76-44.63 6.25-9.38 22.34-29.76 4.69-6.25 44.63-59.51 9.38-12.50 
[Me2SnCl2] >454.78 >100.00 341.08-454.78 75.00-100.00 >454.78 >100.00 
[n-Bu2SnCl2] 41.12-61.68 12.50-18.75 >328.99 >100.00 41.12-61.68 12.50-18.75 
[Ph2SnCl2] 218.08-290.77 75.00-100.00 >290.77 >100.00 >290.77 >100.00 
[n-Bu2SnCl(O2CMe)] 114.32-152.43 37.50-50.00 >304.86 >100.00 114.32-152.43 37.50-50.00 
[Ph2SnCl(O2CMe)] 135.88-203.83 50.00-75.00 >271.77 >100.00 67.94-101.91 25.00-37.50 
[n-Bu2SnCl2(phen)] 77.47-103.30 37.50-50.00 154.94-206.59 75.00-100.00 38.74-51.65 18.75-25.00 
[Me2SnCl2(dione)] >232.60 >100.00 43.61-58.15 18.75-25.00 43.61-58.15 18.75-25.00 
[n-Bu2SnCl2(dione)] 36.48-48.64 18.75-25.00 >194.54 >100.00 145.91-194.54 75.00-100.00 
[Ph2SnCl2(dione)] >180.52 >100.00 33.85-45.13 18.75-25.00 16.92-22.56 9.38-12.50 
 225 
 
Table 4.13 continued. 
Compound 
E. coli P. aeruginosa S. aureus 
M g/mL M g/mL M g/mL 
[n-Bu2SnCl2(dppz)] 63.99-85.31 37.50-50.00 >170.63 >100.00 31.99-42.66 18.75-25.00 
[n-Bu2Sn(picolinate)2] 156.87-209.17 75.00-100.00 >209.17 >100.00 52.29-78.44 25.00-37.50 
[n-Bu2Sn(nicotinate)2] 104.58-156.87 50.00-75.00 >209.17 >100.00 78.44-104.58 37.50-50.00 
[n-Bu2Sn(nicotinate)2(phen)] 113.95-151.94 75.00-100.00 >151.94 >100.00 113.95-151.94 75.00-100.00 
[n-Bu2Sn(nicotinate)2(dppz)] 98.66-131.55 75.00-100.00 >131.55 >100.00 >131.55 >100.00 
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From Table 4.12, it can be seen that on changing from the organotin(IV) dichloride 
to the organochlorotin(IV) acetate, the dimethyl and dibutyl derivatives became less 
active. With regards to the dibutyltin derivatives, introduction of the dinicotinate and 
dipicolinate moieties resulted in a further loss in activity against E. coli but a slight 
increase in activity against S. aureus, in comparison to [n-Bu2Sn(O2CMe)Cl]. 
The opposite, however, is seen in the case of the diphenyl derivatives, with the 
[Ph2Sn(O2CMe)Cl] being more active than its dichloride precursor against both E. 
coli and S. aureus. However, [Ph2Sn(picolinate)2] and [Ph2Sn(nicotinate)2] are, as in 
the case of the dibutyltin(IV) derivatives, less active than [Ph2Sn(O2CMe)Cl]. 
[Me2Sn(O2CMe)Cl], [Me2Sn(nicotinate)2] and [Me2Sn(picolinate)2] did not exhibit 
activity against S. aureus or E. coli and, unfortunately, none of the carboxylate 
derivatives demonstrated any activity against P. aeruginosa.  
Graphs 4.1-4.6 show the activity profiles for the phen, dione and dppz complexes 
that were active against E. coli and S. aureus. Of all of the compounds complexed 
with a phen, dione or dppz ligand, the dione complexes were the most active. 
Moreover, upon complexation of dione with the dimethyl- and diphenlytin(IV) 
dichlorides, an increase in activity was observed in comparison to the parent 
organotin(IV). For example, treatment of S. aureus with [Ph2SnCl2(dione)] resulted 
in a MIC50 of 3.13-4.69 g/mL, whereas, its precursor Ph2SnCl2 was inactive against 
S. aureus. This result may be attributed to chelation theory. As mentioned earlier, a 
reduction in the polarity of the metal can occur upon chelation, resulting in an 
increase in lipophillicity.198-199 This increased lipophilicity can assist the passage of 
the metal complex through cell membranes, in turn, allowing it to interact with the 
cells internal components and therefore inhibit growth.  
The opposite effect is seen with n-Bu2SnCl2, that is, a decrease in activity against E. 
coli and S. aureus is observed upon complexation with phen, dione or dppz. If we 
consider [n-Bu2SnCl2(phen)] and its activity against S. aureus, n-Bu2SnCl2 is more 
active, reaching a MIC50 in the range of 6.25-9.38 g/mL while the phen ligand 
alone is less active than [n-Bu2SnCl2(phen)]. Similar results have been reported 
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previously, and are believed to be due to complexation preventing the binding of the 
metal to the active site.193b  
 
Graph 4.1: Activity profile of [R2SnCl2(phen)] family versus S. aureus, where R = 
Me, n-Bu or Ph. 
 
Graph 4.2: Activity profile of [R2SnCl2(phen)] family versus E. coli, where R = Me, 
n-Bu or Ph. 
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Graph 4.3: Activity profile of [R2SnCl2(dione)] family versus S. aureus, where R = 
Me, n-Bu or Ph. 
 
Graph 4.4: Activity profile of [R2SnCl2(dione)] family versus E. coli, where R = 
Me, n-Bu or Ph. 
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Graph 4.5: Activity profile of [R2SnCl2(dppz)] family versus S. aureus, where R = 
Me, n-Bu or Ph. 
 
Graph 4.6: Activity profile of [R2SnCl2(dppz)] family versus E. coli, where R = Me, 
n-Bu or Ph. 
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In general, the majority of complexes synthesised exhibited little or no activity 
against P. aeruginosa. However, of the active complexes, [Me2SnCl2(dione)] and 
[Ph2SnCl2(dione)] exhibited good activity against P. aeruginosa giving an MIC50 
range of 9.38-12.50 and 12.50-18.75 g/mL, respectively. In both cases, the values 
were less than that of the parent organotin(IV) dichloride but greater than the dione 
ligand alone.  
Of the active complexes listed in Table 4.12, [Ph2SnCl2(dione)] was the most active 
against S. aureus, [n-Bu2SnCl2(dione)] was the most active against E. coli and 
[Me2SnCl2(dione)] was the most active against P. aeruginosa. Considering these 
three complexes differ only by their organic group, it could be suggested that there is 
a degree of selectivity with regards to the bacterium and the type of organic group 
attached to the tin centre.  
A total of twenty two compounds were synthesised and tested in this study, fifteen of 
these exhibited an MIC50, with activity being mainly against E. coli and S. aureus. 
According to the literature, organotin compounds have a tendency to be more active 
against Gram-positive bacteria compared to Gram-negative bacteria.191d,193a,194a,197 
However, within this study, many of the active compounds exhibited similar activity 
against both E. coli and S. aureus and in some cases better activity was observed 
against E. coli in comparison to S. aureus, for example, [n-Bu2SnCl2(dione)]. Gram-
positive and Gram-negative bacteria differ mainly in their cell wall structures, with 
the Gram-negative bacteria having an extra outer membrane in comparison to the 
Gram-positive bacteria.14 Organotin(IV) compounds exhibiting similar activity 
against both E. coli and S. aureus could suggest that the extra outer membrane of the 
Gram-negative E. coli is not an obstacle for these compounds and that perhaps they 
are inhibiting growth by interacting with the internal components of the bacteria. 
Overall, the dibutyltin(IV) derivatives were most active in comparison to the 
dimethyltin(IV) or diphenyltin(IV) derivatives. Introduction of a carboxylate moiety, 
in general, did not promote activity. Complexation with a phen, dione or dppz ligand 
gave mixed results, with the dione complexes exhibiting greatest activity. The 
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organotin(IV) compounds synthesised in this study demonstrated greatest activity 
against E. coli and S. aureus and were almost inactive against P. aeruginosa. 
P. aeruginosa is well-known for its ability to grow as a biofilm, by doing so it 
creates a physical barrier to antibiotics.42 Furthermore, P. aeruginosa produces a 
thick capsule which retards the entry of antibiotics.39 It is possible that it is having 
the same action here, preventing entry of the organotin complexes.  
Although some of the compounds tested here exhibited good activity, no compound 
exhibited activity greater than that of the standard, vancomycin hydrochloride. Of all 
of the organotin(IV) compounds synthesised and tested in this study, 
[Ph2SnCl2(dione)] gave the best MIC50 result of 3.13-4.69 g/mL against S. aureus, 
and thus, was chosen for further testing against Galleria melonella. 
4.3.7 In vivo compound tolerance 
The in vivo toxicity of [Ph2SnCl2(dione)] was tested as described in section 1.2.8, 
using the larvae of the greater wax moth, Galleria melonella (G. melonella). The 
results are presented as the survival of G. mellonella larvae (expressed as %) as a 
function of the [Ph2SnCl2(dione)] dosages administered (Table 4.14). The toxicity of 
dione in G. melonella has been tested previously by McCann et al.71, the results of 
which have been included in Table 4.14 for comparison. 
Table 4.14: Survival of G. mellonella larvae (expressed as %) post injection at 24, 
48 and 72 h. 
Compound 
Dosage concentration  
(g/mL) 
G. mellonella survival 
24 48 72 
     
dione 100 - - 10071 
     
[Ph2SnCl2(dione)] 100 100 100 100 
 50 100 100 97 
 10 100 100 100 
 1 100 100 100 
 
From Table 4.14 it can be seen that, at the highest concentration of 
[Ph2SnCl2(dione)] administered, there was a 100% survival rate. This result is in 
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agreement with that of the dione ligand alone which is also non-toxic at a 
concentration of 100 g/mL, at 72 hours. The same result was also observed at the 
lower concentrations, with the exception of the 50 g/mL dosage at 72 hours, where 
one G. mellonella died. The G. mellonella were also monitored for pupation. It was 
found that after seven days, 90% of the G. mellonella larvae had pupated. This result 
suggests that not only was [Ph2SnCl2(dione)] non-toxic at the highest concentration 
administered, but it also appears to have no effect on the development of the larvae, 
at this concentration. These results for [Ph2SnCl2(dione)] suggest that it may have 
potential as a non-toxic, antibacterial compound.  
4.3.8 Conclusion 
Herein, the synthesis of diorganotin(IV) dichloride complexes of the ligands, phen, 
dione and dppz was undertaken. Diorganochlorotin(IV) acetates and diorganotin(IV) 
dicarboxylates, including complexes of the biologically active groups picolinic acid 
and nicotinic acid, were also synthesised. Complexation reactions of these 
diorganotin(IV) carboxylates with the phen ligands only occurred for the 
[R2Sn(nicotinate)2] compounds. This is probably due to the difficulty in breaking the 
intra- and/or intermolecular interactions involved in the diorganotin(IV) carboxylate 
derivatives. In general, good yields were obtained for the majority of compounds, 
with the greatest yields obtained for the diorganotin(IV) dichloride complexes of the 
phen, dione and dppz ligands. The use of three different organic groups, combined 
with organic groups capable of unidentate and/or bidentate coordination modes, 
allowed for the generation of a variety of structures amongst the diorganotin(IV) 
compounds. All of the organotin(IV) compounds synthesised were characterised by 
CHN analysis, 1H and 13C NMR and IR spectroscopies.  
Overall, the organotin(IV) compounds tested here demonstrated greatest activity 
against E. coli and S. aureus and were almost inactive against P. aeruginosa. In 
general, the addition of either a nicotinic acid or picolinic acid did not promote the 
inhibition of bacterial growth. Amongst the phen, dione and dppz ligands tested, the 
dione was the most active, producing MIC80 values in the range of 6.25-9.38 g/mL 
for E. coli, 4.69-6.25 g/mL for P. aeruginosa and 9.38-12.50 g/mL for S. aureus. 
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Of the phen, dione and dppz complexes synthesised, the [R2SnCl2(dione)] complexes 
demonstrated greatest activity. Within the [R2SnCl2(dione)] series, the dimethyl was 
the most active against P. aeruginosa, the di-n-butyl was most active against E. coli, 
and the diphenyl was most active against S. aureus, indicating a possible degree of 
selectivity with regards to the R group.  
Although many of the organotin(IV) compounds exhibited activity, no compound 
exhibited activity greater than that of the standard antibacterial agent, vancomycin 
hydrochloride, against E. coli or S. aureus. However, [Ph2SnCl2(dione)] gave a S. 
aureus MIC50 value in the range of 3.13-4.69 g/mL, a value close to that exhibited 
by vancomycin hydrochloride (2.35-3.13 g/mL). 
[Ph2SnCl2(dione)] was the most active organotin(IV) compound tested here and was 
therefore brought forward for an in vivo toxicity study. The results indicated that, at 
concentrations in the range of 1-100 g/mL, [Ph2SnCl2(dione)] is non-toxic to G. 
mellonella. 
4.3.9 Future Work 
Having given the best result in inhibiting bacterial growth, specifically the growth of 
S. aureus, an investigation into the bactericidal activity of [Ph2SnCl2(dione)] would 
be of interest. Although the number of Methicillin-Resistant S. aureus (MRSA) 
infections in Ireland has seen a decrease from 2004 to 2013, Ireland was ranked 10th 
highest amongst twenty-eight European countries in 2011.31 Furthermore, with 
regards to the MRSA proportions (%) of S. aureus infections, many European 
countries, such as Portugal and Italy, have been reported as having some of the 
highest (between 25 and 50% in 2012).31 Therefore, an assessment of the activity of 
[Ph2SnCl2(dione)] against MRSA would also be worthwhile. In the in vivo toxicity 
assay, [Ph2SnCl2(dione)] was found to be non-toxic against G. mellonella at 
concentrations in the range of 1-100 g/mL, a result similar to that of the previously 
reported dione ligand alone.71 However, at higher concentrations, that is, 1000 
g/mL, dione has demonstrated a 90% mortality rate in the G. mellonella toxicity 
assay.71 Therefore, it would be of interest to examine the toxicity of 
[Ph2SnCl2(dione)] at higher concentrations. 
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In this study, it was the [R2SnCl2(dione)] complexes that exhibited activity against 
all three bacteria. As mentioned earlier, an interesting trend was observed amongst 
the [R2SnCl2(dione) complexes with regards to the R group and the bacterium to 
which it was most active against, suggesting a possible degree of selectivity. It 
would be interesting to examine if this selectivity would be retained after alteration 
of the X group, that is, the dichloride. Additionally, it could be worth varying the R 
group in an effort to obtain an R group that would result in activity against all three 
bacteria. 
The molecular target of these organotin(IV) complexes is currently unknown. 
Considering that dione alone has the ability to bind DNA it would be interesting to 
investigate the biological mode of action of these complexes. An investigation into 
the DNA binding capabilities of the complexes, along with an assessment of the 
proteomic response of the bacterium to the complexes, could give insight into a 
possible mode of action. 
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4.4 Experimental  
The synthesis of 1,10-phen-5,6-dione (dione)232a 
 
An ice-cold solution of sulphuric acid (40 mL) and nitric acid (20 mL) was added to 
1,10-phenanthroline (4.0 g, 22.2 mmol) and potassium bromide (4.0 g, 33.6 mmol) 
on ice. The reaction mixture was heated to reflux for 3 hours and then poured into 
500 mL of ice-cold water. The yellow solution was neutralised with 5M NaOH and 
the product extracted with CHCl3 (3 x 200 mL) and dried over Na2SO4. The CHCl3 
was removed under reduced pressure and the product was purified by hot EtOH 
recrystallisation.  
Yellow solid (4.08 g, 88%); m.p. 258-262 oC (lit 270 oC)222; 1H NMR (300 MHz, 
DMSO-d6) 8.98 (dd, J = 4.7, 1.7 Hz, 2H, H2), 8.39 (dd, J = 7.8, 1.7 Hz, 2H, H4), 
7.68 (dd, J = 7.8, 4.7 Hz, 2H, H3); 13C NMR (75 MHz, DMSO-d6) 177.7 (C=O) 
154.3 (C2), 152.3 (C=N), 135.6 (C4), 129.1 (C4’), 125.2 (C3); IR (KBr) 1686 
(C=O), 1574 (C=N), 1567 (C=C), 1415 (C-H), 738 (C-N-C) cm-1; LC/TOF-MS 
calcd for C12H6N2O2 210.0434, found 211.0502 (M+H+). 
The 1H NMR data for dione was also obtained in CDCl3. 
1H NMR (300 MHz, CDCl3)  9.10 (dd, J = 4.7, 1.8 Hz, 2H, H2), 8.49 (dd, J = 7.8, 
1.8 Hz, 2H, H4), 7.57 (dd, J = 7.8, 4.7 Hz, 2H, H3), these data match reported 
literature values248. 
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The synthesis of dipyrido[3,2-a:2’,3’-c]phenazine (dppz)232b  
 
1,10-Phen-5,6-dione (0.5 g, 2.4 mmol) and o-phenylenediamine (0.3 g, 2.8 mmol) 
were heated in EtOH (198 mL) at 50 oC for 2 hours followed by an overnight reflux. 
The reaction mixture was allowed to cool to room temperature and the EtOH 
removed under reduced pressure. The resulting solid was allowed to sit for 8 hours at 
room temperature after which MeOH:water (10:90) was added and the product 
collected via filtration. The product was purified by hot MeOH recrystallisation. 
Yellow solid (0.5 g, 75% recrystallised); m.p. 246-250 oC (lit 246-247 oC)249; 1H 
NMR (300 MHz, DMSO-d6)  9.49 (dd, J = 8.1, 1.8 Hz, 2H, H2), 9.20 (dd, J = 4.4, 
1.8 Hz, 2H, H4), 8.36 (dd,  J = 6.5, 3.4 Hz, 2H, H5), 8.04 (dd,  J = 6.5, 3.4 Hz, 2H, 
H6),  7.92 (dd, J = 8.1, 4.4 Hz, 2H, H3), these data match reported literature 
values250; 13C NMR (75 MHz, DMSO-d6)  152.3 (C4), 147.8 (C=N), 141.7 (C=N), 
140.7 (C5’), 133.0 (C2), 131.2 (C6), 129.1 (C5), 126.9 (C4’), 124.5 (C3); IR (KBr) 
1634 (C=N), 1585 (C=C) 1490, 1415, 1362, 1338 (C-H), 1075 (C-N), 741 (C-N-C) 
cm-1; LC/TOF-MS calcd for C18H10N4 282.0905, found 283.0982 (M+H+). 
The 1H NMR data for dione was also obtained in CDCl3. 
1H NMR (300 MHz, CDCl3) 9.64 (dd, J = 8.1, 1.7 Hz, 2H, H2), 9.26 (dd, J = 4.5, 
1.7 Hz, 2H, H4), 8.35 (dd, J = 6.5, 3.4 Hz, 2H, H5), 7.92 (dd, J = 6.5, 3.4 Hz, 2H, 
H6), 7.80 (dd, J = 8.1, 4.5 Hz, 2H, H3). 
1H NMR (300 MHz, DMSO-d6, 80 oC)  9.41 (dd, J = 8.1, 1.7 Hz, 2H, H2), 9.13 (d, 
J = 4.3, 2H, H4), 8.27 (dd, J = 6.5, 3.4 Hz, 2H, H5), 7.98 (dd, J = 6.5, 3.4 2H, H6), 
7.85 (dd, J = 8.1, 4.3 Hz, 2H, H3); 13C NMR (75 MHz, DMSO-d6)  152.1 (C4), 
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147.7 (C=N), 141.6 (C=N), 140.5 (C5’), 132.9 (C2), 131.0 (C6), 128.9 (C5), 126.7 
(C4’), 124.3 (C3). 
1H NMR (300 MHz, DMSO-d6, 95 oC)  9.45 (dd, J = 8.1, 1.7 Hz, 2H, H2), 9.15 
(app br s, 2H, H4), 8.30 (dd, J = 6.5, 3.5 Hz, 2H, H5), 7.99 (dd, J = 6.5, 3.5 Hz, 2H, 
H6), 7.87 (dd, J = 8.1, 4.4 Hz, 2H, H3); 13C NMR (75 MHz, DMSO-d6)  161.6 
(C4), 151.9 (C=N), 141.6 (C=N), 140.4 (C5’), 132.8 (C2), 130.9 (C6), 128.8 (C5), 
126.7 (C4’), 124.1 (C3). 
General procedure for the synthesis of [R2Sn(O2CMe)Cl], R = Me, n-Bu 
 
The appropriate diorganotin(IV) dichloride (4.5 mmol) and acetic acid (9.1 mmol) 
were dissolved in toluene (25 mL). Triethylamine (10 mmol) was added slowly and 
the reaction mixture heated to reflux for 3 hours under nitrogen. On cooling, a white 
solid precipitated, which was removed by filtration through celite. The resulting 
filtrate was collected and the solvent was removed under reduced pressure. 
 
[Me2Sn(O2CMe)Cl]  
White solid (0.80 g, 73%); m.p. >300 oC; 1H NMR (300 MHz, CDCl3) 1.93 (s, 3H, 
O2CCH3), 0.78 (s, 3H, CH3, 2J(119/117Sn, 1H) = 92.7/82.2 Hz), 0.75 (s, 3H, CH3, 
2J(119/117Sn, 1H) = 139.8/126.6 Hz); 13C NMR (75 MHz, CDCl3)  177.7 (C=O), 22.9 
(O2CCH3), 8.8 (CH3), 6.0 (CH3); IR (KBr) 3439, 3004, 2915, 1564 (νaCOO-), 1420 
(νsCOO-), 1336 (C-H), 1022 (C-O) cm–1; Anal. (%) calcd for C4H9ClO2Sn C, 19.75; 
H, 3.73; found C, 20.19; H, 3.55. 
 
[n-Bu2Sn(O2CMe)Cl] 
White waxy solid (1.30 g, 88%); m.p. 36-39 oC; 1H NMR (300 MHz, CDCl3) 1.95 
(s, 3H, OCOCH3), 1.58-1.68 (m, 4H, CH2), 1.31-1.42 (m, 8H, CH2), 0.87-0.93 (m, 
6H, CH3); 13C NMR (75 MHz, CDCl3) 177.2 (C=O), 27.5 (CH2), 27.2 (CH2), 26.9 
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(CH2), 26.7 (CH2), 22.9 (O2CCH3), 13.5 (CH3); IR (KBr) 3429, 2958, 2928, 2872 
(CH), 1637, 1571 (νaCOO-), 1428, 1376 (νsCOO-), 1312, 1012, 737 cm–1; Anal. (%) 
calcd for C10H21ClO2Sn·1/4(C6H5CH3) C, 40.27; H, 6.81; found C, 39.28; H, 6.84. 
The synthesis of [Ph2Sn(O2CMe)Cl] 
 
Diphenyltin(IV) dichloride (4.5 mmol) and acetic acid (10 mmol) were dissolved in 
benzene (25 mL). Potassium carbonate (10 mmol) was added and the reaction 
mixture was allowed to reflux overnight under nitrogen. The reaction mixture was 
allowed to cool and was filtered through celite. The filtrate was collected and the 
solvent removed under reduced pressure. 
Cream solid (1.29 g, 79%); m.p. >300 oC;  
The NMR spectra obtained for [Ph2Sn(O2CMe)Cl] were poorly resolved due to the 
lack of solubility of the compound.  
1H NMR (300 MHz, CDCl3):  7.63-7.74 (m, phenyl CH), 7.35-7.50 (m, phenyl 
CH), 2.15 (s, O2CCH3); 13C NMR (75 MHz, CDCl3):  178.5 (C=O), 136.8 (phenyl 
CH), 129.9 (phenyl CH), 128.8 (phenyl CH), 20.7 (O2CCH3), (the phenyl quaternary 
carbon is believed to be under one of the above peaks); IR (KBr) 3044, 1551 
(νaCOO-), 1480, 1429 (νsCOO-), 1076, 728, 696, 443 cm-1; Anal. (%) calcd for 
C14H13ClO2Sn C, 45,77; H, 3.57; found C, 45.08; H, 3.24. 
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General procedure for the synthesis of [R2Sn(nicotinate)2] and 
[R2Sn(picolinate)2], R = Me, n-Bu or Ph 
        
    Diorganotin(IV) dipicolinate             Diorganotin(IV) dinicotinate 
 
Method A: 
The appropriate acid (2.4 mmol) and triethylamine (2.4 mmol) were stirred in 
toluene for 10 minutes. The appropriate diorganotin(IV) dichloride (1.2 mmol) was 
then added and the solution was allowed to reflux for 3 hours. The reaction mixture 
was allowed to cool and the solvent was removed under reduced pressure to give a 
white solid.  
 
Method B:  
The appropriate diorganotin(IV) oxide (1.2 mmol) and the desired acid (2.4 mmol) 
were brought to reflux in toluene for 2 hours. The reaction mixture was allowed to 
cool and the solvent was removed under reduced pressure. The resulting white solid 
was washed with cold MeOH and collected via filtration. 
 
[Me2Sn(picolinate)2] 
White solid (method A: 0.41 g, 86% crude, method B: 0.39 g, 83%); m.p. 259-262 
oC, (lit 258-261 oC)243; 1H NMR (300 MHz, CDCl3)  8.73 (d, J = 5.0 Hz, 2H, Ha), 
8.39 (d, J = 8.0 Hz, 2H, Hd), 8.02 (app t, J = 7.8 Hz, 2H, Hc), 7.56-7.61 (m, 2H, 
Hb), 0.59 (s, 6H, CH3, 2J(119/117Sn, 1H) = 76.5/73.5 Hz); 13C NMR (75 MHz, CDCl3) 
 164.7 (C=O), 146.3 (Ce), 144.6 (Ca), 140.9 (Cc), 128.0 (Cb), 125.8 (Cd), 8.5 
(CH3); IR (KBr) 3421, 3097, 2920, 1675 (νaCOO-), 1625 (C=C), 1601 (N=C), 1561 
(νaCOO-), 1386 (νsCOO-), 1349 (νsCOO-), 1013, 850, 693, 635 (C=N), 547 (Sn-C) 
cm-1; Anal. (%) calcd for C14H14N2O4Sn C, 42.79; H, 3.59; N, 7.13; found C, 42.17; 
H, 3.66; N, 6.99. 
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[n-Bu2Sn(picolinate)2] 
White solid (method B: 0.46 g, 80%); m.p. 186-190 oC; 1H NMR (300 MHz, CDCl3) 
 8.73 (d, J = 5.1 Hz, 2H, Ha), 8.40 (d, J = 8.1 Hz, 2H, Hd), 8.02 (app t, J = 8.1 Hz, 
2H, Hc), 7.55-7.60 (m, 2H, Hb), 1.14-1.29 (m, 12H, CH2), 0.73 (t, J = 7.0 Hz, 6H, 
CH3); 13C NMR (75 MHz, CDCl3)  165.4 (C=O), 147.1 (Ce), 145.4 (Ca), 140.6 
(Cc), 127.6 (Cb), 125.6 (Cd), 28.0 (CH2), 27.3 (CH2, 2J(119Sn, 13C) = 33.8 Hz), 26.2 
(CH2, 3J(119/117Sn, 13C) = 124.5/122.3 Hz), 13.3 (CH3); IR (KBr) 3421, 3091, 2958, 
2921, 2861 (CH), 1670 (aCOO-), 1627 (C=C), 1608 (N=C), 1564 (aCOO-), 1384 
(sCOO-), 1347 (sCOO-), 1012, 703, 635 (C=N), 542 (Sn-C) cm-1, these data match 
reported literature values251; Anal. (%) calcd for C20H26N2O4Sn C, 50.34; H, 5.49; N, 
5.87; found C, 51.51; H, 5.68; N, 5.82. 
 
[Ph2Sn(picolinate)2] 
White solid (method B: 0.48 g, 77%); m.p. 273-276 oC (lit 274-277 oC)243; 1H NMR 
(300 MHz, CDCl3) 8.64 (d, J = 5.0 Hz, 2H, Ha), 8.40 (d, J = 7.7 Hz, 2H, Hd), 7.91 
(app t, J = 7.7 Hz, 2H, Hc), 7.42-7.49 (m, 6H, Hb & phenyl CH), 7.13-7.18 (m, 6H, 
phenyl CH); 13C NMR (75 MHz, CDCl3)  164.6 (C=O), 146.3 (Ce), 145.8 (phenyl 
quaternary C), 144.2 (Ca), 141.4 (Cc), 134.5 (phenyl CH), 129.2 (phenyl CH), 128.6 
(phenyl CH), 128.4 (Cb), 125.9 (Cd); IR (KBr) 3433, 3068, 1678 (νaCOO-), 1600 
(N=C), 1467, 1332 (νsCOO-), 1160, 851, 696, 643 (C=N), 534 (Sn-C) cm-1; Anal. 
(%) calcd for C24H18N2O4Sn C, 55.74; H, 3.51; N, 5.42; found C, 55.41; H, 3.45; N, 
5.31. 
 
[Me2Sn(nicotinate)2] 
White solid (method B: 0.36 g, 76%); m.p. dec; 1H NMR (300 MHz, DMSO-d6)  
9.05 (s, 2H, Ha), 8.71 (d, J = 4.7 Hz, 2H, Hb), 8.24 (dt, J = 7.8, 1.9 Hz, 2H, Hd), 
7.78 (dd, J = 7.8, 4.7 Hz, 2H, Hc), 0.94 (s, 6H, CH3); 13C NMR (75 MHz, DMSO-d6) 
 170.2 (C=O), 152.4 (Cb), 150.3 (Ca), 136.9 (Cd), 128.4 (Ce, 3J(119Sn, 13C) = 51.8 
Hz), 123.5 (Cc), 11.4 (CH3); IR (KBr) 3422, 3063, 1605 (νaCOO-), 1593 (N=C), 
1554 (C=C), 1441, 1417, 1399 (νsCOO-), 1195, 867, 712, 435 (Sn-O) cm-1; Anal. 
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(%) calcd for C14H14O2N2O4Sn requires C, 42.29; H, 3.59; N, 7.13; found C, 42.38; 
H, 3.21; N, 7.32. 
 
[n-Bu2Sn(nicotinate)2] 
White solid (method B: 0.41 g, 72%); m.p. 152-158 oC; 1H NMR (300 MHz, 
DMSO-d6)  9.07 (s, 2H, Ha), 8.75 (d, J = 4.2 Hz, Hb), 8.26 (d, J = 7.8 Hz, 2H, Hd), 
7.52 (dd, J = 7.8, 4.2 Hz, 2H, Hc), 1.53-1.63 (m, 8H, CH2), 1.24-1.36 (m, 4H, CH2), 
0.81 (t, J = 7.3 Hz, 6H, CH3);  13C NMR (75 MHz, DMSO-d6) 170.9 (C=O), 152.6 
(Cb), 150.3 (Ca), 136.9 (Cd), 127.9 (Ce), 123.6 (Cc), 29.8 (CH2), 26.8 (CH2, 
2J(119Sn, 13C) = 40.5 Hz), 25.6 (CH2), 13.5 (CH3); IR (KBr)  3426, 2955, 2925, 2867 
(CH), 1609 (aCOO-), 1551, 1592 (N=C), 1434, 1409 (sCOO-),  1196, 863, 756, 
518 (Sn-C), 431 (Sn-O) cm–1, these data match reported literature values251,241; Anal. 
(%) calcd for C20H26N2O4Sn·H2O C, 48.51; H, 5.70; N, 5.66; found C, 49.11; H, 
5.52; N, 5.50. 
 
[Ph2Sn(nicotinate)2] 
White solid (method A: 0.56 g, 90% crude, method B: 0.45 g, 73%); m.p. >300 oC; 
1H NMR (300 MHz, DMSO-d6):  9.11 (s, 2H, Ha), 8.77 (d, J = 4.8 Hz, 2H, Hb), 
8.31 (d, J = 8.4 Hz, 2H, Hd), 7.80 (d, J  = 8.5 Hz, 4H, phenyl CH), 7.52 (dd, J = 8.4, 
4.8 Hz, 2H, Hc), 7.23-7.37 (m, 6H, phenyl CH), these data match reported literature 
values252; 13C NMR (75 MHz, DMSO-d6)  *169.3 (C=O), 153.1 (Cb), 150.4 (Ca), 
*148.6 (phenyl quaternary C), 137.1 (Cd), 134.0 (phenyl CH), 128.7 (phenyl CH), 
128.1 (phenyl CH), 127.0 (Ce), 123.7 (Cc); IR (KBr) 3422, 3076, 1608 (νaCOO-), 
1592 (N=C), 1541 (C=C), 1440 ,1412 (νsCOO-), 1195, 871, 695, 446 (Sn-O) cm–1; 
Anal. (%) calcd for C24H18N2O4Sn C, 55.74; H, 3.51; N, 5.42; found C, 55.91; H, 
3.49; N, 5.28. *The compound is not very soluble and as a result these signals are 
very weak. 
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General procedure for the synthesis of 1,10-phenanthroline derivatives of 
[R2SnCl2] R = Me, n-Bu or Ph 
The appropriate diorganotin(IV) compound (4.5 mmol) and the appropriate 1,10-
phenanthroline derivative (4.5 mmol) were dissolved in EtOH (25 mL) and heated to 
reflux for 3 hours. On cooling a solid precipitated which was collected by filtration, 
was washed with EtOH and allowed to dry to yield the desired product. 
       
[Me2SnCl2(phen)]  
White solid (1.68 g, 92%); m.p. dec (lit 264 oC)244a; 1H NMR (300 MHz, DMSO-d6) 
 9.32 (dd, J = 4.6, 1.7 Hz, 2H, H2), 8.74 (dd, J = 8.1, 1.7 Hz, 2H, H4), 8.16 (s, 2H, 
H5), 8.00 (dd,  J = 8.1, 4.6 Hz, 2H, H3), 0.97 (s, 6H, CH3, 2J(119/117Sn, 1H) = 
114.5/109.5 Hz); 13C NMR (75 MHz, DMSO-d6)  148.9 (C2), 142.4 (C=N), 138.2 
(C4), 129.1 (C4’), 127.1 (C5), 124.4 (C3), 24.0 (CH3); IR (KBr) 3435, 2920 (CH), 
1622 (C=N), 1572, 1519, 1429, 853, 727 (C-N-C) cm-1; Anal. (%) calcd for 
C14H14N2Cl2Sn C, 42.05; H, 3.53; N, 7.01; found C, 42.90; H, 3.75; N, 7.37.  
[Me2SnCl2(phen)] showed improved solubility in DMSO-d6 at 70 oC and hence the 
data were recorded at 70 oC. 
1H NMR (300 MHz, DMSO-d6, 70 oC) 9.38 (dd, J = 4.6, 1.6 Hz, 2H, H2), 8.75 
(dd, J = 8.1, 1.6 Hz, 2H, H4), 8.15 (s, 2H, H5), 8.02 (dd, J = 8.1, 4.6, Hz, 2H, H3), 
0.99 (s, 6H, CH3, 2J(119/117Sn, 1H) = 113.1/108.0Hz); 13C NMR (75 MHz, DMSO-d6) 
 148.1 (C2), 141.3 (C=N), 138.1 (C4), 128.8 (C4’), 126.7 (C5), 124.1 (C3), 23.3 
(CH3). 
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[n-Bu2SnCl2(phen)] 
White solid (2.12 g, 98%); m.p. 192-195 oC (lit 198-199 oC)253; 1H NMR (300 MHz, 
DMSO-d6)  9.44 (dd, J = 4.7, 1.4 Hz, 2H, H2), 8.90 (dd, J = 8.2, 1.4 Hz, 2H, H4), 
8.27 (s, 2H, H5), 8.16 (dd, J = 8.2, 4.7 Hz, 2H, H3), 1.37-1.40 (m, 4H, CH2), 1.19-
1.31 (m, 4H, CH2), 0.93-1.05 (m, 4H, CH2), 0.58 (t, J = 7.3 Hz, 6H, CH3); 13C NMR 
(75 MHz, DMSO-d6) 148.7 (C2), 140.7 (C=N), 139.6 (C4), 129.3 (C4’), 127.4 
(C5), 125.2 (C3), 40.9 (CH2), 27.5 (CH2, 2J(119Sn, 13C) = 46.5 Hz), 25.2 (CH2, 
3J(119/117Sn, 13C) = 172.5/171.8 Hz), 13.3 (CH3, 4J(119Sn, 13C) = 12.0 Hz); IR (KBr) 
3434, 2956, 2919, 2852 (CH), 1622 (C=N), 1590 (C=C), 1519, 1428, 854, 729 (C-N-
C) cm-1; Anal. (%) calcd for C20H26Cl2N2Sn C, 49.63; H, 5.41; N, 5.79; found C, 
49.40; H, 5.83; N, 5.85.  
[Ph2SnCl2(phen)] 
White solid (2.19 g, 93%); m.p. dec (lit 235 oC with dec)254; 1H NMR (300 MHz, 
DMSO-d6)  *9.50 (app s, 2H, H2), #9.06 (d, J = 8.3 Hz, 2H, H2), *8.74 (app s, 2H, 
H4), #8.54 (d, J = 4.7 Hz, 2H, H4), #8.43 (br s, 2H, H5), #8.25 (d, J = 8.3 Hz, 2H, 
phenyl CH), #8.16-8.18 (m, 2H, H3), *8.12 (br s, 2H, H5), *8.05 (app br s, 2H, H3), 
#7.92 (d, J = 7.1 Hz, 2H, phenyl CH), *7.72 (d, J = 7.1 Hz, 4H, phenyl CH), #7.42-
7.55 (m, 6H, phenyl CH), *7.08-7.24 (m, 6H, phenyl CH); IR (KBr) 3433, 3049, 
1622 (C=N), 1572 (C=C), 1519, 1429, 1103, 854, 727 (C-N-C) cm-1; Anal. (%) 
calcd for C24H18Cl2N2Sn·H2O C, 53.18; H, 3.72; N,5.17; found C, 53.44; H, 3.75; N, 
5.22. 
*Trans-isomer and #Cis-isomer (Trans/Cis ratio = 1.0:0.2) 
[Ph2SnCl2(phen)] data were recorded at 70 oC in order to investigate the presence of 
isomers. 
1H NMR (300 MHz, DMSO-d6, 70 oC)  9.50 (app br s, 2H, H2), 8.73 (app br s, 2H, 
H4), 8.00-8.14 (m, 4H, H3 & H5), 7.75 (app br s, 4H, phenyl CH), 7.17 (app br s, 
6H, phenyl CH); 13C NMR (75 MHz, DMSO-d6, 70 oC)  154.8 (phenyl quaternary 
C), 148.5 (C2), 141.3 (C=N), 138.3 (C4), 133.5 (phenyl CH), 128.9 (C4’), 127.4 
(phenyl CH), 127.0 (phenyl CH), 126.9 (C5), 124.2 (C3). 
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[Me2SnCl2(dione)] 
Yellow solid (1.88 g, 97%); m.p. dec; 1H NMR (300 MHz, DMSO-d6)  9.00 (dd, J 
= 4.7, 1.8 Hz, 2H, H2), 8.41 (dd, J = 7.8, 1.8 Hz, 2H, H4), 7.69 (dd, J = 7.8, 4.7 Hz, 
2H, H3), 1.03 (s, 6H, CH3, 2J(119/117Sn, 1H) = 113.7/108.9 Hz); 13C NMR (75 MHz, 
DMSO-d6)  177.6 (C=O), 154.2 (C2), 152.0 (C=N), 135.8 (C4), 129.1 (C4’), 125.3 
(C3), 22.9 (CH3, 1J(119/117Sn, 13C) = 1014.0/968.3 Hz); IR (KBr) 3442, 3071, 1701 
(C=O), 1573 (C=N), 1474, 1429, 1302, 732 (C-N-C) cm-1; Anal. (%) calcd for 
C14H12Cl2N2O2Sn·EtOH C, 40.38; H, 3.81; N, 5.89; found C, 41.24; H, 3.01; N, 
6.79. 
[n-Bu2SnCl2(dione)] (See section 4.3.5.1) 
Yellow solid (2.31 g, 99%); m.p. dec; IR (KBr) 3421, 3076, 2955, 2920, 2862 (CH), 
1620 (C=O), 1584 (C=N), 1436, 1376, 1069, 1042, 720 cm-1; Anal. (%) calcd for 
C20H24Cl2N2O2Sn·H2O C, 45.15; H, 4.93; N, 5.27; found C, 45.07; H, 4.69; N, 5.46. 
[Ph2SnCl2(dione)] 
Yellow solid (2.42 g, 97%); m.p. dec; 1H NMR (300 MHz, DMSO-d6)  9.00 (dd, J 
= 4.7, 1.6 Hz, 2H, H2), 8.40 (dd, J = 7.8, 1.6 Hz, 2H, H4), 7.90 (d, J = 7.0 Hz, 4H, 
phenyl CH), 7.68 (dd, J = 7.8, 4.7 Hz, 2H, H3), 7.25-7.37 (m, 6H, phenyl CH); 13C 
NMR (75 MHz, DMSO-d6) 177.3 (C=O), 155.1 (phenyl quaternary C), 153.9 (C2), 
151.6 (C=N), 136.0 (C4), 134.5 (phenyl CH, 2J(119Sn, 13C) = 69.8 Hz), 129.3 (C4’), 
127.8 (phenyl CH), 127.3 (phenyl CH), 125.3 (C3), these data match reported 
literature values246; IR (KBr) 3444, 3058, 1694 (C=O), 1576 (C=N), 1477, 1430, 727 
(C-N-C), 700 cm-1; Anal. (%) calcd for C24H16Cl2N2O2Sn C, 52.03; H, 2.91; N, 5.06; 
found C, 52.29; H, 3.34; N, 5.19.  
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[Me2SnCl2(dppz)] 
Yellow solid (2.13 g, 94%); m.p. 269-272 oC; 1H NMR (300 MHz, DMSO-d6) 9.42 
(dd, J = 8.1, 1.6 Hz, 2H, H2), 9.20 (dd, J = 4.4, 1.6 Hz, 2H, H4), 8.29 (dd, J = 6.5, 
3.4 Hz, 2H, H5), 8.01 (dd, J = 6.5, 3.4 Hz, 2H, H6), 7.91 (dd, J = 8.1, 4.4 Hz, 2H, 
H3), 1.03 (s, 6H, CH3); IR (KBr) 3434, 3066, 1632 (C=N), 1572 (C=C), 1494, 1420, 
1359, 1075, 772, 734 (C-N-C) cm-1; Anal. (%) calcd for C20H16Cl2N4Sn C, 47.85; H, 
3.21; N, 11.16; found C, 47.27; H, 3.04; N, 10.74. 
[Me2SnCl2(dppz)] showed improved solubility in DMSO-d6 at 80 oC and hence the 
data were recorded at 80 oC. 
1H NMR (300 MHz, DMSO-d6, 80 oC)  9.46 (d, J = 8.0 Hz, 2H, H2), 9.21 (app br s, 
2H, H4), 8.30 (dd, J = 6.5, 3.5 Hz, 2H, H5), 7.99 (dd, J = 6.5, 3.5 Hz, 2H, H6), 7.91 
(dd, J = 8.0, 4.4 Hz, 2H, H3), 1.08 (s, 6H, CH3, 2J(119/117Sn, 1H) = 108.3/103.8 Hz); 
13C NMR (75 MHz, DMSO-d6)  152.3 (C4), 147.8 (C=N), 142.3 (C=N), 141.0 
(C5’), 133.8 (C2), 131.6 (C6), 129.6 (C5), 127.6 (C4’), 125.0 (C3), 21.4 (CH3). 
[n-Bu2SnCl2(dppz)] 
Pink solid (2.54 g, 96%); m.p. 197-202 oC; 1H NMR (300 MHz, CDCl3)  9.93 (dd, J 
= 8.2, 1.5 Hz, 2H, H2), 9.83 (dd, J = 4.9, 1.5 Hz, 2H, H4), 8.41 (dd, J = 6.6, 3.4 Hz, 
2H, H5), 8.14 (dd, J = 8.2, 4.9 Hz, 2H, H3), 8.03 (dd, J = 6.6, 3.4 Hz, 2H, H6), 1.62-
1.68 (m, 4H, CH2), 1.36-1.51 (m, 4H, CH2), 1.03-1.10 (m, 4H, CH2), 0.62 (t, J = 6.9 
Hz, 6H, CH3); 13C NMR (75 MHz, CDCl3)  150.5 (C4), 142.9 (C=N), 142.7 (C=N), 
139.3 (C5’), 136.9 (C2), 132.1 (C6), 129.7 (C5), 129.3 (C4’), 126.3 (C3), 41.9 
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(CH2), 28.2 (CH2), 25.9 (CH2), 13.4 (CH3); IR (KBr) 3431, 2954, 2916, 2858 (CH), 
1630 (C=N), 1493, 1076 (C-N), 736 (C-N-C) cm-1; Anal. (%) calcd for 
C26H28Cl2N4Sn C, 53.28; H, 4.81; N, 9.56; found C, 52.89; H, 5.22; N, 9.47. 
[Ph2SnCl2(dppz)] 
Light yellow solid (2.76 g, 98%); m.p. 272-282 oC; 1H NMR (300 MHz, DMSO-d6) 
 9.44 (dd, J = 8.1, 1.7 Hz, 2H, H2), 9.26 (app br s, 2H, H4), 8.28 (dd, J = 6.5, 3.4 
Hz, 2H, H5), 8.00 (dd, J = 6.5, 3.4 Hz, 2H, H6), 7.95 (dd, J = 8.1, 4.6 Hz, 2H, H3), 
7.23-7.89 (d, J = 6.7 Hz, 4H, phenyl CH), 7.37 (m, 6H, phenyl CH); 13C NMR (75 
MHz, DMSO-d6)  *155.1 (phenyl quaternary C), 151.9 (C4), *146.9 (C=N), 141.6 
(C=N), 140.4 (C5’), 134.5 (phenyl CH), 133.5 (C2), 131.3 (C6), 129.1 (C5), 127.7 
(phenyl CH), 127.3 (phenyl CH), 127.1 (C4’), 124.8 (C3); IR (KBr) 3443, 3067, 
1627 (C=N), 1574 (C=C), 1494, 1420, 1361, 1078, 735, (C-N-C) cm-1; Anal. (%) 
calcd for C30H20Cl2N4Sn C, 57.55; H, 3.22; N, 8.95; found C, 57.09; H, 3.23; N, 
9.22. *The compound is not very soluble and as a result these signals are very weak. 
General procedure for the synthesis of 1,10-phenanthroline derivatives of 
[R2Sn(nicotinate)2] R = Me, Bu or Ph 
The appropriate diorganotin(IV) compound (4.5 mmol) and the appropriate 1,10-
phenanthroline derivative (4.5 mmol) were dissolved in EtOH (25 mL) and heated to 
reflux for 3 hours. In the case of the [R2Sn(nicotinate)2] compounds where R = Me 
and Bu, the reaction mixture was allowed to cool and solvent was removed under 
reduced pressure to give the desired product. With [Ph2Sn(nicotinate)2(phen)], after 
cooling, the reaction mixture was filtered to removed unreacted starting materials 
and the filtrate reduced under pressure. The remaining solid was then washed with 
cold EtOH to remove any remaining 1,10-phenanthroline & the filtrate reduced 
under pressure to give the product. 
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[Me2Sn(nicotinate)2(phen)] 
Pink solid (1.99 g, 77%); m.p. 212-220 oC; 1H NMR (300 MHz, DMSO-d6)  9.46 
(d, J = 4.7 Hz, 2H, H2), 9.15 (br s, 2H, Ha), 8.71-8.76 (m, 4H, H4 & Hb), 8.30 (d, J 
= 7.7 Hz, 2H, Hd), 8.15 (s, 2H, H5), 8.00 (dd, J = 8.5, 4.7 Hz, 2H, H3), 7.50 (dd, J = 
7.7, 4.4 Hz, 2H, Hc), 0.92 (s, 6H, CH3); 13C NMR (75 MHz, DMSO-d6)          
170.3 (C=O), 152.1 (Cb), 150.5 (Ca), 149.5 (C2), 142.0 (C=N), 138.4 (C4), 136.9 
(Cd), 129.1 (Ce), 129.0 (C4’), 127.0 (C5), 124.5 (C3), 123.4 (Cc), 14.5 (CH3); IR 
(KBr) 3431, 3055, 1645, 1590, 1428, 1332, 1027, 846, 756 cm–1; Anal. (%) calcd for 
C26H22N4O4Sn C, 54.48: H, 3.87: N, 9.77; found C, 54.62; H, 3.85; N, 9.66. 
 
[n-Bu2Sn(nicotinate)2(phen)] 
Pink solid (2.75 g, 93%); m.p. 121-127 oC; 1H NMR (300 MHz, DMSO-d6)  9.48 
(d, J = 4.3 Hz, 2H, H2), 9.17 (br s, 2H, Ha), 8.77 (d, J = 7.5 Hz, 2H, H4), 8.71 (d, J 
= 4.8 Hz, 2H, Hb), 8.32 (d, J = 7.7 Hz, 2H, Hd), 8.17 (s, 2H, H5), 8.02-8.06 (m, 2H, 
H3), 7.48 (dd, J = 7.7, 4.8 Hz, 2H, Hc), 1.50-1.56 (m, 4H, CH2), 1.29 (br s, 4H, 
CH2), 0.98-1.05 (m, 4H, CH2), 0.52 (t, J = 8.7 Hz, 6H, CH3); 13C NMR (75 MHz, 
DMSO-d6):  170.3 (C=O), 152.0 (Cb), 150.5 (Ca), 149.8 (C2), 142.3 (C=N), 138.5 
(C4), 136.9 (Cd), 129.3 (C4’), 129.0 (Ce), 127.1 (C5), 124.6 (C3), 123.4 (Cc), 31.9 
(CH2), 26.9 (CH2), 25.4 (CH2), 13.3 (CH2); IR (KBr) 3429, 3047, 2948, 2925, 2865, 
1648, 1599, 1588, 1552, 1426, 1332, 1143, 848, 424 cm–1; Anal. (%) calcd for 
C32H36N4O4Sn·2H2O C, 55.43; H, 5.52; N, 8.08; found C, 55.08; H, 5.04; N, 7.85. 
 
[Ph2Sn(nicotinate)2(phen)]  
Peach solid (0.35 g, 10%); m.p. dec; 1H NMR (300 MHz, DMSO-d6)  9.09 (app br 
s, 2H, H2), 9.03 (br s, 2H, Ha), 8.71 (app br s, 2H, Hb), 8.49 (app br s, 2H, H4), 8.24 
(app br s, 2H, Hd), 7.96 (app br s, 3H, H5 & phenyl CH), 7.82 (d, J = 6.1 Hz, 2H, 
phenyl CH), 7.78 (app br s, 2H, H3), 7.48-7.52 (m, 2H, Hc), 7.37-7.45 (m, 6H, 
phenyl CH), 7.12 (app br s, 1H, phenyl CH); 13C NMR (75 MHz DMSO-d6)  167.2 
(C=O) 153.1 (Cb), 150.5 (Ca), 150.2 (C2), 145.5 (phenyl quaternary C), 143.4 
(C=N), 137.5 (Cd), 136.8 (C4), 136.5 (phenyl CH), 129.3 (phenyl CH), 128.8 (C4’), 
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128.7 (phenyl CH), 128.3, (Ce), 127.1 (C5), 124.2 (Cc), 123.9 (C3); IR (KBr) 3432, 
3070, 1709, 1655, 1596, 1419, 1324, 1302, 1033, 748 cm–1; Anal. (%) calcd for 
C36H26N4O4Sn·H2O C, 60.44; H, 3.95; N, 7.83; found C, 60.44; H, 3.74; N, 8.17. 
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[Me2Sn(nicotinate)2(dppz)] 
Yellow solid (2.97 g, 98%); m.p. dec; 1H NMR (300 MHz, DMSO-d6)  9.55 (d, J = 
7.9 Hz, 2H, H2), 9.27 (d, J = 4.7 Hz, 2H, H4), 9.07 (d, J = 1.5 Hz, 2H, Ha), 8.74 (dd, 
J = 4.9, 1.9 Hz, 2H, Hb), 8.39 (dd, J = 6.6, 3.5 Hz, 2H, H5), 8.26 (app dt, J = 7.8, 1.9 
Hz, 2H, Hd), 8.07 (dd, J = 6.6, 3.5 Hz, 2H, H6), 7.98 (dd, J = 7.9, 4.7 Hz, 2H, H3), 
7.50 (dd, J = 7.8, 4.9 Hz, 2H, Hc), 0.95 (s, 6H, CH3); IR (KBr) 3427, 1605, 1592, 
1554, 1486, 1415, 1400, 1362, 1336, 1073, 741 cm–1; Anal. (%) calcd for 
C32H24N6O4Sn C, 56.92; H, 3.58; N, 12.45;  found C, 56.49; H, 3.57; N, 12.53. 
 
[Me2Sn(nicotinate)2(dppz)] showed improved solubility in DMSO-d6 at 80 oC and 
hence the data were recorded at 80 oC. 
1H NMR (300 MHz, DMSO-d6, 80 oC)  9.47 (d, J = 7.9 Hz, 2H, H2), 9.22 (app br s, 
2H, H4), 9.07 (br s, 2H, Ha), 8.70 (dd, J = 4.8, 1.5 Hz, 2H, Hb), 8.29 (dd, J = 6.5, 
3.4 Hz, 2H, H5), 8.25 (d, J = 7.8 Hz, 2H, Hd), 7.99 (dd, J = 6.5, 3.4 Hz, 2H, H6), 
7.90 (dd, J = 7.9, 4.3 Hz, 2H, H3), 7.46 (dd, J = 7.8, 4.8 Hz, 2H, Hc), 1.02 (s, 6H, 
CH3, 2J(119/117Sn, 1H) = 101.7/97.5 Hz); 13C NMR (75 MHz, DMSO-d6)  168.6 
(C=O), 151.8 (Cb), 151.5 (C4), 149.9 (Ca), 147.0 (C=N), 141.3 (C=N), 140.1 (C5’), 
136.2 (Cd), 132.7 (C2), 130.6 (C6), 128.6 (C5), 128.2 (Ce), 126.5 (C4’), 123.9 (C3), 
122.8 (Cc), 11.8 (CH3). 
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[n-Bu2Sn(nicotinate)2(dppz)]  
Yellow solid (3.07 g, 90%); m.p. dec; 1H NMR (300 MHz, DMSO-d6) 9.40 (d, J = 
7.8 Hz, 2H, H2), 9.31 (app br s, 2H, H4), 9.11 (br s, 2H, Ha), 8.73 (d, J = 5.0 Hz, 
2H, Hb), 8.28 (d, J = 7.8 Hz, 2H Hd), 8.23 (dd, J = 6.5, 3.4 Hz, 2H, H5), 7.92-8.02 
(m, 4H, H6 & H3), 7.51 (dd, J = 7.8, 5.0 Hz, 2H, Hc), 1.44-1.62 (m, 8H, CH2), 1.17-
1.24 (m, 4H, CH2), 0.72 (t, J = 7.2 Hz, 6H, CH3); IR (KBr) 3425, 2955, 2924, 2868 , 
1606, 1593, 1553, 1407, 1361, 1337, 1074, 740 cm–1; Anal. (%) calcd for 
C38H36N6O4Sn C, 60.10; H, 4.78; N, 11.07; found C, 60.91; H, 4.90; N, 10.40. 
 
[n-Bu2Sn(nicotinate)2(dppz)] showed improved solubility in DMSO-d6 at 95 oC and 
hence the data were recorded at 95 oC. 
1H NMR (300 MHz, DMSO-d6, 95 oC)  9.38 (dd, J = 7.9, 1.7 Hz, 2H, H2), 9.14 (d, 
J = 3.9 Hz, 2H, H4), 9.03 (br s, 2H, Ha), 8.68 (dd, J = 4.9, 1.7 Hz, 2H, Hb), 8.19-
8.24 (m, 4H, Hd & H5), 7.94 (dd, J = 6.6, 3.4 Hz, 2H, H6), 7.84 (dd, J = 7.9, 3.9 Hz, 
2H, H3), 7.46 (dd, J = 8.0, 4.9 Hz, 2H, Hc), 1.61-1.71 (m, 4H, CH2), 1.42-1.56 (m, 
4H, CH2), 1.23-1.36 (m, 4H, CH2), 0.80 (t, J = 7.3 Hz, 6H, CH3); 13C NMR (75 
MHz, DMSO-d6)  168.4 (C=O), 152.2 (Cb), 151.9 (C4), 150.0 (Ca), 147.3 (C=N), 
141.6 (C=N), 140.3 (C5’), 136.5 (Cd), 132.9 (C2), 130.8 (C6), 128.8 (C5), 128.3 
(Ce), 126.7 (C4’), 124.2 (C3), 123.2 (Cc), 26.4 (CH2), 25.6 (CH2), 12.9 (CH3). 
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Appendix 
Appendix A 
 
Figure A1: 1H NMR spectra for compound 12 in (a) CDCl3 at 50 oC, (b) CDCl3 at 
25 oC and (c) CD3OD at 25 oC. Solvent residual 1H signals were also observed in 
each spectrum. 
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Appendix B 
Table B1: Phenylamino acrylates and malonates tested for bacteriostatic activity. 
 
Quinolone R R’ 
3.1a H CN 
3.2a F CN 
3.3 H CO2Et 
3.4 F CO2Et 
        a Tested as mixture of E/Z isomers 
Table B2: Quinolone compounds tested for bacteriostatic activity. 
 
Quinolone R1 R3 R5 R7 
3.5 H CN H H 
a3.6a H CN H F 
a3.6b H CN F H 
3.7 H CO2Et H H 
b3.8a H CO2Et H F 
b3.8b H CO2Et F H 
3.9 Et CN H H 
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Table B2 continued 
Quinolone R1 R3 R5 R7 
3.10a Et CN H F 
3.10b Et CN F H 
3.11a Et CO2Et H H 
3.12b Et CO2Et H F 
3.12c Et CO2Et F H 
3.13 Et CO2H H H 
3.14 Et CO2H H F 
3.15 Et CO2H H OMe 
3.16 Et CN H Piperazine 
3.17 Et CO2H H Piperazine 
3.18 Et CN H N-Methylpiperazin
e 3.19 Et CO2H H N-Methylpiperazin
e 3.20 Et CN4 H H 
a Tested as mixture of 3.6a and 3.6b, b tested as mixture of 3.8a and 3.8b.  
Table B3: O-Alkyl quinolone compounds tested for bacteriostatic activity. 
 
Quinolone R1 R3 R5 R7 
3.11b - CO2Et H H 
3.12a - CO2Et H F 
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Figure B1: 1H and NOE spectra of 3.10b. 
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Figure B2: 1H and NOEdiff spectra for 3.12b. 
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Figure B3: IR spectrum of 3.20. 
Table B4: Crystal structure and refinement of 1-ethyl-3-(1H-tetrazol-5-yl)quinolin-
4(1H)-one, 3.20. 
Empirical formula C12 H13 N5 O2 
Formula weight 259.27 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P2(1)/n 
Unit cell dimensions a = 14.993(3) Å = 90° 
 b = 4.3819(10) Å = 92.197(4)° 
 c = 17.908(4) Å  = 90° 
Volume 1175.7(5) Å3 
Z 4 
Density (calculated) 1.465 Mg/m3 
Absorption coefficient 0.105 mm-1 
F(000) 544 
Crystal size 0.37 x 0.07 x 0.04 mm3 
Crystal description yellow needle 
Theta range for data collection 1.74 to 26.43° 
Index ranges -18<=h<=18, -5<=k<=5, -22<=l<=22 
Reflections collected 9737 
Independent reflections 2428 [R(int) = 0.0644] 
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Table B4 continued 
Completeness to theta = 26.43° 100.0% 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9958 and 0.9621 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2428 / 3 / 181 
Goodness-of-fit on F2 1.009 
Final R indices [I>2sigma(I)] R1 = 0.0478, wR2 = 0.1017 
R indices (all data) R1 = 0.0911, wR2 = 0.1196 
Largest diff. peak and hole 0.166 and -0.206 e.Å-3 
 
Table B5: Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for 3.20. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
 X Y Z U(eq) 
N(1) 7234(1) 7632(4) 10324(1) 24(1) 
C(1) 7919(1) 6967(5) 10799(1) 24(1) 
C(2) 8594(1) 4988(5) 10644(1) 22(1) 
C(3) 9288(1) 4391(5) 11218(1) 24(1) 
N(2) 9335(1) 5638(5) 11893(1) 29(1) 
N(3) 10080(1) 4435(5) 12245(1) 33(1) 
N(4) 10476(1) 2555(5) 11808(1) 31(1) 
N(5) 9981(1) 2511(4) 11160(1) 25(1) 
C(4) 8604(1) 3514(5) 9926(1) 23(1) 
O(1) 9213(1) 1709(4) 9758(1) 32(1) 
C(5) 7857(1) 4239(5) 9412(1) 22(1) 
(C6) 7794(2) 2902(5) 8699(1) 27(1) 
C(7) 7079(1) 3493(5) 8216(1) 29(1) 
C(8) 6411(2) 5468(5) 8430(1) 29(1) 
C(9) 6450(1) 6839(5) 9122(1) 27(1) 
C(10) 7175(1) 6249(5) 9623(1) 22(1) 
C(11) 6523(1) 9644(5) 10593(1) 29(1) 
C(12) 5753(2) 7877(6) 10899(1) 37(1) 
O(1W) 7968(1) 8009(4) 12778(1) 38(1) 
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Table B6: Bond lengths [Å] and angles [°] for 3.20. 
N(1)-C(1) 1.339(3) N(4)-N(5) 1.353(2) 
N(1)-C(10) 1.395(3) C(4)-O(1) 1.253(2) 
N(1)-C(11) 1.478(3) C(4)-C(5) 1.458(3) 
C(1)-C(2) 1.370(3) C(5)-C(6) 1.405(3) 
C(2)-C(4) 1.438(3) C(5)-C(10) 1.411(3) 
C(2)-C(3) 1.457(3) C(6)-C(7) 1.377(3) 
C(3)-N(2) 1.327(3) C(7)-C(8) 1.388(3) 
C(3)-N(5) 1.333(3) C(8)-C(9) 1.375(3) 
N(2)-N(3) 1.367(2) C(9)-C(10) 1.406(3) 
N(3)-N(4) 1.296(3) C(11)-C(12) 1.510(3) 
    
C(1)-N(1)-C(10) 119.86(18) O(1)-C(4)-C(2) 122.04(19) 
C(1)-N(1)-C(11) 117.90(18) O(1)-C(4)-C(5) 122.38(19) 
C(10)-N(1)-C(11) 122.06(17) C(2)-C(4)-C(5) 115.57(19) 
N(1)-C(1)-C(2) 124.3(2) C(6)-C(5)-C(10) 118.60(19) 
C(1)-C(2)-C(4) 119.91(19) C(6)-C(5)-C(4) 120.40(19) 
C(1)-C(2)-C(3) 118.93(19) C(10)-C(5)-C(4) 120.99(19) 
C(4)-C(2)-C(3) 121.16(19) C(7)-C(6)-C(5) 121.1(2) 
N(2)-C(3)-N(5) 108.06(18) C(6)-C(7)-C(8) 119.7(2) 
N(2)-C(3)-C(2) 125.5(2) C(9)-C(8)-C(7) 121.0(2) 
N(5)-C(3)-C(2) 126.44(19) C(8)-C(9)-C(10) 119.9(2) 
C(3)-N(2)-N(3) 105.99(18) N(1)-C(10)-C(9) 121.04(19) 
N(4)-N(3)-N(2) 110.62(17) N(1)-C(10)-C(5) 119.33(19) 
N(3)-N(4)-N(5) 106.13(17) C(9)-C(10)-C(5) 119.6(2) 
C(3)-N(5)-N(4) 109.19(18) N(1)-C(11)-C(12) 112.55(19) 
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Appendix C 
                               
 [Ph2SnCl2(phen)]*                 [Ph2SnCl2(phen)]# 
 
 
Figure C1: COSY NMR spectrum of [Ph2SnCl2(phen)]. *[Ph2SnCl2(phen)] in red 
(trans-isomer) and #[Ph2SnCl2(phen)] in blue (cis-isomer). 
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Figure C2: 1H NMR of [Ph2SnCl2(phen)] at 25 oC (DMSO-d6). 
 
Figure C3: 1H NMR of [Ph2SnCl2(phen)] at 70 oC (DMSO-d6). 
